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Abstract 
The aim of this research thesis was to extend the structure activity relationship (SAR) of 
ferrocenyl peptide bioconjugates, a novel class of potential anticancer agents, and to 
investigate their mode of action in preparation for in vivo testing. A series of N-(6-ferrocenyl-
2-naphthoyl), N-{para-(ferrocenyl)cinnamoyl} and N-{para-(ferrocenyl)benzoyl} amino acid 
and dipeptide derivatives was prepared. Both the conjugated linker and the ester portions 
of the molecule were varied. The compounds were fully characterised by spectroscopic 
techniques including 1H NMR, 13C NMR, IR, UV-Vis and MS. 
A further SAR study was undertaken varying both the substitution pattern of the conjugated 
linker and replacement of the ester portion of the molecule with the free amine N-terminus 
on the amino acid or dipeptide. The synthesis of N-(5-ferrocenyl-1-naphthoyl) amino acid 
and dipeptide esters was attempted by coupling of 1-amino-5-ferrocenyl-naphthalene with 
the C-terminus of the amino acid or dipeptide.  
Biological evaluation was performed in vitro in A549 and H1299 non small cell lung cancer 
and HT-144, Lox-IMVI and Malme-3M metastatic melanoma. The most active derivative, N-
(6-ferrocenyl-2-naphthoyl)-glycine-glycine methyl ester had an IC50 of 0.2 µM on A549, Lox-
IMVI and HT-144 and 0.3 µM on H1299 and Malme-3M cells. Toxicity studies demonstrated 
a similar level of toxicity to cisplatin while evaluation in resistant cell lines showed that N-(6-
ferrocenyl-2-naphthoyl)- glycine-glycine methyl ester does not share cross resistance with 
temozolomide on the Malme-3M cell line. Cell cycle analysis showed a significant increase in 
the sub G0 phase while the TUNEL assay confirmed that the compounds undergo apoptosis 
leading to cell death. 
Guanine oxidation studies were carried out via HPLC-EC for N-(6-ferrocenyl-2-naphthoyl)-
glycine-glycine ethyl ester and N-(ferrocenylmethyl-L-alanine)-3,4,5-trifluorobenzene 
carboxamide). This confirmed that both classes of compounds are capable of generating 
reactive oxygen species (ROS) via Fenton chemistry. DNA binding as a possible mode of 
action was explored and a B12 conjugate was prepared as a potential drug delivery vehicle to 
overcome drug solubility issues in vivo. 
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Chapter 1 
Cancer, chemotherapy and bioorganometallic anticancer agents. 
 Cancer 
1.1.1 Introduction 
Cancer is the term used to describe a set of diseases characterised by abnormal and 
uncontrolled cell growth which evolves into a population of cells that can invade tissues and 
metastasise to other parts of the body. It is a major cause of death worldwide. There were 
12.7 million cases of cancer in 2008 and it is expected to rise to 21 million by 20301. 
It is estimated that approximately 70 % of cancers are preventable through diet and lifestyle. 
Few cancers are hereditary with environmental factors such as smoking, infectious agents, 
radiation, industrial chemicals, pollution, medication, nutrition, physical activity and body 
composition having a large impact. The world cancer research fund makes several 
recommendations for the reduction of lifestyle related cancers; to be as lean as possible 
within a healthy body weight, daily physical activity, the reduction of calorie dense foods, a 
high consumption of plant based foods, the reduction of red meats, alcohol and salt, and an 
adequate intake of nutrients through diet as opposed to supplementation2. 
 
Figure 1.1: Relative frequency of the main invasive cancers diagnosed 2008-2010 
reproduced from the annual report of the national cancer registry 20133. 
 According to the annual report of the national cancer registry, cancer was the second most 
common cause of death in Ireland after circulatory diseases in 20103. In the period 2008-
2010 an average of 32,500 cases of cancer were reported per year. The cumulative risk of 
developing cancer is 1 in 3 for Irish men and 1 in 4 for Irish women with the most commonly 
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diagnosed cancers being breast, prostate, colorectal and lung cancers. These also represent 
almost 50 % of all cancer deaths in Ireland as can be seen in figure 1.1 
  
Figure 1.2: Relative frequency of the main cancer deaths 2010 reproduced form the 
annual report of the national cancer registry 20133. 
1.1.2  Lung cancer 
Lung cancer is the most common cancer in the world. In 2008 it accounted for 12.7 % of all 
new cancers and 1.61 million new cases. It was also the most common cause of death from 
cancer with 1.38 million deaths (18.2 % of total cancer deaths)4. In Ireland it was the third 
most commonly diagnosed type of cancer in men and women between 2005 and 20093. It 
accounted for 20 % of all cancer deaths in Ireland in 2010. It has a relatively poor survival 
rate compared to its incidence rate as can be seen from figures 1.1 and 1.2. It has a poor 5 
year relative survival rate of just over 10 % based on figures between 2005 and 2009. 
Smoking is well known to be the greatest cause of lung cancer as it is responsible for 85 % of 
lung cancers. There are two main types of lung cancer, small cell lung cancer (SCLC) and non-
small cell lung cancer (NSCLC). NSCLC represents approximately 84 % of all lung cancers5. 
1.1.3  Melanoma 
Melanoma accounted for 4.4 % of all cancer deaths in Ireland in the period 2008-2010. While 
melanoma comprises of only 5 % of skin cancers it accounts for 77 % of skin cancer deaths 
worldwide5. Early stage melanoma is very treatable and easy to detect however advanced 
melanoma is aggressive with a tendency to form metastases and is resistant to 
chemotherapy.  It is one of the most aggressive forms of skin cancer and is one of the most 
rapidly increasing cancers in the world. While the five year survival rate for localised 
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melanoma is 98 %, advanced metastatic melanoma has a poor prognosis with a five year 
survival rate of just 15 %. 
1.1.4  Cancer chemotherapy 
Cancer is characterised by abnormal, unregulated cell growth. This growth may be benign or 
malignant. Malignant growths are characterised by their ability to form metastases; 
secondary growths which may often be distant from the location of the original tumour6. 
Cancer may be treated by surgery, radiotherapy, chemotherapy or a combination of these.  
Many classical cancer chemotherapy drugs target cell replication as cancer cells are 
reproducing at a faster rate than most normal cells. However, they will also kill cells which 
divide rapidly under normal conditions such as those in the bone marrow, the lining of the 
digestive tract and in the hair follicles. This can lead to some of the more common side effects 
associated with cancer such as myleosuppression, inflammation of the digestive tract and 
loss of hair. 
Resistance to chemotherapeutic drugs may be intrinsic; a property already possessed by the 
tumour before exposure to chemotherapeutic drugs, or acquired; resistance that occurs 
when a tumour is initially responsive to chemotherapy and later becomes resistant.  
Tumours may become resistant to cancer drugs through loss of cell surface receptors or 
transporters for a drug or alteration of the target molecule of a drug; however these result 
in resistance only to a small number of related drugs7. Multiple drug resistance (MDR) may 
occur when protein efflux pumps remove toxic chemotherapeutic chemicals from the cell or 
when there is decreased cellular uptake of these compounds by transporter proteins8. 
Phosphoglycoprotein (Pgp), the multidrug transporter, normally expels toxins from cells. Pgp 
is widely expressed in many human cancers and can detect and bind to a wide variety of 
hydrophobic drug molecules as they enter the plasma membrane thus leading to multidrug 
resistance. 
 Much work has been undertaken to counter these effects by finding a drug that will actively 
compete with or inhibit Pgp and counter drug resistance9. As MDR occurs when a tumour 
becomes resistant to more than one compound used to treat it, many chemotherapeutics 
are given in combination therapy. Combination therapy offers several advantages to 
treatment with a single agent in that the drugs used differ in their mechanism of action. This 
4 
 
allows the agents to be used at lower dosages reducing toxicity as well as the chance of 
resistance to a particular agent. 
1.1.4.1  Alkylating agents 
Akylating agents are highly electrophilic and react with the nucleophilic regions of DNA in 
one or both strands to form strong covalent bonds. They act by causing crosslinking, creating 
DNA strand breaks and abnormal base pairing10 which leads to the inhibition of cell division. 
Undesirable effects include acute toxicity, acquired resistance and the formation of 
secondary cancers.  They are effective during all phases of the cell cycle but proliferating cells 
are more sensitive to them. These compounds are often prescribed in combination therapy. 
The nitrogen mustards were the first class of modern chemotherapeutic agents to be used 
in vivo. It was noticed during World War II that soldiers exposed to sulphur mustard gas were 
myleosuppressed. It was thought that they may also be used on cancer cells. They were first 
implemented in the 1940’s when the nitrogen mustard, chlormethine 1, which is closely 
related to the sulphur mustard gas that was used in World War II, was used  to treat a patient 
with non-Hodgkins’ lymphoma11.  
 
Figure 1.3: Mechanism for the formation of DNA crosslinks by the aliphatic nitrogen 
mustards12. 
The weakly electrophilic β-carbon of aliphatic nitrogen mustards such as 1 is converted to 
the highly electrophilic aziridine ion by internal nucleophilic substitution. This is followed by 
nucleophilic attack by the N7 of guanine. As the molecule contains two chloride ligands, both 
chains can react with guanine residues to form a cross link. As these molecules are highly 
electrophilic they can react with other nucleophilic molecules within the cell causing 
unwanted toxicity. Chlormethine is too reactive to be administered orally and has to be 
injected intravenously.  
In order to reduce unwanted side effects attempts have been made to stop formation of the 
aziridine ion. Drugs such as melphalan 2 contain an electron withdrawing benzene ring which 
5 
 
reduces the nucleophilic nature of the nitrogen atom. These agents react by direct 
substitution of the β-chlorine atoms by guanine. This allowed for the oral administration of 
nitrogen mustards.  
 
Cyclophosphamide 3 is the most widely used alkylating agent in chemotherapy. It acts as a 
prodrug and is oxidised to the active form in vivo. It was believed the high concentration of 
phosphoramidases contained in tumours would hydrolyse the phosphorous group however 
it has been shown that its activity is due to the formation of a phosphoramide mustard upon 
oxidation by microsomal ensymes in the liver (figure 1.4). 
 
 
Figure 1.4: Formation of cytotoxic phosphoramide mustard. 
Nitrosoureas such as carmustine 4 and lormustine 5 act by attaching a chloroethyl group to 
a nucleic acid base to cause crosslinking. They are lipophilic and thus can cross the blood 
brain barrier and are used in the treatment of brain tumours. 
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1.1.4.2 Antimetabolites 
Antimetabolites were discovered shortly after the introduction of the alkylating agents. 
Unlike the alkylating agents they act by inhibiting the enzymes involved in DNA and 
nucleotide synthesis. The first antimetabolites, the antifolates, came to light when it was 
realised that supplementation of folic acid caused proliferation of acute lymphoblastic 
leukaemia cells in affected children13.  
Methotrexate 6 is one of the most commonly used antimetabloites used in cancer 
chemotherapy. It acts on dihydrofolate reductase (DHFR).  This enzyme is required for the 
maintenance of the cofactor tetrahydrofolate, which in turn is essential for the generation 
of DNA synthesis precursors. Methotrexate mimics the structure of the natural folates and 
has a stronger binding affinity for DHFR than the cofactor tetrahydrofolate and thus depletes 
levels in the cell causing a reduction in DNA synthesis and cell division. 
5-Fluorouracil 7 inhibits thymidylate synthase. It forms a suicide substrate by binding 
irreversibly with the enzyme and disrupting the synthesis of thymidine from uridine. This 
halts DNA synthesis and cell replication. It is often used in combination therapy with 
methotrexate. 
 
1.1.4.3 Agents acting on DNA topoisomerase. 
Topoisomerases are nuclear enzymes which act on DNA topology by breaking and re-joining 
the DNA strand. There are two types, topoisomerase I and topoisomerase II. Topoisomerase 
I acts by inducing a single strand break while topoisomerase II acts by inducing a double 
strand break. Agents which interfere with topoisomerase activity may act as topoisomerase 
poisons or inhibitors14. Topoisomerase poisons do not prevent the enzyme from functioning 
rather just slow it by stabilising the DNA enzyme complex. 
7 
 
 Intercalators contain a planar aromatic ring system which can fit into the DNA sequence and 
distorts the structure.  Anthracyclins such as doxorubicin 8, epirubicin 9, danorubicin 10 and 
idarubicin 11 intercalate and stabilise the DNA enzyme complex at the point where the 
strand is cut. 
 
Etoposide 12 and teniposide 13 are semi synthetic derivatives of the natural product 
podophyllotoxin extracted from the dried rhizome and roots of Podophyllum hexandrum. 
These compounds act by stabilising the intermediate formed at the 5’ break of the DNA 
strand, preventing the rejoining of the strand by topoisomerase II, thus causing double 
strand breaks and cell death. Etoposide is used for treatment of small cell lung cancer, 
testicular cancer, and lymphomas while teniposide is used in paediatric neuroblastoma. 
Camptothecin 14 acts on topoisomerase I. It is a natural product which was extracted from 
the ornamental Chinese tree Camptotheca acuminate (Nyssaceae) in 196615. It was found to 
have activity against leukaemia and lung cancer in 197116. It has shown poor activity in vivo 
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due to poor water solubility and has unacceptable renal toxicity. It wasn’t until 1996 that a 
camptothecin derivative; irinotecan 15 was approved for use by the food and drug 
administration (FDA)17.  Toptecan 16 was also developed, however these drugs are prone to 
resistance.  
1.1.4.4 Anti-microtubule agents 
Tubulin is essential to cell division. Tubulin binding proteins help to polymerise or 
depolymerise of microtubules during cell division. Agents acting on microtubules may either 
bind to tubulin and stop polymerisation or bind to the microtubules themselves and prevent 
depolymerisation. This results in the inability of the cell to divide and induces cell death. 
The vinca alkaloids vincristine 18 and vinblastine 19 are natural products derived from the 
Madagascar periwinkle plant Cartharanthus roseus and have been used in chemotherapy for 
over 35 years18. Their antiproliferative effect was first noticed by the Eli Lilly natural products 
group in 196319. Vincristine is used in the treatment of childhood leukaemia as well as 
lymphomas, small cell lung cancer, cervical cancers and breast cancers. Vinblastine is used 
mainly in the treatment of Hodgkin’s disease. Semisynthethic derivatives including vindesine 
20 have also shown anticancer activity. They inhibit polymerisation of microtubules, 
particularly spindle microtubules and block the cell cycle at M phase, halting mitosis and 
inducing apoptosis.  
 
First extracted from the bark of the pacific yew, Taxus brevifolia, and identified as antitumour 
agents in 1971 20,21 taxanes such as paclitaxel 21 inhibit depolymerisation by binding to the 
β-subunit of tubulin and promoting the production of unusually stable microtubules. 
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Depolymerisation is then unable to occur during cell division. Paclitaxel is used in the 
treatment of ovarian and breast cancer, small cell lung cancer and cancers of the head and 
neck. 
 
  Bioorganometallic chemistry 
Bioorganometallic chemistry is the study of biologically active molecules which contain a 
direct carbon metal bond. In the late 1970’s the field of organometallic chemistry was mainly 
concerned with the well-established area of catalysis, when an interest in its biological 
applications began to unfold. Up until then it was believed that metal complexes rarely 
played a role in biological processes. The discovery of the structure of vitamin B12 and its 
coenzyme methylcobalamin in 1954 showed one of the first naturally occurring metal carbon 
bonds22. The term bioorganometallic chemistry was first used in 1985 to describe the study 
of organometallic species with biological applications23, 24.  As a topic it has expanded 
significantly over the last 20 years as can be seen in figure 1.5. 
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Figure 1.5: Number of articles published and their citations for the last 20 years using 
the query “bioorganometallic” for a search of the Web of Science database 
(September 2010)25. 
1.2.1 Organometallic anticancer agents 
1.2.1.1 Platinum metal complexes 
The most widely used and well known anticancer metal complex (cis-
diaminedichloroplatinum) cisplatin 22, was first synthesised in 1844 by Michele Peyrone and 
was known as Peyrone’s chloride26.  It is a platinum II square planar complex. It was not until 
1965 that its anticancer properties were discovered by Rosenberg, who was investigating the 
effect of electric field on the growth of E. coli27. He noticed that the platinum conducting 
plates inhibited cell division and postulated that this may also be used to stop tumour 
growth. Clinical trials began in 1971 led by Brystol Myers Squib (BMS) and the National 
Cancer Institute (NCI) and in 1978 the drug was licensed by the Food and Drug Administration 
for the treatment of ovarian and testicular cancer28. Before its introduction survivors of 
testicular cancer were rare. Today the survival rate is over 85 % when used in combination 
therapy. It has also been used with some success in ovarian cancer and for palliative 
treatment of small cell lung cancer, bladder cancer, head and neck cancer and cervical 
cancer.  
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Following its huge success much research was carried out on platinum complexes as 
anticancer agents and soon after many other derivatives entered clinical trials. It’s narrow 
spectrum of activity, toxicity and the development of resistance led to the development and 
licensing of several other platinum based compound. Among the most well known of these 
are carboplatin 23 and oxaliplatin 24. Carboplatin was introduced to the clinic in 1981. It had 
a similar activity to cispaltin with less harsh side effects, specifically reduced nephrotoxicity, 
however it shares cross resistance with cisplatin. Oxaliplatin received approval in 1999 and 
shows activity on tumours which are cisplatin  resistant e.g. colorectal cancer. It shows a 
better safety profile than cisplatin or carboplatin and does not share cross resistance with 
cisplatin or carboplatin. Other platinum agents were developed but to date no others have 
received as widespread clinical approval. 
Cisplatin is an alkylating agent and owes its antitumour activity to its DNA binding abilities. 
Cisplatin is administered intravenously. Cisplatin itself is unreactive; high chloride 
concentrations in the extracellular fluid suppress aquation reactions of the ligands and allow 
the uncharged species to penetrate the cell membrane. The chloride concentration in the 
blood is approximately 100 mM, whereas the concentration in the cytoplasm is about 20 
mM. The low concentration of chloride ions in the cytoplasm causes the replacement of the 
chloride ligands with neutral water ligands to give the reactive positively charged species 
(figure 1.6). This occurs to a greater extent once the compound reaches the nucleus where 
chloride concentrations are approximately 4 mM29. Aquated cisplatin is reactive towards 
nucleophilic centres  on DNA, RNA and proteins as H2O is a better leaving group than Cl. 
Carboplatin owes its stability to its bidentate dicarboxylate ligand, which is more than 100 
times more resistant to these aquation reactions, giving it extra stability and a longer half life 
than cisplatin30.  
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Figure 1.6: Loss of chlorine ligands in water and binding to DNA31.  
DNA binding occurs to the N7 atom of the imidazole rings of guanine and adenine, as these 
are the most accessible and reactive sites of the double helix, to produce intra strand 1,2 and 
1,3  crosslinks which block replication and/or prevent transcription32. It is most likely that 1,2  
intra strand crosslinks are responsible for activity as the inactive compound transplatin is 
unable to form these and they are the least effectively removed from DNA by repair 
enzymes. These adducts then inhibit translation and replication triggering cellular apoptosis.
 
Figure 1.7: Two representations of cisplatin DNA binding. (A) Stereo view of X-ray 
structure of DNA crosslinked with cisplatin33 and (B) schematic view of cisplatin with 
guanine units of DNA34. 
1.2.1.2 Non platinum metal complexes 
Transition metal complexes are often used in the development of complexes for treating 
cancer. Interesting physical properties including electronic structure, bonding, chemical and 
spectroscopic properties have led to their increasing use in medicinal chemistry.  Among the 
metal complexes shown recently to have potential in cancer treatment are titanocene, 
vanadacene, molybdenocene, ferrocene and zirconocene35. 
A 
B 
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Titanocene 25 was the first metallocene reported with antitumour activity. It was shown to 
have strong cytotoxic activity against implanted Ehrlich ascites tumours (EATs) in mice in 
1979 by Köpf and Köpf-Maier36. 
It was studied in phase I clinical trials in 199337,38, 39 however dose limiting effects were noted 
including nephrotoxicity, hypoglycaemia, nausea and a reversible metallic taste. It reached 
some phase II clinical trials in metastatic breast carcinoma and advanced renal cell 
carcinomas. It was dropped after phase II as it had no significant advantages over cisplatin 
and was experiencing formulation problems due to low water solubility. 
Recent work has focused on the preparation of different derivatives of titanocene with 
interesting anticancer properties.  Ansa derivatives 26, 27 were prepared to increase water 
solubility and stability. Ansa metallocenes are linked by a bridging group between the two 
cyclopentadienyl rings. The cyclopentadienyl rings were linked for additional stability via a 
chelate effect and the water solubility was increased through the amino moieties40. 
Titanocene Y 28, the para methoxybenzyl derivative, was found to be active against a panel 
of 36 human tumour cell lines and has displayed promising activity in vivo41. In an attempt to 
improve the hydrolytic stability of the compounds the chlorine atoms were replaced with 
carboxylate ligands to give equally active compounds with more favourable 
pharmacokinetics. 
As alternatives to platinum have been sought among the transition metals, ruthenium has 
also shown some promise as an antitumour and antimetastatic agent. It is considered a good 
replacement for platinum as the compounds are less toxic and have shown some specificity 
for cancer cells.  
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Ruthenium has three properties which make it suitable for medicinal use. Slow ligand 
exchange kinetics, multiple accessible oxidation states; ruthenium can access (II) (III) and (IV) 
oxidation states under physiological conditions, and the ability to mimic iron binding through 
albumin and transferrin42. 
To date two ruthenium compounds have made it to human clinical trials NAMI-A 29 and 
KP1019 3043. NAMI-A shows no direct inhibition but has anti metastatic properties44 whereas 
KP1019 has shown antitumour activity on human tumour explants by inducing apoptosis. 
  
Both NAMI-A and KP1019 are Ru(III) complexes. Originally it was thought that these operated 
through the same mechanism as cisplatin, however ruthenium appears to accumulate 
preferentially in neoplastic masses. It is believed that it uses iron transport proteins albumin 
and transferrin to enter tumours. The lower oxygen content and higher acidity of the tumour 
environment then reduces the inactive Ru(III) compound to the active Ru(II) form. 
NAMI-A was the first of these to reach human clinical trials. Phase I ran from 1999 and was 
reported in 2004. The majority of patients showed disease progression in this dose escalation 
study45. It has not yet undergone phase II trials.  KP1019 has also been tested in a phase I 
dose escalation study. The majority of patients showed disease stabilisation however there 
was difficulty administering the maximum dosage as the compound has limited water 
solubility.  
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1.2.2 Ferrocene 
Ferrocene was first discovered accidentally in 1951 by Pauson and Kealy while trying to 
synthesise fulvalene46, 47. They reported a yellow compound that contained two 
cyclopentadienyl rings and an iron atom, that was stable in water, in the presence of both 
strong acid and alkali and on heating to high temperatures. The structures shown in Figure 
1.8  were initially reported. However the correct structure was not proposed until 1952 
independently by both Fischer and Wilkinson48. X-ray crystallographic data was published 
shortly afterwards confirming the sandwich nature of ferrocene49. Until then it was believed 
that bonds between transition metals and hydrocarbons were unstable. After the structure 
of ferrocene was published, synthesis was attempted using most of the other transition 
metals giving rise to the generation of complexes known as sandwich complexes or 
metallocene chemistry. 
Fe
H
H  
Figure 1.8: Initially proposed structures for ferrocene. 
Ferrocene’s sandwich structure is due to orbital overlap between the π electrons in the p 
orbitals of the cyclopentadienyl rings with the d orbitals of the iron atom50. The complex 
follows the 18 electron rule; it forms a stable complex, with a relative energy minimum and 
the electron configuration of the next noble gas, when the sum of the metal d electrons, 
electrons from the ligands and the overall charge of the complex equals 18. The iron centre 
is usually assigned the +2 oxidation state.  Each ring is given a single negative charge, 
corresponding to 6 π electrons. These are then shared with the 6 d electrons of the metal via 
covalent bonding. 
16 
 
 
Figure 1.9: Molecular orbital diagram of ferrocene. 
Fe Fe
+e-
-e-
 
Figure 1.10: Ferrocene and ferricenium ion.  
The cyclopentadienyl rings adopt a staggered conformation around the central iron atom. 
Due to its aromaticity it is often used as a bioisosteric replacement for benzene. Thus the 
name ferrocene was coined.  Sometimes bioisosteric replacement with ferrocene has very 
little effect as in the case of ferrocenyl penicillins and sometimes it gives rise to an activity 
not possessed by the purely organic derivative. Ferrocene readily undergoes one electron 
oxidation from the Fe(II) to the Fe(III) oxidation state to give the ferricenium species which 
is blue green in dilute solution. 
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1.2.2.1 Medicinal chemistry of ferrocene 
Ferrocene has shown many potential medicinal applications as antitumour, antiinfective 
antiviral, antibacterial and antifungal51 agents. Some of the first ferrocenyl antibiotic 
derivatives were prepared in the late 70’s by Edwards et al. in an attempt to address the 
issue of acquired resistance to antibiotics 52, 53, 24. They developed ferrocenyl penicillins 31 
and ferrocenyl cephalosporins 32 as β-lactamase inhibitors. 
 
Edwards replaced the organic moieties with ferrocene. When the ferrocene was placed too 
close to the lactam ring 31a and 32a, antibiotic activity was decreased. When it was attached 
with a methylene spacer 31b and 32b, activity was similar to the organic derivative. When 
attached with a C(CH3)2 spacer 31c and 32c, the desired increase in β-lactamase inhibition 
was achieved but the antibiotic activity decreased. 
 
 In the mid 90’s using a similar strategy to the group of Jaouen, Biot modified the main 
antimalarial drugs in use at the time by attaching a ferrocene moiety54. Analogues of 
chloroquine 33, quinine, mefloquine, artemisinin and atovoquine were synthesised. The 
chloroquine analogue, ferroquine 34 was the most promising compound against both 
chloroquine susceptible and resistant strains of Plasmodium falciparum, the most dangerous 
of the five plasmodium strains responsible for malaria. 
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The mode of action of ferroquine is thought to differ from that of the parent compound. 
More than one potential mode of action has been proposed.  
The parasite ingests haemoglobin as its primary source of amino acids. Ferroquine is believed 
to act in part by forming a complex with haematin and inhibit conversion to hemozoin 
similarly to chloroquine, however it does not accumulate resistance in the same way55. 
Resistance to ferroquine could not be induced in either in vivo or in vitro56. More recently it 
has been shown that the generation of oxidative damage by the ferrocene moiety also plays 
a role in its antimalarial activity57. Increased levels of the HO• radical were detected in the 
digestive vacuole of the parasite after treatment with ferroquine. It is believed that 
alteration of the redox status of the cell causes the breakdown of the membrane and death 
of the parasite. 
Ferroquine finished phase II clinical trials in 2011, at which point clinical testing was 
discontinued for the drug after a decision to further modify the development strategy of the 
drug. No safety issues or unexpected activity was noted during these studies58.  
The group of Metzler-Nolte has worked on the synthesis of antimicrobial peptides (AMPs) as 
antibacterial drugs. In 2005 Chantson et al. prepared peptide sequences incorporating a 
ferrocenyl unit. These sequences varied in length from 3 to 5 amino acids composed of 
arginine, tryptophan and phenylalanine with glycine as a linker59. The chains were prepared 
by solid phase peptide synthesis (SPPS) and the ferrocenyl moiety was attached at the N-
terminus. The compounds were tested against Escherichia coli (gram negative), 
Pseudomonas aeruginosa (gram negative) and Staphylococcus aureus (gram positive) using 
the minimum inhibitory concentration (MIC) test. However these were not found to be very 
active with the most active having a value of 57 µg mL-1 in the E. coli and S. aureus.  In 200660 
the amino acid sequence was modified to a hexapeptide sequence containing just arganine 
and tryptophan. While the compounds showed better activity most did not show any 
particular benefit of the organometallic moiety compared to the organic sequence. 
Compound 35 however was found to be more active than the organic moiety against S. 
aureus. It had an activity of 7.1 µg mL-1 and showed greater activity than the pilosulin control. 
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Interestingly El Arbi et al. tested ferrocenyl tamoxifen derivatives for their bactericidal and 
fungicidal activity compared with purely organic analogues61.  They were tested against the 
bacteria P. aeruginosa, S. aureus and the fungus Candida albicans. 27 compounds were 
tested; 20 ferrocenyl derivatives and 7 organic compounds. Doxycyclin was used as a positive 
control and the compounds were evaluated using the MIC test. The bactericidal and 
fungicidal activity showed no apparent correlation with the cytotoxicity of the compounds. 
The organic and ferrocenyl derivatives were found to have similar activities with the most 
active derivatives bearing two alkylamino side chains. 
One of the few ferrocene based compounds to make it to clinical approval is ferrocerone 36. 
It was licensed in the USSR for the treatment of iron deficient anaemia62. 
 
 
1.2.2.2 Ferrocene and cancer 
The antitumour potential of ferrocene was first noted in 1978 by Fiorina et al63. A series of 
ferrocenylpolyamides including N-(4-ferrocenylbutyryl)-γ-aminobutyramide 37 were tested 
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for their antitumour activity in vivo on murine P-388 lymphocytic leukaemia. Their activity 
was low but showed that the incorporation of a ferrocene moiety could enhance the 
antitumour activity of a compound. 
 
1.2.2.2.1 Ferricenium salts 
The antitumour activity of ferricenium salts was first reported by Köpf-Maier et al. in 198464. 
They examined the activity of several ferricenium complexes against Erhlich ascites tumours 
in rats. Ferricenium picrate 38 and ferricenium trichloroacetate 39 obtained the best anti 
neoplastic activity. These complexes differed from others at the time in that they were water 
soluble and deviated from the trend for cisplatin analogues. 
It was known that ferrocene can convert from the (+2) oxidation state to the ferricenium ion 
(+3) oxidation state at biological potentials. Osella et al. tested several ferrocene species and 
their corresponding ferricenium salts for their cytotoxicity. He showed that only the 
ferricenium salts had activity against Erhlich ascites tumour cells.  It was shown that this was 
independent of water solubility or redox potential65. 
More recently they investigated the activity of five ferricenium complexes in MCF-7 cell lines.  
Ferricenium tetrafluoroborate, decamethylferricenium tetrafluorborate 40, ferricenium 
carboxylic acid tetrafluoroborate, ferricenium boronic acid tetrafluoroborate and 1,1-
dimethyl tetrafluoroborate complexes were prepared and tested. All compounds showed a 
general cytotoxic effect with the decamethylferricenium salt having the highest IC50 value of 
37 µM and the others around 300 µM. It was also shown that these compounds caused DNA 
damage through oxidative stress66.  
1.2.2.2.2 Organometallic selective estrogen receptor modulators 
Breast cancer can be divided into two groups; hormone dependant breast cancers, those 
which express the estrogen receptor [ERα(+)] and hormone independant cancers, those 
which do not express [ERα(-)]. About two thirds are [ERα(+)] and are treatable using selective 
estrogen receptor modulators (SERMs). SERMS bind to the estrogen receptor and may act as 
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estrogen agonists or antagonists. Tamoxifen 41 and its active metabolite, hydroxytamoxifen 
42, are the most common drugs in this class which are used for the treatment of [ERα(+)] 
tumours. A second estrogen receptor ERβ has also been discovered. Malignant breast tissue 
may express ERα, ERα and ERβ, no ER and in rare cases ERβ alone. The ligand binding domain 
of both receptors shows some similarity and SERMS may bind equally well to both, however 
patients diagnosed with ERα(+) breast cancer have a better prognosis than those that have 
ERα(-) suggesting that the receptors do not share the same mechanism of action. 
Tamoxifen acts as an antagonist of the estrogen receptor in breast cancer tissue. It was 
originally designed as a contraceptive agent by Imperial Chemical Industries. Ironically, 
claims in the original patent that it may be useful as a breast cancer treatment, had to be 
removed as they were considered to be ‘fantastical and lacking evidence’67. The compound 
failed in clinical trials as a contraceptive, however, during the 1970’s research began 
investigating its use in breast cancer treatment. 
 
To solve problems associated with tamoxifen’s resistance, side effects and narrow spectrum 
of activity, the group of Gerard Jaouen modified the structure of tamoxifen by attaching an 
organometallic moiety. It was hoped that these organometallic derivatives could combine 
the estrogenic activity with the cytotoxic activity of several known compounds. They wished 
to develop a targeted therapy using tamoxifen as a vector to deliver a cytotoxic agent directly 
to the area of interest. The group tried several different approaches using multiple 
organometallic compounds. 
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Given the success of cisplatin, it was initially proposed that a tamoxifen derivative of a 
platinum agent may be useful in targeting breast cancer. They achieved this by attaching a 
malonate derivative of oxaliplatin to tamoxifen in the hope of transporting a cisplatin 
analogue directly to the estrogen receptor68.  Compound 43 was shown to have an IC50 value 
of 4.0 µM in MCF-7 cells compared with the literature value of 7.4 µM for oxaliplatin and a 
value of 6.3 µM for the unvectorised malonate compound69. The antiproliferative effect was 
however attributed to the cytotoxicity of the platinum and at the concentrations tested it 
was not felt that they brought any benefit to the SERMS. It was proposed that the Pt-N 
coordination bond was too weak, the metal was unable to react with its target as hydrolysis 
occurred too quickly and the compound was too bulky. Results in mammary tumours were 
poor and thus they turned to looking at other potential cytotoxic organometallics to attach 
to SERMS. The group prepared derivatives incorporating Ti, Ru, Re, CO, as well as osmium 
clusters and manganese70, 71, 72, 73. 
 
A series of ruthenocene analogues of tamoxifen was prepared. These displayed a very high 
relative binding affinity (RBA) for the estrogen receptor and had an antiproliferative effect 
similar to tamoxifen in MCF-7 cells, however they had no effect on MDA-MB-231. Therefore 
it was determined that they act in an antiestrogenic fashion with the organometallic moiety 
imparting no particular advantage. 
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The work of Köpf-Maier on dichlorotitanocene ((Cp)2TiCl2) showed that the molecule had 
cytotoxic properties against various tumour types in vivo and in vitro. As titanocene was 
show to have activity against Ehrlich’s ascite tumour Anne Vessières et al. prepared a 
tamoxifen derivative incorporating the dichlorotitanocene moiety 4474. The cytotoxicity of 
the compound was studied in MCF-7 cells. Results showed that 44 acts as an estrogen instead 
of an antiestrogen as expected due to the presence of the dimethylamino chain thought to 
be responsible for the activity of tamoxifen. 
 
 
 
 
 
 
 
 
Perhaps the most successful and well known works of Jaouen are the ferrocifens 45. The 
group of Jaouen first prepared ferrocenyl hydroxytamoxifen derivatives in 199675. They 
decided to attach an antitumour agent and hydroxytamoxifen was the active metabolite of 
tamoxifen.  These compounds are typically prepared by McMurry coupling of the ferrocenyl 
ketone76, which results in a mixture of 50 % (E) and (Z) isomers. These isomers were shown 
to rapidly interconvert in protic solutions, which is also true for Tamoxifen and other stilbene 
based compounds. As this is typical of biological conditions most studies were conducted 
using a mixture of (E) and (Z) isomers. 
 Studies showed a good relative binding affinity (RBA) for the estradiol receptor and IC50 
values of 4.9 µM and 3.4 µM in MCF-7 cells for (E) and (Z) isomers of hydroxyferrocifen (n=2) 
compared with a value of 6.4 µM for tamoxifen under the same conditions. However it was 
found that in vivo hydroxytamoxifen caused a large increase in tumour volume of over 50 % 
in attymic nude mice xenografted with T47D breast cancer cells.  
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The structure of the ligand binding domain (LBD) of the estrogen receptor requires a basic or 
polar side chain to deform the receptor to an open conformation and inhibit activation. It 
was believed that the more bulky ferrocene moiety stopped the compound from deforming 
the ER to its open conformation. It was proposed that increasing the side chain by 1 or 2 
carbons could reverse this77. 
 
 A series of hydroxyferrocifens was prepared78 keeping the hydroxyl group and the dimethyl 
amino side chain that are necessary for binding to the LBD of the ER and thus antiestrogenic 
activity, while varying carbon chain length with n = 2, 3, 4, 5 and 879. All of the compounds 
were shown to have antiestrogenic effects but that activity was dependant on chain length.  
Where n = 2 and 8, RBA values lower than hydroxytamoxifen were observed. For n = 3-5 
values were similar or slightly better in ER(+) MCF-7 cells. Cytotoxicity of the compounds was 
established using a DNA damage detection (3D) test, showing that they have a dual activity, 
as acting as an antiestrogen and a cytotoxic agent80 When these derivatives were also tested 
on ER(-) MDA-MB-231 cells they were found to have a hormone independant mechanism of 
action81. They were also most effective when n = 3-5. Tamoxifen has no effect on ER(-) cell 
lines. This showed ferrocifens to be both useful against ER(+) and ER(-) cell lines. 
It was initially thought that the ferrocifens induced DNA damage through oxidative stress 
however fluorescence activated cell sorting (FACS) analysis showed that hydroxyferrocifen 
produces negligible DNA damage compared to the parent compound hydroxytamoxifen82.  
Further work on the mode of action was carried out using cyclic voltammetry with the 
addition of pyridine as a base83. A reaction mechanism which proceeded via a quinine 
methide was proposed. The ferrocene is initially electrochemically oxidised. This imparts 
partial positive to the hydroxyl group which acidifies the proton and allows it to be abstracted 
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by the pyridine resulting in a phenoxy species with the radical on the alpha carbon to the 
ferrocene. It is then oxidised a second time to give the quinine methide 46. The drug will only 
be activated in the presence of basic species such as DNA nucleobases or peptides, where it 
can cause cellular damage leading to cell death. 
 
Oxidation to a reactive quinine methide has been shown to be the mechanistic basis of many 
phenolic anticancer drugs including tamoxifen. Cell damaging pathways for tamoxifen 
include metabolism to o-quinones, quinine methides and carbocations84. These quinine 
methides may form adducts with DNA, gluthathione (GSH) or proteins85. 
The group moved to further establish this mechanism showing that the proposed quinine 
methides are indeed formed upon oxidative metabolism in rat liver microsomes86. Four 
ferrocifens were tested and quinone methides were isolated and characterised by high 
performance liquid chromatography-mass spectrometry (HPLC-MS) as the major products of 
metabolism. 
In further structure activity relationship (SAR) studies the group prepared a series of 
derivatives, the most active of which was 47 with an IC50 value of 0.44 µM in MDA-MB-231 
cells. From this study it was determined that the ferrocene moiety is necessary for activity 
but not sufficient to elicit a response alone. The phenyl group must be oriented trans to the 
ferrocene and the two phenyl groups must be attached to the same carbon atom. The 
position of the hydroxyl group was important with the para group preferred over the meta. 
No proton coupled intramolecular electron transfer occurred in the case of the meta. It was 
also noted that one ferrocene moiety was more effective than two87. Replacement of the 
phenol group with an alanine or acetanilide further increased the cytotoxic activity88. 
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These compounds have increased lipophilicity compared to the purely organic drug 
tamoxifen due to the presence of the ferrocene moiety. This makes it easier for them to 
penetrate the cell membrane, however, they have poor bioavailability due to the high 
hydrophobicity caused by the phenyl rings. Thus it was necessary to investigate methods of 
formulation to aid drug delivery. The group looked at several formulation strategies. Swollen 
micelles were found to be ineffective as they had poor uptake by the cytoplasm and no 
biological activity. Among the strategies developed to improve solubility was the formulation 
of ferrocenyl tamoxifen adducts with cyclodextrins89, 90. It was found that compounds with 
hydroxyl groups on the phenyl ring formed ferrocifen-cyclodextrin complexes that are 
soluble in polar solvents. On addition of base dissociation of the ferrocene from the 
cyclodextrin occurs allowing conversion to the ferricenium cation. It was found that 
cytotoxicity to MDA-MB-231 cells was unaffected by the cyclodextrin complex making it a 
viable method for increasing water solubility for use in vivo. 
Two promising potential drug candidates, Fc-diOH 47 and DFO 48 showed good activity in 
both MCF-7 and MDA-MB-231 breast cancer cells in vitro but were poorly soluble in 
biological fluids. The group prepared two types of stealth nanoparticles; PEG/PLA 
nanospheres and nanocapsules to address the problem of formulation91. Stealth 
nanocapsules are designed to evade the immune response, increasing the circulation time. 
This gave the slow release of both compounds. They were found to arrest the cell cycle in S-
phase and induce apoptosis. Given their small size they have the ability to undergo 
endocytosis and protect the drug from hydrolysis and oxidation. 
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Fc-di-OH loaded lipid nanocapsules between 20-100 nm were found to be effective on 9L-
glioma cells, with an IC50 value of 0.6 µM. They also showed low toxicity when tested on 
normal cells. Using this strategy the group were able to carry out their first in vivo studies in 
rats showing a significant reduction in both tumour mass and volume evolution92.  
 
The group also prepared a series of pro-drugs of Fc-diOH using either acetyl group or 
palmitate93. These LNC prodrugs have to be activated in situ by enzymatic hydrolysis. The 
acetyl pro-drug had similar effects to that of the parent, whereas the palmitate showed a 
loss of activity. 
Fc-diOH LNC were tested in intracerebral 9L glioma in vitro and in vivo in conjunction with 
external radiotherapy. It was shown that chemotherapy followed by radiotherapy had better 
results than the reverse which was attributed to a radiosensitising effect. It was shown that 
they acted in synergy and not only additive effects were observed94. 
 In another study LNCs were incorporated into MIAMI mesenchymal cells. It was found that 
they did not cause cell death and maintained both their stem cell properties and migration 
capacity. These were shown to have a cytotoxic effect both in vitro and in vivo after 
intertumoural injection in a heterotopic U87MG glioma model in nude mice95. 
More recently they used ferrocenyl hydroxytamoxifen LNCs in vivo in mice bearing 
xenografted triple negative breast cancer tumours. Both stealth and conventional 
nanocapsules were prepared and tested in vitro with IC50 values for both types approximately 
2 µM. In vivo a significant reduction in tumour growth was observed with a 36 % reduction 
after 38 days96.  
 
The most active derivatives to date produced by the Jaouen group are the ferrocenophanes. 
These contain a 3 carbon bridge joining the cyclopentadiene rings. Based on the previous 
work which had shown a great effect with modification of the phenol rings, derivatives were 
prepared maintaining the bis substituted phenol rings and incorporating a 3 ferrocenophane 
structure97. These derivatives were estimated to have IC50 values of approximately 1 and 4 
µM in MCF-7 cells and 0.09 and 0.96 µM in the MDA-MB-231 cells. When the olefin was 
moved from the 2 position 50 to the 1 position 49 on the bridge, activity decreased by an 
order of magnitude. However, they showed mixed estrogenic and antiestrogenic activity and 
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were thus determined to be more suitable for hormone independant cancers. These results 
were significantly lower than those of the ferrociphenol lead compound.  
 
A second series of analogues was prepared using aniline and acetylene ferrocenophane and 
ferrocifen derivatives. In each case, the ferrocenophane was shown to be more active than 
the ferrocene derivative98.  
Given that the bis-substituted phenol compound showed twice the activity of the mono 
substituted derivative in both the ferrocene and ferrocenophane series, with a value of 0.09 
µM compared to 0.47 µM for ferrocenophane and 0.65 µM to 1.1 µM for ferrocene, a series 
of compounds with either mixed or identical bis substitution with protic groups on both 
phenyl rings was prepared 5199.  As was expected the bis-substituted compounds were found 
to be more active with IC50s in the nanomolar range in the MDA-MB-231 cells (0.05-0.92 µM) 
and similar when tested in PC-3 prostate cells (0.02-2.43 µM). The exception to this was the 
case of the derivative with two amide groups, which has IC50 values of 5.64 µM and 12.45 
µM in the MDA-MB-231 and PC-3 cells respectively. This showed that para substitution of 
both rings with protic groups and the 3-ferrocenophane moiety give rise to the most active 
derivates produced by the group. 
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Given that the dianiline species (51h) had been their most active derivative to date a further 
series of dianilines was prepared varying the length of the carbon chain attached100. It was 
found that for increasing number of hydrocarbons the activity of the compound on MDA-
MB-21 cells decreased. It was also shown that the purely organic moiety was less active than 
the ferrocenophane derivative but more active than the ferrocenyl derivative. For tetra 
methylated aniline derivatives the activity was lost, showing that the protic groups are 
required for activity. It is proposed that these groups can be oxidised to an imine methide in 
a similar fashion to the phenol groups. 
Pigeon et al. prepared derivatives of tamoxifen possessing two amino alkyl side chains of the 
form O(CH2)3NMe2 based on both the ferrocenophane motif and the open conformation101. 
Despite having no protic groups these analogues had both a strong affinity for the estrogen 
receptor and excellent antiproliferative activity on both hormone dependant and 
independent cell lines. These are believed to operate via a different mechanism to the 
previous derivatives as they cannot form either quinone methides or quinone imines. The 
organic analogues have a similar activity to the ferrocenyl derivatives in these compounds.  
The activity of 27 of the organometallics SERMS derivatives were investigated on a panel of 
other human cancer cell lines. Ferrocenyl substituted tamoxifens and stilbene analogues 
were tested on SF-295 (human glioblastoma), HCT-8 (human colon cancer) MDA-MB-435 
(human melanoma) HL-60 (human promylocytic leukaemia) cells and evaluated for 
antiproliferative activity, ROS generation and haemolytic activity102.  These compounds were 
found to be least active in the melanoma cell line with low micromolar activities. They were 
most active in the HL-60 cell line with an average IC50 of 2 µM. 
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Previously studied compound 52a and its citrate salt 52b were found to be most active in all 
cell lines.  The di substituted diaminoalkyl compound had been previously shown to have 
good activity on MDB-MA231 cells with an IC50 value of 0.45 µM as well as showing good 
antibacterial and antifungal activity61. 
 
 The compounds, bearing no protic groups cannot form a quinine methide species. The ROS 
studies showed no correlation of ROS generation with antiproliferative activity. Most 
compounds showed no ROS generation in the HL-60 cell line indicating that they operate via 
a mechanism unrelated to oxidative stress. To this effect the haemolytic activity of the 
compounds was investigated.  Six of the compounds, including 52 and tamoxifen showed 
some haemolytic activity suggesting that these compounds may generate cell membrane 
damage. Compounds with high antiproliferative activity and low haemolytic activity were 
considered to present interesting opportunities for further development. 
Besides their activity against breast cancer the ferrocifens have also shown some activity 
against melanoma103. Ferrocifen and ferrociphenol were tested for activity against primary 
WM35, WM793 and metastatic WM9 melanoma cells as well as melanocytes. They were 
found to be selective for the melanoma cells over melanocytes when tested in vitro on hair 
follicles they showed ejection of the hair shaft from the follicle suggesting hair loss may be a 
possible side effect if used as a chemotherapeutic. These were also tested on BR95 and 
MM98 mesothelioma cells where both compounds were found to be more effective at 
stopping cell proliferation than cisplatin. 
1.2.2.2.3 Other ferrocenyl compounds with anticancer activity 
Apart from the work carried out on SERMS the group of Jaouen has also investigated 
derivatising several other types of bioactive compounds with ferrocene. In 2008 they 
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prepared derivatives of the nonsteroidal antiandrogen nilutamide 53104. These were tested 
against prostate cancer cells. Those substituted at the N1 position of the hydantoin ring 
showed only weak antiproliferative effects while those substituted at the C5 position showed 
good cytotoxic activity however this could not be attributed to the organometallic moiety as 
the organic analogue had similar activity on replacement of the ferrocene moiety. 
 
Derivatives of flutamide 55 and bicalcutamide 56 were synthesised105. Compounds had a low 
binding affinity for the androgen receptor and activity was attributed to cytotoxicity rather 
than hormonal effects. The most active bicalcutamide derivative 59 had an IC50 of 17 µM in 
the PC-3 cells but the flutamide derivatives 57 and 58 showed almost no activity against 
hormone dependant LNCaP or hormone independant PC-3 prostate cancer cells. 
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A series of derivatives based on flavonoid structures was synthesised106,107.  These biological 
compounds are credited with numerous health benefits which have been attributed to their 
antioxidant properties.  The B ring of the flavonoid was replaced with the ferrocenyl moiety. 
Aurones, chalcones, flavones and flavonols were prepared and tested in vitro against B16 
murine melanoma cells and endolithial cells. The compounds displayed only modest 
cytotoxic activity; the aurone derivatives having the best activity with IC50 values of 12-18 
µM. They showed some antivascular activity though these did not seem to correlate. 
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Figure 1.11: Structures of flavonoids. 
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Given the success the group achieved targeting the estrogen receptor with the ferrocifens 
and ferrocophanes against breast cancer, the group undertook a similar approach with 
derivatives of the steroidal androgens testosterone 60 and dihydrotestosterone 61 in 
prostate cancer cells108. Several ferrocenyl ethynyl testosterone well as ethynyl ferrocenyl 
and vinyl ferrocenyl androstanes were prepared. Sandwich and semi-sandwich complexes of 
chromium, manganese and rhenium were also prepared, however the ferrocenyl derivatives 
showed the best activity. 
 
A C17 ethynyl ferrocenyl derivative of testosterone 62 and the corresponding 
dihydrotestosterone showed IC50 values of 4.7 and 8.3 µM respectively in PC-3 prostate 
cancer cells. While a C17 β androstanediol showed an IC50 value of 5.5 µM and the C16 
derivative with a ferrocenyl vinyl unit 63 showed and IC50 of 12.2 µM. 
Curcumin 64 is a naturally occurring antioxidant responsible for the yellow colour of 
turmeric.  Several ferrocenyl curcuminoid 65a-d derivatives were prepared using either a 
propanone, methylene or ethanone spacer to attach ferrocene via the central carbon atom 
of curcumin109. The substitution pattern of the ring was also varied. The compounds were 
tested in B16 murine melanoma cells. Curcumin has an IC50 value of 8.5 µM in this cell line. 
The ferrocenyl derivatives with a methylene side chain were found to be most cytotoxic with 
IC50 values of 2.2 to 7.1 µM. The compounds also showed some selectivity for cancer cells 
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with higher IC50 values in normal cells lines. These compounds were also tested for their 
tubulin binding ability and antivascular activity. Ferrocenyl compounds with a propanone 
spacer group were found to have the best tubulin polymerisation inhibition and antivascular 
properties. It was noted that the derivatives with 3, 4-dimethoxy substitution pattern were 
most active. 
 
 
Some of the most recent work undertaken by the group was the addition of suberamides 66 
such as suberoylanilide hydroxamic acid (SAHA) a and N1-phenylsuberamide (PSA) b and 8-
oxo-8-(phenylamino)octanoic acid (OPOA) c to the ferrocifen110 and ferrocenophane111 
structures, replacing the dimethylaminoalkoxy side chain.  SAHA is a histone deacetylase 
inhibitor (HDACi) and is used in the treatment of cutaneous T cell lymphoma. It inhibits 
transcription by adopting a closed conformation with DNA which transcription factors cannot 
access.  
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These new compounds were tested in MDA-MB-21 cells and MCF-7 cell lines. It was found 
that the antiproliferative activity of the compounds was not due to an affinity for the 
estrogen receptor or their ability to inhibit histone deacetylase activity. 
In the MDB-MA-21 cells the IC50 values ranged from 0.5 to 0.9 µM compared with 3.6 µM for 
SAHA alone. The most active was derivative was the ferrocenyl PSA derivative. The ferrocenyl 
derivatives were shown to have a greater activity than the purely organic tamoxifen 
derivatives or the suberamides alone.   
In the MCF-7 cell line values ranged from 0.87 µM for the ferrocenophanic SAHA 67a to 2.0 
µM, however SAHA alone was quite active with a value of 1 µM. Still these represent the 
most active derivatives synthesised by the group to date. OPOA derivatives were prepared 
but had low activity.  
Phenolic derivatives analogous to hydroxytamoxifen were also synthesised 68112. These were 
found to have IC50 values ranging from 1.3 to 4.5 µM in MDA-MB-231 cells and 1.5 to 6.6 µM 
in MCF-7 cells. Compared to organic derivatives with a phenol ring the ferrocenyl derivatives 
were again shown to be more active illustrating that the organometallic derivative 
contributed to the activity. The OPOA derivatives in this instance were found to be more 
active with the phenolic group.  
 
 
1.2.2.2.4 Ferrocenyl peptide conjugates  
N-ferrocenoyl derivatives were prepared by Sheehy et al113. The ferrocenoyl moiety was 
coupled directly to amino acid esters with an initial goal of exploring the potential of 
ferrocenyl peptide conjugates as novel sensor compounds, peptide mimetics or unnatural 
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drugs114.  A benzene ring was added as a conjugated linker and N-para115, ortho116 and 
meta117-ferrocenyl benzoyl amino acid esters were synthesised, also initially as potential 
anion sensing agents, however an in vitro screen showed some cytotoxicity. The N-ortho 
ferrocenyl benzoyl glycine ethyl ester was found to have an IC50 of 48 µM against H1299 lung 
cancer cells118. N-ortho119, meta120 and para121-ferrocenyl benzoyl dipeptide esters were 
synthesised and evaluated.  
The N-{ortho-(ferrocenyl)benzoyl}-glycine-L-alanine ethyl ester derivative 69 was found to 
have a strong antiproliferative effect in the H1299 cell line with an IC50 value of 5.3 µM. The 
meta and para had similar IC50 values of 4.0 and 6.6 µM respectively122. The dipeptide chain 
was subsequently extended to tripeptide and tetrapeptide chains, however, this led to a 
significant decrease in antiproliferative activity, showing that the dipeptide chain is required 
for activity123. 
 
Mooney et al. subsequently replaced the benzoyl linker with a naphthoyl linker, generating 
a series of N-(3-ferrocenyl-2-naphthoyl) dipeptide ethyl and N-(6-ferrocenyl-2-naphthoyl) 
dipeptide ethyl esters124. The N-ferrocenyl-naphthoyl derivatives were found to have IC50 
values in the H1299 cell line ranging from 7.8 µM to 1.3 µM all of which were more active 
than their benzoyl analogues. The most active of these was N-(6-ferrocenyl-2-naphthoyl)-
glycine-L-alanine ethyl ester with an IC50 value of 1.3 ± 0.1 µM which is lower than that of the 
clinically employed anticancer drug cisplatin (IC50 1.5 ± 0.1 µM in H1299 cells). 
Further work utilising the naphthoyl spacer involved the synthesis of N-
(ferrocenyl)naphthoyl amino acid esters. These were evaluated in both H1299 lung cancer 
cells and in Sk-Mel-28 malignant melanoma cell lines125. These compounds showed strong 
antiproliferative effects in the H1299 cells, while the Sk-Mel-28 cells were slightly more 
resistant. The most active of these compounds was found to be the N-(6-ferrocenyl-2-
naphthoyl)-γ-aminobutyric acid ethyl ester with an IC50 value of 0.62 ± 0.07 µM in the H1299 
cell line and 1.41 ± 0.04 µM in the Sk-Mel-28 cell line. 
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Further structure activity relationship studies on the N-(6-ferrocenyl-2-naphthoyl) dipeptide 
ethyl esters investigated the effect on antiproliferative effect of incorporating either α-amino 
acids with branched allyl or aromatic side chains into the dipeptide chain126. Thus a series of 
dipeptide analogues were prepared using either glycine or L-alanine as the first amino acid 
residue and glycine, L-alanine, L-leucine or L-phenylalanine as the second amino acid residue. 
The D-alanine analogue was also synthesised and found to be four times more active in the 
H1299 cell line that the L-alanine with an IC50 value of 0.33 ± 0.02 µM. The most active 
derivative however, was determined to be N-(6-ferrocenyl-2-naphthoy)-glycine-glycine ethyl 
ester 70 with an IC50 value of 1.10 ± 0.13 µM in the Sk-Mel-28 cell line and 0.13 ± 0.02 µM in 
the H1299 cell line, more than 10 times that of cisplatin.  
 
Given that the redox activity of ferrocene has been implicated in its mode of action, 
modification of the structure to generate compounds which could potentially lower the 
oxidation potential of the ferrocenyl moiety has been investigated. One potential route to 
compounds with a lower oxidation potential is the incorporation of an ethynyl spacer. It was 
shown that increasing conjugation by the introduction of a naphthalene moiety in place of a 
benzene increased activity. Thus a series of derivatives was prepared further extending the 
conjugation of the molecule with an ethynyl spacer placed between the redox active core 
and the naphthalene ring127. 
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 N-{6-(ferrocenyl) ethynyl-2-naphthoyl} amino acid and dipeptide ethyl esters were 
synthesised using GABA(OEt), Gly-Gly(OEt), Gly-Ala(OEt), Sar-Gly(OEt), Pro-Gly(OEt), Sar-
Ala(OEt) and Pro-Ala(OEt). Compounds were evaluated in H1299 NCSLC cells. They had IC50’s 
ranging from 3.2 µM - 7.2 µM. The oxidation potential was found to be higher than the N-(6-
ferrocenyl-2-naphthoyl) dipeptide derivatives but lower than the ferrocenyl dipeptide 
derivatives. The most active compound was N-{6-(ferrocenyl) ethynyl-2-naphthoyl}-
sarcosine alanine ethyl ester 71, which also had the lowest oxidation potential of the series, 
however the incorporation of an ethynyl spacer did not result in compounds with lower 
oxidation potentials or an increase in cytotoxicity. 
 
A series of 1-alkyl-1’-N-para-(ferrocenyl) benzoyl dipeptide esters were prepared by Harry et 
al128. It was believed that introduction of an alkyl group could further lower the oxidation 
potential of the ferrocene moiety and thus improve cytotoxicity. The cyclopentadienyl ring 
was substituted with methyl, ethyl and propyl chains while dipeptides Gly-L-Ala(OEt), Gly-L-
Leu(OEt) and Gly-L-Phe(OEt) were used. It was found that as expected the oxidation potential 
for the compounds was significantly lower than the unsubstituted compounds and 
compounds bearing no aromatic moiety. Compounds were tested in H1299 NSCLC cell lines. 
IC50 values of 4.5 µM to 6.6 µM were obtained. It was also noted that Gly-L-Ala derivatives 
were more active than the Gly-L-Leu derivatives which in turn were more active than the Gly-
L-Phe derivatives; showing that chiral side chains with bulky groups decrease the activity of 
the compounds. It was found that activity decreased with increasing alkyl chain length, 
however both methyl and ethyl side chains were more active than the unsubstituted 
compounds. The 1-methyl-1’-N-para-(ferrocenyl) benzoyl glycine-L-alanine ethyl ester was 
found to be most active. 
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1-Alkyl-1’-N-meta-(ferrocenyl) benzoyl dipeptide esters and 1-alkyl-1’-N-ortho-(ferrocenyl) 
benzoyl dipeptide esters were also prepared using Gly-Gly(OEt) as well at the Gly-L-Ala(OEt), 
Gly-L-Leu(OEt) and Gly-L-Phe(OEt) used previously coupled to methyl, ethyl and propyl 
ferrocenyl benzoic acids129. All compounds were screened at 10 µM in H1299 cells. The 1-
alkyl-1’-N-ortho-(ferrocenyl) benzoyl dipeptide esters displayed poor growth inhibition 
ranging from 14-48 % and were not further evaluated. The previously synthesised N-{ortho-
(ferrocenyl) benzoyl}-glycine-L-alanine ethyl ester 69 bearing an unsubstituted 
cyclopentadieneyl ring had and IC50 of 5.3 µM. This shows a significant decrease in 
cytotoxicity for the ortho derivatives on alkylation of the cyclopentadienyl ring. The most 
active compounds were the N-{meta-(ferrocenyl) benzoyl}-glycine-glycine ethyl ester and N-
{meta-(ferrocenyl) benzoyl}-glycine-L-alanine ethyl ester derivates with 70 % or higher 
growth inhibition. Similarly to the 1-alkyl-1’-N-{para-(ferrocenyl) benzoyl} dipeptides it was 
found that cytotoxicity decreases with increasing alkyl chain length and increasing peptide 
side chain size. The 1-methyl-1’-N-{meta-(ferrocenyl) benzoyl}-glycine-L-alanine ethyl ester 
had an IC50 of 6.7 µM compared with 4.0 µM for the unsubstituted cyclopentadieneyl ring 
derivative. Thus cytotoxicity is decreased for ortho and meta derivatives bearing an alkyl 
group on the ferrocene. The most active derivative was 1-methyl-1’-N-{meta-(ferrocenyl) 
benzoyl}-glycine-glycine ethyl ester 72 with an IC50 of 2.6 µM. 
A series of N-(ferrocenylmethyl)fluorobenzene carboxamide derivatives 73 were prepared 
by Kelly et al130. These were shown to have an antiproliferative effect on MDA-MB-435-S-F 
breast cancer cells with the most active 4-fluoro derivative having an IC50 value of 11-14 µM.  
 
X = H, 2F, 3F, 4F, 2 and 6F, 2,3,4,5 and 6F. 
Continuing this work Butler et al. prepared a series of N-(ferrocenylmethyl amino acid) 
fluorinated benzene-carboxamide derivatives using glycine 74 and L-alanine 75 linkers131. 
The compounds were evaluated in MCF-7 cells. The most active compound N-
(ferrocenylmethyl-L-alanine)-3,4,5-triﬂuorobenzene-carboxamide had an IC50 value of 2.84 
µM compared to a value of 16.3 for cisplatin in this cell line. Guanine oxidation studies carried 
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out on this derivative showed that this class of compounds is capable of generating oxidative 
DNA damage via a reactive oxygenated species mediated mechanism. 
 
 
 Conclusion 
Cancer is a disease which may affect any of the organs of the body. It is a major cause of 
death worldwide. Cancer and chemotherapy represent an extensively studied area in the 
fields of both chemistry and biology with the treatment of cancer costing millions each year. 
 The field of organometallic chemistry offers a diverse range of potential compounds which 
can be incorporated into unnatural drugs for the treatment of cancer. Transition metal 
compounds in particular offer a number of different potential bonding modes and oxidation 
states which lend unusual properties to potential drug candidates. To this effect ruthenium, 
titanium, iron, platinum, zinc, vanadium and molybdenum complexes among others have 
been studied extensively.  
Ferrocene complexes in particular have been extensively studied. Ferrocene is nontoxic and 
stable and its ease of derivatisation and redox activity made it an ideal candidate for 
incorporation as a potential chemotherapeutic drug candidate. Ferrocene has been shown 
to undergo oxidation to the ferricenium ion and to generate ROS at biological potentials, 
while ferricenium salts have been shown to have antitumour activity. ROS can potentially 
generate DNA damage and cell death through increased oxidative stress within the cell. 
The incorporation of ferrocene into drug molecules has been used as a strategy in antiviral, 
antibacterial and antifungal compounds among others. It has been seen to increase the 
activity of many potential drug compounds, particularly in the case of the organometallic 
tamoxifen analogues, the ferrocifens, against breast cancer. Ferrocene based compounds 
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which have been used in a clinical setting include the antimalarial ferroquine which made it 
to phase II clinical trials and ferrocerone which was used in the former USSR for the 
treatment of iron deficient anaemia. 
A strong body of evidence has accumulated from recent work within this group to indicate 
that ferrocenyl peptide conjugates may be strong candidates as potential anticancer agents.  
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Chapter 2 
Synthesis and structural characterisation of N-(6-ferrocenyl-2-naphthoyl), N-
{para-(ferrocenyl)cinnamoyl} and N-{para-(ferrocenyl)benzoyl} amino acid and 
dipeptide derivatives. 
2.1 Introduction  
Although any compound containing both an amino group and a carboxylic acid may 
be termed an amino acid, the term is most often used to refer to an α-amino acid in 
which the amine and the carboxylic acid groups are attached to the same carbon 
atom. There are 20 standard amino acids which are found in proteins, nine of which 
are essential meaning that they cannot be synthesised in the body and must be taken 
in through the diet. In addition to the standard amino acids there are other amino 
acids which have biologically important roles such as ƴ-aminobutyric acid (GABA) 
which acts a neurotransmitter. Amino acids are often used in medicinal chemistry as 
they offer a wide range of shapes, different charges and have side chains which may 
form hydrogen bond interactions. 
L-amino acids are the predominant stereoisomer found in nature however D-amino 
acids are also found1. D-amino acids such as D-alanine and D-glutamic acid are found 
principally in the peptidoglycan cell wall of bacteria. In humans they have specific 
roles. D-aspartate plays a regulatory role in adult neurogenesis while D-serine acts as 
a co-agonist of N-methyl-D-aspartate type glutamate receptors in the brain, which 
are involved in learning, memory and behaviour in mammals.  Some peptides contain 
D-amino acids. D-configured amino acid residues in peptides provide resistance to 
proteases, which generally exhibit specificity for the L-isomers. 
The incorporation of amino acids in drug design is a common strategy in medicinal 
chemistry. Amino acid prodrugs may be made for drug delivery to take advantage of 
amino acid transporters within the body2.  
Such transporters largely consist of the solute carrier (SLC) family of transporters of 
which there are over 370 members3. These transporters have a huge variety of 
functions within the cell and are responsible for the transport of neurotransmitters, 
nutrients, lipid derivatives, nucleotides and nucleosides, cations and anions as well 
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as amino acids and short peptides. 59 functional amino acid transportors have been 
identified in 12 different SLC subfamilies4. The SLC36 family have been shown to 
transport small, unbranched, zwitterionic α, β and ƴ amino acids. 
L-type amino acid transporters 1 (LAT1) and 2 (LAT2) are a subfamily of SCL7 and SCL3 
heterodimeric amino acid transporters5. They transport large neutral amino acids 
from the extracellular fluid into the cell and are expressed in various tissues including 
the intestinal wall, the blood brain barrier and the kidneys. Only a few drugs are 
substrates of these transporters, including levodopa and melphalan.  
Two peptide transporters 1 (PEPT1) SLC15A1 and 2 (PEPT2) SLC15A2 have been 
identified in mammals6. The physiological substrates of these transporters are 
dipeptides and tripeptides composed of the 20 protinogenic L-α-amino acids. They 
have been shown to be responsible for the transport of angiotensin converting 
enzyme (ACE) inhibitiors such as Lisinopril. 
This is a strategy often used to increase a drugs bioavailability. Compounds currently 
on the market which contain amino acids in order to increase uptake by use of 
transport proteins include the antihypertensive agents Lisinopril and Valsartan and 
the DNA alkylating agent Mephalan. Lisinopril is a lysine derivative of enalapril and is 
transported by transport proteins for dipeptides. Valsartan is an angiotensin II 
receptor agonist. Mephalan is a nitrogen mustard alkylating agent. It is a 
phenylalanine derivative of chlormethine 1. 
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Figure 2.1: Structures of currently used drugs containing amino acids. 
 Similarly the Levadopa is a prodrug for the neurotransmitter dopamine. It is used in the 
treatment of Parkinson’s disease, a condition caused by a deficiency of the neurotransmitter 
in the brain. Dopamine is too polar to cross the blood brain barrier. Levadopa is even more 
polar, however it is an amino acid and thus is recognised by the amino acid transporters and 
carried across the cell membrane7. It is transported by the phenylalanine transporter. 
Organometallic compounds offer a wide range of potential structures and bonding modes, 
making them an ideal starting point for the synthesis of potential drug compounds. The use 
of metals in medicine can be traced back over 5000 years7. The first important 
organometallic drug was salvarsan which was an arsenic based compound discovered in 1908 
and used to treat syphilis8. The discovery of cisplatin’s anticancer activity in 1965 was a major 
breakthrough for metal based drugs9. Today it is estimated that platinum based coordination 
complexes are used in 50-70 % of chemotherapeutic schedules used to treat cancer 
patients8. 
Ferrocene is an attractive motif for use in medicinal chemistry because it is stable and non-
toxic, it is aromatic and easily undergoes derivitisation. Ferrocene has been shown to have 
anti-tumour, antiinfective, antiviral10 and antifungal11 activity as well as anticancer activity. 
The first organometallic bioconjugates of ferrocene were reported in 195712. Schlӧgl et al. 
reported the synthesis and characterisation of ferrocenylalanine and para-ferrocenyl 
phenylalanine as well as the first N-ferrocenyl methyl amino acid. Ferrocene itself is not 
cytotoxic, however many of its derivatives including ferrocenium species have been shown 
to be. Their ability to produce reactive oxygen species (ROS) which are capable of damaging 
DNA and other biomolecules is thought to be important to their mode of action. Jaouen et 
al. have prepared the most successful series of ferrocene based anticancer drug candidates, 
which selectively target hormone dependant tumours such as breast cancer13. 
Thus the preparation of ferrocenyl peptide conjugates offers an attractive method to target 
cancer cells. Recent research within this group has proved this to be an effective strategy for 
the generation of cytotoxic agents.  Mooney et al. identified 5 lead compounds that had an 
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excellent anti-proliferative activity against the H1299 NSCLC and Sk-Mel-28 metastatic 
melanoma cell line14. Compounds 70 and 76-79 all showed activity greater than that of 
cisplatin, with four of the compounds having an activity in the nanomolar (nm) range in the 
H1299 cell line (table 2.1).  
Table 2.1: IC50 values for the most active compounds in the N-(6-ferrocenyl-2-
naphthoyl) series. 
Compound  H1299 (μM) Sk-Mel-28 
(μM) 
22 Cisplatin  1.50 ± 0.10 - 
70 N-(6-ferrocenyl-2-naphthoyl)-glycine-glycine-OEt 0.13 ± 0.02 1.10 ± 0.13 
76 N-(6-ferrocenyl-2-naphthoyl)-sarcosine-glycine-OEt 0.14 ± 0.02 1.06 ± 0.05 
77 N-(6-ferrocenyl-2-naphthoyl)-γ-aminobutryic acid-OEt 0.62 ± 0.07 1.41 ± 0.04 
78 N-(6-ferrocenyl-2-naphthoyl)-glycine-L-alanine-OEt 1.30 ± 0.10 3.74 ± 0.37 
79 N-(6-ferrocenyl-2-naphthoyl)-glycine-D-alanine-OEt 0.33 ± 0.02 1.83 ± 0.04 
 
The objective of this research was to further extend the SAR study of these molecules. Four 
key areas have been identified for modification of these compounds (figure 2.2). These are 
1; the electroactive ferrocene core, 2; the conjugated linker, 3; the dipeptide chain and 4; 
the ester protecting group.  
 
Figure 2.2: SAR regions of N-(6-ferrocenyl-2-naphthoyl)-glycine-glycine ethyl ester. 
The first region for consideration is the ferrocene core of the molecule. The redox active 
ferrocene core has been shown to be required for activity. Mooney et al. prepared a 2-
naphthoyl-glycine-glycine ethyl ester 80 analogue of the N-(6-ferrocenyl-2-naphthoyl)-
glycine-glycine ethyl ester 70. The non-organometallic analogue was tested alongside the 
other dipeptide esters. It did not show any inhibitory effect against either H1299 lung cancer 
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or Sk-Mel-28 melanoma cell lines when tested at 1 µM. Percentage cell growth was 87.6 ± 
18.4 and 95.6 ± 10.9 for H1299 cells and Sk-Mel-28 cells respectively. 
 
Replacement of the electroactive core by an alternative metallocene is another plausible 
strategy. The most common approach is the substitution of ferrocene by ruthenocene. 
Ruthenium undergoes electrochemical oxidation more readily than ferrocene and a low 
oxidation potential is believed to be necessary for antiproliferative activity. However the 
oxidation of rutheneocene has been reported as both a one electron and a two electron 
irreversible oxidation process15. Pigeon et al. prepared ruthenocene analogues of the 
organometallic tamoxifen derivatives. However a loss of activity in the ER (-) breast cancer 
cell line was reported on replacement of the ferrocene with ruthenocene16. As the reversible 
redox properties displayed by the N-(6-ferrocenyl-2-naphthoyl) and N-{para-
(ferrocenyl)benzoyl} amino acid and dipeptide derivatives are thought to have an important 
role in the mode of action of these compounds it is unlikely that ruthenocenyl analogues 
would have the same biological activity. 
The second region for modification is the conjugated linker.  Corry et al. prepared N-ortho, 
meta and para ferrocenyl benzoyl amino acid and dipeptide derivatives, the most active of 
which, N-{ortho-(ferrocenyl)benzoyl} glycine-L-alanine ethyl ester 69 had an IC50 of  4.0 µM 
in H1299 cells17. Mooney et al. replaced benzoyl linker with a naphthoyl linker. The 
conjugating ability of the linker is thought to be important in decreasing the redox potential 
of these compounds. Thus increasing the conjugation of the ring system seemed a logical 
approach. Both N-(3-ferrocenyl-2-naphthoyl) and N-(6-ferrocenyl-2-naphthoyl) derivatives 
were prepared. The N-(6-ferrocenyl-2-naphthoyl) derivatives were significantly more active 
with the N-(6-ferrocenyl-2-naphthoyl)-glycine-L-alanine ethyl ester 78 having an IC50 of 1.3 
µM14. This is three times more active than the N-{ortho-(ferrocenyl)benzoyl}-glycine-L-
alanine ethyl ester 69.  
There are many possible further modifications to the conjugated liker available, and many 
conjugated aromatic systems available which could be used to replace the benzoyl linker. 
The use of a cinnamoyl linker is an interesting strategy as it also offers a more conjugated 
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system than the benzoyl linker but without having a fully fused ring system as in the case of 
the naphthoyl linker (figure 2.3). This modification may increase the flexibility of the 
molecule. It is an interesting modification for the SAR study as it may help to determine 
whether the fully fused ring is essential for activity.  
                                                                                                                                                                                                                                                                                                                                                                                           
Figure 2.3: Variations of the conjugated linker.  
The peptide region of the compounds has been extensively studied18.  It has been shown that 
an amino acid or dipeptide is essential for the cytotoxic activity of the molecule. Methyl-6-
ferrocenylnaphthalene-2-carboxylate 82 was tested against H1299 and Sk-Mel-28 cell lines 
and displayed no activity19. Tripeptide and tetrapeptide chains have been synthesised, 
however this led to a decrease in activity. Dipeptide derivatives have proved most successful 
when small neutral α-amino acids have been incorporated into the chain. The most active of 
the N-(6-ferrocenyl-2-naphthoyl) amino acid and dipeptide esters are given in table 2.1. The 
amino acid and dipeptide chain configurations from table 2.1 have been maintained in the 
current study. 
The final moiety of the compounds which can be modified is the ester protecting group. To 
date this area of the compound has not been modified. The simplest alteration to this region 
of the molecule is to prepare a series of esters of differing sizes to investigate if ester chain 
length exerts an influence on the cytotoxicity of the molecule.  
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2.2 The synthesis of N-(6-ferrocenyl-2-naphthoyl), N-{para(ferrocenyl)cinnamoyl} 
and N-{para-(ferrocenyl)benzoyl} amino acid and dipeptide derivatives. 
 
The N-(6-ferrocenyl-2-naphthoyl), N-{para-(ferrocenyl)cinnamoyl} and N-{para-
(ferrocenyl)benzoyl} amino acid and dipeptide derivatives were prepared via standard 
peptide coupling methods using N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide 
hydrochloride (EDC) and N-hydroxysuccinamide (NHS). A solution of the appropriate 
ferrocenyl carboxylic acid ester in dichloromethane at 0 °C, was treated with EDC, NHS and 
triethylamine (Et3N) and allowed to stir for an hour. An equimolar amount of the 
corresponding amino acid or dipeptide was then added to the solution with stirring. Scheme 
2.1 outlines the synthetic route for the N-(6-ferrocenyl-2-naphthoyl) amino acid and 
dipeptide derivatives. N-para-(ferrocenyl)cinnamoyl (scheme 2.2) and N-{para-
(ferrocenyl)benzoyl} derivatives (scheme 2.3) and were prepared following the same 
strategy. 
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(i) NaNO2, HCl, 5° C; (ii) NaOH/MeOH, H2O; (iii) EDC, NHS, Et3N, amino acid/dipeptide (iv) 
NaOH/MeOH, H2O. 
Scheme 2.1: General reaction scheme for the synthesis of N-(6-ferrocenyl-2-
naphthoyl) amino acid and dipeptide derivatives. 
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(i) NaNO2, HCl, 5° C; (ii) NaOH/MeOH, H2O; (iii) EDC, NHS, Et3N, amino acid/dipeptide. 
Scheme 2.2: General reaction scheme for the synthesis of N-{para-
(ferrocenyl)cinnamoyl} amino acid and dipeptide ethyl esters. 
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(i) NaNO2, HCl, 5 °C; (ii) NaOH/MeOH, H2O; (iii) EDC, NHS, Et3N, amino acid/dipeptide (iv) 
NaOH/MeOH, H2O. 
Scheme 2.3: General reaction scheme for the synthesis of N-{para-
(ferrocenyl)benzoyl} dipeptide derivatives. 
 
2.2.1.1 Preparation of ferrocenyl carboxylates 
The appropriate naphthoyl, cinnamoyl or benzoyl carboxylate ester was treated with sodium 
nitrite in the presence of hydrochloric acid at a temperature below 5 °C to yield the 
diazonium salt (scheme 2.4). Above 5 °C the diazonium salt decomposes resulting in the 
formation of an aryl carbocation and the evolution of N2 gas. Ferrocene present in situ reacts 
with the aryl carbocation via electrophillic aromatic substitution to give the ferrocenyl 
carboxylate ester as an orange solid.  
59 
 
Na+ -O
N
O
H+
HO
N
O
H+
H2O
+
N
O
H2O
N O+
NH2 N O
+ N+
N
H
H
O H+
N+
N
OH
H
H+N+
N
OH2
+
H
N
+
N
Cl-
H3CO2C H3CO2C
H3CO2C H3CO2C
H3CO2C
 
Scheme 2.4: Diazonium salt formation. 
2.2.1.2 Preparation of ferrocenylnaphthalene-2-carboxylic acid. 
Hydrolysis of the ferrocenyl carboxylate ester in 10 % sodium hydroxide removes the ester 
group to produce ferrocenyl carboxylate. 
2.2.1.3 Preparation of dipeptides 
Dipeptides were prepared by EDC coupling of the N-terminus of one amino acid with the C-
terminus of the other. In order to achieve regiospecific coupling it was necessary to protect 
the C-terminus of the amino acids or dipeptides prior to condensation with the ferrocenyl 
carboxylic acid.  The most common method of protection is esterification. This increases the 
compounds solubility in organic solvent, ensures that an amide bond rather than an 
anhydride is formed and that only mono addition products are formed. 
The conversion of the carboxylic acid to the ester was achieved by treatment of the amino 
acid or dipeptide with thionyl chloride in the presence of the appropriate alcohol to give the 
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ester hydrochloride salt (scheme 2.5). The hydrochloride salt may be neutralised to give the 
corresponding free base, however, these decompose rapidly at room temperature. They are 
therefore generated as required in situ by neutralisation with triethylamine (Et3N). 
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Scheme 2.5: Ester formation using thionyl chloride and methanol. 
 
2.2.1.4 Amide bond formation  
Carboxylic acids are capable of reacting with amines to form an amide bond, however 
elevated temperatures are required in the range of 160-180 °C. These temperatures are 
detrimental to complex peptides. As a result peptide synthesis is usually performed at or 
below room temperature and either the amino group or the carboxylic acid is activated. A 
practical method of activating the amino group has not been found. Electron donating groups 
should increase the nucleophilicity of the nitrogen, however it has been found that this also 
decreases the rate of acylation. Therefore activation of the carboxyl group remains the 
method used in peptide bond formation. It is required that the carboxylic acid is activated 
since carboxylic acids form salts with amines at room temperature under normal conditions. 
The sensitivity of the carbonyl towards nucleophilic attack is reduced by the hydroxyl group 
particularly if the nucleophile is sufficiently basic to form a carboxylate anion.  Therefore the 
-OH group of the acid must be converted into a good leaving group before treatment with 
the amine. This is typically achieved using peptide coupling reagents. 
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2.2.1.4.1 Acyl chlorides 
The simplest way of creating an amide bond is by converting the carboxylic acid to an acyl 
chloride before coupling. The acyl chloride is reacted with the desired amine. Acyl chlorides 
are formed using reagents such as thionyl chloride (SOCl2), oxalyl chloride (COCl)2, 
phosphorus trichloride (PCl3), phosphorus oxychloride (POCl3) and phosphorus pentachloride 
(PCl5). Additional base is usually required to trap the HCl generated and avoid conversion of 
the amine to the unreactive HCl salt. Couplings are normally preformed in dry solvents in the 
presence of a non-nucleophilic tertiary amine such as Et3N. Acyl chlorides have limited value 
in peptide coupling because of the danger of hydrolysis, racemisation and cleavage of 
protecting groups. The tendency of acyl chlorides to racemise under basic conditions can be 
illustrated by the standard synthesis of ketenes (scheme 2.6). Ketenes are formed by reacting 
the α-proton of an acyl chloride with Et3N. The ketene can then react with an amine to yield 
the corresponding addition product with a loss of chirality.  
 
Scheme 2.6: Potential racemisation via ketene formation. 
2.2.1.4.2 Anhydrides 
Symmetrical and mixed anhydrides have been used in amide bond formation. The desired 
anhydride is usually prepared beforehand. This is usually achieved by heating the acid or 
reacting two equivalents of the acid with one equivalent of a reagent such as 1,3-
dicyclohexylcarbodiimide (DCC) to prepare a symmetrical anhydride (scheme 2.7). The 
driving force of the reaction is the formation of a urea by product.  The anhydride is then 
reacted with the selected amine.  In theory no base is required as a carboxylate anion is 
generated in situ. The main limitation is that only half of the acid is effectively coupled with 
the second half wasted. 
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Scheme 2.7: Formation of a symmetrical anhydride. 
To overcome the problem of waste, mixed anhydride methods have been developed where 
the second molecule of acid is cheap and easy to couple to the carboxyl moiety. However 
difficulty can occur in mixed carboxylic anhydrides getting regioselectivity of nucleophilic 
addition. Mixed pivalic anhydrides will give the desired aminolytic selectivity due to the 
presence of the bulky tert-butyl group (scheme 2.8)20. 
 
Scheme 2.8: Coupling via mixed pivalic anhydride. 
Mixed carbonic anhydrides give excellent selectivity (scheme 2.9). The carbonate 
electrophilic centre is more reactive than the carboxylic site as it is less stabilised by 
resonance. 
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Scheme 2.9: Coupling via mixed carbonic anhydrides. 
2.2.1.4.3 Carbodiimides 
Carbodiimides are used to activate carboxylic acids towards nucleophilic attack. In 1955 
Sheehan and Hess proposed DCC as a peptide bond forming reagent21. Activation occurs 
through addition to an N=C double bond in the diimide.  Commonly used carbodiimides 
include 1,3-dicyclohexylcarbodiimide (DCC), N, N-diisopropylcarbodiimide (DIC), N-(3-
dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (EDC) The first step of peptide 
coupling involves addition of the carboxylic acid to the carbodiimide to give an O-acylisourea 
intermediate. 
There are several disadvantages to the use of carbodiimides as coupling reagents for amide 
bond formation. The N, N’-dicyclohexylurea by-product is insoluble in most organic solvents, 
however it is not entirely insoluble especially in the presence of other dissolved materials. It 
therefore frequently contaminates the product of coupling. This can be avoided by the use 
of water soluble carbodiimides. The salts of the urea derivatives may be removed by 
extraction with water.  
Of the 20 amino acids constituent of proteins only alanine and leucine are immune to side 
chain reactions, though not racemisation. A common cause of these side reactions is the 
presence of tertiary bases present in the reaction mixture during activation and coupling. 
These can be somewhat reduced by the avoidance of tertiary bases and the use of 
unprotected amines, as well as amine salts. 
2.2.1.4.3.1 Racemisation. 
Racemisation is an almost exclusively base induced side reaction and is usually only a 
problem at activation and coupling. Deprotonation can occur at the α-carbon of an α-amino 
acid. This results in a carbanion intermediate which may reprotonate on either side (scheme 
2.10). 
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Scheme 2.10: Racemisation by proton abstraction 
Racemisation may also occur through oxazolone formation. Activated acyl amino acids and 
peptides will cyclise under the influence of base to give oxazolones (scheme 2.11). The 
oxazolones are themselves activated towards aminolysis and will lead to peptide formation, 
however, racemisation can occur via the stabilised carbanion. 
 
Scheme 2.11: Racemisation via acyl chlorides. 
2.2.1.4.3.2 Intramolecular acyl transfer. 
Carbodiimides may also be subject to several side reactions which can limit product yield and 
interfere with product purification. Intramolecular rearrangement of the O-acylisourea 
derivative is a possible side reaction with the use of carbodiimides (scheme 2.12). Attack of 
the nearby nucleophile on the activated carbon can result in an O to N shift giving an N-
acylurea as a by-product22.   
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Scheme 2.12: Acyl transfer from O-acylisourea to N-acylurea. 
This is undesirable not only because it results in a loss of the desired product but separation 
of these from the desired product may be difficult. Use of DCC may also be accompanied by 
racemisation at the carboxyl terminal residue. 
 
2.2.1.4.3.3 Auxilary Nucleophiles 
Some of the shortcomings of DCC can be overcome by the use of additives. 1-
hydroxybenzatriazole (HOBt), N-hydroxysuccinimide (NHS) and 3-hydroxy-3,4-dihydro-1,2,3-
benzotriazin-4-one (HOObt) are some of the most frequently used. These were initially 
introduced to reduce the racemisation of the peptides. These act as a secondary nucleophile 
and accelerate the reaction and convert overactive intermediates of the reaction to less 
reactive esters of HOBt or NHS (scheme 2.13).  
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Scheme 2.13: Peptide coupling using EDC and NHS. 
 
2.2.2 Purification and yields of N-(6-ferrocenyl-2-naphthoyl), N-{para-
(ferrocenyl)cinnamoyl} and N-{para-(ferrocenyl)benzoyl} amino acid and dipeptide 
derivatives. 
The N-(6-ferrocenyl-2-naphthoyl), N-{para-(ferrocenyl)cinnamoyl} and N-{para-
(ferrocenyl)benzoyl} amino acid and dipeptide derivatives were prepared by standard 
peptide coupling conditions. The corresponding carboxylic acid was coupled with the N-
terminal of the Boc protected dipeptide. The crude product was purified by column 
chromatography using ethyl acetate and hexane as an eluent.  The purified compounds were 
obtained as orange or red solids with yields ranging from 15 % to 96 %. All compounds gave 
spectroscopic and analytical data in accordance with their proposed structures. 
Yields obtained for the N-(6-ferrocenyl-2-naphthoyl)-glycine-glycine esters were generally 
better than those obtained for the N-{para-(ferrocenyl)benzoyl}-glycine-glycine esters. The 
N-{para(ferrocenyl)cinnamoyl} dipeptide esters showed the lowest yields overall. Given that 
none of the substituents are closely positioned around the conjugated linker and that the 
amino acid chains do not possess any bulky side groups this is unlikely to be due to steric 
effects as has been noted in the case of N-ortho and meta (ferrocenyl)benzoyl dipeptide 
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esters23 and N-(3-ferrocenyl-2-naphthoyl) dipeptide esters24. Yields are typically low for 
secondary amino acids such as sarcosine which has been attributed to the spontaneous 
formation of diketopiperazine on removal of the Boc group. 
Yields for the free carboxylic acid compounds were generally higher than the esters as a 
simple hydrolysis of the ester followed by filtration resulted in the final compound without 
need for further purification. 
Table 2.2: Percentage yields for N-(6-ferrocenyl-2-naphthoyl) amino acid and 
dipeptide derivatives. 
Compound  Number %Yield 
N-(6-ferrocenyl-2-naphthoyl)-Gly-Gly-OMe 100 51 % 
N-(6-ferrocenyl-2-naphthoyl)-Gly-Gly-OPr 101 55 % 
N-(6-ferrocenyl-2-naphthoyl)-Gly-Gly-OBu 102 78 % 
N-(6-ferrocenyl-2-naphthoyl)-Gly-Gly-OBn 103 66 % 
N-(6-ferrocenyl-2-naphthoyl)-Sar-Gly-OMe 104 20 % 
N-(6-ferrocenyl-2-naphthoyl)-GABA-OMe 105 50 % 
N-(6-ferrocenyl-2-naphthoyl)-Gly-L-Ala-OMe 106 26 % 
N-(6-ferrocenyl-2-naphthoyl)-Gly-D-Ala-OMe 107 47 % 
N-(6-ferrocenyl-2-naphthoyl)-Gly-Gly-OH 108 59 % 
N-(6-ferrocenyl-2-naphthoyl)-Sar-Gly-OH 109 72 % 
N-(6-ferrocenyl-2-naphthoyl)-GABA-OH 110 90 % 
N-(6-ferrocenyl-2-naphthoyl)-Gly-L-Ala-OH 111 95 % 
N-(6-ferrocenyl-2-naphthoyl)-Gly-D-Ala-OH 112 96 % 
 
Table 2.3: Percentage yields for N-{para-(ferrocenyl)cinnamoyl} and N-{para-
(ferrocenyl)benzoyl} amino acid and dipeptide deivatives. 
Compound  Number % Yield 
N-{para-(ferrocenyl)cinnamoyl}-Gly-Gly-OEt 113 46 % 
N-{para-(ferrocenyl)cinnamoyl}-Sar-Gly-OEt 114 16 % 
N-{para-(ferrocenyl)cinnamoyl}-GABA-OEt 115 46 % 
N-{para-(ferrocenyl)cinnamoyl}-Gly-L-Ala-OEt 116 36 % 
N-{para-(ferrocenyl)cinnamoyl}-Gly-D-Ala-OEt 117 18 % 
N-{para-(ferrocenyl)benzoyl}-Gly-Gly-OH 118 92 % 
N-{para-(ferrocenyl)benzoyl}-Gly-Gly-OMe 119 15 % 
N-{para-(ferrocenyl)benzoyl}-Gly-Gly-OEt 120 82 % 
N-{para-(ferrocenyl)benzoyl}-Gly-Gly-OPr 121 60 % 
N-{para-(ferrocenyl)benzoyl}-Gly-Gly-OBu 122 46 % 
N-{para-(ferrocenyl)benzoyl}-Gly-Gly-OBn 123 24 % 
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2.2.3 1H NMR studies of N-(6-ferrocenyl-2-naphthoyl), N-{para-
(ferrocenyl)cinnamoyl} and N-{para-(ferrocenyl)benzoyl} amino acid and dipeptide 
derivatives. 
All of the 1H NMR experiments were carried out in DMSO-d6 as the compounds showed 
limited solubility in other deuterated solvents. The amide protons appear downfield in the 
range δ 8.06-8.96. The appearance of these signals in the lowfield region is due to hydrogen 
bonding between the S=O group of the DMSO and the proton of the amide. In CDCl3 amide 
protons typically appear further upfield. 
In the N-(6-ferrocenyl-2-naphthoyl) amino acid and dipeptide derivatives the aromatic region 
shows a singlet, singlet, multiplet doublet doublet splitting pattern, integrating for one, one, 
three and one protons respectively. In the N-{para-(ferrocenyl)cinnamoyl} amino acid and 
dipeptide derivatives the aromatic region shows the characteristic para disubstituted 
splitting pattern of two apparent doublets integrating for two protons each. The trans 
olefinic protons appear as two doublets each integrating for 2 protons in the range δ 6.5-7.5 
with coupling constants of 16 Hz. Similarly in the N-{para-(ferrocenyl)benzoyl} amino acid 
and dipeptide deivatives the aromatic region shows the characteristic para disubstituted 
splitting pattern of two apparent doublets. 
The aromatic peaks of the ferrocene appear upfield of the aromatic region. The protons of 
ferrocene experience more shielding than the protons of benzene as ferrocene is more 
electron dense. The ferrocenyl region of N-(6-ferrocenyl-2-naphthoyl), N-{para-
(ferrocenyl)cinnamoyl} and N-{para-(ferrocenyl)benzoyl} amino acid and dipeptide 
derivatives are relatively similar and confirm the presence of a monosubstituted ferrocene 
ring. In the N-(6-ferrocenyl-2-naphthoyl) derivatives the ortho protons appear as a fine triplet 
or singlet in the range δ 4.96-5.03. The meta protons typically appear as a fine triplet or 
singlet from δ 4.45-4.46 and the unsubstituted (η5-C5H5) protons appear as a singlet at δ 4.04 
- 4.05. In the N-{para-(ferrocenyl)cinnamoyl} derivatives  the signals are slightly further 
upfield. The ortho protons appear at δ 4.90, the meta at δ 4.39-4.45 and the (η5-C5H5) protons 
appear at δ 4.02-4.09. For the N-{para-(ferrocenyl)benzoyl} derivatives the ortho protons 
typically appear as a fine triplet or singlet from δ 4.45-4.46, the meta from δ 4.41-4.42 and 
the (η5-C5H5) protons from δ 4.02-4.09. 
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Table 2.4: Selected 1H NMR spectral data (δ, DMSO-d6) for N-(6-ferrocenyl-2-
naphthoyl), N-{para-(ferrocenyl)cinnamoyl} and N-{para-(ferrocenyl)benzoyl} amino 
acid and dipeptide derivatives. 
       
Compound NH’s N(CH3) αH ortho 
η5(C5H4) 
meta 
η5(C5H4) 
η5(C5H5) 
100 8.42, 8.95 - - 4.97 4.46 4.05 
101 8.40, 8.95 - - 4.96 4.45 4.05 
102 8.39, 8.95 - - 4.97 4.46 4.05 
103 8.06, 8.96 - - 4.96 4.45 4.05 
104 8.59 & 8.51  3.02 - 5.03 4.95 4.04 
105 8.66 - - 4.96 4.45 4.05 
106 8.85, 8.45 - 4.34 4.97 4.46 4.05 
107 8.85, 8.46 - 4.34 4.97 4.46 4.05 
108 8.96, 8.46 - - 4.96 4.45 4.05 
109 8.66 & 8.57 3.01 - 4.97 4.46 4.05 
110 8.66 - - 4.96 4.45 4.04 
111 8.30, 8.85 - 4.26 4.97 4.45 4.04 
112 8.27, 8.90 - 4.23 4.98 4.45 4.05 
113 8.36 - 8.42 - - 4.85 4.40 4.03 
114 8.58 & 8.37 3.20 & 2.93 - 4.87 4.40 4.08 
115 8.12 - - 4.84 4.39 4.03-4.09 
116 8.40, 8.31 - 4.27 4.85 4.40 4.02 
117 8.42, 8.31 - 4.27 4.85 4.40 4.03 
118 7.98, 8.81 - - 4.87 4.41 4.03 
119 8.78, 8.37 - - 4.90 4.42 4.02 
120 8.79, 8.35 - - 4.90 4.41 4.07 
121 8.78, 8.36 - - 4.90 4.42 3.96-4.02 
122 8.78, 8.35 - - 4.90 4.42 4.02-4.11 
123 8.80, 8.40 - - 4.90 4.42 4.02 
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2.2.4. 1H NMR study of N-(6-ferrocenyl-2-naphthoyl)-glycine-L-alanine methyl ester (106). 
 
Figure 2.4: N-(6-ferrocenyl-2-naphthoyl)-glycine-L-alanine methyl ester 106. 
In the 1H NMR spectrum of N-(6-ferrocenyl-2-naphthoyl)-glycine-L-alanine methyl ester 106 
the naphthoyl amide proton peak appears downfield at δ 8.85 as a triplet due to coupling 
with the methylene protons of glycine. The second amide proton signal over laps with a 
singlet due to an aromatic proton in the range δ 8.44-8.45. The remainder of the aromatic 
region appears in the range δ 7.83-8.06 and has the characteristic singlet, multiplet, doublet 
doublet splitting pattern integrating for one, three and one protons respectively which has 
been seen for the 2,6-disubstituted naphthalene ring24. In the ferrocenyl region the ortho 
(η5-C5H4) protons appear furthest downfield as a fine triplet at δ 4.97 with a coupling 
constant of 1.6 Hz, while the meta (η5-C5H4) protons appear also as a triplet at δ 4.46. Each 
integrate for 2 protons. The α-proton of the L-alanine residue appears at δ 4.34 as a quintet. 
The signal for the unsubstituted (η5-C5H5) ring appears at δ 4.05. The methylene protons of 
the glycine residue are observed as two doublets of doublets at δ 3.93 and 4.02. The splitting 
pattern is due to the chiral centre in the molecule. The methylene protons of the glycine 
residue are diastereotopic due to the presence of the L-alanine and geminal coupling is 
observed with a coupling constant of 10.8 Hz together with coupling to the amide proton 
with a coupling constant of 6 Hz. The methyl ester appears as a singlet integrating for 3 
protons at δ 3.64 and the L-alanine methyl group appears as a doublet at δ 1.32. 
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Figure 2.5: 1H NMR spectrum of N-(6-ferrocenyl-2-naphthoyl)-glycine-L-alanine methyl 
ester 106. 
 
2.2.5 1H NMR study of N-{para-(ferrocenyl)cinnamoyl}-ƴ-amino butyric acid ethyl 
ester (115). 
 
Figure 2.6: N-{para-(ferrocenyl)cinnamoyl}-ƴ-amino butyric acid ethyl ester 115. 
In the 1H NMR spectrum of N-{para-(ferrocenyl)cinnamoyl}-ƴ-amino butyric acid ethyl ester 
115 the amide proton peak appears downfield at δ 8.12. The signal appears as a triplet due 
to coupling with the adjacent methylene protons of the ƴ-aminobutyric acid. The aromatic 
protons appear downfield at δ 7.57 and 7.48. They display the characteristic para splitting 
pattern of a disubstituted benzene ring with two apparent doublets. The olefinic protons 
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appear as two doublets at δ 7.40 and 6.59 respectively with a coupling constant of 15.6 Hz. 
In the ferrocenyl region the peak due to the ortho protons on the (η5-C5H4) ring appears 
furthest downfield as a fine triplet at δ 4.84 with a coupling constant of 1.6 Hz. The peak due 
to the meta protons appear as a fine triplet at δ 4.39. The singlet due to the unsubstituted 
(η5-C5H5) ring appears in a multiplet with a quartet due to the methylene protons of the ethyl 
ester from δ 4.03-4.09. The methylene protons of the ƴ-aminobutyric acid appear at δ 3.20, 
2.34 and 1.72 as a quartet, triplet and a quintet, each integrating for 2 protons. The methyl 
protons of the ethyl ester appear as a triplet at δ 1.19 and integrate for 3 protons. 
 
Figure 2.7: 1H NMR spectrum of N-{para-(ferrocenyl)cinnamoyl}-ƴ-amino butyric acid ethyl 
ester 115. 
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2.2.6 1H NMR study of N-{para-(ferrocenyl)benzoyl}-glycine-glycine benzyl ester 
(123). 
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Figure 2.8: N-{para-(ferrocenyl)benzoyl}-glycine-glycine benzyl ester 123. 
In the 1H NMR spectrum of N-{para-(ferrocenyl)benzoyl}-glycine-glycine benzyl ester 123 the 
amide proton peaks appear downfield at δ 8.80 and 8.40. Each appears as a triplet due to 
coupling with the methylene protons of the glycine residue. The aromatic protons appear as 
two apparent doublets at δ 7.84 and 7.64 as is characteristic of para disubstituted aromatic 
compounds. The aromatic protons of the benzyl ester appear as a multiplet integrating from 
δ 7.40-7.30. The methylene protons of the ester appear as a singlet at δ 5.14. In the 
ferrocenyl region the ortho protons on (η5C5H4) appear as a fine triplet with a coupling 
constant of 1.6 Hz at δ 4.90. The meta protons on (η5C5H4) also appear as a fine triplet at δ 
4. The singlet due to the unsubstituted (η5C5H5) appears at 4.02 and integrates for 5 protons. 
The methylene protons of the glycine residues appear as a doublet at δ 3.94. 
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Figure 2.9: 1H NMR spectrum of N-{para-(ferrocenyl)benzoyl}-glycine-glycine benzyl 
ester 123. 
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2.2.7 Variable temperature study of N-(6-ferrocenyl-2-naphthoyl)-sarcosine-
glycine methyl ester (104). 
Rotamers are conformational isomers in which rotations around formally single bonds are 
restricted. The presence of rotamers in solution complicates the 1H NMR spectrum.The N-
methyl group gives rise to multiple signals in the 1H NMR spectrum. The amide bond is 
characterised by short bond lengths, co-planarity and restricted rotation around the C-N 
bond. Rotation about the C-N bond is intrinsically hindered due to its significant double bond 
nature.  
Usually the trans conformers of peptide amide bonds are thermodynamically favoured as 
there is less steric hinderence from the groups at either end of the C-N bond than with the 
cis isomer. This is the case for secondary amides where the cis isomer concentration is less 
than 1 %, however in tertiary amides the steric hinderence is similar for both cis and trans 
isomers. 
 
Figure 2.10: Resonance structures of the amide bond25. 
Rotations around single bonds are restricted by a rotational energy barrier which must be 
overcome to interconvert one form to another. When the solution is heated to the 
coalescence temperature the barrier is overcome and the two forms may interconvert and a 
single broad signal is seen. As the temperature is raised the two forms interconvert more 
rapidly and a sharp signal is seen. 
The 1H NMR spectrum of N-(6-ferrocenyl-2-naphthoyl)-sarcosine-glycine methyl ester gives 
rise to multiple signals in the NMR due to the presence of rotamers in solution caused by the 
presence of the N-methyl group. The rate of interconversion of the rotamers is slow on the 
NMR timescale, therefore NMR experiments must be performed at a higher temperature to 
increase the rate of interconversion. 
A variable temperature study of the 1H NMR spectrum of N-(6-ferrocenyl-2-naphthoyl)-
sarcosine-glycine methyl ester (104) was performed at 20, 30, 40, 50, 60, 70 and 80 °C in 
DMSO-d6 (figure 2.12). 
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Figure 2.11: N-(6-ferrocenyl-2-naphthoyl)-sarcosine-glycine methyl ester 104. 
 
 
Figure 2.12: The 1H NMR spectrum of N-(6-ferrocenyl-2-naphthoyl)-sarcosine-
glycine methyl ester 104 at 20, 30, 40, 50, 60, 70, and 80 °C. 
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Figure 2.13: Variable temperature 1H NMR study of N-(6-ferrocenyl-2-naphthoyl)-
sarcosine-glycine methyl ester 104: the aromatic region (7.4-8.6 ppm). 
At the coalescence temperature the signals due to separate rotamers coalesce to give a 
single broad signal. Above this the signal will become a sharp peak as the exchange between 
rotamers is rapid. In the aromatic region the amide proton of the glycine residue gives rise 
to two broad singlets at δ 8.59 and 8.51 at 20 °C (figure 2.13). As the temperature is raised 
these singlets broaden further, shifting slightly upfield and coalesce at 40 °C. Above 40 °C the 
signal sharpens.  
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Figure 2.14: Variable temperature 1H NMR study of N-(6-ferrocenyl-2-naphthoyl)-
sarcosine-glycine methyl ester 104; the N-methyl region (3.0-4.3 ppm). 
In the ferrocenyl region of the spectrum the methylene protons of the sarcosine residue 
appear at δ 4.2 and 4.0 as 2 broad singlets (figure 2.14). These broaden further as the 
temperature is raised. At 80 °C a broad singlet can be seen at δ 4.11. The methyl ester group 
appears as a broad singlet at δ 3.66 at 20 °C, however from 30 °C this becomes a sharp signal.  
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2.2.8 13C NMR and DEPT 135 NMR studies of N-(6-ferrocenyl-2-naphthoyl), N-
{para-(ferrocenyl)cinnamoyl} and N-{para-(ferrocenyl)benzoyl}  amino acid and 
dipeptide derivatives. 
In the DEPT 135 spectrum methylene carbons typically appear negative, while methyl and 
methine carbons appear positive. Non proton bearing carbons do not appear in the DEPT 
spectrum. 
In the 13C NMR the carbonyl groups due to the amide and ester groups are found in the range 
δ 165.1-175.2. In the N-(6-ferrocenyl-2-naphthoyl) derivatives the aromatic carbons appear 
as 10 signals in the range δ 122.7 - 138.9. The four quaternary carbons were identified using 
DEPT 135. In the 13C NMR of the N-{para-(ferrocenyl)cinnamoyl} derivatives the aromatic 
carbons appear as 4 signals in the range δ 120.6 – 140.9. The olefinic carbons of the N-{para-
(ferrocenyl)cinnamoyl} derivatives appear in the range δ 120.7 - 140.9. In the 13C NMR of the 
N-{para-(ferrocenyl)benzoyl} derivatives the aromatic carbons appear as 4 signals in the 
range δ 125.3-148.3. 
In the ferrocenyl region carbon signals appear in the range δ 66.4 - 88.4. In the 13C NMR of 
the N-(6-ferrocenyl-2-naphthoyl) derivatives the ipso carbon on the substituted 
cyclopentadienyl ring appears from δ 84.0 - 84.1. The unsubstituted (η5-C5H5) ring appears at 
δ 69.4-69.5. The signal due to the meta (η5-C5H4) carbons is in close proximity to (η5-C5H5) or 
overlapping at δ 69.4, while the ortho carbons appear at δ 66.6.  
In the 13C NMR of the N-{para-(ferrocenyl)cinnamoyl} derivatives the location of the 
ferrocenyl signals is similar, with the ipso  (η5-C5H4) carbon appearing at δ 83.7, the (η5-C5H5) 
carbon appearing at δ 69.4 and the meta and ortho carbons appearing at δ 69.3 and δ 66.4-
66.5. In the 13C NMR of the N-{para-(ferrocenyl)benzoyl} derivatives the signals appear over 
a slightly wider range, with the ipso (η5-C5H4) carbon at δ 83.2-88.4, the (η5-C5H5) carbon at 
δ 69.5-74.8 and the meta and ortho carbons at δ 69.5-75.8 and δ 66.6-71.8 respectively. 
The methylene carbons of the dipeptides appear negative in the DEPT 135 spectrum in the 
range δ 31.2-47.6 
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Table 2.5: Selected 13C NMR spectral data (δ, DMSO-d6) for N-(6-ferrocenyl-2-
naphthoyl), N-{para-(ferrocenyl)cinnamoyl} and N-{para-(ferrocenyl)benzoyl}  
amino acid and dipeptide derivatives. 
Compound C=O 
ipso 
(η5-C5H4) 
ortho 
(η5-C5H4) 
meta 
(η5-C5H4) 
 
(η5-C5H5) 
100 170.3-166.5 84.0 66.6 69.4 69.5 
101 169.9-166.6 84.0 66.6 69.4 69.5 
102 169.8-166.5 84.0 66.6 69.4 69.5 
103 169.9 84.0 66.6 69.4 69.5 
104 171.1-168.9 84.1 66.6 69.5 69.5 
105 173.2-166.3 84.1 66.6 69.4 69.4 
106 173.0-166.4 84.1 66.6 69.4 69.4 
107 173.0-166.4 84.0 66.6 69.4 69.4 
108 171.2-166.5 84.0 66.6    69.4 69.5 
109 171.6-168.2 84.1 66.6 69.4 69.5 
110 174.3-166.3 84.1 66.6 69.4 69.4 
111 174.0-166.4 84.1 66.6 69.4 69.4 
112 174.0-166.5 84.0 66.6 69.4 69.5 
113 169.7-165.4 83.7 66.4 69.3 69.4 
114 169.7-166.1 83.7 66.4 69.4 69.3 
115 172.6-165.1 83.7 66.4 69.3 69.4 
116 172.5-165.4 83.7 66.5 69.3 69.4 
117 172.5-165.4 83.7 66.4 69.3 69.4 
118 172.2-166.3 83.2 66.6 69.5 69.5 
119 170.3-166.3 83.2 66.6 69.5 69.5 
110 169.8-166.3 83.2 66.6 69.5 69.5 
111 175.2 88.2 71.8 75.8 74.8 
112 175.1-171.5 88.4 71.8 74.7 74.7 
113 169.7-166.3 83.2 66.6 69.5 69.5 
 
2.2.8 13C and DEPT 135 NMR study of N-{para-(ferrocenyl)cinnamoyl}-glycine-L-
alanine ethyl ester 116. 
 
Figure 2.15: Structure of N-{para-(ferrocenyl)cinnamoyl}-glycine-L-alanine ethyl 
ester 116. 
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The 13C NMR of N-{para-(ferrocenyl)cinnamoyl}-glycine-L-alanine ethyl ester 116 shows 
three carbonyl carbons at δ 172.5, 168.8 and 165.4 which are absent in the DEPT 135. The 
aromatic region shows six signals. The signals at δ 140.9 and 132.2 are not present in the 
DEPT 135 spectrum, indicating that they are the quaternary carbons of the benzene ring. The 
signals at δ 138.9 and 120.7 correspond to the olefinic carbons and the remaining signals at 
δ 127.7 and 126.2 correspond to the remaining carbons on the benzene ring. The signal at δ 
83.7 is not present in the DEPT spectrum and can be attributed to the ipso carbon. At δ 69.4 
the signal of the unubstituted (η5-C5H5) ring is present. The meta (η5-C5H4) carbon is in close 
proximity at δ 69.3 and the ortho (η5-C5H4) carbon appears at δ 66.5.  The signal at δ 60.5 is 
negative in the DEPT 135 spectrum and can be assigned to the methylene carbon of the ethyl 
ester. The signal at δ 40.0 is also negative in the DEPT 135 and may be assigned to the 
methylene carbon of the glycine residue. The signals at δ 47.6 and 17.0 correspond to the 
methine and methyl carbons atoms of the L-alanine residue respectively, while the signal at 
δ 14.0 corresponds to the methyl carbon of the ethyl ester. 
 
Figure 2.16: 13C NMR spectrum of N-{para-(ferrocenyl)cinnamoyl}-glycine-L-alanine 
ethyl ester 116. 
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Figure 2.17: DEPT 135 NMR spectrum of N-{para-(ferrocenyl)cinnamoyl}glycine-L-
alanine ethyl ester 116. 
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2.2.9 HSQC study of N-{para-(ferrocenyl)cinnamoyl}-glycine-L-alanine ethyl ester 
(116). 
HSQC (Heteronuclear Single Quantum Coherence) is a 2D NMR technique that correlates 
each 13C atom to the proton to which it is directly attached, thus allowing for complete 
assignment of proton and carbon spectra.  
 
Figure 2.18: HSQC of N-{para-(ferrocenyl)cinnamoyl}-glycine-L-alanine ethyl ester 
116. 
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Figure 2.19: N-{para-(ferrocenyl)cinnamoyl}-glycine-L-alanine ethyl ester 116. 
 
Table 2.6: HSQC data for N-{para-(ferrocenyl)cinnamoyl}-glycine-L-alanine ethyl 
ester 116. 
Site 1H NMR 13C NMR HSQC 
1  83.7  
2,5 4.85  66.4 
3,4 4.40  69.3 
6 to 10 4.04  69.4 
11  132.2  
12, 16 7.58  126.2 
13, 15 7.49  127.7 
14  140.9  
17 6.73  120.7 
18 7.46  138.9 
19  165.4  
20 3.86 & 3.92  40.0 
21  168.8  
22 4.27  47.6 
23 1.29  17.0 
24  173.5  
25 4.09  60.5 
26 1.19  14.0 
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2.2.10 Infra red studies of N-(6-ferrocenyl-2-naphthoyl), N-{para-
(ferrocenyl)cinnamoyl} and N-{para-(ferrocenyl)benzoyl}  amino acid and 
dipeptide derivatives. 
Any compound which has covalent bonds absorbs frequencies of electromagnetic radiation 
in the infrared region of the electromagnetic spectrum. The region lies at wavelengths that 
are longer than visible light. Molecules are excited to a higher state when they absorb 
infrared radiation. Radiation in this energy range corresponds to stretching and bending 
vibrational frequencies of the covalent bonds in molecules. Only bonds which have a dipole 
moment that changes as a function of time at the same frequency as the incoming infrared 
radiation are capable of absorbing it. 
Table 2.7: Selected IR data for N-(6-ferrocenyl-2-naphthoyl), N-{para-
(ferrocenyl)cinnamoyl} and N-{para-(ferrocenyl)benzoyl}  amino acid and dipeptide 
derivatives. Values are given in cm-1 
Compound 
No. 
N-H  amide I  amide II C=O ester/acid 
100 3418, 3313 1638, 1622 1512 1741 
101 3281 1653 1523 1753 
102 3298 1645 1544 1749 
103 3263 1645 1544 1749 
104 3291 1624 1543 1742 
105 3305 1624 1547 1729 
106 3305 1627 1516 1734 
107 3292 1624, 1645 1513 1747 
108 - 1628, 1600 1544 1690 
109 - 1624 1548 1720 
110 - 1615 1543 1712 
111 2932, 3092 1626 1534 1727 
112 2930, 3094 1628 1535 1723 
113 3287 1626 1549 1732 
114 3293 1642 1592 1745 
115 3277 1616 1563 1739 
116 3310 1621 1529 1732 
117 3307 1622 1527 1729 
118 - 1640 1522 1737 
119 3274 1655 1514, 1550 1727 
120 3389 1644 1515, 1543 1727 
121 3367, 3274 1643 1542, 1515 1727 
122 3298 1633 1549, 1518 1738 
123 3310 1628, 1609 1548, 1519 1734 
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Figure 2.20 IR spectrum of N-(6-ferrocenyl-2-naphthoyl)-ƴ-aminobutyric acid methyl ester 
105. 
 
The fundamental absorptions arise from excitation from the ground state to the lowest 
energy excited state.  However the spectrum is complicated by the presence of weak 
overtone, combination and difference bands. Overtones result from excitation from the 
ground state to higher energy levels, combination bands arise when two vibrational 
frequencies combine to give a vibration of a new frequency and difference bands result a 
new frequency arises from the difference of two frequencies26.   
The IR spectra of N-(6-ferrocenyl-2-naphthoyl), N-{para-(ferrocenyl)cinnamoyl} and N-{para-
(ferrocenyl)benzoyl}  amino acid and dipeptide derivatives were obtained as pure solids. The 
spectra usually show two bands above 3000 cm-1 which correspond to the secondary amide 
groups. In the carbonyl region there are usually at least two bands which correspond to 
primary and secondary amides. The higher frequency band is known as the amide I band and 
the lower frequency band is known as the amide II band. The amide I band appears between 
1673 and 1600 cm-1 and corresponds to the stretching vibration of the C=O band, while the 
amide II band appears between 1563 and 1512 cm-1 and corresponds to the bending 
vibration of the N-H bond. The C=O of the ester appears at a higher frequency between 1753 
and 1712 cm-1. 
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2.2.11 UV-Vis studies of N-(6-ferrocenyl-2-naphthoyl), N-{para-
(ferrocenyl)cinnamoyl} and N-{para-(ferrocenyl)benzoyl}  amino acid and dipeptide 
derivatives. 
Table 2.8: Selected UV-Vis data for N-(6-ferrocenyl-2-naphthoyl), N-{para-
(ferrocenyl)cinnamoyl} and N-{para-(ferrocenyl)benzoyl}  amino acid and dipeptide 
derivatives. 
Compound 
No. 
λmax1 (nm) ε1 λmax2 (nm) ε2 
100 369 3093 451 1344 
101 373 2600 448 1086 
102 375 2717 452 1174 
103 379 2908 452 1281 
104 359 2744 452 1027 
105 371 3127 452 1213 
106 376 3210 452 1302 
107 363 3682 452 1403 
108 373 1545 452 673 
109 365 2513 452 1038 
110 371 1562 451 641 
111 374 2843 450 1158 
112 369 1875 451 862 
113 378 3436 457 1378 
114 387 3487 455 1522 
115 370 3001 452 1059 
116 387 3487 455 1522 
117 313 4118 436 550 
118 351 1987 450 356 
119 354 2858 452 865 
120 354 1584 451 570 
121 355 1737 450 552 
122 356 1532 425 487 
123 313 4835 449 587 
 
The UV-Vis spectrum ranges from 190-800 nm. The transitions that result in the absorption 
of electromagnetic radiation in this region of the spectrum correspond to transitions 
between the electronic energy levels. As the molecule absorbs energy an electron is 
promoted from an occupied orbital to an unoccupied orbital of higher potential energy. The 
most probable transition is from the highest unoccupied energy level (HOMO) to the lowest 
unoccupied energy level (LUMO). For most molecules the lowest energy occupied levels 
correspond to σ bonds. The π orbitals lie at higher energy levels while non-bonding (n) 
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orbitals lie at higher levels still. The highest energy levels correspond to antibonding (σ* and 
π*) orbitals26. 
 
 
Figure 2.21: UV-Vis spectra of N-(6-ferrocenyl-2-naphthoyl)-glycine-glycine propyl 
ester 101, N-para-(ferrocenyl)-cinnamoyl}-glycine-glycine ethyl ester 113 and N-
{para-(ferrocenyl)-benzoyl}-glycine-glycine ethyl ester 120. 
The N-(6-ferrocenyl-2-naphthoyl)-glycine-glycine amino acid and dipeptide esters have the 
strongest absorptions in the UV spectrum with local maxima at 375 nm and 450 nm 
respectively. The N-{para-(ferrocenyl)-benzoyl} dipeptide esters have local maxima at 355 
nm and 450 nm respectively. The absorptions are less intense and occur at slightly shorter 
wavelengths. The UV-Vis spectra of the N-(6-ferrocenyl-2-naphthoyl)-glycine-glycine amino 
acid and dipeptide esters are similar to those of the N-{para-(ferrocenyl)-cinnamoyl} amino 
acid and dipeptide esters. The absorbances for the N-(6-ferrocenyl-2-naphthoyl) and N-
{para-(ferrocenyl)cinnamoyl} derivatives are stronger than those of the N-{para-
(ferrocenyl)benzoyl} derivatives as they have a higher degree of conjugation. 
The absorbance at 375 nm can be attributed to a π to π* transition of the aromatic moiety 
while the absorbance at 450 nm is attributed to a metal to ligand charge transfer band 
(MLCT). The extinction coefficient ε is calculated from the Beer-Lambert Law A=εCl, where A 
is the absorbance, C is the concentration and l is the path length of the cell. All spectra were 
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obtained at a concentration of 1x10-4 M. The extinction coefficients are a function of how 
efficiently a chromophore absorbs UV or visible radiation.  
 
2.2.12 Mass Spectrometric studies of N-(6-ferrocenyl-2-naphthoyl)-glycine-glycine 
esters (100-103). 
Mass spectrometric studies were carried out for N-(6-ferrocenyl-2-naphthoyl)-glycine-
glycine esters 100-103. The N-(6-ferrocenyl-2-naphthoyl)-glycine-glycine esters are non 
volatile and a soft ionisation technique is employed in their analysis. The N-(6-ferrocenyl-2-
naphthoyl)-glycine-glycine esters were analysed by electrospray ionisation (ESI) mass 
spectrometry, which confirmed the correct relative molecular mass for each compound. 
Examination of the mass spectra revealed the presence of radical cation species, [M]+•, as 
well as [M+H]+ species at one mass unit higher. Sequence specific fragment ions were of low 
intensity in the mass spectra. The mass spectrum for N-(6-ferrocenyl-2-naphthoyl)-glycine-
glycine methyl ester 100 is shown (figure 2.22). The signal at m/z 339 is due to cleavage at 
the naphthoyl carbonyl while the signal seen at m/z 396 is cleavage after the first glycine 
residue (figure 2.23). 
 
 
Figure 2.22: Mass spectrum of N-(6-ferrocenyl-2-naphthoyl)-glycine-glycine methyl 
ester (100). 
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Figure 2.23: Product ions observed in the mass spectrum of N-(6-ferrocenyl)-glycine-
glycine methyl ester (100). 
2.3 Approaches to the synthesis and structural characterisation of N-(5-
ferrocenyl-1-naphthoyl) amino acid and dipeptide derivatives. 
2.3.1 Introduction 
The preliminary structure activity relationship (SAR) carried out by the group on ferrocenyl 
bioconjugates has shown the importance of a conjugated linker which is believed to lower 
the oxidation potential of the ferrocene moiety. Previously modification of the conjugated 
linker has been shown to have a significant impact on the biological activity of this class of 
compounds. Replacement of the benzoyl moiety by the naphthalene unit has been shown to 
have a dramatic effect on activity.  The most active of the ferrocenyl benzoyl derivatives, N-
{para-(ferrocenyl)benzoyl} glycine-L-alanine ethyl ester, had an IC50 of  4.0 µM. The 
introduction of the naphthalene linker resulted in an increase in the activity of all of the 
analogues. The N-(6-ferrocenyl-2-naphthoyl) glycine-L-alanine ethyl ester 78 had an IC50 of 
1.3 µM by comparison.  
Also the position of the substituents on the aromatic linker has been shown to be of 
importance. N-{para-(ferrocenyl)benzoyl} derivatives were more active than the ortho and 
meta counterparts, while N-(6-ferrocenyl-2-naphthoyl) amino acid and dipeptide ester 
derivatives were found to be more active than the N-(3-ferrocenyl-2-naphthoyl) derivatives. 
Therefore as part of the ongoing SAR study of these compounds the preparation of a series 
of N-(5-ferrocenyl-1-naphthoyl) derivatives looks to be a logical strategy.  
The proposed synthesis of these N-(5-ferrocenyl-1-naphthoyl) amino acid and dipeptide 
esters follows a different synthetic route than the previously made compounds. As no 5-
amino-1-naphthoic acid was available commercially, 1,5-diaminonaphthalene 124 was 
sourced as a suitable alternative. This starting material would allow an alternative synthesis 
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to structurally similar targets, while utilising mostly synthetic methods well established 
within the group. 
 As 1,5-diaminonaphthalene 124 is a symmetrical molecule, either amino group could be 
protected to give the desired product. Ferrocene could then be introduced via standard 
diazonium coupling. Deprotection would leave a free amino group compared with the usual 
carboxylic acid. This would require a dipeptide moiety with a free hydroxyl group to couple 
with the amine. The dipeptide would thus terminate in an amine as opposed to the usual 
ester group. This can be achieved through standard dipeptide coupling by preparing a 
dipeptide with an ester protecting group on the C-terminus and a Boc protecting group on 
the N-terminus. The ester is removed prior to coupling with the naphthalene linker and the 
Boc group is removed after to give the terminal amino group. 
A series of peptides will be prepared using the most active amino acid and dipeptide 
conformations noted previously from among the N-(6-ferrocenyl-2-naphthoyl) amino acid 
and dipeptide esters; Gly Gly-NH2, GABA-NH2, Gly-L-Ala-NH2, Gly-D-Ala-NH2 and Sar-Gly-NH2. 
Given that peptide chain order has shown a significant impact on activity and that the 
dipeptides will be attached via the C-terminus rather than the N-terminus, the L-Ala-Gly-NH2, 
D-Ala-Gly-NH2 and the Gly-Sar-NH2 derivatives will also be synthesised. 
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2.3.2 Synthesis of N-(5-ferrocenyl-1-naphthoyl) dipeptides. 
 
(i) Pyridine, acetic anhydride, RT, overnight. (ii) Ferrocene, NaNO2, HCl. (iii) MeOH, NaOH, 
reflux. (iv) Boc-dipeptide, EDC, NHS, TEA. (v) TFA, DCM. 
Scheme 2.14: General reaction scheme for the synthesis of N-(5-ferrocenyl-1-
naphthoyl) dipeptides. 
The 1-amino-5-acetyl-naphthalene 125 is prepared by acetylation of the 1, 5-
diaminonaphthalene with acetic anhydride in pyridine. The ferrocene moiety is introduced 
via diazonium coupling to give the 1-acetyl-5-ferrocenyl naphthalene 126. The acetyl group 
is then cleaved by base hydrolysis to give the 1-amino-5-ferrocenyl naphthalene 127. The 
Boc protected dipeptide can then be coupled to the free amino group by standard peptide 
coupling to give the 5-ferrocenyl-1-naphthoyl Boc dipeptide. The Boc protecting group is 
then cleaved by trifluoroacetic acid to give the desired 5-ferrocenyl-1-naphthoyl dipeptide. 
Protection of the of the amino groups of 124 was attempted using Boc anhydride, however 
the reaction gave either low conversion of starting material to products or multiple by-
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products which made purification difficult.  As the molecule possesses two amino groups, 
protection of one or both amino groups may occur. To reduce the potential for protection of 
the second amino group only one equivalent of Boc anhydride was used. Both the di 
protected moiety and the starting material must be removed by column chromatography. 
An alternative route using acetic anhydride was then employed to protect the amino groups 
via acetylation. Conversion to approximately 50 % of the protected amino group was 
achieved with little or no evidence of the protection of the second amine.  Removal of 
unreacted starting material was achieved by column chromatography. 
The N-acetyl ferrocenyl naphthalene 126 was prepared using the standard diazonium 
coupling procedures as outlined previously with only a 9 % yield. The acetyl group was 
removed by base hydrolysis using 30 % sodium hydroxide. 
2.3.2.1 Preparation of Boc protected dipeptides with a free hydroxyl group. 
 
(i) EDC, NHS, TEA, (ii) 10 % NaOH, MeOH, reflux, 12 h. 
Scheme 2.15: General procedure for the synthesis of Boc protected dipeptides. 
Boc protected dipeptides with a free carboxylic acid were prepared by standard peptide 
coupling methods using EDC, NHS and TEA in DCM.  First the C-terminus of the desired 
peptide was protected with a methyl group followed by peptide coupling with the Boc 
protected moiety using standard peptide coupling procedures. The methyl group was then 
removed by base hydrolysis in 10 % NaOH. This gave the free C-terminus for coupling with 
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the amino ferrocenyl naphthoic acid. The Boc protecting group could then be removed with 
TFA to give the final product with the free amine group. 
2.3.2.2 Preparation of N-5-acetyl-1-aminonaphthalene 
2.3.2.2.1 t-Butoxycarbonyl (Boc) protecting groups 
One of the most commonly employed amine protection strategies is protection using the t-
Boc group. It is regularly used in peptide synthesis and has already been employed during 
the preparation of dipeptide esters. The t-Boc protecting group is introduced using di-tert-
butyl dicarbonate (Boc2O).  
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Scheme 2.16: Introduction of the t-Boc protecting group with di-tert-butyl 
dicarbonate. 
It is resistant to basic and nucleophillic attack as well as catalytic hydrogenation due to the 
steric bulk of the t-butyl group which protects the carbonyl group from attack. It can be 
readily cleaved by hydrolysis in acid such as TFA which causes a loss of the t-butyl cation 
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followed by decarboxylation.  This allows the removal of the BOC group without the 
cleavage of peptide or ester bonds. 
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Scheme 2.17: Removal of the t-Boc group with trifluoroacetic acid. 
While alkyl amines react readily without a catalyst, secondary, tertiary and aryl amines react 
poorly and can require a catalyst27. Often a tertiary amine such as 4-dimethylaminopyridine 
(DMAP) or pyridine is added as a catalyst. DMAP increases the rate of reaction, however it 
also increases the number of possible side reactions. 
 
96 
 
 
Scheme 2.18: Boc protection using DMAP as a catalyst. 
2.3.2.2.2 Acetyl protecting groups. 
The acetyl group may be used to protect both hydroxyl groups and amines. It is introduced 
via acetic anhydride with stirring in pyridine. 
O
O
O
R-NH2
RHN
O O
OH
+
 
Scheme 2.19: Acetylation of an amine using acetic anhydride. 
The acetyl group which is stable during the diazonium coupling procedure is then cleaved by 
base hydrolysis using methanol and 30 % NaOH solution to furnish the 1-amino-5-ferrocenyl 
naphthalene 127. 
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2.3.3 Discussion  
The preparation of Boc protected dipeptides was achieved using the usual synthetic route 
followed by hydrolysis to give the free acids required for coupling. The acetylation of 1,5- 
diaminonaphthalene 124 gave good yields of up to 80 % and was used without further 
purification after filtering. The diazonium coupling of 1-amino-5-acetyl-naphthalene 125, 
however, gave very low yields of only 9 % after purification. Despite scaling up the quantity 
of starting material used, after hydrolysis of the N-1-acetyl-5-ferrocenyl naphthalene 126, 
which had a yield of 56 %, the quantity remaining of 1-amino-5-ferrocenyl-naphthalene 127 
was impractical to continue synthesis of the target compounds.  Coupling of the 1-amino-5-
ferrocenyl-naphthalene 127 to Boc-γ-aminobutyric acid was attempted, however no 
evidence of the desired product was detected by NMR after purification was attempted. 
Given that a further two reactions were required reach the desired target, the method was 
deemed impractical for the synthesis of a series of these target compounds. 
A potential reason for the poor yield of the 1-acetyl-5-ferrocenyl naphthalene 126 compared 
with the same reaction of methyl-6-ferrocenylnaphthalene-2-carboxylate 82 may be that the 
NHCOR group is electron donating while the RCOOR group is electron withdrawing. 
Sterically, the 1,5 orientation of the substitution is no more hindered than the 2,6 
substitution. Indeed the effect of steric hindrance does not greatly affect the yield at the 
diazonium coupling stage as the synthesis of methyl-6-ferrocenylnaphthalene-2-carboxylate 
82 gave a yield of 21 % while methyl-3-ferrocenylnaphthalene-2-carboxylate gave a yield of 
30 %24, however it is possible that the effect of the substituent groups may have a role in the 
poor yield of this reaction. 
An electron withdrawing group para to the azo group increases the electrophilicity of the 
diazonium ion. This can be seen in the case of the benzenediazonium cation and the p-
nitrobenzenediazonium cation in figure 5.1. However, in the synthesis of 1-acetyl-5-
ferrocenyl naphthalene 126 the electron withdrawing methyl ester group is replaced by an 
electron donating amide group opposite to the azo group. It is possible that the 
electrophilicity of the diazonium cation is reduced by this substituent effect and undergoes 
electrophilic aromatic substitution less readily than its methyl-6-ferrocenylnaphthalene-2-
carboxylate 82 counterpart. 
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Figure 2.24: Electrostatic potential diagrams of the benzenediazonium cation 
compared with the p-nitrosobenzenediazonium cation. Positive potential areas are 
shown in blue whilst areas of negative potential are shown in red28. 
 
2.4 Conclusions. 
The N-(6-ferrocenyl-2-naphthoyl) dipeptide ethyl esters were previously identified as 
potential anticancer agents with excellent cytotoxicity against H1299 NSCLC cells and Sk-Mel-
28 melanoma cells. This project sought to further explore the SAR of these compounds to 
optimise their cytotoxicity. This was carried out by modification of the previously 
uninvestigated ester region of the compounds in both N-(6-ferrocenyl-2-naphthoyl) and N-
{para(ferrocenyl)benzoyl} derivatives as well as the introduction of a cinnamoyl linker. Thus 
N-(6-ferrocenyl-2-naphthoyl), N-{para(ferrocenyl)benzoyl} and N-
{para(ferrocenyl)cinnamoyl} amino acid and dipeptide derivatives have been prepared. 
These novel compounds have been characterised by 1H NMR, 13C NMR, DEPT 135, HSQC, IR, 
UV-Vis and MS. Each compound gave spectra in accordance with their proposed structures. 
The synthesis of N-(5-ferrocenyl-1-naphthoyl) amino acid and dipeptide derivatives was 
proposed as an interesting strategy for the exploration of the structure activity relationship 
of N-ferrocenylnaphthoyl amino acid and dipeptide derivatives. It was hoped that this series 
of derivatives could be prepared utilising similar chemistry to the previously prepared 
compounds. As described previously the 1-amino-5-acetyl-naphthalene 125 was prepared in 
sufficient yield, however upon diazonium coupling a poor yield was obtained of 
approximately 9 %. This was attributed to a potential electron donating substituent effect of 
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the NHCOH group and this route to the preparation of N-(5-ferrocenyl-1-naphthoyl) amino 
acid and dipeptide derivatives was abandoned. 
An alternative route, however, has been employed where the Boc protected amino acid or 
dipeptide is first attached to the protected naphthalene ring. The acetyl group is then cleaved 
and the ferrocene is coupled secondly. This would eliminate the problematic coupling of the 
acetylated naphthalene ring and circumvent the need for an electron donating protecting 
group at the time of coupling. Preliminary results have shown this method to be more 
successful with diazonium coupling yields in the range of 20 - 30 % in line with those reported 
previously24Error! Bookmark not defined.. 
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Experimental Procedures 
All chemicals were purchased from Sigma-Aldrich, Fluorochem Limited or Tokyo Chemical 
Industry UK Limited; and used as received. Commercial grade reagents were used without 
further purification. Riedel-Haën silica gel was used for thin layer and column 
chromatography. Melting points were determined using a Stuart melting point (SMP3) 
apparatus and are uncorrected. Infrared spectra were recorded on a Perkin Elmer Spectrum 
100 FT-IR with ATR. UV-Vis spectra were recorded on a Hewlett Packard 8452 A diode array 
UV-Vis spectrophotometer. 1H and 13C NMR spectra were recorded in deuterated solvents 
on either a Bruker Avance 400 or 600 NMR. The 1H and 13C NMR chemical shifts are reported 
in ppm (parts per million). Tetramethylsilane (TMS) or the residual solvent peaks were used 
as an internal reference. All coupling constants (J) are in Hertz. The abbreviations for the 
peak multiplicities are as follows: s (singlet), d (doublet), dd (doublet of doublets), t (triplet), 
q (quartet), qt (quintet), m (multiplet) and br (broad). Electrospray ionisation mass spectra 
were performed on a Micromass LCT mass spectrometer or a Brüker Daltonics Esquire-LC ion 
trap mass spectrometer. Elemental analysis was carried out by the microanalytical laboratory 
at University College Dublin. 
General procedure for the preparation of starting materials for N-(6-ferrocenyl-2-
naphthoyl), N-{para-(ferrocenyl)cinnamoyl} and N-{para-(ferrocenyl)benzoyl} 
amino acid and dipeptide derivatives. 
Methyl-6-aminonaphthalene-2-carboxylate hydrochloride 81. 
 
6-Amino-2-naphthoic acid (5.05 g, 27.0 mmol) was dissolved in methanol (30 mL). The 
solution was cooled on ice and thionyl chloride (5 mL) was added. This was heated at reflux 
for 24 h. The solution was cooled and the precipitate was isolated via vacuum filtration to 
yield the title compound as a brown solid (5.48 g, 85 %), mp 250-251 °C (lit24 156-158 °C); 
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1H NMR (600 MHz) δ (DMSO-d6):  8.56 (1H, s, ArH), 8.09 (1H, d, J 8.4 Hz, ArH), 7.94 (1H, d, J 
9 Hz, ArH), 7.90 (1H, d, J 8.4 Hz, ArH), 7.53 (1H, s, ArH), 7.37 (1H, d, J 8.4 Hz), 3.90 (3H, s, -
OCH3); 
13C NMR (150 MHz) δ (DMSO-d6): 166.3 (C=O), 135.9 (Cq), 135.4 (Cq), 131.1, 130.5, 128.5 (Cq), 
127.1, 125.6, 125.1 (Cq), 121.1, 117.6, 52.1 (-OCH3). 
 
Methyl-6-ferrocenylnaphthalene-2-carboxylate 82. 
 
To a solution of methyl-6-aminonaphthalene-2-carboxylate hydrochloride (6.80 g, 28.6 
mmol) in water (20 mL) was added conc. HCl (5 mL). A solution of sodium nitrite (2.30 g, 34.3 
mmol) in water (20 mL) was then added slowly with stirring while the temperature was kept 
below 5 °C to yield the diazonium salt. This was then added to a solution of ferrocene (6.38 
g, 34.3 mmol) in diethyl ether (40 mL) and allowed to stir for 24 hours. The reaction mixture 
was washed with water, the organic layer was dried over magnesium sulphate and the 
solvent was removed in vacuo to yield the crude product. It was purified by column 
chromatography (eluent 5 % diethyl ether: 95 % hexane) to yield the title compound as an 
orange solid (2.63 g, 25 %), mp 130 °C (lit24 158-159 °C); 
1H NMR (400 MHz) δ (DMSO-d6):  8.58 (1H, s, ArH), 8.10 (1H, s, ArH), 8.08 (1H, d, J 12 Hz, 
ArH), 7.93-7.99 (2H, m, ArH), 7.86 (1H, dd, J 12 Hz and 2 Hz, ArH), 4.99 {2H, t, J 2 Hz, ortho 
on (η5-C5H4)}, 4.47 {2H, t, J 2 Hz, meta on (η5-C5H4)}, 4.06 (5H, s, η5-C5H5), 3.92 (3H, s, -OCH3);  
13C NMR (100 MHz) δ (DMSO-d6): 166.4 (C=O), 140.0 (Cq), 135.4 (Cq), 130.6 (Cq), 130.4, 129.2, 
127.8, 126.1, 125.8 (Cq), 125.1, 122.7, 83.7 (Cipso η5-C5H4), 69.6 (η5-C5H5), 69.5 (Cmeta η5-C5H4), 
66.8 (Cortho  η5-C5H4), 52.2 (-OCH3). 
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6-Ferrocenylnaphthalene-2-carboxylic acid 83 
Fe
O
OH
 
Sodium hydroxide (15 mL, 10 %) was added to a solution of methyl-6-
ferrocenylnaphthalene-2-carboxylate (0.30 g, 8.1 mmol) in methanol (15 mL) and allowed 
to reflux for 24 hours. The solution was cooled on ice and acidified to pH 2 with conc. HCl. 
The product was isolated by vacuum filtration as an orange solid (0.27 g, 94 %), mp {lit24 
205 °C (decomp)}; 
1H NMR (600 MHz) δ (DMSO-d6): 12.6 (1H, br.s, -COOH),  8.41 (1H, s, ArH), 7.96 (1H, s, ArH), 
7.92-7.88 (2H, m, ArH), 7.80 (1H, d, J 8.4 Hz, ArH), 7.72 (1H, d, J 8.4 Hz, ArH), 4.87 {2H, s, 
ortho on (η5-C5H4)}, 4.36 {2H, s, meta on (η5-C5H4)}, 3.96 (5H, s, η5-C5H5); 
13C NMR (100 MHz) δ (DMSO-d6): 168.2 (C=O), 138.7 (Cq), 134.8 (Cq), 130.8 (Cq), 129.7, 128.9, 
127.5 (Cq), 127.1, 126.2, 125.6, 122.7, 84.2 (Cipso η5-C5H4), 69.4 (η5-C5H5,  Cmeta η5-C5H4), 66.6 
(Cortho  η5-C5H4). 
para-Ferrocenyl-ethyl cinnamate 84 
Fe
O
O
 
To a solution of ethyl-4-amino cinnamate (1.00 g, 5.2 mmol) in water (20 mL) was added 
conc. HCl (5 mL). A solution of sodium nitrite (0.43 g, 6.3 mmol) in water (20 mL) was then 
added slowly with stirring while the temperature was kept below 5 °C to furnish the 
diazonium salt. This was then added to a solution of ferrocene (1.17 g, 6.3 mmol) in diethyl 
ether (40 mL) and allowed to stir for 24 hours. The reaction mixture was washed with water, 
the organic layer was dried over magnesium sulphate and the solvent was removed in vacuo 
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to yield the crude product. It was purified by column chromatography (eluent 5 % diethyl 
ether: 95 % hexane) to yield the title compound as an orange solid (0.30 g, 16 %), mp 94 °C; 
1H NMR (400 MHz) δ (DMSO-d6):  7.65 (5H, m, ArH, =CH-), 6.61 (1H, d, J 10 Hz, -CH=), 4.87 
{2H, t, J 2 Hz, ortho on (η5-C5H4)}, 4.41 {2H, t, J 1.6 Hz,  meta on (η5-C5H4)}, 4.19 (2H, q, J 7.2 
Hz, 6.8 Hz, -OCH2CH3), 4.02 (5H, s, η5-C5H5), 1.27 (3H, t, J 7.2 Hz, -OCH2CH3); 
13C NMR (100 MHz) δ (DMSO-d6): 166.4 (C=O), 144.3 (-CH=), 142.1 (Cq), 131.4 (Cq), 128.5, 
126.0, 116.7 (-CH=), 83.4 (Cipso η5-C5H4), 69.5 (η5-C5H5),(Cmeta η5-C5H4), 66.5 (Cortho  η5-C5H4), 
59.9 (-OCH2CH3), 14.2 (-OCH2CH3). 
para-Ferrocenyl-cinnamic acid 85 
Fe
O
OH
 
Sodium hydroxide (15 mL, 10 %) was added to a solution of para-ferrocenyl-ethyl 
cinnamate (0.30 g, 8.3 mmol) in methanol (15 mL). This was heated and allowed to reflux 
for 24 hours. The solution was cooled on ice and acidified to pH 2 with conc. HCl. The 
product was isolated by vacuum filtration as an orange solid (0.26 g, 94 %), mp 253-254 °C; 
1H NMR (400 MHz) δ (DMSO-d6):  12.37 (1H, br.s, -OH), 7.61-7.51 (5H, m, ArH, =CH-), 6.52 
(1H, d, J 16 Hz, -CH=), 4.86 {2H, s, ortho on (η5-C5H4)}, 4.40 {2H, s, meta on (η5-C5H4)}, 4.02 
{5H, s, (η5-C5H5)}; 
13C NMR (100 MHz) δ (DMSO-d6): 167.8 (C=O), 143.9 (-CH=), 141.8 (Cq), 131.6 (Cq), 128.4, 
126.0, 117.8 (-CH=), 83.5 (Cipso η5-C5H4), 69.5 (η5-C5H5), 69.4 (Cmeta η5-C5H4), 66.5 (Cortho  η5-
C5H4).  
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para-Ferrocenyl ethyl benzoate 86 
Fe
O
O
 
To a solution of ethyl-4-amino benzoate (1.90 g, 11.5 mmol) in water (20 mL) was added 
conc. HCl (5 mL). A solution of sodium nitrite (1.00 g, 13.8 mmol) in water (20 mL) was then 
added slowly with stirring while the temperature was kept below 5 °C to furnish the 
diazonium salt. This was then added to a solution of ferrocene (2.57 g, 13.8 mmol) in diethyl 
ether (40 mL) and allowed to stir for 24 hours. The reaction mixture was washed with water, 
the organic layer was dried over magnesium sulphate and the solvent was removed in vacuo 
to yield the crude product. It was purified by column chromatography (eluent 5 % diethyl 
ether: 95 % hexane) to yield the title compound as an orange solid (0.81 g, 21 %), mp 92°C 
(lit23 92-94 °C); 
1H NMR (600 MHz) δ (DMSO-d6): 8.09 (2H, d, J 8.4 Hz, ArH), 7.88 (2H, d, J 8.4 Hz, ArH), 4.91 
{2H, t, J 1.8 Hz, ortho on (η5-C5H4)}, 4.46 {2H, t, J 1.8 Hz, meta on (η5-C5H4)}, 4.32 (2H, q, J 7.2 
Hz, 6.6 Hz,-OCH2CH3-), 4.04 (5H, s, η5-C5H4), 1.34 (3H, t, J 6.6 Hz, -OCH2CH3); 
13C NMR (100 MHz) δ (DMSO-d6): 165.7 (C=O), 145.1 (Cq), 129.2, 126.8 (Cq), 125.7, 82.6 (Cipso 
η5-C5H4), 69.8 (η5-C5H5), 69.6 (Cmeta η5-C5H4), 66.8 (Cortho  η5-C5H4), 60.5 (-OCH2CH3), 14.2 (-
OCH2CH3). 
para-Ferrocenyl benzoic acid 87 
Fe
O
OH
 
Sodium hydroxide (15 mL, 10 %) was added to a solution of para-ferrocenyl-ethyl benzoate 
(0.74 g, 2.2 mmol) in methanol (15 mL) and allowed to reflux for 24 hours. The solution was 
cooled on ice and acidified to pH 2 with conc. HCl. The product was isolated by vacuum 
filtration as an orange solid (0.67 g, 99 %), mp. {lit23 203°C (decomp.)}; 
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1H NMR (600 MHz) δ (DMSO-d6): 12.7 (1H, br.s, -COOH), 7.78 (2H, d, J 8.4 Hz, ArH), 7.58 (2H, 
d, J 7.8 Hz, ArH), 4.82 {2H, s, ortho on (η5-C5H4)}, 4.36 {2H, s, meta on (η5-C5H4)}, 3.96 {5H, s, 
(η5-C5H5)}; 
13C NMR (150 MHz) δ (DMSO-d6): 167.3 (C=O), 144.6 (Cq), 129.4, 127.7 (Cq), 125.6, 82.9 (Cipso 
η5-C5H4), 69.7 (η5-C5H5), 69.5 (Cmeta η5-C5H4), 66.8 (Cortho  η5-C5H4).  
 
Glycine-glycine methyl ester hydrochloride 88 
 
Glycine-glycine (4.00 g, 30.3 mmol) was dissolved in methanol (40 mL). Thionyl chloride (5 
mL) was added slowly with cooling. The solution was allowed to stir at room temperature for 
two days. The solvent was removed in vacuo to yield the title compound as a white solid 
(4.12 g, 74 %), mp 107-109 °C; 
1H NMR (400 MHz) δ (DMSO-d6):  9.07 (1H, t, J 5.6 Hz, -CONH-), 8.39 (3H, br.s, NH3CH2-),  3.93 
(2H, d, J 6 Hz, -NHCH2-), 3.64 (3H, s, -OCH3), 3.60 (2H, s, -NH3CH2-); 
13C NMR (100 MHz) δ (DMSO-d6):  170.6 (C=O), 166.5 (C=O), 52.5 (-NHCH2-), 51.8 (NH3CH2-), 
40.6 (-OCH3). 
 
Glycine-glycine ethyl ester hydrochloride 89 
 
The synthesis followed that of 88 using the following reagents; glycine-glycine (0.51 g, 3.8 
mmol), ethanol (40 mL), thionyl chloride (5 mL). The solvent was removed in vacuo to yield 
the title compound as a white solid. (0.52 g, 70 %), mp 178-179 °C; 
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1H NMR (400 MHz) δ (DMSO-d6):  8.95 (1H, t, J 6 Hz, -CONH-), 8.26 (3H, br.s, -NH3),  4.11 (2H, 
q, J 6.8 Hz, -OCH2CH3), 3.93 (2H, d, J 5.6 Hz, -NHCH2-), 3.60 (2H, s, NH3CH2-),  1.20 (3H, t, J 6.8 
Hz, -OCH2CH3); 
13C NMR (100 MHz) δ (DMSO-d6): 169.4 (C=O), 166.5 (C=O), 60.6 (-OCH2CH3), 40.7 (NH3CH2-
), 40.6 (-NHCH2-), 14.0 (-OCH2CH3). 
 
Glycine-glycine propyl ester hydrochloride 90 
 
The synthesis followed that of 88 using the following reagents; glycine-glycine (0.51 g, 3.8 
mmol), propanol (40 mL), thionyl chloride (5 mL). The solvent was removed in vacuo to yield 
the title compound as a white solid. (0.61 g, 76 %), mp 161 °C; 
1H NMR (400 MHz) δ (DMSO-d6):  8.95 (1H, t, J 6 Hz, -CONH-), 8.25 (3H, br.s, -NH3), 4.03 (2H, 
t, J 6.8 Hz, -OCH2CH2-), 3.95 (2H, d, J 6 Hz, -NHCH2-), 3.60 (2H, s, NH3CH2-), 1.60 (2H, m, -
CH2CH3), 0.89 (3H, t, J 7.6 Hz, -CH2CH3); 
13C NMR (100 MHz) δ (DMSO-d6):  169.5 (C=O), 166.5 (C=O), 66.0 (-OCH2-), 40.6 (-NHCH2-), 
39.9 (NH3CH2-), 21.5 (-CH2CH3), 10.2 (-CH2CH3). 
 
Glycine-glycine butyl ester hydrochloride 91 
 
The synthesis followed that of 88 using the following reagents; glycine-glycine (0.50 g, 3.8 
mmol), butanol (20 mL), thionyl chloride (5 mL). The solvent was removed in vacuo to yield 
the title compound as a white solid. (0.59 g, 69 %), mp 155-156°C;  
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1H NMR (400 MHz) δ (DMSO-d6):  8.98 (1H, t, J 5.6 Hz, -CONH-), 8.28 (3H, br.s, -NH3), 4.06 
(2H, t, J 6.8 Hz, -OCH2CH2-), 3.93 (2H, d,  J 5.6 Hz, -NHCH2-), 3.60 (2H, s, NH3CH2-), 1.56 (2H, 
qt, J 6.8 Hz, -CH2CH2CH2-),  (2H, m, -CH2CH3), 0.89 (3H, t, J 7.2 Hz, -CH2CH3); 
13C NMR (100 MHz) δ (DMSO-d6):  169.4 (C=O), 166.5 (C=O), 64.2 (-OCH2-), 40.6 (-NHCH2-), 
39.8 (NH3CH2-), 30.1 (-OCH2CH2-), 18.5 (-CH2CH3), 13.5 (-CH3). 
 
γ-Aminobutyric acid methyl ester hydrochloride 92 
 
The synthesis followed that of 88 using the following reagents; γ-aminobutyric acid (5.00 g, 
48.5 mmol), methanol (40 mL), thionyl chloride (5 mL). The solvent was removed in vacuo to 
yield the title compound as a white solid. (4.33 g, 58 %), mp 115 °C; 
1H NMR (400 MHz) δ (DMSO-d6):  8.14 (3H, br.s, -NH3), 3.60 (3H, s, -OCH3), 2.78 (2H, t, J 7.6 
Hz, -COCH2-),  2.44 (2H, t, J 7.6 Hz, NH3CH2-), 1.81 (2H, qt, J 7.6 Hz,-CH2CH2CH2-); 
13C NMR (100 MHz) δ (DMSO-d6): 172.6 (C=O), 51.4 (-OCH3), 38.1 (-COCH2-), 30.2 (NH3CH2-), 
22.4 (-CH2CH2CH2-). 
 
γ-Aminobutyric acid ethyl ester hydrochloride 93 
 
The synthesis followed that of 88 using the following reagents; γ-aminobutyric acid (2.05 g, 
19.9 mmol), ethanol (30 mL), thionyl chloride (5 mL). The solvent was removed in vacuo to 
yield the title compound as a white solid. (2.19 g, 66 %), mp 47-48 °C; 
1H NMR (600 MHz) δ (DMSO-d6):  8.24 (3H, br. s, -NH3CH2-), 4.06 (2H, q, J 7.2 Hz, -OCH2CH3), 
2.79 (2H, t, J 7.2 Hz, -COCH2-), 2.43 (2H, t, J 7.8 Hz, NH3CH2-), (2H, qt, J 7.2 Hz, -CH2CH2CH2-), 
1.19 (3H, t, J 7.2 Hz, -OCH2CH3); 
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13C NMR (100 MHz) δ (DMSO-d6): 172.1 (C=O), 59.9 (-OCH2CH3), 38.0 (-COCH2-), 30.4 
(NH3CH2-), 22.3,(-CH2CH2CH2-) 14.1 (-OCH2CH3). 
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General procedure for the preparation of Boc protected dipeptide esters 
Boc glycine-glycine benzyl ester 94 
 
 
To a solution of Boc-Glycine-OH (0.62 g, 3.5 mmol) in DCM (50 mL) was added ethyl 
dimethylaminopropyl carbodiimide (EDC) (1.13 g, 5.9 mmol), N-hydroxy succinimide (NHS) 
(0.17 g, 1.5 mmol) and triethylamine (5 mL) . The solution was allowed to stir at 0 °C for one 
hour. Glycine benzyl ester p-toluenesulfonate (1.00 g, 3.0  mmol) was then added. The 
solution was allowed to stir for a further 20 minutes at 0 °C before the temperature was 
raised and the solution was allowed to stir at room temperature for 48 hours. The solvent 
was removed in vacuo and the crude product was purified by column chromatography 
(eluent 50 % ethyl acetate: 50 % hexane) to afford the product as a white solid (0.46 g, 41 
%), mp 76-77 °C; 
1H NMR (400 MHz) δ (DMSO-d6):  8.31 (1H, t, J 5.6 Hz, -CONH-), 7.47-7.37 (5H, m, ArH), 7.10 
(1H, t, J 6 Hz, -CONH-), 5.20 (2H, s, -OCH2Ph), 3.97 (2H, d, J 6 Hz, -NHCH2-), 3.65 (2H, d, J 6.4 
Hz, -NHCH2-), 1.44 {9H, s, -(CH3)3}; 
13C NMR (100 MHz) δ (DMSO-d6): 170.0 (C=O), 169.7 (C=O), 167.3 (C=O), 155.8 (Cq), 128.4, 
128.3, 128.2, 86.3 (Cq), 65.8 (OCH2), 43.0 (NHCH2), 40.6 (NHCH2), 28.2 {(CH3)3}. 
 
Boc-glycine-L-alanine-ethyl ester 95 
 
The synthesis followed that of  94 using the following reagents; Boc-glycine-OH (0.86 g, 5.0 
mmol), L-alanine ethyl ester hydrochloride (1.17 g, 7.6 mmol), NHS (0.32 g, 2.8 mmol), EDC 
(2.15 g, 11.2 mmol). The product was purified by column chromatography (eluent 50 % ethyl 
acetate: 50 % hexane) to yield the title compound as a transparent oil (0.73 g, 53 %);      
110 
 
1H NMR (400 MHz) δ (DMSO-d6):  8.19 (1H, d, J 7.2 Hz, -CONH-), 6.93 (1H, t, J 6 Hz, -CONH-), 
4.25 (1H, qt, J 7.2 Hz, -NHCH-), 4.08 (2H, q,  J 7.2 Hz, -OCH2CH3), 3.57 (1H, dd, J 10.4 Hz and 
6.4 Hz, -NHCH2-), 3.52 (1H, dd, J 10.4 Hz and 6.4 Hz, -NHCH2-), 1.38 {9H, s, -(CH3)3}, 1.27 (3H, 
d, J 7.2 Hz, -CHCH3), 1.18 (3H, t, J 8 Hz, -OCH2CH3); 
13C NMR (100 MHz) δ (DMSO-d6): 172.5 (C=O), 169.2 (C=O), 155.7 (C=O), 77.9 (Cq), 60.4 (-
OCH2CH3-), 47.5 (-NHCH2-), 42.7 (-NHCH2-), 28.1 {-(CH3)3}, 17.0 (-OCH2CH3), 14.0 {-C(CH3)}. 
 
Boc-glycine-D-alanine-ethyl ester 96 
 
The synthesis followed that of 94 using the following reagents; Boc-glycine-OH (6.03 g, 34.4 
mmol), D-alanine ethyl ester hydrochloride (5.00 g, 32.5 mmol), NHS (1.94 g, 16.8 mmol), 
EDC (11.0 g, 57.4 mmol). The product was purified by column chromatography (eluent 50 % 
ethyl acetate: 50 % hexane) to yield the title compound as a transparent oil (2.54 g, 32 %)       
1H NMR (400 MHz) δ (DMSO-d6):  8.19 (1H, d, J 7.2 Hz, -CONH-), 6.92 (1H, t, J 6 Hz), 4.26 (1H, 
qt, J 7.6 Hz, -NHCH-), 4.07 (2H, q, J 7.2 Hz, -OCH2CH3-), 3.60 (1H, dd, J 10.4 Hz and 6.4 Hz, -
NHCH2-), 3.52 (1H, dd, J 10.8 Hz and 6 Hz, -NHCH2-), 1.38 {9H, s, -C(CH3)3}, 1.27 (3H, d, J 7.2 
Hz, -CHCH3), 1.18 (3H, t, J 6.8 Hz, -OCH2CH3) 
13C NMR (100 MHz) δ (DMSO-d6): 172.5 (C=O), 169.2 (C=O), 155.7 (C=O), 77.9 (Cq), 60.4 (-
OCH2), 47.5 (-CHCH3), 42.7 (-NHCH2-), 28.1 {-C(CH3)3}, 17.0 (-OCH2CH3), 14.0 (-CHCH3). 
 
Boc-sarcosine-glycine-ethyl ester 97 
O
O
N
H
N
O
O
O
 
The synthesis followed that of 94 using the following reagents; Boc-sarcosine-OH (9.04 g, 
51.6 mmol), glycine ethyl ester hydrochloride (6.00 g, 43.0 mmol), NHS (2.47 g, 21.5 mmol), 
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EDC (16.48 g, 85.9 mmol). The product was purified by column chromatography (eluent 50 
% ethyl acetate: 50 % hexane) to yield the title compound as a transparent oil (3.2 g, 27 %); 
1H NMR (400 MHz) δ (DMSO-d6): 8.29 (1H, br.s, -CONH-), 4.10 (2H, q, J 7.2 Hz, -OCH2CH3), 
3.74-3.84 {4H, m, -NHCH2-, -N(CH3)CH-}, 2.77 {3H, s, -N(CH3)}, 1.40 {9H, s,  -C(CH3)3}, 1.19 (3H, 
t, J 8 Hz, -OCH2CH3); 
13C NMR (100 MHz) δ (DMSO-d6): 169.6 (C=O), 168.9 (C=O), 156.1 (C=O), 79.3 (Cq), 62.0 (-
OCH2CH3-), 59.5 {-N(CH3)CH}, 41.4 (-NHCH2-), 36.1 -{N(CH3)}, 28.7 {-C(CH3)3}, 14.2 (-OCH2CH3). 
 
Boc-glycine-D-alanine-methyl ester 97 
 
The synthesis followed that of 94 using the following reagents: Boc-glycine-OH (1.63 g, 9.3 
mmol), EDC (3.00 g, 15.6 mmol), NHS (0.45 g, 3.9 mmol) and D-alanine methyl ester 
hydrochloride (1.09 g, 7.8 mmol). The product was purified by column chromatography 
(eluent 50 % ethyl acetate: 50 % hexane) to yield the title compound as a transparent oil 
(0.63 g, 31 %); 
1H NMR (400 MHz) δ (DMSO-d6):  8.22 (1H, d, J 7.2 Hz, -CONH-), 6.93 (1H, t, J 6 Hz, -CONH-), 
4.28 (1H, qt, J 7.2 Hz, -NHCH-), 3.62 (3H, s, -OCH3), 3.60-3.49 (2H, m, -NHCH2-), 1.38 {9H, s, -
C(CH3)3}, 1.27 (3H, d, J 7.2 Hz, -CHCH3); 
13C NMR (100 MHz) δ (DMSO-d6): 178.3 (C=O), 174.4 (C=O), 161.0 (C=O), 83.2 (Cq), 57.1 (-
OCH3), 52.6 (-NHCH-), 48.0 (-NHCH2-), 33.4 {-C(CH3)3}, 22.32 (-CHCH3). 
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Boc-glycine-L-alanine-methyl ester 98 
O
O
N
H
H
N
O
O
O
 
The synthesis followed that of 94 using the following reagents: Boc-glycine-OH (6.02 g, 34.4 
mmol), EDC (11.0 g, 57.4 mmol), NHS (1.65 g, 14.4 mmol) and L-alanine methyl ester 
hydrochloride (4.00 g, 28.7 mmol). The product was purified by column chromatography 
(eluent 50 % ethyl acetate: 50 % hexane) to yield the title compound as a transparent oil 
(2.63 g, 35 %); 
1H NMR (400 MHz) δ (DMSO-d6): 8.22 (1H, d, J 7.2 Hz, -CONH-), 6.93 (1H, t, J 6 Hz, -CONH-), 
4.28 (1H, qt, J 7.2 Hz, -NHCH-), 3.62 (3H, s, -OCH3), 3.60-3.42 (2H, m, -NHCH2-), 1.38 {9H, s, -
C(CH3)3}, 1.27 {3H, d, J 7.2 Hz, -C(CH3}; 
13C NMR (100 MHz) δ (DMSO-d6): 173.0 (C=O), 169.2 (C=O), 155.7 (C=O), 77.9 (Cq), 51.9 (-
OCH3-) 47.4 (-NHCH-), 42.7 (-NHCH2-), 28.2 {-C(CH3)3}, 17.1 (-CHCH3). 
 
Boc-sarcosine-glycine-methyl ester 99 
 
The synthesis followed that of 94 using the following reagents: Boc-sarcosine-OH (6.00 g, 
31.7 mmol), EDC (12.16 g, 63.4 mmol), NHS (1.82 g, 15.9 mmol) and glycine methyl ester 
hydrochloride (4.70 g, 37.4 mmol). The product was purified by column chromatography 
(eluent 50 % ethyl acetate: 50 % hexane) to yield the title compound as a transparent oil 
(1.23 g, 15 %); 
1H NMR (400 MHz) δ (DMSO-d6): 8.31 (1H, br.s, -NHCH2-), 3.79-3.87 (4H, m, -NHCH2-, -
N(CH3)CH2-), 3.63 (3H, s, -OCH3), 2.79 (3H, s, -NCH3), 1.40 and 1.35 {9H, s, s, -(CH3)3}. 
13C NMR (100 MHz) δ (DMSO-d6): 170.3 (C=O), 170.2 (C=O), 169.3 (C=O), 78.7 (Cq), 51.7 (-
OCH3), 51.4 (-NCH3CH2-), 40.4 (-NHCH2-), 35.3 & 35.1(-NCH3), 28.0 & 27.8 {C(CH3)3}. 
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General procedure for the synthesis of N-(6-ferrocenyl-2-naphthoyl)-glycine-
glycine esters. 
N-(6-ferrocenyl-2-naphthoyl)-glycine-glycine methyl ester 100. 
O
HN
O
HN
O
O
Fe
 
Glycine-glycine methyl ester hydrochloride (0.35 g, 1.9 mmol) was added to a solution of 6-
ferrocenylnaphthalene-2-carboxylic acid (0.40 g, 1.1 mmol), 1-hydroxybenzotriazole (0.27 g, 
2.0 mmol), N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (0.37 g, 2.4 
mmol) and triethylamine (5 mL) in dichloromethane (50 mL) at 0 °C. The temperature was 
raised to room temperature after 30 minutes and the reaction was allowed to stir for 48 h. 
The reaction mixture was washed with water and the organic layer was dried over MgSO4 
and the solvent was removed in vacuo. The product was purified by column chromatography 
(eluent 20 % ethyl acetate: 80 % hexane -100 % ethyl acetate) to yield the title compound as 
an orange solid (0.27 g, 51 %), mp 197-198 °C; 
Anal. calc. for C26H24N2O4Fe: C, 64.48; H, 4.99; N, 5.78 %. Found: C, 64.47; H, 5.05; N, 5.65; 
m/z (ESI) 484.1080 [M]+•.  C26H24N2O4Fe requires 484.1085; 
UV-Vis λmax (CH3CN)/nm 369 (ε/dm3mol-1cm-1 3093), 451 (1344); 
I.R. υmax (neat)/ cm-1 3418, 3313, 1741, 1638, 1622, 1512, 1211; 
1H NMR (400 MHz) δ (DMSO-d6):  8.95 (1H, t, J 5.6 Hz, -CONH-), 8.46 (1H, s, ArH), 8.42 (1H, t, 
J 5.6 Hz, -CONH-), 8.07 (1H, s, ArH), 7.94-7.97 (3H, m, ArH), 7.83 (1H, dd, J 7.2 Hz and 1.6 Hz, 
ArH), 4.97 {2H, t, J 1.6 Hz, ortho on (η5-C5H4)}, 4.46 {2H, t, J 1.6 Hz, meta on (η5-C5H4)}, 4.05 
(5H, s, η5-C5H5), 3.98 (2H, d, J 5.6 Hz, -NHCH2-),  3.89 (2H, d, J 6 Hz, -NHCH2-), 3.64 (3H, s, -
OCH3); 
13C NMR (100 MHz) δ (DMSO-d6): 170.3 (C=O), 169.6 (C=O), 166.5 (C=O), 138.8 (Cq), 134.5 
(Cq), 130.6 (Cq), 130.4 (Cq), 128.7, 127.6, 127.3, 125.9, 124.6, 122.7, 84.0 (Cipso η5-C5H4), 69.5 
(η5-C5H5), 69.4 (Cmeta η5-C5H4), 66.6 (Cortho  η5-C5H4), 51.7 (-OCH3), 42.4 (-NHCH2), 40.6 (-NHCH2). 
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 N-(6-ferrocenyl-2-naphthoyl)-glycine-glycine propyl ester 101.    
 
 
 
 
 
 
The synthesis followed that of 100 using the following reagents; glycine-glycine propyl ester 
hydrochloride (0.24 g, 1.1 mmol) and ferrocenylnaphthalene-2-carboxylic acid (0.40 g, 1.1 
mmol). The product was purified by column chromatography (eluent 20 % ethyl acetate: 100 
% hexane -100 % ethyl acetate) to yield the title compound as an orange solid (0.31 g, 55 %), 
mp 115-117 °C;    
m/z (ESI) 512.1380 [M]+•.  C28H28N2O4Fe requires 512.1398;  
I.R. υmax (neat)/cm-1 3281, 1753, 1653, 1523, 1203; 
UV-Vis λmax (CH3CN)/nm 373 (ε/dm3mol-1cm-1 2600), 448 (1086); 
1H NMR (400 MHz) δ (DMSO-d6):  8.95 (1H, t, J 6 Hz, -CONH-), 8.46 (1H, s, ArH), 8.40 (1H, t, J 
6 Hz, -CONH-), 8.06 (1H, s, ArH),  7.94-7.97 (3 H, m, ArH ), 7.83 (1H, dd, J 7.2 Hz and 1.6 Hz, -
ArH), 4.96 {2H, t, J 1.6 Hz, ortho on (η5-C5H4)},  4.45 {2H, t, J  2 Hz, meta on (η5-C5H4)},   4.05-
3.98 {9H, m, (η5-C5H5),  -NHCH2CO,  -OCH2CH2-},  3.89 (2H, d, J 6, -NHCH2-), 1.59 (2H, m, -
CH2CH3), 0.88 (3H, t, J 7.2 Hz, -CH2CH3); 
13C NMR (100 MHz) δ (DMSO-d6): 169.9 (C=O), 169.6 (C=O), 166.6 (C=O), 138.8 (Cq), 134.5 
(Cq), 130.6 (Cq), 130.4 (Cq), 128.7, 127.6, 127.3, 125.9, 124.6, 122.7, 84.0 (Cipso η5-C5H4), 69.5 
(η5-C5H5), 69.4 (Cmeta η5-C5H4), 66.6 (Cortho  η5-C5H4), 65.8(-OCH2CH2-), 42.5(-NHCH2), 40.6(-
NHCH2), 21.5(-OCH2CH2-), 10.2(-CH3). 
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N-(6-ferrocenyl-2-naphthoyl)-glycine-glycine butyl ester 102 
Fe
O
HN
HN
O
O
O  
The synthesis followed that of 100 using-glycine-glycine butyl ester hydrochloride (0.26 g, 
1.2 mmol) and ferrocenylnaphthalene-2-carboxylic acid (0.50 g, 1.4 mmol). The product was 
purified by column chromatography (eluent 20 % ethyl acetate: 80 % hexane -100 % ethyl 
acetate) to yield the title compound as an orange solid (0.49 g, 78 %), mp 134-135 °C; 
m/z (ESI) 526.1541 [M]+•.  C29H30N2O4Fe requires 526.1555 ; 
I.R. υmax (neat)/cm-1 3298, 1749, 1645, 1544, 1175; 
UV-Vis λmax (CH3CN)/nm 375 (ε/dm3mol-1cm-1 2717), 452 (1174); 
1H NMR (400 MHz) δ (DMSO-d6):  8.95 (1H, t, J 6 Hz, -CONH-), 8.46 (1H, s, ArH), 8.39 (1H, t, J 
6 Hz, -CONH-), 8.06 (1H, s, ArH), 7.92-7.97 (3H, m, ArH),  7.83 (1H, dd, J 6.8 Hz and 1.6 Hz, 
ArH), 4.96 {2H, t, J 2 Hz, ortho on (η5-C5H4)}, 4.45 {2H, t, J 1.6 Hz, meta on (η5-C5H4)}, 3.99-
4.07 (7H, m, (η5-C5H5) -OCH2CH2-), 3.98 (2H, d, J 6 Hz, -NHCH2-) 3.88 (2H, d, J 5.6 Hz, -NHCH2-
), 1.56 (2H, qt, J 4.4 Hz, -OCH2CH2-), 1.32 (2H, sex, J 7.6 Hz, -CH2CH3), 0.88 (3H, t, J 7.6 Hz, -
CH2CH3); 
13C NMR (100 MHz) δ (DMSO-d6): 169.8 (C=O), 169.6 (C=O), 166.5 (C=O), 138.8 (Cq), 134.5 
(Cq), 130.6 (Cq), 130.4 (Cq), 128.7, 127.6, 127.3, 125.9, 124.6, 122.7, 84.0 (Cipso η5-C5H4), 69.5 
(η5-C5H5), 69.4 (Cmeta η5-C5H5), 66.6 (Cortho  η5-C5H4), 64.0 (-OCH2CH2-), 42.5 (-NHCH2-), 40.7 (-
NHCH2-), 30.1 (-OCH2CH2-), 18.5 (-CH2CH3), 13.5 (-CH3). 
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N-(6-ferrocenyl-2-naphthoyl)-glycine-glycine benzyl ester 103 
 
 
 
 
 
 
 
The synthesis followed that of 100 using the following reagents; boc-glycine-glycine benzyl 
ester (0.34 g, 1.1 mmol) and ferrocenylnaphthalene-2-carboxylic acid (0.30 g, 0.8 mmol). The 
product was purified by column chromatography (eluent 20 % ethyl acetate: 80 % hexane -
100 % ethyl acetate) to yield the title compound as an orange solid (0.31 g, 66 %), mp 137-
139 °C; 
m/z (ESI) 560.1392 [M]+•.  C32H28N2O4Fe requires 560.1398; 
I.R. υmax (neat)/cm-1 3263, 1749, 1645, 1544, 1175; 
UV-Vis λmax (CH3CN)/nm 379 (ε/dm3mol-1cm-1 2908), 452 (1281); 
1H NMR (400 MHz) δ (DMSO-d6):  8.96 (1H, t, J 6 Hz, -CONH-), 8.45 (2H, m, ArH, -CONH-), 8.07 
(1H, s, ArH), 8.06 (1H, s, ArH), 7.94-8.04 (3H, m, ArH), 7.83 (1H, dd, J 7.2 Hz and 1.6 Hz, ArH), 
7.31-7.38 (5H, m, ArH), 5.14 (2H, s, -OCH2Ph), 4.96 {2H, t, J 2 Hz, ortho on (η5-C5H4)}, 4.45 {2H, 
t, J 1.6 Hz, meta on (η5-C5H4)}, 4.05 (5H, s, η5-C5H5),  3.99 (2H, d, J 5.6 Hz, -NHCH2-),  3.95 (2H, 
d, J 6 Hz, -NHCH2-); 
13C NMR (100 MHz) δ (DMSO-d6): 169.9 (C=O), 169.7 (C=O), 166.6 (C=O), 138.9 (Cq), 135.9( 
Cq), 134.5 (Cq), 130.6 (Cq), 130.4 (Cq), 128.7, 128.4, 128.1, 127.9, 127.6, 127.3, 125.9, 124.6, 
122.7, 84.0 (Cipso η5-C5H4), 69.5 (η5-C5H5), 69.4 (Cmeta η5-C5H4), 66.6 (Cortho  η5-C5H4), 65.8{-
CH2(C6H5)-}, 42.5 (-NHCH2-), 40.7 (-NHCH2-). 
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General procedures for the synthesis of N-(6-ferrocenyl-2-naphthoyl)-dipeptides 
and amino acids esters. 
N-(6-ferrocenyl-2-naphthoyl)-sarcosine-glycine methyl ester 104. 
 
Fe
O
N
O
HN
O
O
 
Sarcosine-glycine methyl ester trifluoroacetate salt (1.00 g, 3.5 mmol) was added to a 
solution of 6-ferrocenylnaphthalene-2-carboxylic acid (1.47 g, 4.1 mmol), EDC (1.32 g, 6.9 
mmol), NHS (0.20 g, 1.7 mmol) and  triethylamine (5 mL) in dichloromethane (50 mL) at 0 °C. 
The temperature was raised to room temperature after 30 minutes and the reaction  was 
allowed to stir for 48 h. The reaction mixture was washed with water and the orgainc layer 
was dried over MgSO4 and the solvent was removed in vacuo. The product was purified by 
column chromatography (eluent 20 % ethyl acetate: 80 % hexane -100 % ethyl acetate) to 
yield the title compound as an orange solid (0.33 g, 20 %), mp 86-87 °C; 
I.R. υmax (neat)/cm-1 3291, 1742, 1624, 1543, 1205; 
UV-Vis λmax (CH3CN)/nm 359 (ε/dm3mol-1cm-1 2744), 452 (1027); 
1H NMR (400 MHz) δ (DMSO-d6):  8.59 & 8.51 (1H, br.s, br.s, -CONH-), 8.08 (1H, s, ArH), 8.05-
7.89 (3H, m, ArH), 7.81 (1H, d, J 8.4 Hz, ArH), 7.65-7.58 (1H, m, ArH), 5.0 {2H, t, J 1.6 Hz, ortho 
on (η5-C5H4)}, 4.48 {2H, t, J 1.6 Hz, meta on (η5-C5H4)}, 4.20 {1H, s, -N(CH3)CH2}, 3.92-4.04 {9H, 
m, (η5-C5H5), -N(CH3)CH2-, -NHCH2-}, 3.66 (3H, d, J 6.4 Hz, -OCH3), 3.02 {3H, s,  -N(CH3)}; 
13C NMR (100 MHz) δ (DMSO-d6): 171.1 (C=O), 170.2 (C=O), 168.9 (C=O), 138.2 (Cq), 133.5 
(Cq), 132.4 (Cq), 130.7 (Cq), 128.6, 127.5, 126.5, 125.9, 124.8, 122.8, 84.1 (Cipso η5-C5H4), 69.5 
(η5-C5H5), 69.4 (Cmeta η5-C5H4), 66.6 (Cortho η5-C5H4), 53.8 (-NHCH2-), 49.7 {-N(CH3)CH2-}, 51.8 (-
OCH3), 38.4 & 34.1 {-N(CH3)}. 
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N-(6-ferrocenyl-2-naphthoyl)-γ-aminobutyric acid-methyl ester 105. 
 
Fe
O
HN
O
O
 
The synthesis followed that of 104 using the following reagents; γ-aminobutyric acid methyl 
ester (0.20 g, 1.3 mmol) and 6-ferrocenylnaphthalene-2-carboxylic acid (0.39 g, 1.1 mmol), 
EDC (0.42 g, 2.2 mmol), NHS (0.06g, 0.6 mmol). The product was purified by column 
chromatography (eluent 20 % ethyl acetate: 80 % hexane -100 % ethyl acetate) to yield the 
title compound as an orange solid (0.25 g, 50 %), mp 128-129 °C; 
I.R. υmax (neat)/cm-1 3305, 1729, 1624, 1547, 1166; 
UV-Vis λmax (CH3CN)/nm 371 (ε/dm3mol-1cm-1 3127), 452 (1213); 
1H NMR (400 MHz) δ (DMSO-d6):  8.66 (1H, t, J 5.6 Hz, -CONH-), 8.37 (1H, s, ArH), 7.96-7.89 
(3H, m, ArH), 7.82 (1H, dd, J 7.2 Hz and 1.6 Hz, ArH), 4.96 {2H, t, J 1.6 Hz, ortho on (η5-C5H4)}, 
4.45 {2H, t, J 1.6 Hz, meta on (η5-C5H4)}, 4.05 {5H, s, (η5-C5H5)}, 3.62 (3H, s, -OCH3), 2.43 (2H, 
t, J 6.4 Hz, -COCH2-), 1.83 (2H, quin, J 7.2 Hz, -CH2CH2CH2-), 1.17 (2H, t, J 7.2 Hz, -NHCH2-); 
13C NMR (100 MHz) δ (DMSO-d6): 173.2 (C=O), 166.3 (C=O), 138.6 (Cq), 134.4 (Cq), 131.0 (Cq), 
130.7 (Cq), 128.7, 127.3, 127.2, 125.9, 124.5, 122.7, 84.1 (Cipso η5-C5H4), 69.4 (η5-C5H5), 
(Cmeta  η5-C5H4), 66.6 (Cortho  η5-C5H4), 51.3 (-OCH3), 38.6 (-NHCH2-), 30.8 (-COCH2-), 24.5 (-
CH2CH2CH2-). 
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N-(6-ferrocenyl-2-naphthoyl)-glycine-L-alanine-methyl ester 106. 
Fe
O
HN
O
HN
O
O
 
The synthesis followed that of 104 using the following reagents; glycine-L-alanine methyl 
ester trifluoroacetate salt (1.46 g, 5.1 mmol), 6-ferrocenylnaphthalene-2-carboxylic acid 
(1.50 g, 4.2 mmol), EDC (1.61 g, 8.42 mmol), NHS (0.24 g, 2.1 mmol) and triethylamine (5 
mL). The product was purified by column chromatography (eluent 20 % ethyl acetate: 80 % 
hexane -100 % ethyl acetate) to yield the title compound as an orange solid (0.53 g, 26 %), 
mp 137-139°C; 
I.R. υmax (neat)/cm-1 3305, 1734, 1627, 1516, 1200; 
UV-Vis λmax (CH3CN)/nm 376 (ε/dm3mol-1cm-1 3210), 452 (1302); 
1H NMR (400 MHz) δ (DMSO-d6):  8.85 (1H, t, J 5.6 Hz, -CONH-), 8.45 (2H, s, ArH), 8.06 (1H, s, 
ArH), 7.97-7.93 (2H, m, ArH), 7.83 (1H, dd, J 6.8 Hz and 1.6 Hz, -CONH-), 4.97 {2H, t, J 1.6 Hz, 
ortho on (η5-C5H4)}, 4.46 {2H, t, J 2 Hz, meta on (η5-C5H4)}, 4.34 (1H, qt, J 7.2, -NHCH-), 4.05 
(5H, s, η5-C5H4), 3.98 (2H, qd, J 10.8 Hz, 6 Hz, -NHCH2-), 3.64 (3H, s, -OCH3), 1.31 (3H, d, J 7.2 
Hz, -CHCH3); 
13C NMR (100 MHz) δ (DMSO-d6): 173.0 (C=O), 168.9 (C=O), 166.4 (C=O), 138.8 (Cq), 134.5 
(Cq), 130.6 (Cq), 130.4 (Cq), 128.7, 127.6, 127.3, 125.9, 124.5, 122.7, 84.1 (Cipso η5-C5H4), 69.4 
(η5-C5H5), (Cmeta  η5-C5H4), 66.6 Cortho η5-C5H4), 51.8 (-OCH3), 47.5 (-NHCH2-), 40.1 (NHCH-), 17.1 
(-CHCH3).  
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N-(6-ferrocenyl-2-naphthoyl)-glycine-D-alanine-methyl ester 107. 
Fe
O
HN
HN
O
O
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The synthesis followed that of 104 using the following reagents; glycine-D-alanine methyl 
ester trifluoroacetate salt (0.29 g, 1.0 mmol) and 6-ferrocenylnaphthalene-2-carboxylic acid 
(0.30 g, 0.8 mmol), EDC (0.33 g, 1.7 mmol), NHS (0.05 g, 0.4 mmol). The product was purified 
by column chromatography (eluent 20 % ethyl acetate: 80 % hexane -100 % ethyl acetate) to 
yield the title compound as an orange solid (0.19 g, 47 %), mp 142-144 °C; 
I.R. υmax (neat)/cm-1 3292, 1747, 1624, 1645, 1513, 1206; 
UV-Vis λmax (CH3CN)/nm 363 (ε/dm3mol-1cm-1 3682), 452 (1403); 
1H NMR (400 MHz) δ (DMSO-d6):  8.85 (1H, t, J 5.6 Hz, -CONH-), 8.46 (2H, m, -CONH-, ArH), 
8.06 (1H, s, ArH), 7.97-7.93 (3H, m, ArH), 7.83 (2H, dd, J 6.8 Hz and 1.6 Hz, ArH), 4.97 {2H, t, 
J 1.6 Hz, ortho on (η5-C5H4)}, 4.46 {2H, t, J 2 Hz, meta on (η5-C5H4)}, 4.34 (1H, qt, J 7.2 Hz, -
NHCH-), 4.05 {5H, s, (η5-C5H5)}, 3.98 (2H, dd, J 10.8 Hz and 6 Hz, -NHCH2-), 3.64 (3H, s, -OCH3); 
13C NMR (100 MHz) δ (DMSO-d6): 173.0 (C=O), 168.9 (C=O), 166.4 (C=O), 138.8 (Cq), 134.5 
(Cq), 130.6 (Cq), 130.4 (Cq), 128.7, 127.5, 127.3, 125.9, 124.5, 122.7, 84.0 (Cipso η5-C5H4), 69.4 
(η5-C5H5), ( Cortho η5-C5H4), 66.6 (Cmeta  η5-C5H4), 51.9 (-OCH3), 47.5 (-NHCH2-), 42.2 (NHCH-), 
17.1 (-NHCH3). 
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General procedures for the synthesis of N-(6-ferrocenyl-2-naphthoyl)-dipeptides 
and amino acids. 
N-(6-ferrocenyl-2-naphthoyl)-glycine-glycine-OH 108. 
Fe
O
HN
HN
O
HO
O  
N-(6-ferrocenyl-2-naphthoyl)-glycine-glycine ethyl ester (0.09 g, 0.2 mmol) was dissolved in 
methanol (15 mL) and sodium hydroxide (15 mL, 0.5 M) and allowed to reflux 24 hours. The 
solution was cooled on ice and acidified to pH 2. The product was isolated by vacuum 
filtration as an orange solid (0.05 g, 59 %), mp 155-157 °C; 
I.R. υmax (neat)/cm-1 3277, 1690, 1628, 1600, 1544, 1392, 1243; 
UV-Vis λmax (CH3CN)/nm 373 (ε/dm3mol-1cm-1 1545), 452 (673); 
1H NMR (400 MHz) δ (DMSO-d6):  12.79 (1H, br.s, -OH), 8.96 (1H, t, J 5.6 Hz, -CONH-), 8.46-
8.44 (1H, m, ArH), 8.29 (1H, t, J 6 Hz, -CONH-), 8.06 (1H, s, ArH), 7.98-7.91 (3H, m, ArH), 7.83 
(1H, d, J 8.4 Hz, ArH), 4.96 {2H, s, ortho on (η5-C5H4)}, 4.45 {2H, t, J 1.6 Hz, meta on (η5-C5H4)}, 
4.05 {5H, s, (η5-C5H5)}, 3.98 (2H, d, J 5.6 Hz, -NHCH2-), 3.80 (2H, d, J 6 Hz, -NHCH2-); 
13C NMR (100 MHz) δ (DMSO-d6): 171.2 (C=O), 169.4 (C=O), 166.5 (C=O), 138.8 (Cq), 136.9 
(Cq), 134.6 (Cq), 130.4 (Cq), 128.8, 127.6, 127.3, 125.9, 124.6, 122.7, 84.0 (Cipso η5-C5H4), 69.5 
(η5-C5H5), 69.4 (Cortho η5-C5H4), 66.6 (Cmeta η5-C5H4), 42.5 (-NHCH2-), 40.6 (-NHCH2-). 
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N-(6-ferrocenyl-2-naphthoyl)-sarcosine-glycine-OH 109. 
Fe
O
N
N
O
O
HO
 
The synthesis followed that of 108 using N-(6-ferrocenyl-2-naphthoyl)-sarcosine-glycine 
methyl ester (0.30 g, 0.6 mmol) as the starting material. This yielded the title compound as 
an orange solid (0.21 g, 72 %), mp 132 °C;  
I.R. υmax (neat)/cm-1 3301, 1720, 1624, 1548, 1310, 1235;  
UV-Vis λmax (CH3CN)/nm 365 (ε/dm3mol-1cm-1 2513), 452 (1038); 
1H NMR (400 MHz) δ (DMSO-d6):  13.1 (1H, br.S, -OH),  8.66 & 8.57 (1H, br.s, br.s, -NHCH2-), 
8.24 (1H, s, ArH), 7.85-8.21 (3H, m, ArH), 7.84 (1H, s, ArH), 7.39 (1H, d, J 8.4 Hz, ArH) 4.97 
{2H, s, ortho on (η5-C5H4)}, 4.46 {2H, s, meta on (η5-C5H4)}, 4.20-3.74 {9H, m, (η5-C5H5), 
N(CH3)CH2-, -NHCH2-}, 3.01 {3H, s, -N(CH3)}. 
13C NMR (100 MHz) δ (DMSO-d6): 171.6 (C=O), 170.0 (C=O), 168.2 (C=O), 138.2 (Cq), 133.5 
(Cq), 132.4 (Cq), 130.7 (Cq), 128.6, 127.5, 126.5, 125.9, 124.8, 122.8, 84.1 (Cipso η5-C5H4), 69.5 
(η5-C5H5), 69.4 (Cmeta η5-C5H4), 66.6 (Cortho η5-C5H4), 53.8 (-NHCH2-), 49.7 {-N(CH3)CH2-}, 38.4 & 
34.1 {-N(CH3)}. 
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N-(6-ferrocenyl-2-naphthoyl)-γ-aminobutyric acid 110. 
Fe
O
HN
O
OH
 
The synthesis followed that of 108 using N-(6-ferrocenyl-2-naphthoyl)-γ-aminobutyric acid 
methyl ester (0.20 g, 0.4 mmol) as the starting material. This yielded the title compound as 
an orange solid (0.17 g, 90 %), mp 213 °C (decomp.); 
I.R. υmax (neat)/cm-1 3276, 1712, 1615, 1543, 116, 1220; 
UV-Vis λmax (CH3CN)/nm 371 (ε/dm3mol-1cm-1 1562), 451 (641); 
1H NMR (400 MHz) δ (DMSO-d6):  8.66 (1H, t, J 5.6 Hz, -CONH-), 8.39 (1H, s, ArH), 8.05 (1H, s, 
ArH), 7.96-7.88 (3H, m, ArH), 7.82 (1H, dd, J 6.8 Hz and 1.6 Hz, ArH), 4.96 {2H, t, J 2 Hz, ortho 
on (η5-C5H4)}, 4.45 {2H, t, J 1.6 Hz, meta on (η5-C5H4)}, 4.04 {5H, s, (η5-C5H5)}, 3.36-3.31 (2H, 
m, -COCH2), 2.32 (2H, t, J 7.2 Hz, -NHCH2-), 1.80 (2H, qt, J 7.2, -CH2CH2CH2-); 
13C NMR (100 MHz) δ (DMSO-d6): 174.3 (C=O), 166.3 (C=O), 138.6 (Cq), 134.4 (Cq), 131.0 (Cq), 
130.7 (Cq), 128.7, 127.3, 127.2, 125.9, 124.5, 122.7, 84.1 (Cipso η5-C5H4), 69.4 (η5-C5H5, Cmeta η5-
C5H4), 66.6 (Cortho  η5-C5H4), 38.7 (-COCH2), 31.2 (-NHCH2-), 24.5 (-CH2CH2CH2-). 
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N-(6-ferrocenyl-2-naphthoyl)-glycine-L-alanine-OH 111. 
Fe
O
HN
O
HN
HO
O  
The synthesis followed that of 108 using N-(6-ferrocenyl-2-naphthoyl)-glycine-L-alanine 
methyl ester (0.14 g, 0.3 mmol) as the starting material. This yielded the title compound as 
an orange solid (0.13 g, 95 %), mp 125 °C; 
I.R. υmax (neat)/cm-1 3308, 3092, 2932, 1727, 1626, 1534, 1401, 1227; 
UV-Vis λmax (CH3CN)/nm 374 (ε/dm3mol-1cm-1 2843 ), 450 (1158); 
1H NMR (400 MHz) δ (DMSO-d6):  8.85 (1H, t, J 8 Hz, -CONH-), 8.44 (1H, s, ArH), 8.30 (1H, d, J 
7.2 Hz -CONH-), 8.06 (1H, s, ArH), 7.93-7.96 (3H, m, ArH), 7.83 (1H, dd, J 6.4 Hz and 1.2 Hz, 
ArH), 4.97 {2H, t, J 1.6 Hz, ortho on (η5-C5H4)}, 4.45 {2H t, J 2 Hz, meta on (η5-C5H4)}, 4.26 (1H, 
qt, J 6.8 Hz, -CHCH3), 4.04 {5H, s, (η5-C5H5)}, 4.01 (1H, dd, J 10.8 Hz and 4.8 Hz, -NHCH2-), 3.93 
(1H, dd, J 10.8 Hz and 6.4Hz, -NHCH2-), 1.30 (3H, d, J 7.2 Hz, -CCH3); 
13C NMR (100 MHz) δ (DMSO-d6): 174.0 (C=O), 168.7 (C=O), 166.4 (C=O), 138.8 (Cq), 134.5 
(Cq), 130.7 (Cq), 130.5 (Cq), 128.7, 127.6, 127.3, 125.9, 124.5, 122.7, 84.1 (Cipso η5-C5H4), 69.4 
(η5-C5H5), (Cmeta η5-C5H4), 66.6 (Cortho  η5-C5H4), 47.5 (-NHCH-), 42.3 (-NHCH2-), 17.3 (-NHCH3). 
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N-(6-ferrocenyl-2-naphthoyl)-glycine-D-alanine-OH 112. 
Fe
O
HN
HN
O
HO
O  
The synthesis followed that of 108 using N-(6-ferrocenyl-2-naphthoyl)-glycine-D-alanine 
methyl ester (0.50 g, 10.0 mmol) as the starting material. This yielded the title compound 
as an orange solid (0.47 g, 96 %), mp 185°C; 
I.R. υmax (neat)/cm-1 3311, 3094, 2930, 1723, 1628, 1535, 1410, 1228;  
UV-Vis λmax (CH3CN)/nm 369 (ε/dm3mol-1cm-1 1875), 451 (862); 
1H NMR (400 MHz) δ (DMSO-d6): 8.90 (1H, t, J 6 Hz, -CONH-), 8.44 (1H, s, ArH), 8.27 (1H, d, J 
4 Hz, -CONH-), 8.06 (1H, s, ArH), 7.93-7.96 (3H, m, ArH), 7.80 (1H, dd, J 8 Hz and 1.2 Hz, ArH), 
4.98 {1H, s, ortho on (η5-C5H4)}, 4.45 {1H, s, meta on (η5-C5H4)}, 4.23 (1H, m, -CHCH3), 3.90-
4.05 {7H, m, (η5-C5H4), -NHCH2-}, 1.30 (3H, d, J 4.8 Hz, -CHCH3). 
13C NMR (100 MHz) δ (DMSO-d6): 174.0 (C=O), 168.7 (C=O), 166.5 (C=O), 138.8 (Cq), 134.5 
(Cq), 130.7 (Cq), 130.4 (Cq), 128.8, 127.6, 127.4, 125.9, 124.5, 122.7, 84.0 (Cipso η5-C5H4), 69.5 ( 
η5-C5H5), 69.4 (Cortho η5-C5H4), 66.6 (Cmeta η5-C5H4), 47.6 (-NHCH-), 42.3 (-NHCH2-), 17.3 (-
NHCH3). 
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General procedure for the synthesis of N-{para-(ferrocenyl)cinnamoyl} dipeptide 
esters.  
N-{para-(ferrocenyl)-cinnamoyl}-glycine-glycine ethyl ester 113. 
 
To a solution of N-para-(ferrocenyl)cinnamic acid (0.30 g, 0.9 mmol) in DCM (50 mL) was 
added ethyl dimethylaminopropyl carbodiimide (EDC) (0.34 g, 1.8 mmol), N-
hydroxysuccinimide (NHS) (0.05 g, 4.5 mmol) and triethylamine (5 mL) . The solution was 
allowed to stir at 0 °C for one hour. Glycine-glycine ethyl ester hydrochloride (0.17 g, 0.9  
mmol) was then added. The solution was allowed to stir at 0 °C for a further 20 minutes the 
temperature was raised and the solution was allowed to stir at room temperature for 48 
hours. The product was washed with water and dried over MgSO4 . The solvent was removed 
in vacuo and the crude product was purified by column chromatography (eluent 20 ethyl 
acetate: 80 % hexane – 100 % hexane) to afford the product as an orange solid (0.20 g, 46 
%), mp 203-204 °C; 
m/z (ESI) 474.1220 [M]+•.  C26H24N2O4Fe requires 474.1242; 
I.R. υmax (neat)/ cm-1: 3287, 3089, 1732, 1651, 1626, 1549, 1211; 
UV-Vis λmax (CH3CN)/nm 378 (ε/dm3mol-1cm-1 3436), 457 (1378); 
1H NMR (400 MHz) δ (DMSO-d6): 8.36-8.42 (2H, m, -NHCH2-, -NHCH2-), 7.58 (2H, d, J 8 Hz, 
ArH), 7.50 (2H, d, J 8.4 Hz, ArH), 7.43 (1H, d, J 16 Hz, -CH=),  6.73 (1H, d, J 16 Hz, -CH=), 4.85 
{2H, t, J 1.6 Hz, ortho on (η5-C5H4)}, 4.40 {2H, t, J 1.6 Hz, meta on (η5-C5H4)}, 4.10 (2H, q, J 7.2 
Hz, -CH2CH3),  4.03 (5H, s, η5-C5H5), 3.89 (2H, d, J 6 Hz, -NHCH2-), 3.86 (2H, d, J 5.6 Hz, -NHCH2-
), 1.20 (3H, t, J 7.2 Hz, -CH2CH3); 
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13C NMR (100 MHz) δ (DMSO-d6): 169.7 (C=O), 169.5 (C=O), 165.4 (C=O), 140.9 (=CH-), 138.9 
(Cq), 132.2 (Cq), 127.7, 126.2, 120.6 (=CH-), 83.7 (Cipso η5-C5H4), 69.4 (η5-C5H5), 69.3 (Cmeta η5-
C5H4), 66.4 (Cortho  η5-C5H4), 60.4 (-OCH2CH3), 41.9 (-NHCH2-), 40.6 (-NHCH2-), 14.0 (-OCH2CH3). 
N-{para-(ferrocenyl)-cinnamoyl}-sarcosine-glycine ethyl ester 114. 
Fe
O
N
HN
O
O
O  
The synthesis followed that of 113 using the following reagents; sarcosine-glycine ethyl ester 
trifluoroacetate salt (0.31 g, 1.1 mmol) and N-{para-(ferrocenyl)cinnamic acid (0.30 g, 0.9 
mmol), EDC (0.35 g, 1.8 mmol), NHS (0.05 g, 0.5 mmol). The product was purified by column 
chromatography (eluent 20 % ethyl acetate: 80 % hexane - 100 % ethyl acetate) to yield the 
title compound as an orange solid (0.07 g, 16 %), mp 145°C; 
I.R. υmax (neat)/cm-1 3293, 3095, 1745, 1674, 1673, 1642, 1592, 1526, 1200; 
UV-Vis λmax (CH3CN)/nm 387 (ε/dm3mol-1cm-1 3487), 455 (1522); 
1H NMR (400 MHz) δ (DMSO-d6): 8.58 & 8.37 (1H, t, t, J 5.6 Hz, 6 Hz, -CONH-), 7.44-7.72 (5H, 
m, ArH, =CH-), 7.21 & 7.03 (1H, d, d, J 15.2 Hz,  =CH-), 4.87 {2H, s, ortho on (η5-C5H4)}, 4.40 
{2H, s, meta on (η5-C5H4)}, 4.27 {1H, s, -N(CH3)CH2-}, 4.09-4.13 {3H, m, -OCH2, -N(CH3)CH2-}, 
4.08 {5H, s, ( η5-C5H4)}, 3.87 (2H, dd, J 10 Hz and 6 Hz, -NHCH2-), 3.20 & 2.93 (3H, s, s, -
N(CH3)CH2-), 1.15-1.24 (3H, m, -OCH2CH3); 
13C NMR (100 MHz) δ (DMSO-d6): 169.7- (C=O), 168.9 (C=O), 166.1 (C=O), 141.5 (Cq), 141.1 
(Cq), 128.2, 128.1, 126.0, 125.9, 117.1 (-CH=), 116.9 (-CH=) 83.7 (Cipso η5-C5H4), 69.4 (η5-C5H5), 
69.3(Cmeta η5-C5H4), 66.4(Cortho  η5-C5H4), 60.5 (-OCH2-), 52.0 & 50.0 (-N(CH3)CH2-), 40.6 (-NHCH-
), 39.0 & 36.2 {-N(CH3)}, 14.0 (-OCH2CH3). 
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N-{para-(ferrocenyl)-cinnamoyl}-γ-aminobutric acid ethyl ester 115. 
 
The synthesis followed that of 113 using the following reagents; ƴ-aminobutyric acid ethyl 
ester hydrochloride (0.09 g, 0.6 mmol) and N-para-(ferrocenyl)cinnamic acid (0.23 g, 0.7 
mmol), EDC (0.22 g, 1.2 mmol) and NHS (0.03 g, 0.3 mmol). The product was purified by 
column chromatography (eluent 20 % ethyl acetate: 80 % hexane -100 % ethyl acetate) to 
yield the title compound as an orange solid (0.12 g, 46 %), mp 152-153 °C; 
m/z (ESI) 445.1344 [M]+•.  C26H24N2O4Fe requires 445.1340; 
I.R. υmax (neat)/ cm-1: 3277, 3093, 1739, 1652, 1616, 1563, 1176; 
UV-Vis λmax (CH3CN)/nm 370 (ε/dm3mol-1cm-1 3001), 452 (1059); 
1H NMR (400 MHz) δ (DMSO-d6): 8.12 (1H, t, J 5.6 Hz, -CONH-), 7.57 (2H, d, J 8.4 Hz, ArH), 
4.48 (2H, d, J 8.4 Hz, ArH), 7.40 (1H, d, J 15.6 Hz,  =CH-), 6.59 (1H, d, J 15.6 Hz, =CH-), 4.84 
{2H, t, J 1.6 Hz, ortho on (η5-C5H4)}, 4.39 {2H, t, J 2 Hz, meta on (η5-C5H4)}, 4.03-4.09 {7H, m, -
OCH2CH3, ( η5-C5H4)}, 3.20 (2H, q, J 6.8 Hz, -NHCH2-), 2.34 (2H, t, J 7.2 Hz,-CH2C=O-), 1.72 (2H, 
qt, J 7.2 Hz, -CH2CH2CH2-), 1.19 (3H, t, J 6.8 Hz, -OCH2CH3); 
13C NMR (100 MHz) δ (DMSO-d6): 172.6 (C=O), 165.1 (C=O), 140.8 (=CH-), 138.5(Cq), 
132.3(Cq), 127.6, 126.1, 120.9 (=CH-), 83.7(Cipso η5-C5H4), 69.4 (η5-C5H5), 69.3 (Cmeta η5-C5H4), 
66.4 (Cortho  η5-C5H4), 59.8 (-OCH2CH3),  38.0 (-NHCH2-), 31.0 (-CH2C=O), 24.6 (-CH2CH2CH2-), 
14.1 (-OCH2CH3). 
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N-{para-(ferrocenyl)-cinnamoyl}-glycine-L-alanine ethyl ester 116. 
 
The synthesis followed that of 113 using the following reagents; glycine-L-alanine ethyl ester 
trifluoroacetate salt (0.31 g, 1.1 mmol) and N-para-(ferrocenyl)cinnamic acid (0.30 g, 0.9 
mmol), EDC (0.35 g, 1.8 mmol) and NHS (0.5 g, 0.5 mmol). The product was purified by 
column chromatography (eluent 20 % ethyl acetate: 80 % hexane -100 % ethyl acetate) to 
yield the title compound as an orange solid (0.16 g, 36 %), mp 201-202 °C; 
I.R. υmax (neat)/ cm-1: 3310, 3083, 1732, 1684, 1621, 1529, 1200; 
UV-Vis λmax (CH3CN)/nm 387 (ε/dm3mol-1cm-1 3487), 455 (1522); 
1H NMR (600 MHz) δ (DMSO-d6): 8.40 (1H, d, J 7.2 Hz, -CONH-), 8.31 (1H, t, J 5.6 Hz, -CONH-
), 7.58 (2H, d, J 8.4 Hz, ArH), 7.49 (2H, d, J 8.4 Hz, ArH), 7.46 (1H, d, J 16 Hz,  =CH-), 6.73 (1H, 
d, J 16 Hz,  =CH-), 4.85 {2H, t, J 2 Hz, ortho on (η5-C5H4)}, 4.40 {2H, t, J 1.6 Hz, meta on (η5-
C5H4)}, 4.27 (1H, qt, J 7.2 Hz, -NHCH-), 4.09 (2H, q, J 6.8 Hz, -OCH2CH3), 4.02 (5H, s, η5-C5H5), 
3.92 (1H, dd, J 11.4 Hz and 5.4 Hz, -NHCH2-), 3.86 (1H, dd, J 10.8 Hz and 6 Hz, -NHCH2-), 1.29 
(3H, d, J 7.2 Hz, -CH3), 1.19 (3H, t, J 7.2 Hz, -OCH2CH3); 
13C NMR (150 MHz) δ (DMSO-d6): 172.5 (C=O), 168.8 (C=O), 165.4 (C=O), 140.9 (=CH-), 138.9 
(Cq), 132.2 (Cq), 127.7, 126.2, 120.7 (=CH-), 83.7 (Cipso η5-C5H4), 69.4 (η5-C5H5), 69.3 (Cmeta η5-
C5H4), 66.5 (Cortho η5-C5H4), 60.5 (-OCH2-), 47.6 (-CHCH3), 41.7 (-NHCH2-), 17.0 (-CHCH3), 14.0 
(-OCH2CH3). 
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N-{para-(ferrocenyl)-cinnamoyl}-glycine-D-alanine ethyl ester 117. 
 
Fe
O
HN
HN
O
O
O  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
The synthesis followed that of 113 using the following reagents; glycine-D-alanine ethyl ester 
trifluoroacetate salt (0.31 g,  1.1 mmol) and N-para-(ferrocenyl)cinnamic acid (0.3 g, 0.9 
mmol), EDC (0.35 g, 1.8 mmol), NHS (0.05 g, 0.5 mmol). The product was purified by column 
chromatography (eluent 20 % ethyl acetate: 80 % hexane -100 % ethyl acetate) to yield the 
title compound as an orange solid (0.08 g, 18 %), mp 202-203 °C; 
I.R. υmax (neat)/ cm-1: 3307, 2925, 1729, 1646, 1622, 1527, 1216; 
UV-Vis λmax (CH3CN)/nm 313 (ε/dm3mol-1cm-1 4118), 436 (550); 
1H NMR (400 MHz) δ (DMSO-d6): 8.42 (1H, d, J 7.2 Hz, -CONH-), 8.31 (1H, t, J 5.6 Hz, -CONH-
), 7.58 (2H, d, J 8.4 Hz, ArH), 7.49 (2H, d, J 8.4 Hz, ArH), 7.46 (1H, d, J 16 Hz, =CH-), 6.73 (1H, 
d, J 16 Hz, =CH-), 4.85 {2H, t, J 2 Hz, ortho on (η5-C5H4)}, 4.40 {2H, t, J 1.6 Hz, meta on (η5-
C5H4)}, 4.27 (1H, qt, J 7.2 Hz, -NHCH-), 4.09 (2H, q, J 6.8 Hz, -OCH2CH3), 4.03 (5H, s, η5-C5H5), 
3.82-3.95 (2H, m, -NHCH2-), 1.29 (3H, d, J 7.2 Hz, -CH3), 1.19 (3H, t, J 7.2 Hz, -OCH2CH3); 
13C NMR (100 MHz) δ (DMSO-d6): 172.5 (C=O), 168.8 (C=O), 165.4 (C=O), 140.9 (=CH-), 138.9 
(Cq), 132.2 (Cq), 127.7, 126.2, 120.7 (=CH-), 83.7 (Cipso η5-C5H4), 69.4 (η5-C5H5), 69.3 (Cmeta η5-
C5H4), 66.4 (Cortho η5-C5H4), 60.5 (-OCH2CH3), 47.6 (-CHCH3), 41.7(-NHCH2-), 17.0 (-CHCH3), 14.0 
(-OCH2CH3).  
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General procedures for the synthesis of N-{para-(ferrocenyl)-benzoyl}-glycine-
glycine esters. 
N-{para-(ferrocenyl)-benzoyl}-glycine-glycine 118. 
 
N-{para-(ferrocenyl)benzoyl}-glycine-glycine ethyl ester (0.30 g, 0.7 mmol) was dissolved in 
methanol (15 mL) and sodium hydroxide (15 mL, 0.5 M) and allowed to reflux 24 hours. The 
solution was cooled on ice and acidified to pH 2. The product was isolated by vacuum 
filtration as an orange solid (0.26 g, 92 %), mp 162-164 °C; 
I.R. υmax (neat)/cm-1 3334, 1737, 1640, 1522, 1345, 1230; 
UV-Vis λmax (CH3CN)/nm 351 (ε/dm3mol-1cm-1 1987), 450 (556); 
1H NMR (400 MHz) δ (DMSO-d6):  8.81 (1H, t, J 5.2 Hz, -CONH-), 7.98 (1H, t, J 8 Hz, -CONH-), 
7.83 (2H, d, J 8 Hz, ArH), 7.63 (2H, d, J 8 Hz, ArH), 4.87 {2H, s, ortho on (η5-C5H4)}, 4.41 {2H, s, 
meta on (η5-C5H4)}, 4.03 {5H, s, (η5-C5H5)}, 3.90 (2H, d, J 5.6 Hz, -NHCH2-), 3.65 (2H, d, J 4.8 
Hz, -NHCH2-). 
13C NMR (100 MHz) δ (DMSO-d6): 171.2 (C=O), 169.0 (C=O), 166.3 (C=O), 142.8 (Cq), 131.0 
(Cq), 127.5, 125.3, 83.2 (Cipso η5-C5H4), 69.5 (η5-C5H5, Cmeta η5-C5H4), 66.6 (Cortho η5-C5H4), 42.5 (-
NHCH2-), 41.5 (-NHCH2-). 
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N-{para-(ferrocenyl)-benzoyl}-glycine-glycine methyl ester 119. 
Fe
O
HN
O
HN
O
O  
To a solution of para-ferrocenyl benzoic acid (0.37 g, 1.2 mmol) in DCM (50 mL) was added 
ethyl dimethylaminopropyl carbodiimide (EDC) (0.38 g, 2.0 mmol), N-hydroxy succinimide 
(NHS) (0.23 g, 0.5 mmol) and triethylamine (5 mL) . The solution was allowed to stir at 0 °C 
for one hour. Glycine-glycine methyl ester hydrochloride (0.19 g, 1.0 mmol) was then added. 
The solution was allowed to stir at 0 °C for a further 20 minutes before the temperature was 
raised and the solution was allowed to stir at room temperature for 48 hours. The product 
was washed with water and dried over MgSO4 . The solvent was removed in vacuo and the 
crude product was purified by column chromatography (eluent 20 % ethyl acetate: 80 % 
hexane -100 % ethyl acetate) to afford the product as an orange solid (0.67 g, 15 %), mp 170-
171 °C; 
I.R. υmax (neat)/cm-1 3274, 1727, 1655, 1550, 1514, 1221; 
UV-Vis λmax (CH3CN)/nm 354 (ε/dm3mol-1cm-1 2858), 452 (865); 
1H NMR (400 MHz) δ (DMSO-d6):  8.78 (1H, t, J 5.6 Hz, -CONH-), 8.37 (1H, t, J 5.6 Hz, -CONH-
), 7.83 (2H, d, J 8.4 Hz, ArH), 7.64 (2H, d, J 8.4 Hz, ArH), 4.90 {2H, t, J 2 Hz, ortho on (η5-C5H4)}, 
4.42 {2H, t, J 1.6 Hz, meta on (η5-C5H4)}, 4.02 {5H, s, (η5-C5H4)}, 3.92 (2H, d, J 6 Hz, -NHCH2-), 3.87 
(2H, d, J 5.6 Hz, -NHCH2-), 3.64 (3H, s, -OCH3); 
13C NMR (100 MHz) δ (DMSO-d6): 170.3 (C=O), 169.7 (C=O), 166.3 (C=O), 142.8 (Cq), 131 (Cq), 
127.5, 125.3, 83.2 (Cipso η5-C5H4), 69.5 (η5-C5H5, Cmeta η5-C5H4), 66.6 (Cortho  η5-C5H4), 51.7 (-
OCH3), 42.4 (-NHCH2-), 40.5 (-NHCH2-). 
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N-{para-(ferrocenyl)-benzoyl}-glycine-glycine ethyl ester 120. 
Fe
O
HN
O
HN
O
O  
The synthesis followed that of 119 using the following reagents; glycine-glycine ethyl ester 
hydrochloride (0.19 g, 1.0 mmol) and N-para-(ferrocenyl)benzoic acid (0.37 g, 1.2 mmol), 
EDC (0.36 g, 1.9 mmol), NHS (0.06g, 0.5 mmol). The product was purified by column 
chromatography (eluent 20 % ethyl acetate: 80 % hexane -100 % ethyl acetate) to yield the 
title compound as an orange solid. (0.32 g, 82 %), mp 134-135 °C; 
I.R. υmax (neat)/ cm-1: 3389, 3274, 1727, 1644, 1543, 1515, 1214; 
UV-Vis λmax (CH3CN)/nm 354 (ε/dm3mol-1cm-1 1584), 451 (570); 
1H NMR (400 MHz) δ (DMSO-d6): 8.79 (1H, t, J 6 Hz, -CONH-), 8.35 (1H, t, J 6 Hz, -CONH-), 7.84 
(2H, d, J 8.4 Hz, ArH), 7.63 (2H, d,  J 8.4 Hz, ArH), 4.90 {2H, t, J 1.6 Hz, ortho on (η5-C5H4)}, 4.41 
{2H, t, J 1.6 Hz, meta on (η5-C5H4)}, 4.11 (2H, q, J 13.2 Hz, (-OCH2CH3), 4.07 {5H, s, (η5-C5H5)}, 
3.92 (2H, d, J 6, -NHCH2-), 3.85 (2H, d, J 6 Hz, -NHCH2-), 1.19 (3H, t, J 7.2 Hz, -OCH2CH3); 
13C NMR (100 MHz) δ (DMSO-d6): 169.8 (C=O), 169.7 (C=O), 166.3 (C=O), 142.8 (Cq), 131.0 
(Cq), 127.5, 125.3, 83.2 (Cipso η5-C5H4), 69.5 (η5-C5H5),(Cmeta  η5-C5H4), 66.6 (Cortho  η5-C5H4), 
60.4 (-OCH2-), 42.4 (-NHCH2-), 40.7 (-NHCH2-), 14.1 (-OCH2CH3). 
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N-{para-(ferrocenyl)-benzoyl}-glycine-glycine propyl ester 121. 
Fe
O
HN
O
HN
O
O  
The synthesis followed that of 119 using the following reagents; glycine-glycine propyl ester 
hydrochloride (0.17 g, 0.8 mmol) and para-(ferrocenyl)benzoic acid (0.30 g, 1.0 mmol), EDC 
(0.31, 1.6 mmol) and NHS (0.05g, 0.4 mmol). The product was purified by column 
chromatography (eluent 20 % ethyl acetate: 80 % hexane -100 % ethyl acetate) to yield the 
title compound as an orange solid (0.23 g, 60 %), mp 115-117 °C; 
I.R. υmax (neat)/ cm-1: 3367, 3274, 1727, 1644, 1543, 1515, 1215; 
UV-Vis λmax (CH3CN)/nm 355 (ε/dm3mol-1cm-1 1737), 450 (552); 
1H NMR (400 MHz) δ (DMSO-d6): 8.78 (1H, t, J 6 Hz, -CONH-), 8.36 (1H, t, J 6 Hz, -CONH-), 7.83 
(2H, d, J 8.4 Hz, ArH), 7.64 (2H, d, J 8.4 Hz, ArH), 4.90 {2H, t, J 1.6 Hz, ortho on (η5-C5H4)}, 4.42 
{2H, t, J 1.6 Hz, meta on (η5-C5H4)}, 3.96-4.02 (7H, m, η5-C5H5, -OCH2CH2-), 3.92 (2H, d, J 5.6 Hz, -
NHCH2-), 3.86 (2H, d, J 6 Hz, -NHCH2-), 1.59 (2H, m, -OCH2CH2-), 0.90 (3H, t, J 13.2 Hz, -CH2CH3); 
13C NMR (100 MHz) δ (DMSO-d6): 175.2 (C=O), 175.2 (C=O), 172.0 (C=O),  148.3 (Cq), 135.9 
(Cq), 132.8, 130.6, 88.2 (Cipso η5-C5H4), 74.8 (η5-C5H5), 74.8 (Cmeta η5-C5H4), 71.8 (Cortho  η5-
C5H4), 71.3 (-OCH2CH2-), 47.6 (-NHCH2-), 45.9 (-NHCH2-), 26.6 (-OCH2CH2-), 15.4 (-CH2CH3). 
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N-{para-(ferrocenyl)-benzoyl}-glycine-glycine butyl ester 122. 
Fe
O
HN
O
HN
O
O  
The synthesis followed that of 119 using the following reagents; glycine-glycine butyl ester 
hydrochloride (0.20 g, 0.9 mmol) and para-(ferrocenyl)benzoic acid (0.33 g, 1.1 mmol), EDC 
(0.34 g, 1.8 mmol) and NHS (0.05 g, 0.4 mmol). The product was purified by column 
chromatography (eluent 20 % ethyl acetate: 80 % hexane -100 % ethyl acetate) to yield the 
title compound as an orange solid. (0.20 g, 46 %), mp 134-135 °C; 
I.R. υmax (neat)/ cm-1: 3298, 1738, 1633, 1549, 1518, 1235; 
UV-Vis λmax (CH3CN)/nm 356 (ε/dm3mol-1cm-1 1532), 425 (487); 
1H NMR (400 MHz) δ (DMSO-d6): 8.78 (1H, t, J 6 Hz, -CONH-), 8.35 (1H, t, J 6 Hz, -CONH-), 7.83 
(2H, d, J 8.4 Hz, ArH), 7.64 (2H, d, J 8.4 Hz, ArH), 4.90 {2H, t, J 2 Hz, ortho on (η5-C5H4)}, 4.42 
{2H, t, J 1.6 Hz, meta on (η5-C5H4)}, 4.02-4.11 {7H, m, (η5-C5H5), -OCH2CH2-}, 3.92 (2H, d, J 5.6 
Hz, -NHCH2-), 3.86 (2H, d, J 6 Hz, -NHCH2-), 1.55 (2H, qt, J 6.8 Hz, -OCH2CH2-), 1.32 (2H, m, -
CH2CH3), 0.88 (3H, t, J 13.2 Hz, -CH2CH3); 
13C NMR (100 MHz) δ (DMSO-d6): 175.1 (C=O), 174.9 (C=O), 171.5 (C=O), 148.0 (Cq), 136.2 
(Cq), 132.8, 130.5, 88.4 (Cipso η5-C5H4), 74.7 (η5-C5H5, Cmeta η5-C5H4), 71.8 (Cortho  η5-C5H4), 69.3 
(-OCH2CH2CH2-), 47.6 (-NHCH2-), 45.9 (-NHCH2-), 35.4 (-OCH2CH2CH2-), 23.8 (-CH2CH3), 18.8 (-
CH2CH3). 
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N-{para-(ferrocenyl)-benzoyl}-glycine-glycine benzyl ester 123. 
 
Fe
O
HN
O
HN
O
O
 
The synthesis followed that of 119 using the following reagents; glycine-glycine benzyl ester 
(0.48 g, 1.5 mmol) and para-(ferrocenyl)benzoic acid (0.38 g, 1.2 mmol), EDC (0.48 g, 2.5 
mmol) and NHS (0.07 g, 0.6 mmol). The product was purified by column chromatography 
(eluent 20 % ethyl acetate: 80 % hexane-100 % ethyl acetate) to yield the title compound as 
an orange solid. (0.15 g, 24 %), mp 137-139 °C; 
I.R. υmax (neat)/ cm-1 3310, 1734, 1628, 1609, 1548, 1519, 1235; 
UV-Vis λmax (CH3CN)/nm 313 (ε/dm3mol-1cm-1 4835), 449 (587); 
1H NMR (400 MHz) δ (DMSO-d6):  8.80 (1H, t, J 6 Hz, -CONH-), 8.40 (1H, t, J 5.6 Hz, -CONH-), 
7.84 (2H, d, J 8.8 Hz, ArH), 7.64 (2H, d, J 8.4 Hz, ArH), 7.40-7.30 (5H, m, ArH), 5.14 {2H, s, -
OCH2(C6H5}, 4.90 {2H, t, J 1.6 Hz, ortho on (η5-C5H4)}, 4.42 {2H, t, J 2 Hz, meta on (η5-C5H4)}, 
4.02 {5H, s, (η5-C5H5)}, 3.94 (4H, d, J 5.6 Hz, -NHCH2-); 
13C NMR (100 MHz) δ (DMSO-d6): 169.7 (C=O), 169.7 (C=O), 166.3 (C=O), 142.8 (Cq), 135.9 
(Cq), 131.0 (Cq), 128.4, 128.0, 127.9, 127.5, 125.3, 83.2 (Cipso η5-C5H4), 69.5 (η5-C5H5, Cmeta η5-
C5H4), 66.6 (Cortho  η5-C5H4), 65.8 {-OCH2(C6H5)}, 42.4 (-NHCH2-), 40.7 (-NHCH2-). 
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General procedures for the preparation of the starting materials of N-(5-ferrocenyl-
1-naphthoyl) amino acid and dipeptide derivatives. 
N-1-amino-5-acetyl-naphthalene 125. 
 
Acetic anhydride (3 mL, 27.2 mmol) was added to 1, 5-diaminonaphthalene acid (3.0 g, 19.0 
mmol) in a solution of water (70 mL) and pyridine (5 mL). The reaction was allowed to stir 
overnight at room temperature. The reaction mixture was poured onto 10% HCl on ice and 
the product was collected by vacuum filtration to yield a grey-purple solid (3.13 g, 82 %), mp 
(decomp.) 214 °C (lit29 166 °C). 
1H NMR (400 MHz) δ (DMSO-d6):  9.96 (1H, s, -CONH-), 7.92 (1H, d, J 8.4 Hz, ArH), 7.69 (1H, 
d, J 7.2 Hz, ArH), 7.52 (1H, t, J 8 Hz, ArH), 7.23 (1H, d, J 7.2 Hz, ArH), 7.06 (1H, t, J 7.6 Hz, ArH), 
6.60 (1H, d, J 7.2 Hz, ArH), 5.43 (2H, s, -NH2-), 2.19 (3H, s, -COCH3). 
13C NMR (100 MHz) δ (DMSO-d6): 168.9 (C=O), 144.5 (Cq), 133.9 (Cq), 128.5 (Cq), 125.4, 124.3, 
123.7 (Cq), 121.9, 119.9, 110.0, 107.4, 23.4 (-COCH3). 
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N-1-acetyl-5-ferrocenyl naphthalene 126. 
  
To a solution of 1-amino-5-acetyl naphthalene (3.00 g, 15.0 mmol) in water (50 mL) was 
added conc. HCl (5 mL). A solution of sodium nitrite (1.24 g, 18.0 mmol) in water (20 mL) was 
then added slowly with stirring while the temperature was kept below 5 °C to give the 
diazonium salt. This was then added to a solution of ferrocene (3.35 g, 18.0 mmol) in diethyl 
ether (40 mL) and allowed to stir overnight. The reaction mixture was washed with water, 
the organic layer was dried over magnesium sulphate and the solvent was removed in vacuo 
to yield the crude product. It was purified by column chromatography (eluent 20-40 % diethyl 
ether: 80-60 % hexane) to obtain an orange-brown solid (0.35 g, 9 %), mp 178 °C. 
1H NMR (400 MHz) δ (DMSO-d6): 10.02 (1H, s, -NH-), 8.33 (1H, d, J 8.4 Hz, ArH), 7.99 (1H, d, J 
8.4 Hz, ArH), 7.91 (1H, d, J 6.8 Hz, ArH), 7.61 (1H, d, J 7.2 Hz, ArH), 7.52 (2H, q, J 8, J 6.8, ArH), 
4.68 {2H, t, J 2 Hz, ortho on (η5-C5H4)}, 4.46 {2H, t, J 2 Hz, meta on (η5-C5H4)}, 4.21 {5H, s, (η5-
C5H5)}, 2.19 (3H, s, -COCH3). 
13C NMR (100 MHz) δ (DMSO-d6): 169.0 (C=O), 135.8 (Cq), 134.0 (Cq), 133.5, 131.9 (Cq), 128.5 
(Cq), 128.1, 125.1, 123.0, 121.8, 121.6, 86.4 (Cipso η5-C5H4), 70.2 (η5-C5H5), 69.5 (Cmeta η5-C5H4), 
68.2(Cortho η5-C5H4), 23.4 (-COCH3). 
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N-1-amino-5-ferrocenyl-naphthalene 127. 
  
1-acetyl-5-ferrocenyl naphthalene (0.71 g, 19.2 mmol) was dissolved in methanol (10 mL) . 
To this was added sodium hydroxide (10 %, 10 mL). The mixture was heated to reflux for 24 
hours. The solution was cooled on ice and acidified to pH 2. Vacuum filtration yielded a 
brown solid (0.35 g, 56 %), mp 157-158 °C. 
1H NMR (400 MHz) δ (DMSO-d6):  7.99 (1H, d, J 8.4 Hz, ArH), 7.8 (1H, d, J 6 Hz, ArH), 7.61 (1H, 
d, J 8.8 Hz, ArH), 7.35 (1H, t, J 7.2 Hz, ArH), 7.19 (1H, t, J 8.4 Hz, ArH), 6.66 (1H, d, J 7.2 Hz, 
ArH), 5.68 (2H, s, -NH2), 4.62 {2H, t,  J 1.6 Hz, ortho on (η5-C5H4)}, 4.41 {2H, t, J 1.6 Hz, meta 
on (η5-C5H4)}, 4.20 {5H, s, (η5-C5H5)}. 
13C NMR (100 MHz) δ (DMSO-d6): 144.9 (Cq), 135.1 (Cq), 132.4 (Cq), 127.8, 126.3, 123.0 (Cq), 
122.9, 121.0, 113.4, 107.3, 87.3 (Cipso η5-C5H4), 70.1 (η5-C5H5), 69.5 (Cmeta η5-C5H4), 69.4 
(Cortho η5-C5H4). 
 
General procedures for the preparation of Boc protected dipeptide esters. 
Boc-D-alanine-glycine-methyl ester 128 
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The synthesis followed that of  Boc glycine glycine benzyl ester using the following reagents; 
Boc-D-alanine-OH (9.04 g, 47.8 mmol), glycine methyl ester hydrochloride (5.0 g, 39.8 mmol), 
NHS (2.29 g, 19.9 mmol), EDC (15.3 g, 79.6 mmol). The product was purified by column 
chromatography (eluent 50 % ethyl acetate: 50 % hexane) to give the title compound as a 
transparent oil (3.08 g, 30 %)       
1H NMR (400 MHz) δ (DMSO-d6):  8.25 (1H, t, J 5.6 Hz, -CONH-), 6.98 (1H, d, J 7.6 Hz, -CONH-
), 4.01 (1H, qt, J 7.2 Hz, -NHCH-), 3.93 (1H, dd, J 6 Hz, J 11.2 Hz, -NHCH2-), 3.84 (1H, dd, J 6 Hz, 
J 11.6 Hz, -NHCH2-), 3.67 (3H, s, -OCH3), 1.43 {9H, s, -C(CH3)3},  1.23 (3H, d, J 7.2 Hz, -CHCH3). 
13C NMR (100 MHz) δ (DMSO-d6): 178.5 (C=O), 175.5 (C=O), 160.2 (C=O), 83.2 (Cq), 56.9 (-
OCH3), 54.7 (-NHCH2-), 45.7 (-NHCH-), 33.4 {C(CH3)3}, 23.4 (-CHCH3). 
 
Boc-L-alanine-glycine-methyl ester 129 
O
O
N
H
H
N
O
O
O
 
The synthesis followed that of Boc glycine glycine benzyl ester using the following reagents: 
Boc-L-alanine-OH (9.04 g, 47.8 mmol), EDC (15.26 g, 79.6 mmol), NHS (2.29 g, 19.9 mmol) 
and glycine methyl ester hydrochloride (5.00 g, 39.8 mmol). The product was purified by 
column chromatography (eluent 50 % ethyl acetate: 50 % hexane) to give the title compound 
as a transparent oil (3.75 g, 36 %). 
1H NMR (400 MHz) δ (DMSO-d6): 8.19 (1H, t, J 5.6 Hz, -CONH-), 6.94 (1H, d, J 7.6 Hz, -CONH-
), 4.04 (1H, qt, J 6.8 Hz, -COCH-), 3.89 (1H, dd, J 11.2 Hz, 6.4 Hz, -NHCH2-), 3.80 (1H, dd, J 12 
Hz, 5.6 Hz, -NHCH2-), 3.62 (3H, s, -OCH3), 1.38 (1H, s, -CH(CH3)3), 1.19 (3H, d, J 7.2 Hz, -CHCH3). 
13C NMR (100 MHz) δ (DMSO-d6): 173.3 (C=O), 170.3 (C=O), 155.0 (C=O), 77.9 (Cq), 59.7 (-
OCH3), 51.6 (-NHCH2-), 49.4 (-NHCH-), 28.1 {-C(CH3)3}, 18.1 (-CHCH3). 
 
General procedures for the preparation of Boc protected dipeptides. 
Boc-D-alanine-glycine-OH 130 
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Boc-D-alanine-glycine methyl ester (1.24 g, 4.8 mmol) was dissolved in methanol (10 mL). To 
this was added sodium hydroxide (0.5 M, 10 mL). The solution was heated to reflux for 24 h. 
The solution was acidified with citric acid and the solvent was removed in vacuo to yield the 
product as a transparent oil (1.11 g, 93 %). 
1H NMR (600 MHz) δ (DMSO-d6):  7.24 (1H, br.s, -CONH-), 7.19 (1H, d, J 7.8 Hz, -CONH-), 3.93 
(1H, qt, J 7.8 Hz, -CHCH3), 3.26 (2H, d, J 4.2 Hz, -NHCH2-), 1.36 (3H, s, -CHCH3), 1.49 {9H, s, -
C(CH3)3}. 
13C NMR (100 MHz) δ (DMSO-d6): 174.6 (C=O), 171.4 (C=O), 170.3 (C=O), 78.0 (Cq), 49.9 (-
CHCH3), 44.0 (-NHCH2-), 28.2 {-CHCH3)3}, 25.3 (-CHCH3). 
 
Boc-L-alanine-glycine-OH 131. 
 
The synthesis followed that of 135 using the following reagents; Boc-L-alanine-glycine methyl 
ester (3.50 g, 13.4 mmol), to yield the product as a transparent oil (2.91 g, 88 %). 
1H NMR (400 MHz) δ (DMSO-d6):  7.32 (1H, t, J 4.4 Hz, -CONH-), 7.17 (1H, d, J 9.6 Hz, -CONH-
), 3.94 (1H, qt, J 7.2 Hz, -COCH-), 3.35 (2H, d, J 4 Hz, -COCH2-), 1.38 (9H, s, -C(CH3)3), 1.16 (3H, 
d, J 6.4 Hz, -CHCH3). 
13C NMR (100 MHz) δ (DMSO-d6): 171.7 (C=O), 171.5 (C=O), 155.1 (C=O), 78.1 (Cq), 49.8 (-
CHCH3), 43.7(-NHCH2-), 28.1 {-CHCH3)3}, 25.1 (-CHCH3). 
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Chapter 3 
Biological evaluation of N-(6-ferrocenyl-2-naphthoyl), N-{para-
(ferrocenyl)cinnamoyl} and N-{para-(ferrocenyl)benzoyl} amino acid and 
dipeptide derivatives. 
3.1 Introduction  
As previously discussed N-(6-ferrocenyl-2-naphthoyl)-glycine-glycine ethyl ester 70 has been 
shown to be the most active of the N-ferrocenyl amino acid and dipeptide esters to date with 
an IC50 value of 0.13 ± 0.02 µM in H1299 NSCLC cells and 1.10 ± 0.13 µM in Sk-Mel-28 
metastatic melanoma cells. The aims of this research project were to extend the SAR study 
of the ferrocenyl peptide conjugates, to investigate the mode of action of this class of 
compounds and to begin in vivo studies. In order to extend the SAR study of the project N-
(6-ferrocenyl-2-naphthoyl), N-{para-(ferrocenyl)cinnamoyl} and N-{para-
(ferrocenyl)benzoyl} amino acid and dipeptide derivatives have been prepared maintaining 
the most active dipeptide configurations previously used whilst altering both the conjugated 
linker and the ester functionality. N-(6-ferrocenyl-2-naphthoyl)-glycine-glycine ethyl ester 70 
as prepared by Dr. Aine Mooney was evaluated in conjunction with the newly synthesised 
compounds for comparison. The compounds were evaluated on a panel of lung cancer and 
melanoma cell lines; H1299 and A549 lung cancer and HT-144, Lox-IMVI and Malme-3M 
melanoma cells. It was necessary to carry out preliminary evaluation of all the compounds 
prepared in in vitro studies, both for initial assessment and to identify the most promising 
compounds for the commencement of in vivo studies. Biological evaluation was carried out 
by James Murphy1. 
3.1.1 Cell culture 
The historical development of cell culture began in 1907 when Ross Harrison grew embryonic 
nerve cells on microscope slides2.  He developed the hanging drop technique by suspending 
nerve tissue from frog embryos in lymph fluid as a drop on the underside of a microscope 
slide and was able to study cell growth for several weeks. Burrows and Carrel developed 
techniques for the culture of a range of mammalian cells achieving sub culture of the cells 
for several years without infection. Before 1940 the widespread use of culture techniques 
was limited by the sterility controls necessary. It was not until the late 1940’s with the 
development of antibiotics that further developments in cell culture took place.  Large scale 
cultures were first considered when it was discovered that viruses could be propagated in 
cell cultures and used as vaccines. In the early 1950’s Earle and Eagle analysed the nutritional 
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requirements of cultured cells and in 1955 Eagle’s minimum essential medium (EMEM) was 
developed for HeLa cancer cells. Since the 1950’s the range of cell lines available has 
increased considerably. 
Cell culture was devised as a means of studying animal cells free of systematic changes which 
might occur in vivo during normal homeostasis or due to the stress of an experiment3. Cell 
culture offers several advantages over animal testing. It allows the ability to control 
physiochemical parameters such as pH, temperature, pressure, and O2 and CO2. Cell culture 
is homogenous as it is randomly mixed with each sub culture. It allows for greater economy 
as cultures may be exposed to a reagent at a lower and defined concentration with direct 
access to the cell. Thus less reagent is required for injection than in vivo where up to 90 % 
may be lost by excretion and distribution to tissues other than those desired. Screening tests 
with many replicates and variables are cheaper and the legal and ethical evaluations 
associated with animal testing are avoided. The use of multi well plates or robotics have 
allowed an increase in scale and reduction in time. 
In vitro miniaturised colorimetric assays are used extensively in the determination of a 
substance’s ability to enhance cell growth or promote cell death4. The most commonly used 
measure of toxicity is inhibition of cell growth determined by reduced cell numbers 
compared with untreated controls. Colorimetric endpoint assays will not distinguish 
between cytotoxic and cytostatic effects when used after 6 or 7 days of exposure to the test 
chemical. Cytotoxic agents cause irreversible cell death through apoptosis, necrosis or 
autophagy, while cytostatic agents have only a temporary effect on growth and growth rates 
return to normal once the cytostatic agent is removed. Several in vitro miniaturised 
colorimetric assays have been developed for the quantification of cell growth. These include 
the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, neutral red 
assay and staining with crystal violet or sulforhodamine B and the acid phosphatase assay5.  
Cell viability assays often rely on a breakdown in membrane integrity measured by the 
uptake of a dye to which the cell in normally impermeable or the release of a dye which is 
normally retained. The MTT colourimetric endpoint assay was introduced in 19836. This 
technique relies on the metabolic reduction of tetrazolium dye in viable cells to a coloured 
formazan product before reading the optical density. The formazan product is insoluble in 
aqueous media and an extra solubilisation step must be taken before reading the optical 
density. The neutral red assay is based on the release of the neutral red dye which is normally 
taken up and retained by viable cells.  The absorbance of the eluted dye is measured at 570 
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nm. The crystal violet assay and the sulforhodamine B assays are protein staining assays. 
Sulphordamine B has been shown to differentiate between cytotoxicity and cytostatic 
behaviour. 
The acid phosphatase assay is based on the ability of the acid phosphatase enzyme in the 
lysosome of cells to hydrolyze p-nitrophenyl phosphate yielding the p-nitrophenyl 
chromophore. This can be measured in strong alkali at 405 nm. It has fewer steps and fewer 
reagents than the MTT assay and is more convenient as the product does not require an 
extra solubilisation step. The reproducibility between replicate wells is excellent and in many 
cases has been found to be better than the neutral red or MTT assays7. The acid phosphatase 
end point assay was the chosen endpoint assay for the biological evaluation of the N-(6-
ferrocenyl-2-naphthoyl) amino acid and dipeptide esters.  
 
Figure 3.1: Acid phosphatase end-point assay: (i) Phosphatase catalysed reaction in 
water; (ii) colour reaction in base (NaOH). 
 
3.2 Biological evaluation of N-(6-ferrocenyl-2-naphthoyl)-glycine-glycine esters.  
The most active derivative to date of the N-(6-ferrocenyl-2-naphthoyl) amino acid and 
dipeptide ester series was determined to be the N-(6-ferrocenyl-2-naphthoyl)-glycine-
glycine ethyl ester 70 with an IC50 value of 0.13 ± 0.02 µM in H1299 non-small cell lung cancer 
cells and 1.10 ± 0.13 µM in Sk-Mel-28 melanoma cells8. Therefore the series of N-(6-
ferrocenyl-2-naphthoyl)-glycine-glycine esters were prepared and evaluated for their 
biological activity. N-(6-ferrocenyl-2-naphthoyl)-glycine-glycine methyl ester 100, N-(6-
ferrocenyl-2-naphthoyl)-glycine-glycine ethyl ester 70, N-(6-ferrocenyl-2-naphthoyl propyl 
ester 101, N-(6-ferrocenyl-2-naphthoyl)-glycine-glycine butyl ester 102 and N-(6-ferrocenyl-
2-naphthoyl)-glycine-glycine benzyl ester 103 were evaluated against a panel of A549 lung 
cancer, Malme-3M, Lox-IMVI and HT144 melanoma cell lines. All compounds were screened 
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at 10 µM and 1 µM. The results of the preliminary screen are presented in figures 3.1 and 
3.2. 
 
Figure 3.1: Evaluation of compounds 70, 100-103 at 10 µM. Growth is expressed 
relative to compounds treated with an equivalent volume of DMSO. Error bars 
represent the standard deviation of triplicate assays. 
As can be seen in figure 3.1, all compound show excellent growth inhibition at 10 µM, with 
growth inhibition above 70 % in all cell lines and for all compounds. Thus a further screen at 
1 µM was performed for all compounds tested (figure 3.2). At 1 µM growth inhibition can be 
seen to be above 60 % for only the N-(6-ferrocenyl-2-naphthoyl)-glycine-glycine methyl ester 
100 and the N-(6-ferrocenyl-2-naphthoyl)-glycine-glycine ethyl ester 70, with compounds 
101, 102 and 103 all having less than 10 % growth inhibition at this concentration. Therefore 
both the methyl and ethyl esters were selected for further biological evaluation. 
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Figure 3.2: Evaluation of compounds 70, 100-103 at 1 µM. Growth is expressed 
relative to compounds treated with an equivalent volume of DMSO. Error bars 
represent the standard deviation of triplicate assays. 
 
3.2.1 In vitro evaluation in A549 and H1299 lung cancer cell lines. 
IC50 values were then determined for compounds 100 and 70 along with cisplatin 22. An 
excellent value of 0.7 ± 0.07 µM was obtained for 70 in the A549 cell line. The most active 
compound however was 100, with a value of 0.2 ± 0.03 µM. A value of 0.3 ± 0.04 was 
obtained for 100 in the H1299 cell line. This is higher than the literature value obtained for 
70 at 0.13 ± 0.02, however both values were significantly lower than those obtained for 
cisplatin 22 at 2.6 ± 0.10 and 2.1 ± 0.20 µM. 
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Table 3.1: Percentage growth of A549 cells in the presence of compounds 100-103 
and IC50 values. 
A549 Compound % growth at 10 μM % growth at 1 μM IC50 (μM) 
 100 10.0 ± 1.4 12.9 ± 0.4 0.2 ± 0.03 
 70 9.4 ± 1.2 24.8 ± 1.9 0.7 ± 0.07 
 101 5.1 ± 3.3 93.2 ± 1.8  
 102 5.2 ± 3.0 96.1 ± 3.4  
 103 23.8 ± 5.2 96.4 ± 7.9  
 22   2.6 ± 0.10 
 
Table 3.2: Percentage growth of H1299 cells in the presence of compounds 100-103 
and IC50 values. *Literature value for 708. 
 
H1299 Compound % growth at 10 
μM 
% growth at 1 
μM 
IC50 (μM) 
 100 4.7 ± 1.0 16.9 ± 2.0 0.3 ± 0.04 
 70 2.9 ± 0.6 21.5 ± 3.3 0.13 ± 0.02* 
 101 2.5 ± 0.1 93.6 ± 4.0  
 102 2.5 ± 0.1 93.7 ± 5.2  
 103 2.7 ± 0.0 92.6 ± 6.6  
 22   2.1 ± 0.20 
 
3.2.2 In vitro evaluation in Lox-IMVI, Malme-3M and HT144 metastatic melanoma 
cell lines. 
In the Lox-IMVI cell line IC50 values of 0.2 ± 0.06 µM and 0.5 ± 0.04 µM were determined for 
100 and 70 respectively (table 3.3). In the Malme-3M cell line values of 0.3 ± 0.05 µM and 
0.5 ± 0.02 µM were determined for 100 and 70 (table 3.4), while in the HT144 cell line values 
of 0.2 ± 0.02 µM and 0.5 ± 0.06 µM were determined for 100 and 70 and (table 3.5). Values 
of approximately 2.9 ± 0.90 µM, 2.7 ± 0.50 µM and 3.0 ±0.40 µM were obtained for cisplatin 
in each cell line. As can be seen 100 and 70 were considerably more active than cisplatin 22 
across all cell lines. 
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Table 3.3: Percentage growth of Lox-IMVI cells in the presence of compounds 70, 
100-103 and IC50 values. 
Lox-IMVI Compound % growth at 10 μM % growth at 1 μM IC50 (μM) 
 100 3.0 ± 1.3 17.0 ± 2.6 0.2 ± 0.06 
 70 4.0 ± 2.4 20.6 ± 4.7 0.5 ± 0.04 
 101 2.1 ± 1.4 96.4 ± 3.4  
 102 3.0 ± 1.5 98.4 ± 3.6  
 103 3.1 ± 1.5 96.5 ± 2.3  
 22   2.9 ± 0.90 
 
Table 3.4: Percentage Growth of Malme-3M cells in the presence of compounds 70, 
100-103 and IC50 values. 
Malme-3M Compound % growth at 10 μM % growth at 1 
μM 
IC50 (μM) 
 100 2.1 ± 0.1 29.5 ± 3.2 0.3 ± 0.05 
 70 2.1 ± 0.1 34.7 ± 3.5 0.5 ± 0.02 
 101 2.1 ± 1.4 94.8 ± 6.3  
 102 2.1 ± 0.1 93.7 ± 6.5  
 103 2.2 ± 0.1 92.6 ± 6.6  
 22   2.7 ± 0.50 
 
Table 3.5: Percentage Growth of HT-144 cells in the presence of compounds 70, 
100-103 and IC50 values. 
HT144 Compound % growth at 10 
μM 
% growth at 1 
μM 
IC50 (μM) 
 100 7.0 ± 1.6 10.8 ± 2.9 0.2 ± 0.02 
 70 9.2 ± 2.3 22.8 ± 2.0 0.5 ± 0.06 
 101 9.1 ± 1.2 94.0 ± 2.3  
 102 9.2 ± 1.1 97.3 ± 4.2  
 103 9.7 ± 0.7 95.1 ± 4.8  
 22   3.0 ± 0.40 
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3.2.3 In vitro evaluation in normal human dermal fibroblast (NHDF) cells. 
Toxicity is a common side effect of chemotherapeutic agents. Platinum compounds in 
particular are known for their harsh side effects9, 10. IC50 values were determined for 100 and 
70 as well as cisplatin 22 in normal human dermal fibroblast cells (NHDF) (table 3.6) to 
determine their toxicity to normal cells. Normal human dermal fibroblast are non cancerous 
cells which are isolated form the dermis of the juvenile foreskin or adult skin on the face, 
breasts, abdomen and thighs. They are often used in wound healing studies and 
dermatological research as well as in cancer and tissue engineering. 
Standard deviations are calculated based on triplicate assays. As standard deviations overlap 
the student’s t test was performed to determine significant difference between results. The 
students t test is used to determine significant difference between two sets of data. A value 
of p < 0.05 indicates a strong probability against the two sets of data having no significant 
difference. For 70 p <0.05 indicating that there is significant difference, however for 100 it 
cannot be shown that there is significant difference in the toxicity from cisplatin 22. 
However we can see from the results that 100 and 70 are much more active in cancer cells 
than on NDHF cells. While 100 and 70 both have IC50’s of less than 1 µM across all cell lines, 
the activity decreases to above 10 µM in the NHDF cells. This indicates that they have some 
selectivity for cancer cells. 
Table 3.6: IC50 values of compounds 100 and 70 in normal human dermal fibroblast 
cells. 
Cell Line Compound IC50 (µM) ± 
NDHF Cisplatin 10.0 1.8 
 70 14.2 2.4 
 100 12.0 3.8 
 
3.2.4 In vitro evaluation in resistant cell lines. 
Along with toxicity, resistance is among the problems associated with commonly used 
chemotherapeutic drugs11, 12. Resistance may be intrinsic or acquired. The development of 
resistance to one chemotherapeutic agent may contribute to the development of resistance 
to another due to similarities in the mode of action. With our target compounds we wish to 
retain or improve the cytotoxic activity of these drugs while reducing the side effects such as 
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resistance. As resistance is common, evaluation in resistant cell lines could identify niches 
where these compounds may be of use. Thus we have examined the effect of compounds 
100 and 70 in resistant cell lines. For lung cancer the A549 cell line resistant to cisplatin 22 
(A549/Cpt) was studied and for melanoma the Malme-3M cell line resistant to temozolomide 
132 (Malme-3M/TMZ) was used (table 3.7).  
Table 3.7: IC50 values of compounds 100 and 70 in resistant cell lines. 
Cell Line 100 (µM) 70 (µM) 22 (µM) 
A549 0.2 ± 0.04 0.7 ± 0.04 3.6 ± 0.70 
A549/Cpt 0.4 ± 0.10 2.4 ± 0.60 6.2 ± 0.90 
 
Cell Line 100 (µM) 70 (µM) 132 (µM) 
Malme-3M 0.3 ± 0.05 0.5 ± 0.10 209.0 ± 27.00 
Malme-3M/TMZ 0.3 ± 0.10 2.8 ± 0.50 483.0 ± 32.00 
 
For the resistant A549 lung cancer cell line IC50 values of 0.4 ± 0.10 µM and 2.4 ± 0.60 µM 
were obtained for 100 and 70, while the resistant Malme-3M cell line gave IC50 values of 0.3 
± 0.05 µM and 2.8 ± 0.50 µM respectively. When compared with the A549 cells the A549/Cpt 
cells showed 1.72 fold resistance to cisplatin 22 with an IC50 of 3.6 ± 0.70 µM in A549 and 6.2 
± 0.90 µM in A549/Cpt cells. The Malme-3M/TMZ showed 2.3 fold resistance to 
temozolomide 132 with an IC50 of 209 ± 27.00 µM in Malme-3M cells compared with Malme-
3M/TMZ cells. Cross resistance can be seen for 70 in each cell line. In the lung cancer cell line 
the IC50 value increases 3.4 times from 0.7 ± 0.04 µM to 2.4 ± 0.60 µM while in the melanoma 
cell line it increases 5.6 times from 0.5 ± 0.10 µM to 2.8 ± 0.50 µM. For compound 100 a 
twofold increase is seen in the lung cancer cell line with an increase from 0.2 ± 0.04 µM to 
0.4 ± 0.10 µM. However in the melanoma cell line the IC50 values remained constant for both 
resistant and normal cell lines at 0.3 ± 0.05 µM, suggesting that this compound is not 
susceptible to the same mechanism of acquired temozolomide 132 resistance in the Malme-
3M cell line. 
3.2.6 Apoptosis Assays 
Apoptosis is programmed cell death. It is the cells main method of selective cell removal. It 
controls cell numbers and removes infected, stressed or damaged cells. During apoptosis 
 154 
 
stress induced damage does not kill cells directly but rather triggers an apoptotic signalling 
pathway that leads to controlled cell death. Necrosis is an unregulated form of traumatic cell 
death caused by cellular injury13. The majority of human cancers are characterised by an 
inability to undergo apoptosis. Therefore we would like to selectively trigger apoptosis over 
necrosis14. 
There are several known methods for determining apoptosis, among them are electron 
microscopy, the TUNEL assay and cell cycle analysis. Also used are microfluidic devices, single 
molecule spectroscopy and electrochemical devices. These techniques have been 
reviewed15.  Here we have used both flow cytometry and the TUNEL assay to determine if 
cell death is apoptotic. 
3.2.6.1 Cell cycle analysis 
The cell cycle consists of 4 stages, synthesis (S), mitosis (M), and two gap phases (G1) and 
(G2). Cells while non-dividing remain in (G0). The boundary between G1 and S phases is the 
main check point for cells. It is at this point that the cell must decide to divide or die. It is 
possible to determine the stages of the cell cycle due to changes in the concentration of DNA 
in the nucleus. The Guava cell cycle assay uses the fluorescent nuclear DNA stain propidium 
iodide (PI) to measure the quantity of DNA in each stage of the cell cycle.  Resting cells in the 
G0/G1 phase contain two copies of each chromosome. As the cell progresses towards mitosis 
they begin to synthesis DNA (S phase) until the DNA content has doubled (G2/M phase). 
These cells will then fluoresce with twice the intensity. Cells in which the DNA has 
fragmented or degraded, such as apoptotic cells, appear as sub G0. 
Cell cycle analysis was performed for one cell line of each the lung cancer and melanoma 
cells lines, A549 for the lung cancer cell line and HT144 for the melanoma cell line, as well as 
on control samples. The cells were treated with 100 at concentrations of 2, 1, 0.5, 0.25, 0.125 
and 0.06125 µM.  
In the A549 cell line (figure 3.3) a significant increase in the sub G0 cells can be seen at as 
low as 0.125 µM, with a corresponding decrease in the G1/G0 phase. This can be seen most 
markedly at the 2 µM concentration where we can see an approximately 15 fold increase in 
the Sub G0 phase, with a decrease in the G1/G0 of nearly one third when compared with the 
control.  
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Figure 3.3: Graph of cell cycle distribution for A549 after incubation with 100. 
Similar results can be seen for the HT144 cells (figure 3.4). Again we can see a large increase 
in the Sub G0 population with a corresponding decrease in the G1/G0 population. These 
results are suggestive of apoptosis in the A549 and HT144 cell lines since apoptosis is 
characterised by DNA fragmentation and consequently a decrease in nuclear DNA content. 
However further studies of early and late apoptotic cells are required to confirm that cell 
death is occurring by apoptotic cell death. 
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Figure 3.4: Graph of cell cycle distribution for HT-144 cells after incubation with 
100. 
 
3.2.6.2 TUNEL Assay 
In order to further confirm the death of cells by apoptosis TUNEL assays were performed in 
addition to cell cycle analysis. This assay measures late stage apoptosis. It detects DNA 
fragmentation which results from apoptotic signalling cascades through a quantitative 
fluorescence assay. Nicks in DNA are labelled with bromo-deoxyuridine (BrdU) by terminal 
deoxynucleotidyl transferase (TdT) at the 3’-hydroxyl ends. This allows the cells undergoing 
apoptosis to be differentiated from cells undergoing necrosis. This test when performed 
correctly should label only cells in the last stage of apoptosis16,17. 
The assays were again performed for A549 and HT144 cell lines. They were carried out at 2, 
1, 0.5, 0.25 µM of N-(6-ferrocenyl-2-naphthoyl)-glycine-glycine methyl ester. These were 
accompanied with a 1 µM carboplatin control, a DMSO control and untreated cells. In the 
A549 cell line (figure 3.5), at concentrations ranging from 0.5 to 2 µM, cell death can be 
mainly attributed to apoptosis, with it making up approximately 80% of all cell death at the 
2 µM concentration. 
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Figure 3.5: Graph showing apoptotic versus non apoptotic cell death in A549 cells 
after incubation with 100. 
In the HT144 cell line we can see similar results to the A549 cell line (figure 3.6). At 
concentrations from 0.5 to 2 µM cell death is occurring mainly through apoptosis with 80 % 
of cell death occurring due to apoptosis in the 1 and 2 µM ranges. These results further 
confirm the results of the cell cycle analysis and it can be seen that the N-(6-ferrocenyl-2-
naphthoyl)-glycine-glycine esters induce cell death through apoptosis.  
 
Figure 3.6: Graph showing apoptotic versus non apoptotic cell death in HT-144 cells 
after incubation with 100. 
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3.3 Biological evaluation N-{para-(ferrocenyl)cinnamoyl} and N-{para-
(ferrocenyl)benzoyl} amino acid and dipeptide derivatives. 
A preliminary screen was performed for N-{para-(ferrocenyl)-benzoyl}-glycine-glycine esters 
and N-{para-(ferrocenyl)cinnamoyl} dipeptide ethyl esters at 10 and 1 µM in the HT144 
melanoma cell line (table 3.8). While these compounds showed some growth inhibition at 
10 µM with compounds 113, 115, 116, 120 and 121 having greater than 50 % growth 
inhibition, none of the compounds tested showed significant growth inhibition at 1 µM. 
Therefore no IC50 values were determined for the N-{para-(ferrocenyl)-benzoyl}-glycine-
glycine esters and N-{para-(ferrocenyl)cinnamoyl} dipeptide ethyl esters. 
Table 3.8: % growth inhibition of compounds 109-113 and 115-117 at 10 and 1 µM 
in the HT144 cell line. 
HT144 Compound % Growth 10 µM % Growth 1 µM 
 113 16.84 90.91 
 114 74.42 86.06 
 115 7.98 76.82 
 116 11.40 92.9 
 117 75.32 87.98 
 120 14.82 66.44 
 121 16.50 76.52 
 122 53.53 86.96 
 
3.4 Solubility studies 
The aromatic portion of the ferrocenyl peptide bioconjugates make the molecule quite 
lipophilic. Whilst this may be useful for crossing biological membranes, it presents some 
problems with water solubility. For in vitro studies the compounds were administered 
dissolved in DMSO. In order to progress the biological evaluation of the ferrocenyl peptide 
conjugates to in vivo studies it was necessary to reduce the quantity of DMSO used for 
administration. Solubility studies were carried out for compound 100 with a selection of 
biological media in a ratio of 25 % DMSO to 75 % of the biological medium.  
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Table 3.9: % growth in A549 cells at 1 µM of N-(6-ferrocenyl-2-naphthoyl)-glycine-
glycine ethyl ester 70 using a variety of vehicles for delivery. The control group 
tested an equivalent amount of each vehicle without 70. 
 % growth 
Vehicles (25 % DMSO) control 70 (1 µM) 
80 mM Citrate Buffer 98.8 % 83.8 % 
5% carboxymethyl cellulose 98.9 % 86.0 % 
1 % carboxymethyl cellulose 96.8 % 60.2 % 
50 % propylene glycol 
solution  
103.1 % 96.1 % 
Kolliphor EL 4.2 % 15.0 % 
 
Compound 70 is known to have a growth inhibition of 75.2 ± 1.9 % in A549 cells at 1 µM. 
Kolliphor EL shows the greatest growth inhibition of the compounds tested with only 15 % 
growth, however the control group shows a growth inhibition of 95.8 % suggesting that the 
medium itself has an antiproliferative effect. Of the remaining vehicles tested 1 % 
carboxymethyl cellulose shows the greatest growth inhibition of 39.8 %. This is almost a 2 
fold decrease in activity compared with administration in DMSO alone. This decrease in 
antiproliferative activity when diluted in a medium is not acceptable for the continuation of 
biological studies and a suitable alternative method of delivery is required. 
PEGylation involves the covalent attachment of poly ethylene glycol (PEG) to another 
molecule. PEGylation offers improved water solubility and stability as well as reduced 
clearance by the kidneys leading to longer circulation time18. It has allowed the therapeutic 
application of molecules with limited water solubility, toxicity or a poor pharmokinetic 
profile19. A PEGylated derivative of N-(6-ferrocenyl-2-naphthoyl)-glycine-glycine ethyl ester 
was prepared by Dr. Andy Harry1. It was found to be water soluble to 10 mM, however an 
IC50 value could not be obtained up to a concentration of 20 µM in A549 cells. 
3.5 Conclusions 
The aims of this research were to extend the SAR study of the ferrocenyl peptide conjugates, 
to investigate the mode of action and to begin in vivo studies. In order to advance the project 
it was necessary to carry out preliminary evaluation of the new compounds synthesised.  
The N-(6-ferrocenyl-2-naphthoyl)-glycine-glycine esters all showed excellent activity at 10 
µM. The N-(6-ferrocenyl-2-naphthoyl)-glycine-glycine ethyl ester 70 and the N-(6-ferrocenyl-
2-naphthoyl)-glycine-glycine methyl ester 100 showed the greatest growth inhibition at 1 
µM and IC50’s were obtained. IC50 values were in the range 0.2 - 0.3 µM in all the cell lines for 
100 whilst the IC50 values for 70 ranged from 0.5 - 0.7 µM. 100 proved to be more active than 
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70 in all the cell lines tested apart from H1299, for which the literature value is given. When 
tested at 1 µM, none of the N-{para-(ferrocenyl)cinnamoyl} and N-{para-
(ferrocenyl)benzoyl} amino acid and dipeptide derivatives showed significant growth 
inhibition and thus IC50’s were not obtained.  
From this it can be concluded that the naphthoyl linker is required for activity. It is likely that 
the extra conjugation of the system makes it a better linker than either the benzyl or the 
cinnamoyl linker. The loss of the bottom section of the second naphthalene ring may have 
introduced more flexibility into the molecule which may also have resulted in the loss of 
activity. Of the SAR study of the ester portion of the molecule it is apparent that an increase 
in ester chain length decreases the activity of the molecule. As the methyl ester is more active 
than the ethyl ester in 4 of the 5 cell lines with the propyl failing to significantly inhibit growth 
at 1 µM , it is likely that the ester is cleaved in the cell and that the active form of the 
compound is actually the free acid.  
Compounds were less active on normal human dermal fibroblast cells and showed a toxicity 
similar to cisplatin. When tested in resistant cell lines 70 showed cross resistance in both 
camptothecin resistant A459 cells and temozolomide resistant Malme-3M cell but 100 
showed no cross resistance in the temozolomide resistant cell line suggesting it may 
overcome the mechanism of resistance to temozolomide in this cell line. Cell cycle analysis 
and TUNEL assays show that compounds induce cell death via apoptosis in both lung cancer 
and melanoma cell lines. 
Solubility studies show that the compounds are very hydrophobic and require a high 
concentration of an organic solvent such as DMSO for administration. This presented 
considerable difficulties when preparing compounds for in vivo evaluation. A PEGylated 
derivative was prepared which increased activity, however it failed to achieve an IC50 value 
up to 20 µM. In order to progress the biological evaluation to in vivo studies further 
modification of the compounds or optimisation of a drug delivery method or targeting 
system is required. 
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Experimental procedures 
Cells and reagents 
Growth Media and Foetal Calf Serum (FCS) were obtained from Sigma-Aldrich. Cell lines were 
maintained at 37  °C with 5 % CO2. 
Cell Name Source Cell Type Media + Additives 
HT144 ATCC Melanoma RPMI + 10 % FCS 
Lox-IMVI NCI Melanoma RPMI + 10 % FCS 
Malme-3M NCI Melanoma RPMI + 10 % FCS 
Malme-3M-
TMZ 
NICB Cell 
Bank 
Temozolomide Resistant 
Melanoma 
RPMI + 10 % FCS 
Sk-Mel-28 NCI Melanoma RPMI + 10 % FCS 
A549 ATCC Adenocarcinoma DMEM/Ham’s F12 + 10 % 
FCS 
A549-Cpt NICB Cell 
Bank 
Carboplatin resistant 
Adenocarcinoma 
DMEM/Ham’s F12 + 10 % 
FCS 
H1299 ATCC Non-small Cell Lung 
Carcinoma 
RPMI + 10 % FCS + 10 mM L-
Glutamine 
SKBR3 ATCC Breast Cancer RPMI + 10 % FCS 
MDA-MB-361 ATCC Breast Cancer RPMI + 10 % FCS 
NHDF Clonetics Normal human dermal 
fibroblast 
DMEM + 10 % FCS 
 
Proliferation assays 
Proliferation was measured using an acid phosphatase assay. 1 x 103 cells/well were seeded 
in 96-well plates, except for HT144 and Malme-3M which were seeded at 2 x 103 cells/well. 
Plates were incubated overnight at 37 °C followed by addition of drug at the appropriate 
concentrations and incubated for a further 5 days until wells were 80 % to 90 % confluent. 
All media was removed and the wells were washed once with PBS (Sigma). 10 mM 
paranitrophenol phosphate substrate (Sigma-Aldrich) in 0.1 M sodium acetate buffer (Sigma) 
with 0.1 % Triton X (Sigma) pH 5.5 was added to each well and incubated at 37 °C for 2 hours. 
50 μL of 1 M NaOH (Sigma) was added and the absorbance was read at 405 nM (reference – 
620 nM).  
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Cell cycle analysis 
2.5 x 104 cells were seeded per well in 24-well plates and incubated overnight at 37 °C. After 
24 hours appropriate concentrations of test compound were added to the wells. Plates were 
then incubated at 37 °C for a further 72 hours. Media was collected and the wells washed 
once with PBS (Sigma). Cells were trypsinised and added to the media collected for each 
sample. Cells were centrifuged at 300 x g for 5 minutes and the media was aspirated. The 
cell pellet was re-suspended in 150 μL PBS and transferred to a round bottomed 96 well 
plate. The plate was centrifuged at 300 x g for 5 minutes and the supernatant aspirated 
leaving approximately 15 μL in each well. The remaining volume was used to resuspend the 
cells and 200 μL of ice cold 70 % ethanol (Fluka) was added. The plates were then stored at -
20 °C for 2 hours. After fixing, the cells were centrifuged at 450 x g for 5 minutes, the 
supernatant removed, washed with 200 μL of PBS and centrifuged again at 450 x g. The PBS 
was then removed and 200 μL of Guava Cell Cycle reagent (Millipore) was added to each 
well. The cells were mixed by pipetting and stored at room temperature shielded from light 
for 30 minutes. Cells were analysed on the Guava EasyCyte (Guava Technologies).  
 
TUNEL assay 
2.0 x 104 cells were seeded per well in 24-well plates and incubated overnight at 37 °C, 
followed by addition of test compound at the appropriate 51 concentrations. After 72 hours, 
media was removed and the wells washed once with PBS (Sigma). Cells were trypsinised and 
resuspended in 1 mL of media before being transferred to an eppendorf. Cells were 
centrifuged at 300 x g for 5 minutes and the medium was aspirated. The pellet was re-
suspended in 150 μL of PBS and transferred to a round bottomed 96 well plate. 50 μL of 4 % 
para-formaldehyde (Sigma) prepared in PBS was added to the wells and mixed. Cells were 
incubated at 4 °C for 60 minutes. The plate was centrifuged at 300 x g for 5 minutes and the 
supernatant aspirated leaving approximately 15 μL in each well. The remaining volume was 
used to resuspend the cells and 200 μL of ice cold 70 % ethanol (Fluka) was added to the 
cells. The plates were then stored at -20 °C for at least 2 hours (maximum 2 weeks). After 
fixation, the cells including positive and negative controls (Millipore) were centrifuged at 300 
x g for 5 minutes. The supernatant was aspirated, and the cells washed with 200 μL of wash 
buffer (Millipore) and then centrifuged again at 300 x g for 5 minutes. The wash buffer was 
aspirated and 25 μL of DNA labelling mix (Millipore) was added to each well and the cells 
mixed. The plates were covered with parafilm and incubated for 60 minutes at 37 °C. 200 μL 
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of rinsing buffer (Millipore) was then added to each well and the plates centrifuged at 300 x 
g for 5 minutes. The supernatant was aspirated and 50 μL of anti-BrdU staining mix 
(Millipore) added to each well, with the plate stored in the dark at room temperature for 30 
minutes. At the end of the incubation 150 μL of rinsing buffer was added to each well. Cells 
were analysed on the Guava EasyCyte (Guava Technologies). Positive and negative controls 
were performed with each assay.  
 
Statistical analysis 
IC50 values were calculated using CalcuSyn Software (BioSoft). Student t-test (two tailed with 
unequal varience) was used to compare the activity of test compounds to their 
corresponding control group. 
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Chapter 4 
Mode of action studies and drug targeting  
4.1 Introduction 
The structure activity relationship of the ferrocenyl bioconjugates has been extensively 
studied. Corry et al. investigated the effect of the substitution pattern on the benzene ring 
and of modifying the peptide chain1, 2, while Mooney et al. investigated the effect of 
replacement of the benzoyl ring with a naphthoyl linker3, 4, 5. Harry et al. investigated the 
introduction of an ethynyl spacer and substitution of the cyclopentadienyl ring6, 7. Recent 
work has extended the SAR study to include modification of the ester portion of the 
molecule. A structure has been obtained which shows a high toxicity in vitro. The N-(6-
ferrocenyl-2-naphthoyl)-glycine-glycine methyl ester has been found to have an excellent 
activity with IC50 values of 0.2 ± 0.03 µM in A459 and 0.3 ± 0.04 µM in H1299 lung cancer 
cells, 0.2 ± 0.06 µM in LOX-IMVI, 0.3 ± 0.05 µM in Mal-Me and 0.2 ± 0.02 µM in HT144 
melanoma cells.     
Further work on the ferrocenyl bioconjugates will require the transition of biological testing 
from in vitro to in vivo models. The in vitro biological evaluation carried out on the N-(6-
ferrocenyl-2-naphthoyl)-glycine-glycine esters has highlighted two key areas for the 
development of this class of compounds. 
 Firstly, further investigation of the mode of action of these compounds is required. The 
biological evaluation discussed in chapter 3 has shown that the N-(6-ferrocenyl-2-
naphthoyl)-glycine-glycine esters generate DNA damage causing cell death and confirmed 
that this cell death is apoptotic. However to date it has not been confirmed how this DNA 
damage is generated. One potential mode of action for these compounds is DNA 
intercalation. Ethidium bromide displacement assays were carried out to determine if this 
was a possible mechanism for the generation of DNA damage. It has been proposed that 
the compounds may cause DNA damage by the generation of reactive oxygen species. To 
further elucidate the mode of action of these compounds a high performance liquid 
chromatographic (HPLC) study of guanine oxidation has been undertaken to investigate the 
generation of ROS.  
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Secondly, biological evaluation has highlighted that the compounds limited water solubility 
presents a barrier to the further study of this class of compounds by in vivo studies. As a 
considerable amount of structure optimisation has been undertaken, a method of 
increasing the compounds water solubility without dramatically altering the structure of 
the compounds is highly desirable. A system whereby the limited water solubility is 
overcome by attaching the compound to a targeting molecule is proposed. This may also 
increase the specificity of the drug while allowing greater accumulation in cancer tissues. 
4.1.1 Cancer Cells 
Cancer cells are formed when normal cells lose the regulatory mechanisms which control 
their growth and multiplication. Several genetic faults can lead to cancer such as the 
activation of oncogenes and the suppression of antioncogenes Proto-oncogenes code for 
proteins which are involved in cell division and differentiation. When these become 
mutated and the cell becomes cancerous they are referred to as oncogenes. When DNA 
becomes damaged certain proteins detect the damage and block DNA replication until the 
damage is repaired. If it cannot be repaired the cell undergoes apoptosis. Tumour 
suppressor genes or antioncogenes code for these proteins. If a gene becomes damaged 
and the defects are replicated, the chances of a cell becoming cancerous are increased. 
Hanahan and Weinberg8, 9 identify 6 biological capabilities acquired by tumour cells as the 
hallmarks of cancer; self sufficiency in growth signals, insensitivity to growth inhibitory 
signals, evasion of apoptosis, the development of cell immortality, sustained angiogenesis 
and the ability to metastasise. 
4.1.2. The cell cycle 
The cell cycle consists of four phases; G1, S, G2 and M phase (figure 4.1)10. During G1 (gap 1) 
the cell is growing in size and preparing to replicate its DNA. During S phase, synthesis 
occurs and DNA is replicated. After this the cell enters the second gap phase, G2. Here it 
prepares itself for division. Copied DNA is checked and any damaged copies are repaired. 
During M phase mitosis occurs and the cell divides to produce two daughter cells each with 
a full set of chromosomes. From here the cells either enter G1 again or go to G0, a dormant 
phase. 
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Figure 4.1: The cell cycle. 
There are various points during the cell cycle at which a decision is made whether to 
advance to the next phase. The restriction point frequently becomes abnormal in tumour 
cells. There are also several checkpoints at the start of S phase and the end of G2 where 
DNA is checked and either repaired or the cell undergoes apoptosis. These can also be 
defective in tumour cells. 
Cell cycle control is regulated by proteins called cyclins and enzymes called cyclin 
dependant kinases (CDKs). Binding of a cyclin with its CDK advances the cell from one stage 
to the next. Cell cycle progression is controlled by sequential activation of cyclins and CDKs 
and is inhibited by CDK inhibitiors. Restraining proteins are present which can modify the 
effect of cyclins including p15 and p16. These block the activity of cyclin D-CDK complex. 
P21 which is controlled by p53 monitors the health of the cell and DNA integrity.  
 
4.1.3. Abnormal signalling pathways 
The decision for a cell to grow and divide depends on signals it receives from surrounding 
cells, the most important of which come from hormones called growth factors. Most 
cancers suffer from a defect in the signalling pathway which instructs for the transcription 
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of the proteins and enzymes required for growth and division.  Many cancers are capable of 
producing their own growth factors whilst other cancers can produce abnormal receptors 
which are always switched on without the need for growth factors. Receptors may also be 
overexpressed making the cell sensitive to low levels of growth factors. External hormones 
counter the effects of growth factors and signal the inhibition of cell growth and division. 
An insensitivity to these can also increase the risk of a cell becoming cancerous. 
4.1.4. Apoptosis 
There are both intrinsic and extrinsic pathways for apoptosis. The intrinsic pathway can be 
triggered by DNA damage from exposure to chemicals, drugs or oxidative stress. When the 
cell detects increased levels of damage it increases the production of tumour suppressor 
protein p53. At sufficient levels it will trigger apoptosis11. 
Extrinsic factors such as a lack of growth factors or hormones may cause apoptosis. Death 
activator proteins may also bind to cell membrane proteins called tumour necrosis factor 
receptors (TNF-R) which triggers apoptosis. It may also be triggered by T-lymphocytes. 
When they detect damaged cells they inject the cell with an enzyme called granzyme which 
initiates apoptosis. Metastatic cancer cells have undergone genetic changes which allow 
them to avoid this process. 
4.1.5. Cell immortality 
The lifetime of normal cells is determined by the number of times their DNA can divide; 
usually 50-60 divisions. Cancer cells may become ‘immortal’ with no limit to the number of 
times they can divide. This is due to the structure of chromatin. The telomere is a 
polynucleotide region at the 3’ end of a chromosome. It contains several thousand repeats 
of a short 6 base sequence.  About 50 to 100 bases are lost from the telomere during each 
replication because DNA polymerase is unable to completely replicate the ends. Eventually 
the telomere becomes too short to function and the DNA becomes unstable triggering 
apoptosis. Cancer cells produce an enzyme called telomerease which allows them to break 
free of this restriction and become immortal. Telomerease has the ability to add hexagonal 
nucleotide repeats on to the end of DNA and thus maintain its length. It is expressed in 
over 90 % of human cancers12. 
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4.1.6. Angiogenisis 
As cancer cells grow they need a supply of nutrients, hormones and growth factors from 
the blood to continue to grow and divide. Almost all cells are located within 100 µm of a 
capillary blood vessil. As a cancer grows its cells become further and further from the blood 
supply resulting in a lack of resources and a lack of oxygen, particularly in tumours. Hypoxia 
occurs when there is not enough oxygen to supply the tissue. Hypoxia-inducible factors 
(HIF) are produced and upregulate the release of vascular endolithial growth factor (VEGF) 
and fibroblast growth factor (FGF-2). These stimulate nearby blood vessels to divide leading 
to the branching of capillaries known as angiogenesis. The chance of metastasis is 
increased because the newly developing endolithial cells may release proteins such as 
interleukin-6 which stimulate metastasis. Blood vessels which result from angiogenesis are 
abnormal, dilated, leaky, disorganised in structure with excessive branching and erratic 
blood flow13. 
4.1.7. Metastasis 
Malignant cancers are dangerous because they have developed the ability to break away 
from the tumour and enter the circulation allowing them to develop anywhere in the body. 
Normal cells have cell adhesion molecules on their surface which ensure that they adhere 
to similar cells and the extracellular matrix. Molecules called integrins are involved in the 
anchoring process. When a cell becomes detached apoptosis is triggered. Metastasised 
cancer cells are missing cell adhesion molecules, they do not undergo apoptosis on 
detatchment and have the ability to attach to the extracellular matrix in other parts of the 
body.  
4.2. DNA binding assays 
4.2.1. Targeting DNA 
Many important drugs target nucleic acids, especially in the fields of anticancer and 
antibacterial therapy. DNA is known to be the cellular target for many cytotoxic anticancer 
agents and understanding how drugs interact with DNA is currently an active research area. 
Targeting DNA affects protein interaction with DNA and can cause inhibition of 
transcription and replication and DNA repair processes. Many of the anticancer 
chemotherapeutic drugs that are used today are DNA damaging agents. Targeting of DNA 
 170 
 
has been shown to cause relatively potent and selective destruction of tumour cells. The 
clinical potential of DNA damaging agents is limited by their adverse side effects while their 
genotoxicity increases the tendency for the formation of secondary cancers. 
DNA present in the body takes the form of a double helix. Each strand is composed of the 
four nucleosides adenine (A), thymine (T), guanine (G) and cytosine (C) attached to a 
deoxyribose sugar and a phosphate backbone. Within each strand nucleotides are joined by 
phosphodiester linkages and the strands are held together by hydrogen bonds. Adenine 
forms 2 hydrogen bonds with thymine, while cytosine forms 3 hydrogen bonds with 
guanine (figure 4.2). The region where the two strands are close to each other is called the 
minor groove and is deep and narrow, while the region where the strands are far apart is 
called the major groove and is shallow and wide.  
 
Figure 4.2: Structure of DNA illustrating bonding within the molecule. 
4.2.2 DNA binding. 
Most anticancer drugs currently used exert their antitumour effect through either covalent 
or non-covalent binding with DNA. DNA binding agents can be classified by the type of 
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interactions they have with DNA. This includes covalent binding and non-covalent binding. 
Alkylating agents such as cisplatin 22 bind covalently with DNA. Non covalent bonding 
results in a reversible interaction with nucleic acids. Non covalent interactions interrupt 
replication and transcription and lead to cell death. There are six potential modes for non-
covalent interaction with the DNA strand14.  These are 1; intercalation with DNA bases in 
the major groove, 2; intercalation with DNA bases in the minor groove, 3; threading 
intercalation interactions, 4; interactions with the DNA major groove, 5; interactions with 
the DNA minor groove and 6; electrostatic interactions with the anionic sugar phosphate 
backbone of DNA. These can be broadly classed as either intercalators, groove binders and 
more recently backbone binders. Strong interactions fall into two catagories; intercalation 
and hydrogen bonding interactions in the DNA grooves. While most compound display 
specificity for either groove binding or intercalation some compounds can exhibit both 
modes.  
4.2.2.1 Classical DNA intercalators 
Classical intercalators contain planar aromatic or heteroaromatic features which insert 
between neighbouring base pairs of the DNA double helix and bind through π stacking15. 
DNA base pairs form the top and bottom intercalation sites. This type of intercalator 
includes ethidium bromide 133, proflavine 134 and benzopyrene 135 (figure 4.3). This 
mode of DNA binding was first proposed by Lerman in 196116 to explain the strong 
interaction with DNA of aromatic dyes such as acridine. 
  
Figure 4.3: Classical intercalators; ethidium bromide 133, proflavine 134, 
benzopyrene 135. 
Ethidium bromide 133 is an intercalator which also functions as a fluorescent tag. On 
binding to DNA it fluoresces orange intensely under UV light. When unbound its 
fluorescence is quenched by molecules of water which are removed upon binding with the 
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hydrophobic DNA. Proflavine 134 is an antibacterial compound of the class of 
aminoacridines. It was used in WWI and WWII to treat deep surface wounds. Proflavine is 
completely ionised at pH7 and interacts with bacterial DNA. It interacts with base pairs 
through van der Waals interactions and aminium cations form ionic bonds with the 
negatively charged phosphate groups on the backbone10. Benzopyrene 135 is a component 
of burnt foods and cigarette smoke.  
Intercalation is known to occur without breaking hydrogen bonds between base pairs and 
obeys the nearest neighbour exclusion principle; when DNA is saturated with intercalators, 
every second potential intercalation site on the DNA helix remains vacant. In order for 
intercalation to occur the DNA base pairs separate 3.4 Å to form a cavity for the incoming 
planar ligand. Localised left handed unwinding of the DNA sequence occurs. The ethidium 
cation unwinds DNA by about 26° while the proflavine cation unwinds it by 17° 14. 
Intercalation lengthens, widens, stiffens and unwinds the DNA. This results in unwinding of 
the DNA and distortion of the conformation of the DNA backbone. It therefore interrupts 
the DNA protein interaction and results in frameshift mutations. 
Intercalation is considered to be the result of hydrophobic interaction. The hydrophobic 
aromatic molecule is drawn to the hydrophobic environment of the base pairs away from 
the hydrophilic aqueous environment. Intercalation complexes are stabilised by frontier 
orbital interactions between the lowest unoccupied molecular orbital (LUMO) of the 
intercalator and the highest occupied molecular orbital (HOMO) of the adjacent purine 
bases17. An increase in complex stability is seen when the aromatic intercalator is a cation. 
Computational studies on proflavine indicate that the positive charge causes a lowering in 
the energy of the LUMO energy of the ligand, favouring the interaction with the HOMO of 
the DNA bases18. Classical intercalators may also contain ionised groups which interact with 
the phosphate backbone. 
The extended planar aromatic system is usually required for a potential drug to act as a 
successful intercalator. With less extended systems intercalation can be prevented through 
the clashing of the ancillary ligands with the phosphodiester backbone. This may result in 
only partial intercalation.  
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4.2.2.2 Threading intercalators 
Threading intercalators usually have two side chains on opposite sides of a planar aromatic 
system. The aromatic system is inserted between the base pairs while one cationic 
substituent binds with the major groove and one with the minor. A threading intercalator 
occupies and interacts strongly with both the major and minor grooves of DNA 
simultaneously. Interactions of the side chains with the major and minor grooves add to 
the stability of the complex. An example of this is naphthalene diimide 13614 . 
 
 
 
4.2.2.3 Groove binders 
While intercalators insert between DNA bases, groove binding agents bind to either the 
major or minor grooves of DNA. Groove binders must have flexible structures and the 
distortion caused is smaller than that caused by classical intercalators (figure 4.4).  
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Figure 4.4: Classical intercalation of proflavine between base pairs of DNA (A) and 
groove binding of the minor groove of DNA by a tris-benzimidazole drug (B)19. 
The environment of each of the grooves differ. The major grooves have multiple interaction 
sites and a stronger binding ability for guest molecules. It is 11.6 Å wide and 8.5 Å deep and 
offers easy access to bulky molecules. The minor grooves are smaller in size with a depth of 
8.2 Å and have less binding sites. As most drug molecules are small molecules this is the 
main binding site.  
Some compounds bind to the minor groove by van der Waals interactions and hydrogen 
bonding interactions. Minor groove binding drugs typically have several aromatic rings such 
as pyrrole, furan or benzene connected by bonds possessing torsional freedom. They are 
usually narrow curved shaped (figure 4.5). 
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Figure 4.5: Groove binders; dapi 137, netropsin 138 and dystamicin 139. 
4.2.2.4 Electrostatic backbone binders 
The stability of folded DNA requires interaction with metal cations such as Mg2+ or Na+ from 
solution. Interaction of organic cationic molecules with DNA neutralises the phosphate 
charges. These charge interactions depend on the salt concentration of the solution. At 
physiological pH they are weak for molecules without intercalating or groove bonding 
modes. It does have an impact on the binding energy of highly charged molecules such as 
proteins.  
 
Drugs operating via this type of interaction are among the most recently discovered20. 
Triplatin NC 140 has three cationic platinum (II) centres and hydrogen bonding 
functionalities linked by flexible hydrophobic segments. It does not intercalate nor bind 
either groove. It binds to the phosphate oxygen atoms and associates with the backbone. It 
forms a bidentate NH-O-NH complex known a ‘phosphate clamp’ with DNA through 
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hydrogen bonding. It displays both ‘backbone tracking’ and ‘groove spanning’ forms of 
binding (figure 4.6). It has been shown to have micromolar in vitro activity in human 
ovarian cancer cells21 and in vivo activity against ovarian carcinoma xenografts. 
                      
Figure 4.6: Interaction of Triplatin NC 140 with the phosphate backone of DNA. A; 
‘backbone tracking’ and B; ‘groove spanning’ modes. Views perpendicular to the 
helix and along the helix are shown. 
 
4.2.2.5 Metallointercalators 
The covalent attachment of organic intercalators to transition metal complexes produces 
metallointercalators which may interact with DNA in a novel way that could affect 
biological activity22. Metal complexes with δ bonded ligands with aromatic side arms as 
intercalators or organometallic complexes with π bonded arenes as intercalators can have 
dual functions. Where the aromatic side arms or arene ligands can intercalate between 
DNA bases while the metal coordinates directly to a DNA base. Metal complexes with sigma 
A B 
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bonded side arms can act by both binding to DNA via metal coordination and through 
intercalation of the attached ligand. Metallointercalators have been shown to act by 
intercalation or insertion. While metallointercalators unwind the DNA and insert their 
planar ligands between the DNA bases, metalloinserters eject the DNA bases of a single 
base pair and their planar ligand acts as a π stacking replacement for the base pair. 
4.2.3 N-(6-ferrocenyl-2-naphthoyl) amino acid and dipeptide esters as potential 
intercalating agents. 
Sartorius and Schneider investigated the intercalation potential of 38 small molecule 
ligands based on benzene, naphthalene and quinolone with double stranded calf thymus 
DNA23. Naphthalene shaped ligands showed similar affinities regardless of the presence of 
nitrogen atoms or charges within the aromatic system. It was shown that quinolinum and 
naphthalene derivatives only intercalate if they bear a positively charged side chain and 
had similar binding constants. Amide functions were insufficient to enable naphthalene 
intercalation. They found no evidence for non-classical intercalation by partial insertion and 
no intercalation of phenyl units occurs unless forced to by other binding units. 
  
Figure 4.7: The N-(6-ferrocenyl-2-naphthoyl) derivatives adopt a planar 
conformation4 , while the N-(3-ferrocenyl-2-naphthoyl) derivatives are forced to 
adopt a strained conformation due to steric hinderance. 
The methyl-6-ferrocenylnaphthalene-2-carboxylate 82 (figure 4.7) was shown to have a 
planar conformation with similar results observed for the N-{para-(ferrocenyl) benzoyl} 
derivatives24. The methyl-3-ferrocenylnaphthalene-2-carboxylate however, is forced out of 
the plane with ferrocene and is accompanied by a corresponding decrease in activity. While 
the planar conformation of these drugs is desirable for intercalation, it is possible that they 
may not undergo classical or threading intercalation. Despite this, the affinity of 
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naphthalene for DNA is quite possible through groove binding interactions or other 
interactions with DNA.  
A potential method for investigating the DNA binding capacity of ferrocenyl bioconjugates 
is the ethidium bromide fluorescencing quenching assay. Fluorescence enhancement or 
quenching can be observed upon interaction of ethidium bromide with nucleic acids. A 
simple method for an ethidium bromide fluorescence quenching assay has been reported 
in the literature25.  Calf thymus DNA (ctDNA) is treated with ethidium bromide which 
fluoresces on binding to DNA. Upon displacement of ethidium bromide by the reagent 
under investigation a decrease in fluorescence is observed corresponding to the amount of 
bound intercalator. An Ethidium bromide/Hoecht 33258 competative binding assay can be 
used to determine the preference for intercalation verses groove binding. 
4.3. Redox modulation in cancer therapy. 
4.3.1 Reactive oxygen species (ROS). 
Reactive oxygen species (ROS) are constantly generated in living organisms; as by-products 
of respiration in the mitochondria, through redox cycling involving Fenton reactions by 
heavy metals, exposure to chemotherapeutic agents, transition metals and chemical 
oxidants. They are also produced by macrophages and neutrophils at the sites of infection 
and inflammation.  In normal cells they are required for cell signalling before elimination. 
ROS include the superoxide anion (O2-), hydrogen peroxide (H2O2), the hydroxyl radical 
(OH•) and ozone (O3). Accumulation of ROS within the cell can lead to oxidative stress. 
The first factors in the defence against ROS are antioxidants. Natural antioxidants are the 
cells defence mechanism to scavenge radical species. Endogenous antioxidants include 
glutathione (GSH), enzymatic superoxide dismutase (SOD), catalase (CAT), glutathione 
peroxidases (GPXs), thioredoxins (TRX) and peroxiredoxins (PRXs). Other antioxidants such 
as ascorbic acid (vitamin C), tocopherol (vitamin E), β-carotene (vitamin A) and polyphenol 
metabolites may be obtained from the diet. 
The damaging effects of these ROS on the cell depends on both their intracellular 
concentration and the levels of endogenous antioxidant species within the cell. Oxidative 
stress is implicated in a number of human diseases such as neurodegenerative diseases, 
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inflammatory diseases, cardiovascular disease, allergies, immune system dysfunction, 
diabetes, aging and cancer. 
4.3.2 Oxidative stress and cancer 
Cancer cells have an accelerated metabolism and thus require higher ROS concentrations 
to function. Cancer cells exhibit increased intrinsic ROS stress due to oncogenic stimulation, 
increased metabolic activity, and mitochondrial malfunction. When the balance between 
the oxidant and antioxidant species is lost, accumulation of ROS occurs and the cell is 
subjected to oxidative stress. This may lead to the damage of intracellular species including 
DNA, RNA and proteins. 
This balance may be manipulated in cancer therapy. Targeting the redox chemistry of the 
cell has been suggested as potentially an effective strategy26. In order to exploit the higher 
level of oxidative stress in cancer cells both antioxidant and prooxidant therapy have been 
employed27. 
A large number of metal anticancer agents have a potential redox arm to their mechanism 
of action. Combination therapy in conjunction with redox modulators could increase anti-
cancer activity and potentially lower the dosage of metal complexes required. 
4.3.3. Antioxidant therapy 
Antioxidants are the cellular mechanism of defence against oxidative stress and ROS. They 
modulate redox homeostasis within the cell. Dietary antioxidants have been shown to have 
a protective effect against cancer development. Treatment with antioxidants has been 
shown to be effective in combating tumour cells in vitro however they have had little 
clinical success as a standalone therapy28. Antioxidants have however been used in 
combination with chemotherapy to reduce harmful side effects of chemotherapeutic 
agents. It was believed that antioxidant treatment would negatively impact treatment with 
chemotherapy and radiotherapy however they have been shown in some cases to have a 
synergistic effect29. 
4.3.4 Prooxidant therapy 
Although oxidative stress leads to tumour formation, it can also increase the sensitivity to 
treatment. Cancer cells may adapt to the higher concentration of ROS by upregulating 
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detoxification enzymes. Therefore in order to be effective a cancer treatment must 
increase the ROS concentration past a threshold that is incompatible with cell viability.  
A crucial problem to be solved for the treatment of cancer with ROS is how to target ROS 
production selectively in cancer tissues. The mitochondrial respiratory chain is a major 
source of ROS generation in cells and mitochondrial DNA is particularly vulnerable to ROS 
mediated damage. During oxidative phosphorylation electrons are passed through the 
mitochondrial complexes and a proton gradient is established across the inner 
mitochondrial membrane as an energy source for respiration. When electrons escape from 
the electron transport chain they can react with oxygen to form superoxide. In this manner 
superoxide is continuously generated and can react to form H2O2 and other ROS. 
Mitochondria are therefore considered the major source of cellular ROS. Under normal 
conditions these are regulated by a system of antioxidants. 
Overproduction of cellular ROS or a reduction in the ability of the cell to eliminate them can 
result in oxidative stress. This can cause significant cellular damage such as lipid 
peroxidation, oxidative DNA modifications, protein oxidation and enzyme inactivation. 
Accumulation of ROS in cancer cells may exhaust the capacity of antioxidant defences. 
Because normal cells have lower levels of ROS stress they have a greater capacity to cope 
with increased levels of oxidative stress than cancer cells. It is therefore possible to use 
agents which generate ROS and cause ROS accumulation to preferentially kill cancer cells. 
Strategies to kill cancer cell through ROS induction can include either direct exposure to 
ROS generating agents, inhibition of antioxidant enzymes or a combination of both. 
4.3.4.1. Agents that generate ROS. 
Many currently used, well established, anticancer agents have been shown to cause 
increased cellular ROS generation in addition to their primary mechanism of action, 
including arsenic trioxide As2O3 (ATO) , cisplatin, oxaliplatin, 5-fluorouracil and paclitaxel. 
Arsenic trioxide is currently used in the treatment of acute promyelocytic leukaemia and 
has been shown to generate ROS through hindering mitochondrial electron transport and 
increasing superoxide radical generation in human leukaemia cells30. 
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While cisplatins activity has been attributed to its ability to alkylate DNA it has also been 
shown to cause increased intracellular ROS31. Only 1 % of intravenously administered 
cisplatin has been shown to reach the nucleus32. Up to 60 % is thought to react with GSH. 
Both GSH and cisplatin-GSH adducts may inhibit selenoenzyme thioredoxin reductase 
(TrxR), which has NAPDH binding sites. Cisplatin also alters mitochondrial function, 
depleting NAPDH which may increase OH• and O2-. Depleted levels of GSH have also been 
shown to increase cisplatin induced apoptosis33.  
5-fluorouracil and oxaliplatin have been linked to ROS production. In a study of patients 
with colorectal cancer, patients were treated with 5-fluorouracil and oxaliplatin in 
combination therapy.  Generation of oxidative stress was measured by urinary excretion of 
8-oxo-7,8-dihydro-2-deoxyguanosine (8-oxodG) and 8 oxoguanine. It was found that 
treatment elevated levels by around 15 %34. 
Similarly paclitaxel has been shown to have some ROS mediated activity. It was found that 
ROS generated by paclitaxel accumulate outside of the cell while intracellular levels remain 
unchanged. This causes a cytotoxic bystander effect whereby surrounding cells which have 
not been exposed to paclitaxel itself are damaged. This has also been shown to occur for 
other microtubule agents such as vincristine and taxotere35. 
Similarly ROS have been shown to play a role in mediating apoptosis many other 
chemotherapeutic agents including anthracyclins such as daunorubicin36 and doxorubicin37, 
bleomycin38, synthethic retinoids39, bortezomib40, dithiophene41 and irradiation42. 
Among compounds still in development piperlongumine 141, a recently patented small 
molecule which has been shown to selectively kill cancer cells through the generation of 
oxidative stress, production of ROS and generation of apoptosis has been extensively 
studied in preclinical studies43. It is believed to generate ROS selectively in cancer cells over 
normal cells by acting on oxidative stress response enzymes which are unregulated in 
cancer cells. 
Fucoidan 142 is a molecule extracted mainly from brown seaweed. It is a polysaccharide 
with L-fucose and sulphate ester groups and a number of variant structure have been 
identified including that extracted from F. vesiculosus44. It has recently been shown to have 
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some ROS activity45. Fucoidan was shown to increase ROS production in a MCF-7 cells and 
induce apoptosis by an ROS dependant mechanism.  
 
4.3.4.2 Agents that inhibit antioxidants. 
Antioxidant inhibitors were proposed in 1998 by Kong and Lillehei46. Treatment with 
antioxidant inhibitors can increase in the potency of a drug when co administered and thus 
reduce the dosage required. This reduction of the dose required may be beneficial in that it 
also results in a reduction of the associated side effects. Administration of an antioxidant 
inhibitor may also help to overcome drug resistance by resensitising resistant cells. 
Arsenic trioxide, as well as generating ROS can inhibit glutathione peroxidase resulting in 
increased H2O2. In a study on human prostate cancer cells in combination with IR it has 
been shown to generate an increased level of ROS compared to either treatment alone47. 
 2-Methoxy estradiol (2-ME) 143 causes accumulation of ROS by inhibition of super oxide 
dismutase SOD. It is a natural metabolite of estradiol and has undergone several phase two 
clinical trials. It has been tested in hormone resistant prostate cancer48, 49 has been tested 
alone and in combination with sunitinib against renal cell carcinoma50 and been used in 
combination with bevacizumab against metastic carcinoid tumours51.  It has however had 
mixed results, with some studies showing low response rate and some toxicity. Further 
analogues are still undergoing development.  
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Buthionine sulfoximime (BSO) 144 inhibits the synthesis of γ-glutamylcystine, a precursor of 
BSO, which decreases the level of glutathione (GSH) produced. It has been shown to reduce 
intracellular GSH levels in vitro and in vivo and has been shown to increase the sensitivity of 
cancer cells to chemotherapeutic agents which rely on GSH detoxification. 
Recently it has been demonstrated to increase the potency of organometallic ruthenium, 
iridium and osmium complexes in A2780 human ovarian cancer cells when co-incubated by 
up to 16 fold. Dependence on concentration was shown to be nonlinear with 
concentrations above an optimum dose showing no further improvement26. When used 
alone in high concentrations it has been shown to increase ROS to the point of inducing 
apoptosis52 however at high concentrations it can deactivate certain anticancer drugs such 
as paclitaxel53. 
 It has been shown to sensitize HL-60 and NB4 cells to ATO and it has been used in phase I 
clinical trials in combination with melphalan54.  
4.3.5 Oxidative DNA damage. 
DNA may be damaged by spontaneous reactions such as hydrolysis, by products of 
metabolism such as reactive oxygen and nitrogen species or by exogenous chemical and 
physical agents. Types of DNA damage produced include double and single strand breaks, 
mismatches, inter or intrastrand crosslinks as well as chemical modifications to the bases or 
sugar moieties. The cellular response to oxidative DNA damage may include DNA repair, 
cell cycle arrest and apoptosis. 
Guanine 145 has the lowest oxidation potential of the four bases and is thus the most 
easily damaged. When the cell is exposed to oxidative stress DNA damage is often 
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generated in the form of 7, 8-dihydro-8-oxo-guanine (8-oxoguanine) 146. It is considered to 
be the clinical biomarker for oxidative stress55. Guanine may be oxidised at the C4, C5 or C8 
postion. At the C4 or C5 position, a radical 4 or 5 hydroxyguanine species is formed which 
readily reforms guanine. The C8 position, however, gives G-8OH which can undergo further 
oxidation to 8-oxoguanine. 8-Oxoguanine has a carbonyl group on the C8 carbon and a 
hydrogen atom on the N7 position. 8-oxoguanine has a lower oxidation potential and can 
be further oxidised. 
 
When present during DNA replication 8-oxoguanine on the replicating strand results in 
frequent incorporation of adenine in the opposite strand (figure 4.8). This results in C:G to 
A:T transversion mutations which are one of the most common mutation in lung, breast, 
ovarian , gastric, and colorectal cancers. In one small cell lung cancer cell line C:G to A:T 
transversion mutations were identified as 34 % of all somatic mutations present56. It was 
also identified as the second most prevalent mutation in melanoma cells57. 
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Figure 4.8: Structure of 8-oxoguanine incorporated opposite adenine in DNA 
strand58. 
Guanine may be oxidised to 8-oxoguanine in vivo by hydroxyl radicals generated through 
Fenton chemistry within the cell. The majority of iron in the body is bound in either 
haemoglobin or myoglobin where the metal is responsible for the binding and release of 
oxygen. Its most important property is the ability to redox cycle under physiological 
conditions. However, as it may also generate free hydroxyl radicals, it must always be 
tightly bound in a non-redox form by proteins such as ferritin or transferrin when being 
stored or transported59. Neither O2- nor H2O2 are strongly oxidising agents and they can 
react with few cellular components, however, when they come into contact with labile iron 
a Fenton type reaction may occur generating hydroxyl radicals (equation 4.1). H2O2 is 
generated from O2- by SOD. A hydroxyl radical is formed when iron reacts with H2O2. It is a 
very strong oxidising agent and reacts rapidly near the site of formation. H2O2 can diffuse 
through biological membranes in the cell and easily reach nuclear DNA.  
Fe2+ + H2O2 → Fe3+ + HO• + OH-          (Eq. 4.1) 
The rate of formation of 8-oxoguanine from free guanine 125 and DNA using Fenton 
chemistry was previously studied60. It was shown that 8-oxoguanine 126 was produced 
from Fenton reagent in oscillating concentrations. As it was not formed in a linear fashion 
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increasing over time, it is likely that many reactions may be occurring simultaneously and 
that 8-oxoguanine is consumed and regenerated.  This was attributed to a complex 
mechanism involving further oxidation. As 8-oxoguanine has a lower oxidation potential 
than guanine it is highly susceptible to further oxidation. Since the 8-oxoguanine is 
eventually consumed it was proposed that it is only an intermediate in the oxidation of 
guanine. 
In a similar study nickel (II) catalysed oxidative damage to guanine and DNA was measured 
by HPLC-UV-EC61 giving a similar oxidation profile.  A simplified mechanism (Scheme 4.1) 
was proposed based on the mass spectrometric analysis of further known oxidation 
products of guanine, however the exact pathway has not been fully elucidated yet and the 
products generated may be pH dependant. Oxidation of guanine to 8-oxoguanine occurs 
through a two step oxidation. Further oxidation gives a highly reactive 8oxoG+ moiety, two 
molecules of which react to give oxidised guanidnohydantoin (oxGH) and regenerate 8-
oxoguanine (scheme 4.1). 
 
Scheme 4.1: Proposed mechanism for the generation of an 8-oxoguanine from 
guanine61. 
Iron mediated further oxidation of DNA bases and nucleosides has previously been studied. 
Oxidised guanidinohydantoin (Ghox) and spiroiminodihydantoin (Sp) were found to be the 
major products of iron mediated 8-oxoguanine and 8-oxo-7,8-dihydro-2-deoxyguanosine 
(8oxodG) oxidation respectively with oxaluric acid being a minor product62. It was proposed 
that the ROS generated by the iron reactions are not responsible for the initiation of 8-
oxoguanine oxidation, rather metal complexation to 8-oxoguanine occurs generating the 
reactive intermediate 8oxoGua•+. Followed by the addition of H2O2 this gives GHox or Sp in 
the case of 8oxodG. It was found that levels of these more stable oxidation products 
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remained almost constant over a 96 hour period with only minor further oxidation 
products detected. 
Among the best currently available methods for the determination of oxidative DNA 
damage is high performance liquid chromatography with electrochemical detection (HPLC-
EC). It generates very low levels of artifactual oxidation and is qualitative and sensitive63. 
The electrochemical method of detection is carried out with a flow through an EC cell –the 
eluent and sample flow through a small area close to auxillary and working electrodes 
(figure 4.9). Analysis is carried out at a constant potential with the current measured as a 
function of time. Guanine and 8-oxoguanine can both theoretically be detected by UV 
detection however UV cannot detect levels of 8-oxoguanine at the concentrations found in 
biological samples. 8-Oxoguanine can therefore be selectively detected by electrochemical 
detection using a voltage at which only 8-oxoguanine is oxidised at the electrode. This is 
easily achieved due to 8-oxoguanine having a lower oxidation potential than guanine. 
 
Figure 4.9: ECD schematic reproduced from the handbook of electrochemistry64. 
 
4.3.6 Guanine oxidation studies 
Redox modulation by has been proposed as a potentially effective method in the treatment 
of cancer offering multiple targets and selectivity over normal cells. Significant research has 
been carried out on the redox chemistry of metal anticancer complexes in the treatment of 
cancer26.  The generation of ROS  by many commonly used chemotheraphy agents can be 
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seen to generate DNA damage and induce apoptosis, which likely contributes to their 
cytotoxic effect in addition to their established mode of action. 
A potential mechanism by which ferrocenyl peptide conjugates may exert their cytotoxicity 
is through oxidative DNA damage by the generation of Fenton reaction induced ROS. 
Ferricenium salts have been shown to produce hydroxyl radicals and cause oxidative DNA 
damage65. Given that ferrocene has the ability to undergo a one electron oxidation at 
biological potentials to the ferricenium ion and that ferricenium salts have been shown to 
exhibit anti tumour activity, it seems a logical strategy to investigate the ability of 
ferrocenyl peptide conjugates to generate oxidative DNA damage. 
 
4.3.6.1 N-(ferrocenylmethylamino acid) fluorinated benzene carboxamide 
derivatives. 
As part of the extended SAR study of ferrocenyl bioconjugates a series of N-
(ferrocenylmethylamino acid) fluorinated benzene carboxamide derivatives were 
synthesised by Butler et al. concurrently with the N-(6-ferrocenyl-2-naphthoyl) dipeptide 
esters66. This was a continuation of research carried out by Kelly et al. who prepared a 
series of N-(ferrocenylmethyl)-fluorinated benzene carboxamide derivatives. Fluorinated 
benzene carboxamides were prepared by condensation of ferrocenyl methylamine with the 
corresponding fluorinated benzene carboxmides. The substitution pattern of fluorine was 
varied using 2-fluoro, 3-fluoro, 4-fluoro, 2- and 6-fluoro and 2-, 3-, 4-, 5- and 6-
fluorobenzoic acids. The compounds were tested against MDA-MB-435-SF estrogen 
receptor positive breast cancer cells67. IC50 values were obtained for selected compounds. 
The most active compound was N-(ferrocenylmethyl)-4-fluorobenzene carboxamide with 
an IC50 value in the range of 11-14 µM. 
Similarly to the N-(6-ferrocenyl-2-naphthoyl) amino acid and dipeptide esters the N-
(ferrocenylmethylamino  acid) fluorinated benzene carboxamide derivatives consist of 1; a 
redox active ferrocene core and 2; an amino acid linker component to interact with 
biological systems within the cell via hydrogen bonding. They also contain 3; a fluorinated 
aromatic component (figure 4.10). The incorporation of C-F bonds is a recognised strategy 
often employed in the development of pharmaceuticals68. The success of fluorine 
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substitution is evident from the large number of fluorinated drugs approved by the FDA 
and currently being used as anticancer, antidepressant, antiviral and anesthetic agents. 
There are generally two consequences of introducing fluorine into a potential drug 
molecule.  Firstly there are the physiochemical properties. Fluorine has the ability to 
modulate electronic, lipophilic and steric parameters that can critically influence the 
pharmacological properties of a potential drug molecule.  The introduction of a fluorine 
atom will generally increase lipophilicity, decrease basicity and alter the hydrogen bonding 
interactions of a molecule.  Secondly, there is the influence of fluorine substitution on the 
biological stability through altering the metabolism of the drug molecule. In this study the 
position and also the number of fluorine atoms on the aromatic ring were investigated and 
several analogues were shown to have an anti-proliferative effect.   
 
 
Figure 4.10: Structure of the N-(ferrocenylmethylamino acid) fluorinated benzene 
carboxamides. 
The SAR study was extended by the introduction of amino acids and altering the number 
and substitution pattern of fluorine atoms on the benzene ring. Glycine, L-alanine and β-
alanine were used as the amino acid linker and a fluorinated benzene ring with varying 
substitution patterns of 2-fluoro, 3-fluoro, 4-fluoro, 2- and 4-fluoro, 2- and 6-fluoro, 3- and 
5-fluoro, 3,4,5-fluoro and 2,3,4,5-fluorobenzene carboxamide were used as the aromatic. 
All compounds were tested at 10 µM in MCF-7 cells. IC50 values were obtained for selected 
compounds. The β-alanine compounds showed no activity at 10 µM. The best activities 
were obtained for glycine and L-alanine derivatives which had more than one fluorine 
substituent on the benzene ring. The N-(ferrocenylmethylalanine)-3,4,5-trifluorobenzene 
carboxamide 75g and N-(ferrocenylmethylglycine)-pentafluorobenzene carboxamide 74h 
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derivatives were found to be the most active with  IC50’s of 2.84 µM and 10.3 µM 
respectively. 
 
 
4.3.7 N-(6-ferrocenyl-2-naphthoyl)-glycine-glycine ethyl ester (70) and N-
(ferrocenylmethyl-L-alanine)-3,4,5-trifluorobenzene carboxamide (75g) mediated 
DNA damage. 
 
N-(6-ferrocenyl-2-naphthoyl)-glycine-glycine ethyl ester 70 and N-(ferrocenylmethyl-L-
alanine)-3,4,5-trifluorobenzene carboxamide 75g were selected as the most active 
compounds in the N-(ferrocenylnaphthoyl) dipeptide ester and  N-(ferrocenylmethyl amino 
acid) fluorinated benzene-carboxamide series respectively.  N-(6-ferrocenyl-2-naphthoyl)-
glycine-glycine ethyl ester had an IC50 of 0.13 µM in H1299 lung cancer cells and an IC50 of 
1.10 µM  in Sk-Mel-28 melanoma cells5, while N-(ferrocenylmethyl-L-alanine)-3,4,5-
trifluorobenzene carboxamide had an IC50 of 2.84 µM in an MCF-7 breast cancer cell line66. 
Guanine oxidation studies were undertaken on both compounds to investigate if they could 
opperate through this mode of action and if both series exhibited the same mode of action. 
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To investigate if the compounds generated Fenton reaction mediated ROS, the rate of 8-
oxoguanine formation from guanine was monitored. Guanine was oxidised using either N-
(6-ferrocenyl-2-naphthoyl)-glycine-glycine ethyl ester 70 or N-(ferrocenylmethyl-L-alanine)-
3,4,5-trifluorobenzene carboxamide 75g and H2O2 and incubated at 37°C. Samples were 
taken in duplicate every 30 seconds after addition over a period of 15 minutes. Each 
sample was injected in triplicate and analysed by HPLC-EC using an electrochemical 
detector at +550mV versus Ag/AgCl. The separations were preformed using the protocols 
previoulsy established for the separation of DNA bases69. 
The iron mediated Fenton oxidation of guanine and the kinetic profile of 8-oxoguanine 
formed as a result has previously been investigated, utilisng FeSO4 as the model iron 
complex62. To examine if the N-(6-ferrocenyl-2-naphthoyl)-glycine-glycine ethyl ester and 
N-(ferrocenylmethyl-L-alanine)-3,4,5-trifluorobenzene carboxamide induced guanine 
oxidation via a similar mechanism, kinetic 8-oxoguanine formation profiles were 
compared using both ferrocenyl conjugates and FeSO4 complexes.  
Control experiments were carried out utilising each of the iron complexes in the absence 
of peroxide, and peroxide in the absence of iron, to verify that any oxidation was Fenton 
mediated. Additionally, they ensured that no artifactual oxidation was occuring from the 
sample preparation or analysis methodology.  For these experiments, deionised water 
was used to sequentially replace each of the reagents used. The highest background 
reading for these controls is plotted as the base line in figures 4.11, 4.12 and 4.13. Error 
bars show the standard deviation of duplicate samples injected in triplicate.   
Incubation of free guanine with FeSO4 and peroxide lead to oscillating concentrations of 
8-oxoguanine over the incubation as previously reported.  The formation is significantly 
higher than the control baselines, confirming the oxidation is Fenton mediated. The 8-
oxoguanine concentration maxima were 1.39 µM at 6 minutes and 2.29 µM at 8.5 
minutes (figure 4.11). This trend is analagous to that reported previously. These maxima 
occur with a different oscillation frequency, which can be attributed to differences in 
solution pH (previously these maxima were reported at 4 and 15 minutes respectively).  
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Figure 4.11: 8-oxoguanine concentration as a function of time after incubation of 
free guanine with reagents Fe(II) and H2O2 at 37 °C. The mean of each of the 
duplicate samples injected in triplicate is taken. 
Incubation of free guanine with 70 or 75g and peroxide, which were suspected to result in 
Fenton mediated oxidation, also resulted in the formation of oscillating concentrations of 
8-oxoguanine over the incubation period, as found with FeSO4. In both cases, the 
formation is significantly higher than the control baselines, clearly illustrating that both 
the iron complex and peroxide are required to form this concentration of 8-oxoguanine, 
confirming that the oxidation of guanine was Fenton mediated.  
 The maximum concentration of 8-oxoguanine formed using 70 was 0.62 µM  and was 
reached after 30 seconds with a concentration of 0.56 µM at 2 minutes (figure 4.12).  
Following intial maxima the concentration of 8-oxoguanine decreased but continued to 
oscillate with concentrations increasing again towards 15 minutes. 
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Figure 4.12: 8-Oxoguanine concentration as a function of time after incubation of 
free guanine with N-(6-ferrocenyl-2-naphthoyl)-glycine-glycine ethyl ester 70 and 
H2O2 at 37 °C. 
The maximum concentration of 8-oxoguanine formed using 75g was 0.72 µM on addition 
of the peroxide (Figure 4.13). The oxidation profile is similar to 70, in respect to maxima 
being generated almost immeadiately on addition of peroxide, however in the case of 
75g, after 2 minutes the concentration of 8-oxoguanine decreases but continues to 
oscillate for the rest of the incubation period while remaining low. 
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Figure 4.13: 8-Oxoguanine concentration as a function of time after incubation of 
free guanine with N-(ferrocenylmethyl-L-alanine)-3,4,5-trifluorobenzene 
carboxamide) 75g and H2O2 at 37 °C. 
The concentrations of 8-oxoguanine generated by 70 and 75g are both significantly lower 
than that of the FeSO4. Ferrocene may produce a weaker response than the FeSO4 due to 
the presence of the cyclopentadienyl ligands and the size of the molecule. However the 
generation of 8-oxoguanine by both compounds illustrates that the oxidation is occurring 
by Fenton chemistry and that they are capable of generating DNA damage via a ROS 
mediated mechanism. 
The oscillation period for 8-oxoguanine mediated by 70 and 75g differs from that of 
FeSO4, however after the initial maxima, the 8-oxoguanine concentration continues to 
oscillate for the rest of the incubation period, with concentrations consistently higher 
than control levels, further confirming that oxidation is Fenton mediated. 
4.4 Drug targeting 
4.4.1 Introduction. 
Among the problems encountered in the development of useful chemotherapeutics is a 
lack of specificity. Many commonly used chemotherapeutics are non-selective for cancer 
cells and thus a higher dose must be administered. This results in unwanted side effects 
and toxicity. Drug targeting gives increased specificity of delivery and therefore an 
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increased dose of the cytotoxic compound to the tumour relative to the rest of the body. 
Recently focus has switched to use of targeting molecules which are essential to the growth 
of the tumour. Vitamin B12, folic acid, biotin and riboflavin are essential for the division of 
all cells but more particularly for the growth of tumours. 
Vitamin B12 (cobalamin) is a complex molecule consisting of a nucleotide moiety and a 
planar corrin ring which contains a central cobalt (III) atom. It is an essential nutrient 
cofactor required for DNA synthesis. Active forms of cobalamin include methylcobalamin 
and adenosylcobalamin. The more stable cyanocobalamin is used in vitamin supliments and 
hydroxocobalamin is the most common form taken in in the diet. Both of these can be 
converted to the active forms in vivo. The use of dietry uptake pathway of B12 to deliver 
pharmaceuticals has received attention since the 1970’s with much work undertaken by 
Russell et al. in the 1990’s. 
Upon ingestion vitamin B12 is bound by transcobalamin I which is released by salivary 
glands and gastric mucosa and transported to the duodenum. Pancreatic enzymes digest 
the transcobalamin I receptor and it is bound to intrinsic factor which facilitates transport 
across the intestine. It is then transported by transcoballamin II in the blood plasma and 
internalised by the cell by endocytosis at the transccoballamin II receptor70. 
Conjugation of molecules to B12 has been successful at 3 major sites: peripheral 
propionamide sites on the corrin ring (although the highlighted site is the only one which 
will not interfere with transport and binding), through the 5’-hydroxy group of the ribose 
unit and through the phosphate unit (figure 4.14). 
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Figure 4.14: Location of successful conjugation sites on vitamin B12 highlighted in 
red. 
 
The transcobalamin receptor II has been reported to be over expressed in leukemic cells, 
lymphoma cells, breast, lung, bone, thyroid, colon, prostate and brain cells. The receptor is 
undetectable on non-dividing cells but highly expressed when cells are stimulated to divide.  
The degree of over expression has been shown to correlate with the stage of tumour 
growth with the highest found on stage IV tumours. The uptake of vitamin B12 into tumours 
has been monitored using fluorescent labels. Most tumours have been shown to over 
express, however some do not. The binding of fluorinated polymers leads to rapid 
internalisation and accumulation to levels ranging from 2 to 30 times higher than the non-
conjugated polymers. 
There are two limitations of using B12 as a targeting agent. Firstly the dose which can be 
delivered is quite small. Only one molecule of the active drug may be delivered with each 
molecule of vitamin B12 and only a limited amount of B12 can be transported into the cell 
before all the cellular receptors have been used up. Secondly the small size of the B12-drug 
complex means that it will be excreted by the kidneys. This causes the drug to be 
reabsorbed by the proximal tubules and accumulate in the kidney. 
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These limitations can be overcome by using polymer bound drug complexes which would 
both increase the dose of the target drug per molecule of vitamin B12 and increase the size 
of the complex allowing exploitation of the enhanced permeability and retention (EPR) 
effect. The EPR effect allows spontaneous accumulation of the cytotoxic or passive 
targeting. In tumours the endolithial wall lining the blood vessils becomes more permeable 
and lymphatic drainage is poor. Large molecules loaded with a pharmaceutical agent can 
transport the active agent into the area with increased permeability where the active drug 
can be released from the carrier. The EPR effect is typically seen for large molecules of over 
40 kDa in molecular weight. Small molecules are not retained and return to circulation by 
diffusion.  
The vitamin B12 delivery pathway has been extensively researched in the delivery of protein 
and peptide drugs as it avoids the problems of degradation in the stomach and inadequate 
absorption71. 
The effect of targeting on the delivery of cytotoxins was investigated in vitro and in vivo 
using methothrexate72.  The drug was linked to hydroxpropylmethacrylic acid (HPMA) and 
the polymer drug conjugate was modified with B12. In the case of methotrexate, it was 
found that the methotrexate polymer conjugate was more effective than either 
methotrexate alone or a direct B12 conjugate of the drug. The B12 drug polymer conjugate 
was slightly less active. 
Howard et al. prepared a chlorambucil cobalamin derivative in 1997 to investigate the 
release of cobalamin conjugates by solvolysis73. This group has also worked on doxorubicin 
conjugates. 
A cobalamin-colchicine conjugate was linked by a hydrazone linker by Bagnato et al. Upon 
uptake by the cell the linker was hydrolysed in the lysosome74. The active drug causes cell 
death by microtubule stabilisation. The conjugate showed preferential uptake by cancer 
cells and exhibited a nanomolar LC50 against breast, brain and melanoma cells in vitro. The 
conjugate was found to be highly water soluble. 
4.4.2 Drug targeting for the N-(6-ferrocenyl-2-naphthoyl) dipeptide derivatives. 
Although the generation of ROS has been shown to have some specificity for cancer tissues 
due to elevated levels of oxidative stress, additional tumour targeting could increase 
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specificity of the ferrocenyl peptide conjugates. The incorporation of a molecule of vitamin 
B12 was proposed as a potential strategy to both enhance the specificity and increase the 
water solubility and bioavailability of the ferrocenyl peptide conjugates. The N-(6-
ferrocenyl-2naphthoyl) dipeptide esters have shown excellent activity in vitro, however 
their low water solubility has prevented advancement to in vivo studies. As rapidly dividing 
cells require high levels of B12 for thymidine synthesis for DNA replication before cell 
division, cobalamin can be covalently modified to allow the attachment of various drugs 
without affecting the corrin ring pharmacopore which is recognised by the B12 transport 
proteins, thus increasing uptake by the cells. 
Although the incorporation of the drug candidate into a large biological molecule may 
reduce the quantity of active drug delivered, the quantity of active drug delivered to the 
target site could potentially be increased thus reducing the quantity necessary for activity. 
In this case a direct B12-drug conjugate was prepared in conjunction with Dr. Fabio Zobi of 
the University of Switzerland. 
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Figure 4.15: Structue of B12-N-(6-ferrocenyl-2-naphthoyl)-ƴ-aminobutyric acid 
conjugate. 
To date the N-(6-ferrocenyl-2-naphthoyl)-γ-aminobutyric acid has been conjugated to 
Vitamin B12 (figure 4.15). The compound was prepared in approximately 15-20 % yield via 
HPLC. The coupling was carried out via activation of the N-(6-ferrocenyl-2-naphthoyl)-γ-
aminobutyric acid with carbonyldiimidazole (CDI) and attachment to the Vitamin B12 
complex. The compound was identified by mass spectrometry (figure 4.16).  
Further work will include coupling of other compounds including N-(6-ferrocenyl-2-
naphthoyl)-glycine-glycine, followed by in vitro testing in both melanoma and lung cancer 
cell lines. This strategy presents a promising method for the solubilisation and targeting of 
this class of compounds for future potential in vivo studies. 
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Figure 2: Mass spectrum of N-(6-ferrocenyl-2-naphthoyl)-γ-aminobutyric acid. 
Figure 4.16: Mass spectrum of the B12-N-(6-ferrocenyl-2-naphthoyl)-ƴ-aminobutyric 
acid conjugate. 
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Figure 4.17: Chem draw 3D model of the B12-N-(6-ferrocenyl-2-naphthoyl)-ƴ-
aminobutyric acid conjugate. 
A chemdraw 3D model (figure 4.17) shows the B12-N-(6-ferrocenyl-2-naphthoyl)-ƴ-
aminobutyric acid conjugate. The ferrocenyl moiety is exposed and should easily be able to 
undergo oxidation. The amino acid side chain also appears to protrude significantly from 
the main body of the B12 complex. This should allow for cleavage of the active drug by 
esterases or amidases in the cell. 
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4.5 Conclusions 
Future work for the development of the N-(6-ferrocenyl-2-naphthoyl) amino acid and 
dipeptide esters will necessarily require the transition of biological testing from in vitro to 
in vivo models. This transition will require firstly an in depth understanding of how these 
compounds elicit their cytotoxic activity and secondly a reliable method for their delivery 
and uptake in cancer tissue.  
We have established in chapter 3 that our compounds are capable of generating apoptosis 
by cell cycle analysis and TUNEL assays. One of the proposed mechanisms of action for 
these compounds is the generation of reactive oxygen species. In chapter 4 we have looked 
at the ability of these compounds to cause oxidative DNA damage via the generation of 
ROS as well as their potential as intercalating agents. 
It is clear that the N-(6-ferrocenyl-2-naphthoyl) amino acid and dipeptides act through 
more than one mode of action. It has been proposed that the increase in conjugation when 
the benzoyl linker was replaced with the naphthoyl linker, lowered the oxidation potential 
of the ferrocene moiety, thus increasing the cytotoxicity of the molecule. However a 
decrease in the measured oxidation potential of these complexes is not always 
accompanied by an increase in cytotoxicity. It has been seen that N-(3-ferrocenyl-2-
naphthoyl) dipeptide esters possess lower redox potentials than N-(6-ferrocenyl-2-
naphthoyl) dipeptide esters while displaying less cytotoxicity75. Still, the oxidation 
potentials of both are significantly lower than those of the ferrocenyl dipeptide derivatives 
lacking a conjugated linker76. 
It is likely that other features of these derivatives contribute to the cytotoxic activity. 
Classical intercalators typically possess an extended planar system and studies with 
naphthalene type ligands have shown that they are often poor intercalators. However, 
intercalation of the compounds is possible. Hydrogen bond donors and acceptors in the 
peptide chain could then interact with DNA bases in the centre of the helix. The bulky 
ferrocene core (10.5 Å) will not fit into the major groove of DNA (8.5 Å), however it is 
possible that the planar rings and side chain may play a part in its binding through 
hydrogen bonding or other non-covalent bonding with DNA. Given the low oxidation 
potential of these derivatives it is also possible that the ferrocene moiety in its oxidised Fe3+ 
state could interact with the phosphate backbone. The N-(6-ferrocenyl-2-naphthoyl) 
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derivatives have been found to be planar  which is desirable for DNA intercalation, whereas 
the N-(3-ferrocenyl-2-naphthoyl) derivatives which are less active are bent out of the plane 
with ferrocene due to the steric hindrance between the ferrocene moiety and the 
dipeptide chain. This loss of activity accompanied by the loss of planarity supports the 
currently suggested mode of action.   
Thus there are at least two potential modes of action both of which could interfere with 
replication. These may act alone or in synergy to elicit the cytotoxic response from cancer 
cells. It is plausible that both intercalation and the generation of reactive oxygen species by 
the bound drug may occur simultaneously. Ethidium bromide displacement assays may 
offer a valuable insight into this potential mode of action and how the ferrocenyl 
bioconjugates elicit their cytotoxic activity.  
A method for delivery and targeting of the N-(6-ferrocenyl-2-naphthoyl) amino acid and 
dipeptide esters has been proposed which should require minimal changes to the 
structure of these compounds. The incorporation of a B12 conjugate represents a 
promising strategy to overcome the compounds water solubility issues while also offering 
a potential method for both targeting and increasing uptake in cancer tissues.  The B12 
conjugate will be tested in both lung cancer and melanoma cell lines. 
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Experimental Procedures 
Guanine oxidation  
10 mM guanine prepared in 84 % 50 mM ammonium acetate, 85 mM acetic acid buffer 
and 16 % 1 M NaOH was incubated with 1 mM Iron (II) sulphate (FeSO4.6H2O) or  1 mM  
N-(6-ferrocenyl-2-naphthoy)-glycine-glycine ethyl ester and 0.5 M hydrogen peroxide 
(H2O2) at 37 °C with constant stirring. Aliquots of 100 µl were taken in duplicate at 
various incubation times. The reaction was quenched with 1 mL cold ethanol. The 
solution was dried immediately under a stream of nitrogen gas.  Samples were stored at 
-20 °C until further use. Prior to analysis they were redissolved in 1 mL 84 % 50 mM 
ammonium acetate, 85 mM acetic acid buffer and 16 % 1 M NaOH. Samples were 
injected in triplicate. 
HPLC-EC analysis of 8-oxoguanine formation 
For 8-oxoguanine analysis, the HPLC System consisted of a Varian ProStar 230 solvent 
delivery module and a Varian ProStar 310 UV-VIS dectector.  A Phenomenex Onyx 
Monolithic C18 reversed phase column (100 x 4.6 mm) with 1 cm guard column was 
used. The eluent comprised 1.2 % acetonitrile (ACN), 50 mM ammonium acetate and 
was adjusted to pH 4.6 with glacial acetic acid. It was run at a flow rate of 4 mL min-1 
with an injection volume of 20 µl. The column temperature was ambient and 8-
oxoguanine formation was monitored using an electrochemical detector at a detection 
potential of +550 mV versus an Ag/AgCl reference electrode. 
Controlled experiments 
Control incubations were performed with guanine to ensure that no artificial oxidation 
was caused by the reaction conditions. Each of the reagents was replaced with deionised 
water to insure that none of them could generate oxidative damage individually. 
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A 
A  absorbance; adenine 
ACE  angiotensin converting enzyme 
ACN  acetonitrile 
Ag/AgCl silver/silver chloride (reference electrode) 
AMP  antimicrobial peptide 
Anal.  Analysis 
ATO  arsenic trioxide 
 
B  
BMS  Brystol Myers Squib 
Boc  tert-butoxycarbonyl 
Br.  broad (spectral) 
BSO  buthionine sulfoximinme 
 
C 
C  cytosine 
Calc.  calculated 
CAT  catalase 
CDCl3  deuterated chloroform 
CDK  cyclin dependant kinase 
Cl  chlorine 
Co   cobalt 
Cp  cyclopentadienyl 
Cq  quaternary carbon  
Cu   copper 
C=O  carbonyl 
 
D 
d  doublet (spectral) 
D-Ala  D-alanine 
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DCM  dichloromethane 
DCU  Dublin City University 
dd  double doublets (spectral) 
decomp. decomposition 
DEPT   distortionless enhancement by polarisation transfer 
DHFR  dihydrofolate reductase 
DMSO-d6 deuterated dimethylsulfoxide 
DNA  deoxyribonucleic acid 
 
E 
e-  electron 
EAT  Ehrlich ascites tumour 
ECD  electrochemical detector 
E. coli  Escherichia coli 
EDC  N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride 
EMEM  Eagle’s minimum essential medium 
EPR  enhanced permeability and retention  
ER  estrogen receptor 
ER (+)  estrogen receptor positive cells 
ER (-)  estrogen receptoe negative cells 
ESI  electrospray ionisation  
Et3N  triethylamine 
EtOH  ethanol 
 
F 
FACS  fluorescence activated cell sorting     
FCS  foetal calf serum 
FDA  food and drug administration  
Fe  iron 
Fe (II)  ferrous ion  
Fe (III)  ferric ion  
213 
 
FeSO4  Iron sulphate 
FGF   fibroblast growth factor  
 
G 
G  guanine 
G0/G1/G2 gap phase 
GABA  ƴ-aminobutyric acid 
Gly  glycine 
GPX  gluthathione peroxidase 
GSH  glutathione 
 
H 
H   hydrogen  
H2O  water 
H2O2   hydrogen peroxide 
HCl  hydrochloric acid 
HDACi  histone deacetylase inhibitor 
HIF  hypoxia inducible factor 
HO•  hydroxyl radical 
HOMO  highest occupied molecular orbital 
HPMA  hydropropylmethacrylic acid 
HPLC  high performance liquid chromatography 
HRB  Health Research Board 
HSQC  heteronuclear single quantum coherence 
 
I 
IC50  half maximal inhibitory concentration  
IR  infra red 
 
J 
J  coupling constant (spectral) 
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K 
 
L 
L  path length (in cm) 
L-Ala  L-alanine 
LBD  ligand binding domain 
LNC  lipid nanocapsules 
LUMO  lowest unoccupied molecular orbital 
 
M 
m  meta 
m  multiplet (spectral) 
M  mitosis phase 
MDR  multiple drug resistance 
MeOH  methanol 
MgSO4  magnesium sulphate 
MIC  minimum inhibitory concentration 
MLCT  metal-ligand charge transfer 
Mp  melting point 
MS  mass spectrometry 
MTT  3-(4,5-dimethylthiazol-2-yl)-2, 5-dipheyltetrazolium bromide 
m/z  mass to charge ratio 
 
N 
N  nitrogen 
NaNO2  sodium nitrite 
NaOH  sodium hydroxide 
NADP   nicotinamide adenine dinucleotide phosphate 
NCI  National Cancer Institute 
215 
 
NHDF  normal human dermal fibroblast 
NHS  N-hydroxysuccinimide 
NICB  National Institute for Cellular Biotechnology 
NMR  nuclear magnetic resonance 
No.  number 
NSCLC  non small cell lung cancer 
 
O 
O  oxygen 
OD  optical density 
OEt  ethoxy 
OH  hydroxyl 
OMe  methoxy 
OPOA  8-oxo-8-(phenylamino)octanoic acid 
 
P 
P  para 
P. aeruginosa Pseudomonas aeruginosa 
PEG  poly ethyleneglycol 
Pgp  P-glycoprotein 
PRX  peroxiredoxin 
PSA  N1-phenylsuberamide 
 
Q 
q  quartet (spectral) 
qt  quintet (spectral) 
   
R 
RBA  relative binding affinity 
RNA  ribonucleic acid 
ROS  reactive oxygen species 
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Ru  ruthenium 
 
S 
s  singlet (spectral) 
S  synthesis phase 
SAHA  suberoylanilide hydroxamic acid 
SAR  structure activity relationship 
Sar  sarcosine 
S. aureus Staphylococcus aureus 
SCLC  small cell lung cancer 
SERM  selective estrogen receptor modulator 
Sn  tin 
SOCl2  thionyl chloride 
SOD  superoxide dismutase 
SPPS  solid phase peptide synthesis 
 
T 
t  triplet (spectral); thymine 
Tc  Coalescence temperature 
TFA  trifluoroacetic acid 
Ti  titanium 
TMS  tetramethylsilane 
TNF-R  tumour necrosis factor receptor 
TRX  thioredoxin 
TUNEL  terminal deoxynucleotidyl transferase dUTP nick end labeling 
 
U 
UV  ultraviolet 
 
V 
VEGF  vascular endolithial growth factor 
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Vis  visable 
 
Z 
z  charge   
Miscellaneous 
(E)  Entegen (opposite) 
(Z)  Zusammen (together) 
αH  alpha hydrogen 
ε  extinction coefficient 
λmax  maximum absorbance 
η5-C5H4  mono substituted cyclopentadienyl ring 
η5-C5H5  unsubstituted cyclopentadienyl ring 
±  plus/minus 
~  approximately 
<  less than 
>  greater than 
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Units 
Å  Angstrom 
cm  centimetre 
cm-1  wavenumber(s)/per centimetre 
g  gram 
h  hour 
Hz  hertz 
l  litre 
M  molar 
MHz  megahertz 
mg  milligrams 
ml  millilitre 
mm  millimeters 
Nm  nanometers 
mM  millimolar 
mmol  millimole 
mol  mole 
µg  microgram 
µg mL-1  microgram per millilitre 
µl  microliter 
µm  micrometer 
µM  micromolar 
nm  nanometer 
nM  nanomolar 
°  degrees 
°C  degrees Celcius 
Ppm  parts per million 
s  second 
δ  chemical shift (ppm) 
%  percentage 
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ABSTRACT: In this article, we report the ﬁndings of a
comprehensive structure−activity relationship study of N-(6-
ferrocenyl-2-naphthoyl) dipeptide ethyl esters, in which novel
analogues were designed, synthesized, and evaluated in vitro
for antiproliferative eﬀect. Two new compounds, 2 and 16,
showed potent nanomolar activity in the H1299 NSCLC cell
line, with exceptional IC50 values of 0.13 and 0.14 μM,
respectively. These compounds were also found to have
signiﬁcant activity in the Sk-Mel-28 malignant melanoma cell
line (IC50 values of 1.10 and 1.06 μM, respectively). Studies
were also conducted to elucidate the mode of action of these novel organometallic anticancer compounds. Cell cycle analysis in
the H1299 cell line suggests these compounds induce apoptosis, while guanine oxidation studies conﬁrm that 2 is capable of
generating oxidative damage via a ROS-mediated mechanism.
■ INTRODUCTION
The medicinal application of ferrocene derivatives is currently a
thriving area of research,1 with applications in the area of cancer
research being the most popular and well-researched.2 To date,
the most promising ferrocene-based drug candidates have been
reported by Jaouen and co-workers;3 these anticancer
compounds contain a [3]-ferrocenophane motif and have a
potent in vitro antiproliferative eﬀect in breast and prostate
cancer cells lines.
Our work is focused on developing a series of novel
ferrocenyl-peptide bioconjugates that were found to exert a
strong antiproliferative eﬀect on the H1299 nonsmall cell lung
cancer (NSCLC) cell line during preliminary in vitro studies.4
These ferrocenyl-peptide bioconjugates are composed of three
key moieties, namely, (i) an electroactive core, (ii) a conjugated
aromatic linker, (iii) an amino acid or peptide derivative that
can interact with other molecules via hydrogen bonds. One key
feature of ferrocene is the ease by which it undergoes oxidation
to form the ferricenium cation (Fc → Fc+). This occurs in a
reversible manner and is accommodated readily by the loss/
gain of an electron from a nonbonding high energy molecular
orbital. The redox properties of ferrocene have often been
implicated in its cytotoxicity.5 Indeed, ferricenium salts that are
known to inhibit tumor growth have been shown to produce
hydroxyl (HO•) radicals under physiological conditions,
leading to oxidatively damaged DNA.6 In the case of our
ferrocenyl-peptide bioconjugates, the presence of the conjugat-
ing aromatic linker between the ferrocene and peptide units
lowers the redox potential to within the range of biologically
accessible potentials, allowing for the interconversion between
the ferrocene and ferricenium species. The catalytic generation
of intracellular reactive oxygen species (ROS) such as the HO•
radical oﬀers an attractive and alternative method to target and
kill cancer cells.7
In a previous study, we identiﬁed N-(6-ferrocenyl-2-
naphthoyl)-glycine-L-alanine ethyl ester 1, as a potential drug
candidate since it has an in vitro antiproliferative eﬀect that is
comparable with cisplatin in the H1299 NSCLC cell line (IC50
value =1.3 ± 0.1 μM).8 We have since conducted further
studies in order to seek molecules that may have an even higher
eﬃcacy than 1. Recently, we reported a study of N-
(ferrocenyl)naphthoyl amino acid esters which found that N-
(6-ferrocenyl-2-naphthoyl)-γ-aminobutyric acid ethyl ester was
two times more potent than 1 in the H1299 NSCLC cell line
(IC50 value =0.62 ± 0.07 μM).
9 This compound was also tested
for in vitro antiproliferative activity in the Sk-Mel-28 malignant
melanoma cell line and was found to have an encouraging IC50
value of 1.41 ± 0.04 μM. We herein report the results of a
comprehensive structure−activity relationship (SAR) study of
N-(6-ferrocenyl-2-naphthoyl) dipeptide ethyl esters that was
conducted concomitantly. In addition, we report the results of
Received: March 22, 2012
Published: May 1, 2012
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cell cycle analysis and guanine oxidation studies that were
conducted to elucidate the mode of action of these novel
organometallic anticancer compounds.
■ RESULTS AND DISCUSSION
Structure−Activity Relationship of 1. For our initial SAR
study, we focused our attention on preparing a set of peptide
chain analogues of 1 (Chart 1) to probe the steric and
stereochemical requirements for potent antiproliferative
activity. Previous studies of N-(ferrocenyl)benzoyl dipeptide
derivatives had indicated that the in vitro antiproliferative eﬀect
is best when the small, neutral α-amino acids glycine and L-
alanine are present in the peptide chain.4c However, the eﬀect
of the incorporation of α-amino acids with either branched
alkyl or aromatic side chains into the dipeptide chain has yet to
be investigated. A set of peptide chain analogues 2−8
containing either glycine or L-alanine as the ﬁrst amino acid
(aa) residue, and either glycine, L-alanine, L-leucine or L-
phenylalanine as the second aa residue, were prepared by
solution-phase peptide coupling of 6-ferrocenylnaphthalene-2-
carboxylic acid to the appropriate free N-terminal dipeptide
ethyl ester, using EDC/HOBt as the coupling reagent (Scheme
1). Inversion of the stereocenter of 1 was also investigated by
preparing the inverse peptide chain analogue 9. This was easily
achieved by incorporating D-alanine as the second aa residue in
the dipeptide chain 9a, prior to solution-phase peptide coupling
to 6-ferrocenylnaphthalene-2-carboxylic acid using EDC/HOBt
(Scheme 2).
In Vitro Evaluation in the H1299 NSCLC Cell Line. The
in vitro antiproliferative eﬀect of the peptide chain analogues
2−9 was evaluated by performing a comprehensive screen at a
single dose (10 μM) in the H1299 NSCLC cell line (Table 1).
Compound 1 was also included in the screening to allow for the
direct comparison of antiproliferative eﬀect. At 10 μM,
compounds 1−9 were all found to strongly inhibit cell
proliferation in the H1299 cell line. The weakest antiprolifer-
ative eﬀect was observed for 8; however, this compound still
achieved an appreciable level of cell growth inhibition (>50%).
Four compounds in particular were shown to inhibit cell
growth by almost 99%. Interestingly, none of these compounds
contained either L-leucine or L-phenylalanine in the dipeptide
chain. This indicates that although incorporation of bulkier
amino acids is not completely detrimental to the antiprolifer-
ative eﬀect, the presence of small, neutral aa residues glycine
and L-alanine within the dipeptide chain is more favorable for
biological activity.
Since compounds 1−9 were all found to inhibit cell growth
by at least 50%, it was necessary to repeat the screening at the
lower dose of 1 μM in order to identify the most potent
derivatives. This second round of screening identiﬁed three
compounds that inhibited cell growth by more than 50%:
compounds 1 (∼70% growth inhibition), 2 (∼95% growth
inhibition), and 9 (∼55% growth inhibition). IC50 values were
determined for analogues 2 and 9 in the H1299 cell line. The
inverse peptide chain analogue 9 was found to be four times
more potent than 1, with an IC50 value of 0.33 ± 0.02 μM.
Thus, the in vitro antiproliferative activity of 1 was optimized
by inverting the stereochemistry of the C-terminal α-carbon
atom. This increase in antiproliferative eﬀect may be a
consequence of the increased resistance of 9 to degradation
by proteases.10
An exceptional IC50 value of 0.13 ± 0.02 μM was calculated
for 2; the antiproliferative eﬀect of this analogue is an order of
magnitude greater than that of both cisplatin (IC50 value of 1.5
± 0.1 μM) and 1 in the H1299 cell line. Previous studies
determined an IC50 value of 20 μM for N-{ortho-(ferrocenyl)-
benzoyl}-glycine−glycine ethyl ester in the same cell line.4d
Thus, in this instance, over a 150-fold improvement in
biological activity has been achieved by replacing the benzoyl
linker with the naphthoyl linker. This is an extremely
encouraging ﬁnding; there are only a number of other
ferrocenyl compounds that have been reported recently in
the literature to have comparable IC50 values, and these
derivatives have been tested in breast and prostate cancer cell
lines.3
In Vitro Evaluation in Sk-Mel-28 Malignant Melanoma
Cell Line. The in vitro antiproliferative eﬀect of compounds
1−9 was also evaluated in the Sk-Mel-28 malignant melanoma
Chart 1. N-(6-Ferrocenyl-2-naphthoyl)-glycine-L-alanine
Ethyl Ester 1
Scheme 1. Synthesis of Peptide Chain Analogues 2−8
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cell line at a single dose of 10 μM (Table 2). The Sk-Mel-28
cell line was found to be more resistant to treatment with 1−9
than the H1299 cell line. Only three compounds were found to
inhibit cell growth by more than 50%: compounds 1 (∼99%
growth inhibition), 2 (∼80% growth inhibition), and 9 (∼85%
growth inhibition). IC50 values of 3.74 ± 0.37 μM, 1.10 ± 0.13
μM, and 1.83 ± 0.04 μM were calculated for compounds 1, 2,
and 9, respectively. Although the antiproliferative eﬀect of these
compounds is not as strong in the Sk-Mel-28 cell line as in the
H1299 cell line, these results are promising nonetheless since
metastatic melanoma is notoriously resistant to chemo-
therapeutic drugs.11
Structure−Activity Relationship of 2. Considering the
remarkable antiproliferative eﬀect of 2, we decided to continue
our SAR study by focusing on optimizing the biological activity
of this compound. To determine if the unique chemistry of the
redox active ferrocene unit was critical to the antiproliferative
eﬀect of 2, a nonorganometallic analogue 10 was prepared by
solution-phase peptide coupling of 2-naphthoic acid to
glycine−glycine ethyl ester hydrochloride, using EDC/HOBt
(Scheme 3).
Previous studies of the N-(ferrocenyl)benzoyl peptide
derivatives indicated that β-alanine and γ-aminobutyric acid
could be of use as a potential isosteric replacement for glycine
in the peptide chain.12 For this reason, these two nonessential
aa residues were incorporated into the dipeptide chain to yield
a set of peptide chain analogues 11−14 (Chart 2).
Our ﬁnal strategy was to prepare N-methylated derivatives of
2. This was achieved by incorporating the unusual aa sarcosine
(N-methyl-glycine) into the dipeptide chain to yield the
peptide chain analogues 15-17 (Chart 2). N-Methylation is a
strategy widely used by scientists to alter pharmacological
properties of peptides, such as metabolic stability, selectivity,
potency, and bioavailability.13 The inclusion of N-methyl amino
acids within the dipeptide chain may also yield information
concerning the importance of hydrogen bond formation for
biological activity since the presence of an N-methyl group
blocks the ability of the nitrogen atom to act as a hydrogen
bond donor (HBD).
These unusual and nonessential aa residues were incorpo-
rated into compounds 11−17 by ﬁrst of all preparing the Boc-
protected dipeptide ethyl esters 11a−17a. This was achieved by
Scheme 2. Synthesis of Inverse Peptide Chain Analogue 9
Table 1. Percentage Cell Growth of H1299 Cells in Presence of Compounds 1−9 and IC50 Valuesa
compd R1 1st aa 2nd aa % cell growth at 10 μM % cell growth at 1 μM IC50
b (μM)
1 Fcc Gly L-Ala 0.4 ± 0.7 31.3 ± 12.1 1.3 ± 0.1d
2 Fc Gly Gly 0.5 ± 0.8 4.4 ± 0.9 0.13 ± 0.02
3 Fc Gly L-Leu 4.9 ± 0.9 103.2 ± 11.0
4 Fc Gly L-Phe 16.2 ± 5.3 102.9 ± 22.2
5 Fc L-Ala Gly 0.4 ± 0.7 118.0 ± 9.1 7.8 ± 0.2d
6 Fc L-Ala L-Ala 0.1 ± 0.6 85.8 ± 5.7 3.7 ± 0.6d
7 Fc L-Ala L-Leu 13.0 ± 3.5 107.4 ± 16.1
8 Fc L-Ala L-Phe 40.7 ± 8.0 98.8 ± 10.9
9 Fc Gly D-Ala 1.9 ± 0.7 44.8 ± 3.0 0.33 ± 0.02
cisplatin 1.5 ± 0.1
aMean of at least three independent experiments ± standard deviation. bIC50 values were only determined for compounds having an antiproliferative
eﬀect, on H1299 at 1 μM, greater than 50%. cFc = ferrocenyl (η5-C5H4−Fe-C5H5). dValues are from ref 8.
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solution-phase peptide coupling of the appropriate Boc-
protected aa to the corresponding aa ethyl ester hydrochloride
using EDC/HOBt (Scheme 4). Removal of the Boc-protecting
groups from 11a−17a was achieved using an excess of
triﬂuoroacetic acid in dichloromethane. The Boc-deprotected
dipeptides were then coupled to 6-ferrocenylnaphthalene-2-
carboxylic acid in the usual manner.
In Vitro Evaluation in H1299 and Sk-Mel-28 Cell Lines.
The in vitro antiproliferative eﬀect of compounds 10−17 was
evaluated at a single dose of 1 μM in the H1299 cell line and 10
μM in the Sk-Mel-28 cell line (Table 3). Nonorganometallic
analogue 10 did not exhibit an inhibitory eﬀect on cell growth
in either cell line. This dramatic loss of antiproliferative eﬀect
upon removal of the ferrocene unit from 2 demonstrates
conclusively that this organometallic unit is essential for in vitro
biological activity.
For the peptide chain analogues 11−14, compound 11 was
the only derivative to exert an antiproliferative eﬀect in the Sk-
Mel-28 cell line (∼85% growth inhibition); however, this
compound did not have any inhibitory eﬀect on cell growth in
the H1299 cell line. Compounds 12−14 failed to inhibit cell
growth in either cell line. Thus, the isosteric replacement of the
glycine residues in 2 with either β-alanine or γ-aminobutyric
acid does not improve the in vitro biological activity.
In the case of the N-methylated analogues 15−17,
compound 15 exhibited a strong antiproliferative eﬀect in the
Sk-Mel-28 cell line (∼97% growth inhibition) but did not have
any eﬀect on cell growth in the H1299 cell line. Compound 16,
however, was shown to be a potent inhibitor of cell growth in
both the H1299 (∼95% growth inhibition) and Sk-Mel-28
(∼85% growth inhibition) cell lines. Compound 17 failed to
inhibit cell growth in either cell line. Thus, compound 16 was
the only derivative for which IC50 values were calculated: 0.14
± 0.02 μM in the H1299 cell line and 1.06 ± 0.05 μM in the
Sk-Mel-28 cell line. These IC50 values are comparable with
those determined for compound 2. Therefore, N-methylation
of the ﬁrst glycine residue does not alter the observed in vitro
antiproliferative eﬀect. This could prove to be a valuable
modiﬁcation for future studies since N-methyl derivatives are
more resistant to degradation by proteases in vivo.13 However,
N-methylation of the second glycine residue results in a loss of
potency in the H1299 cell line, while N-methylation of both
residues produces a fall in antiproliferative eﬀect in both cell
lines. Thus, the ability of the nitrogen atom in the second
glycine residue to act as a HBD is clearly important for
biological activity.
Cell Cycle Analysis. Cell cycle analysis was performed on
control samples and H1299 cells treated with the two most
active compounds, 2 and 16, at concentrations of 0.5 μM and
1.0 μM (Figure 1). Table 4 summarizes the percentage of
H1299 cells in each stage of the cell cycle following incubation
with 2 for a period of 48 and 72 h. After 48 h, H1299 cells
treated with 0.5 μM of 2 showed a signiﬁcant increase in the
sub-G0/G1 population (p = 0.006). There was also a signiﬁcant
decrease in the number of cells in the S phase of the cell cycle
(p = 0.017). The sub-G0/G1 population was found to increase
by approximately 2-fold when the concentration of 2 was
increased to 1.0 μM. At this higher concentration, the increase
in the sub-G0/G1 peak was accompanied by a concomitant
decrease in the G0/G1 (p = 0.001) and S phase (p = 0.005) cell
populations. Similar observations were made following
incubation with 2 for 72 h; there was a signiﬁcant increase in
the sub-G0/G1 population of H1299 cells treated with 0.5 μM
(p = 0.032) and 1.0 μM (p = 0.006) of 2.
The cell cycle distribution of H1299 cells incubated with 16
for a period of 48 and 72 h follows a similar pattern (Figure 2
and Table 5). After 48 h, there was a signiﬁcant increase in the
sub-G0/G1 population (p = 0.040) accompanied by a decrease
in the number of cells in the S (p = 0.009) phase of the cell
cycle, following treatment with the lower concentration (0.5
μM) of 16. Doubling the concentration of 16 to 1.0 μM also
doubled the sub-G0/G1 population. At this higher concen-
tration, there was also a signiﬁcant decrease in the number of
cells in the G0/G1 (p = 0.0004) and S (p = 0.002) phases of
the cell cycle. After 72 h of incubation, there was a signiﬁcant
increase in the sub-G0/G1 population of H1299 cells treated
with 0.5 μM (p = 0.012) and 1.0 μM (p = 0.015) of 16.
Thus, the exposure of H1299 cells to compounds 2 and 16
leads in both cases to an accumulation of hypodiploid cells
(cells with a lower nuclear DNA content compared to that of
normal diploid cells). These ﬁndings suggest that both
compounds most likely induce apoptosis in H1299 cells since
apoptotic cells are characterized by DNA fragmentation and
Table 2. Percentage Cell Growth of Sk-Mel-28 Cells in the
Presence of Compounds 1−9 and IC50 Values
a
compd R1 1st aa 2nd aa % cell growth at 10 μM IC50
b (μM)
1 Fcc Gly L-Ala 0.7 ± 0.8 3.74 ± 0.37
2 Fc Gly Gly 19.0 ± 5.6 1.10 ± 0.13
3 Fc Gly L-Leu 79.0 ± 18.2
4 Fc Gly L-Phe 95.4 ± 10.7
5 Fc L-Ala Gly 74.7 ± 23.8
6 Fc L-Ala L-Ala 55.9 ± 34
7 Fc L-Ala L-Leu 86.3 ± 15.8
8 Fc L-Ala L-Phe 102.6 ± 3.9
9 Fc Gly D-Ala 15.6 ± 4.0 1.83 ± 0.04
aMean of at least three independent experiments ± standard deviation.
bIC50 values were only determined for compounds having an
antiproliferative eﬀect, on Sk-Mel-28 at 10 μM, greater than 50%.
cFc = ferrocenyl (η5-C5H4−Fe-C5H5).
Scheme 3. Synthesis of Nonorganometallic Analogue 10
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consequently a decrease in nuclear DNA content. Similar
observations have been made for the ferrocenyl derivative,
ferrociphenol in the MCF-7 breast cancer cell line.14 However,
further ﬂow cytometry studies that speciﬁcally measure the
levels of early and late apoptotic cells would be required to
conﬁrm the induction of apoptosis by these novel compounds,
as the presence of hypodiploid cells is not conclusive proof of
apoptotic death.15
Guanine Oxidation Studies. A potential mechanism by
which these novel organometallic anticancer compounds may
induce DNA damage is by the catalytic generation of ROS. This
is possible via a Fenton-type reaction, in which HO• radicals are
generated from the superoxide dismutation product, hydrogen
peroxide (H2O2). To investigate this, the rate of Fenton
reaction mediated 8-oxo-7,8-dihydroguanine (8-oxoGua)16
formation from guanine was monitored. Guanine was chosen
as it has the lowest oxidation potential of all the DNA bases and
is considered the clinical biomarker for oxidatively damaged
DNA.17
The Fenton-mediated oxidation of guanine and the kinetic
proﬁle of 8-oxoGua formed as a result have previously been
investigated using iron(II) sulfate (FeSO4) and H2O2 to
generate HO• radicals.18 To examine if compound 2 induces
guanine oxidation via a similar mechanism, kinetic 8-oxoGua
formation proﬁles were obtained by incubating free guanine
with (i) FeSO4 and H2O2 at 37 °C (Figure 3), and (ii) 2 and
H2O2 at 37 °C (Figure 4). Samples were taken in duplicate over
15 min. Each sample was injected in triplicate and analyzed by
HPLC-UV-EC using an electrochemical detector to detect 8-
oxoGua at +550 mV versus Ag/AgCl. Control experiments
were also carried out using either FeSO4 or 2 in the absence of
H2O2 and H2O2 in the absence of both iron compounds, to
verify that any oxidation was Fenton-mediated. Additionally,
they ensured that no artifactual oxidation was occurring from
the sample preparation or analysis methodology.
Chart 2. Peptide Chain Analogues 11−17
Scheme 4. Synthesis of Boc-Protected Dipeptide Ethyl Esters 11a−17a
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Incubation of free guanine with (i) FeSO4 and H2O2 led to
oscillating concentrations of 8-oxoGua over the incubation
period as previously reported.18 The formation is signiﬁcantly
higher than the control baselines, conﬁrming the oxidation is
Fenton-mediated. The 8-oxoGua concentration maxima were
1.39 μM at 6 min and 2.29 μM at 8.5 min. This trend is
analogous to that reported previously. These maxima occur
with a diﬀerent oscillation frequency, which can be attributed to
diﬀerences in solution pH (previously, these maxima were
reported at 4 and 15 min, respectively).
Table 3. Percentage Cell Growth of H1299 and Sk-Mel-28 Cells in the Presence of Compounds 10−17 and IC50 Values
a
compd R1 1st aa 2nd aa % cell growth at 1 μM in H1299
IC50 (μM) in
H1299 % cell growth at 10 μM in Sk-Mel-28
IC50
b (μM) in Sk-Mel-
28
10 H Gly Gly 87.6 ± 18.4 95.6 ± 10.9
11 Fcc Gly β-Ala 72.9 ± 5.2 14.8 ± 3.5
13 Fc Gly GABA 97.5 ± 14.3 62.5 ± 30.7
12 Fc β-Ala Gly 87.7 ± 8.1 98.4 ± 7.6
14 Fc GABA Gly 102.8 ± 4.6 89.1 ± 17.8
15 Fc Gly Sar 98.1 ± 4.4 3.2 ± 3.4
16 Fc Sar Gly 4.8 ± 1.4 0.14 ± 0.02 15.7 ± 9.86 1.06 ± 0.05
17 Fc Sar Sar 102.2 ± 16.4 65.0 ± 29.8
cisplatin 1.5 ± 0.1
aMean of at least three independent experiments ± standard deviation. bIC50 values were only determined for compounds having an antiproliferative
eﬀect, on H1299 at 1 μM, greater than 50%. cFc = ferrocenyl (η5-C5H4−Fe-C5H5).
Figure 1. Sample graphs of H1299 cell cycle distribution after 72 h: (a) control, (b) 0.5 μM solution of 2, (c) 1.0 μM solution of 2, and (d) DMSO
control. The data obtained from the ﬂow cytometry was analyzed using ModFit software. This software calculates the number of diploid cells in G0/
G1, S, and G2/M phases of the cell cycle, as well as cell debris and cell aggregates. Hypodiploid cells appear as a sub-G0/G1 peak.
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Incubation of free guanine with (ii) 2 and H2O2, which was
suspected to result in Fenton-mediated oxidation, also resulted
in the formation of oscillating concentrations of 8-oxoGua over
the incubation period. Again, the formation is signiﬁcantly
higher than the control baselines, clearly illustrating that both 2
and H2O2 are required to form this concentration of 8-oxoGua
and conﬁrming that the oxidation of guanine was Fenton-
mediated. The maximum concentrations of 8-oxoGua formed
with 2 were 0.62 μM after 30 s and 0.56 μM at 2 min. The
concentration of 8-oxoGua generated by 2 is signiﬁcantly lower
than that generated by FeSO4. Ferrocene may produce a
weaker response than the FeSO4 due to the presence of the
cyclopentadienyl ligands and the size of the molecule. However,
the generation of 8-oxoGua by 2 illustrates that the oxidation is
occurring by Fenton chemistry and that 2 is generating
oxidative damage via a ROS-mediated mechanism.
The oscillation period for 8-oxoGua formation mediated by 2
diﬀers from that of FeSO4. After the initial maxima at 0.5 and 2
min, the 8-oxoGua concentration continues to oscillate for the
rest of the incubation period, with concentrations consistently
higher than control levels, further conﬁrming that oxidation is
Fenton-mediated.
■ CONCLUSIONS
Our comprehensive structure−activity relationship study has
shown that N-(6-ferrocenyl-2-naphthoyl) dipeptide ethyl esters
are promising novel organometallic anticancer compounds. We
have established the structural modiﬁcations that have a
Table 4. Cell Cycle Distribution of H1299 Cells Incubated
with 2 for 48 or 72 h, Then Analyzed by Flow Cytometrya
sub G0/G1 G0/G1 S G2/M
48 h
control 4.6 ± 1.1 40.9 ± 0.7 44.9 ± 1.8 9.6 ± 1.9
0.5 μM 11.9 ± 0.3** 39.6 ± 2.0 39.2 ± 0.8* 9.4 ± 1.4
1.0 μM 21.8 ± 1.6** 34.5 ± 0.8** 37.1 ± 1.2** 6.7 ± 1.4
DMSO
control
5.3 ± 0.9 40.8 ± 0.9 44.4 ± 2.9 9.6 ± 1.3
72 h
control 2.4 ± 0.3 46.6 ± 0.4 41.3 ± 0.8 9.7 ± 1.2
0.5 μM 7.5 ± 1.7* 44.5 ± 2.0 39.2 ± 1.8 8.9 ± 2.0
1.0 μM 12.2 ± 1.5** 41.5 ± 3.1 37.9 ± 1.6* 8.4 ± 2.3
DMSO
control
2.2 ± 0.4 47.9 ± 3.1 40.2 ± 3.6 9.7 ± 0.9
aStandard deviations have been calculated using data obtained from
three independent experiments. Student’s t-test was performed to
determine signiﬁcance: * denotes p < 0.05; ** denotes p < 0.01, when
comparing treatment with the control or DMSO control.
Figure 2. Sample graphs of H1299 cell cycle distribution after 72 h: (a) control, (b) 0.5 μM solution of 16, (c) 1.0 μM solution of 16, and (d)
DMSO control. The data obtained from ﬂow cytometry was analyzed using ModFit software. This software calculates the number of diploid cells in
G0/G1, S, and G2/M phases of the cell cycle, as well as cell debris and cell aggregates. Hypodiploid cells appear as a sub-G0/G1 peak.
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positive impact and those that have a negative impact on the
biological activity of these novel compounds. We have also
clearly demonstrated that the organometallic ferrocene unit is
essential for in vitro biological activity. Our study has identiﬁed
two new compounds (2 and 16) that have a potent nanomolar
activity in H1299 NSCLC cell line, with IC50 values of 0.13 and
0.14 μM, respectively. These compounds also have signiﬁcant
activity in the Sk-Mel-28 malignant melanoma cell line (IC50
values of 1.10 and 1.06 μM, respectively).
With regard to the proposed mode of action of these novel
compounds, cell cycle analysis in the H1299 cell line has shown
2 and 16 to cause a signiﬁcant increase in the sub-G0/G1 peak,
which is suggestive of apoptosis. This observation is
encouraging since the production of intracellular ROS has
been shown to lead to cancer cell apoptosis.19
Guanine oxidation studies conﬁrm that 2 is capable of
causing oxidative damage to guanine, and it does so by the
generation of HO• radicals from H2O2. This ﬁnding is also
consistent with the proposed mode of action. Further studies
with ds-DNA are now required to demonstrate that 2 is capable
of generating oxidatively damaged DNA. In addition, studies to
detect the generation of intracellular ROS by these novel
compounds are currently in progress.
■ EXPERIMENTAL SECTION
Chemistry. All chemicals were purchased from Sigma-Aldrich,
Lennox Chemicals, Fluorochem Limited, or Tokyo Chemical Industry
UK Limited, and used as received. Commercial grade reagents were
used without further puriﬁcation. When necessary, all solvents were
puriﬁed and dried prior to use. Riedel-Haen̈ silica gel was used for thin
layer and column chromatography. Melting points were determined
using a Stuart melting point (SMP3) apparatus and are uncorrected.
Optical rotation measurements were made on a Perkin-Elmer 343
Polarimeter and are quoted in units of 10−1 deg cm2 g−1. Infrared
spectra were recorded on a Perkin-Elmer Spectrum 100 FT-IR with
ATR. UV−vis spectra were recorded on a Hewlett-Packard 8452 A
diode array UV−vis spectrophotometer. 1H and 13C NMR spectra
were recorded in deuterated solvents on either a Bruker Avance 400
NMR or a Bruker Avance Ultrashield 600 NMR. The 1H and 13C
NMR chemical shifts are reported in ppm (parts per million).
Tetramethylsilane (TMS) or the residual solvent peaks have been used
as an internal reference. All coupling constants (J) are in Hertz. The
abbreviations for the peak multiplicities are as follows: s (singlet), d
(doublet), dd (doublet of doublets), t (triplet), q (quartet), qt
(quintet), m (multiplet), and br (broad). Electrospray ionization mass
spectra were performed on a Micromass LCT mass spectrometer or a
Brüker Daltonics Esquire-LC ion trap mass spectrometer. Tandem
mass spectra were obtained on a Micromass Quattro micro LC-MS/
MS triple quadrupole mass spectrometer. Elemental analyses (C, H,
N) of the target compounds, which were performed at the
Microanalysis Laboratory at University College Dublin, are within
0.4% of the calculated values, conﬁrming ≥95% purity. As reported
previously for related compounds,20 fractional moles of ethyl acetate
and/or water could not be prevented despite 24−72 h of drying in
vacuum.
Cyclic voltammograms were recorded in anhydrous acetonitrile
(Sigma-Aldrich), with 0.1 M tetrabutylammonium perchlorate
(TBAP) as a supporting electrolyte, using a CH Instruments 600a
electrochemical analyzer (Pico-Amp Booster and Faraday Cage). The
experiments were carried out at room temperature. A three-electrode
cell consisting of a glassy carbon working electrode, a platinum wire
counter electrode, and an Ag|AgCl reference electrode was used. The
glassy carbon electrode was polished with 0.3 μm alumina followed by
0.05 μm alumina between each experiment to remove any surface
Table 5. Cell Cycle Distribution of H1299 Cells Incubated with 16 for 48 or 72 h, Then Analyzed by Flow Cytometrya
sub G0/G1 G0/G1 S G2/M
48 h
control 3.6 ± 0.4 40.5 ± 0.6 46.4 ± 1.3 9.6 ± 1.0
0.5 μM 11.3 ± 2.8* 37.2 ± 2.0 41.3 ± 1.3** 10.2 ± 2.5
1.0 μM 19.5 ± 3.0** 34.0 ± 0.7** 38.9 ± 1.4** 7.6 ± 1.3
DMSO control 4.7 ± 1.0 39.8 ± 1.6 45.7 ± 2.9 9.8 ± 2.9
72 h
control 2.9 ± 0.2 42.4 ± 1.1 43.9 ± 0.1 10.8 ± 1.0
0.5 μM 6.0 ± 0.7* 41.1 ± 1.0 42.0 ± 1.0 10.8 ± 0.6
1.0 μM 11.3 ± 1.9* 38.4 ± 0.4* 40.3 ± 0.5** 10.1 ± 1.1
DMSO control 2.0 ± 0.4 44.0 ± 1.8 43.0 ± 0.7 11.0 ± 0.7
aStandard deviations have been calculated using data obtained from three independent experiments. Student’s t-test was performed to determine
signiﬁcance: * denotes p < 0.05; ** denotes p < 0.01, when comparing treatment with the control.
Figure 3. Concentration of 8-oxoGua formed as a function of time
after the incubation of guanine with FeSO4 and H2O2 at 37 °C. Error
bars show the standard deviation of duplicate samples injected in
triplicate.
Figure 4. Concentration of 8-oxoGua formed as a function of time
after the incubation of guanine with 2 and H2O2 at 37 °C. Error bars
show the standard deviation of duplicate samples injected in triplicate.
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contaminants. The scan rate was 0.1 V s−1. The concentration range of
the ferrocene compounds was 1.0 mM in acetonitrile. The E0 ́ values
obtained for the test samples were referenced relative to the ferrocene/
ferricenium redox couple.
General Procedure for the Synthesis of N-(Ferrocenyl)-
naphthoyl Dipeptide Ethyl Esters. 6-Ferrocenylnaphthalene-2-
carboxylic acid was treated in DCM at 0 °C with 1.3 equiv of N-(3-
dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride and 1.3
equiv of 1-hydroxybenzotriazole. After 30 min, an excess of
triethylamine (5 mL) and 1 equiv of the corresponding dipeptide
ethyl ester salt were added to the solution; the resulting mixture was
raised to room temperature, and the reaction was allowed to proceed
for 48 h. The reaction mixture was washed with water, and the DCM
layer was then dried over MgSO4. The solvent was removed in vacuo
to give a residue that was then puriﬁed by silica gel column ﬂash
chromatography, eluting with a 1:1 mixture of hexane/ethyl acetate.
N-(6-Ferrocenyl-2-naphthoyl)-glycine−glycine Ethyl Ester 2.
Orange solid (0.33 g, 83%); mp 179−180 °C; E0 ́ 47 mV vs Fc/Fc+. IR
νmax (KBr): 3407, 3340, 1732, 1654, 1650, 1558, 1494, 1213 cm
−1.
UV−vis λmax CH3CN: 375 (ε 3485), 450 (ε 1497) nm. 1H NMR (400
MHz, DMSO-d6): 8.94 (1H, t, J = 5.6 Hz, −CONH-), 8.46 (1H, s,
ArH), 8.38 (1H, t, J = 5.6 Hz, −CONH-), 8.06 (1H, s, ArH), 7.92−
7.97 (3H, m, ArH), 7.82 (1H, dd, J = 1.6 and 8.4 Hz, ArH), 4.96 {2H,
t, J = 1.6 Hz, ortho on (η5-C5H4)}, 4.45 {2H, t, J = 1.6 Hz, meta on (η
5-
C5H4)}, 4.10 (2H, q, J = 7.2 Hz, -OCH2CH3), 4.05 (5H, s, η
5-C5H5),
3.98 (2H, d, J = 5.6 Hz, -NHCH2-), 3.87 (2H, d, J = 5.6 Hz, -NHCH2-
), 1.20 (3H, t, J = 7.2 Hz, -OCH2CH3);
13C NMR (100 MHz, DMSO-
d6): 169.8 (CO), 169.6 (CO), 166.5 (CO), 138.8, 134.5, 130.6,
130.4, 128.7, 127.6, 127.3, 125.9, 124.6, 122.7, 84.0, 69.5, 69.4, 66.6,
60.4 (-ve DEPT), 42.5 (-ve DEPT), 40.7 (-ve DEPT), 14.0; HRMS
(ESI+) m/z 499.1320 calcd. [M + H]+; found, 499.1296. Anal.
(C27H26N2O4Fe) C, H, N.
N-(6-Ferrocenyl-2-naphthoyl)-glycine−L-leucine Ethyl Ester
3. Orange solid (0.32 g, 58%); mp 160−161 °C; E0 ́ 60 mV vs Fc/Fc+;
[α]D
20 −12 (c 0.06 in CH3CN); IR νmax (neat) 3298, 2955, 1744,
1682, 1644, 1624, 1512, 1184 cm−1. UV−vis λmax (CH3CN): 370 (ε
3336), 445 (ε 1422) nm. 1H NMR (400 MHz, DMSO-d6): 8.82 (1H,
t, J = 5.6 Hz, −CONH-), 8.44 (1H, s, ArH), 8.34 (1H, d, J = 8.4 Hz,
−CONH-), 8.06 (1H, s, ArH), 7.93−7.97 (3H, m, ArH), 7.82 (1H, dd,
J = 1.2 and 8.4 Hz, ArH), 4.96 {2H, t, J = 2.0 Hz, ortho on (η5-C5H4)},
4.45 {2H, t, J = 2.0 Hz, meta on (η5-C5H4)}, 4.30−4.35 (1H, m,
-NHCH-), 4.07−4.13 (7H, m, -OCH2CH3, η5-C5H5), 3.93−3.99 (2H,
m, -NHCH2-), 1.48−1.72 (3H, m, −CH2CH-), 1.19 (3H, t, J = 7.2 Hz,
-OCH2CH3), 0.86−0.92 {6H, m, −CH(CH3)2}. 13C NMR (100 MHz,
DMSO-d6): 172.5 (CO), 169.1 (CO), 166.5 (CO), 138.8,
134.5, 130.7, 130.5, 128.7, 127.5, 127.3, 125.9, 124.5, 122.7, 84.1, 69.4,
66.6, 60.4 (-ve DEPT), 50.3, 42.2 (-ve DEPT), 40.1 (-ve DEPT), 24.2,
22.7, 21.4, 14.0; HRMS (ESI+) m/z 555.1946 calcd. [M + H]+; found,
555.1931. Anal. (C31H34N2O4Fe) C, H, N.
N-(6-Ferrocenyl-2-naphthoyl)-glycine−L-phenylalanine
Ethyl Ester 4. Orange solid (0.15 g, 56%); mp 53−54 °C; E0 ́ 59 mV
vs Fc/Fc+; [α]D
20 +18 (c 0.06 in CH3CN); IR νmax (neat) 3290, 3062,
1735, 1640, 1521, 1298, 1209 cm−1. UV−vis λmax (CH3CN): 370 (ε
2894), 445 (ε 1242) nm. 1H NMR (400 MHz, DMSO-d6): 8.86 (1H,
t, J = 5.6 Hz, −CONH-), 8.43−8.47 (2H, m, −CONH-, ArH), 8.10
(1H, s, ArH), 7.97−8.00 (3H, m, ArH), 7.86 (1H, dd, J = 1.2 and 8.4
Hz, ArH), 7.23−7.33 (5H, m, −CH2Ph), 5.00 {2H, t, J = 1.6 Hz, ortho
on (η5-C5H4)}, 4.49−4.56 {3H, m, -NHCH-, meta on (η5-C5H4)},
3.93−4.10 (9H, m, -OCH2CH3, η5-C5H5, -NHCH2-), 2.98−3.13 (2H,
m, −CH2Ph), 1.15 (3H, t, J = 7.2 Hz, -OCH2CH3). 13C NMR (100
MHz, DMSO-d6): 171.4 (CO), 169.1 (CO), 166.4 (CO),
138.8, 136.9, 134.5, 130.7, 130.4, 129.1, 128.7, 128.2, 127.5, 127.3,
126.6, 125.9, 124.5, 122.7, 84.1, 69.4, 66.6, 60.5 (-ve DEPT), 53.7, 42.3
(-ve DEPT), 36.9 (-ve DEPT), 14.1; HRMS (ESI+) m/z 588.1711
c a l c d . [ M ] + • ; f o u n d , 5 8 8 . 1 6 9 3 . A n a l .
(C34H32N2O4Fe·0.6C4H8O2·0.15H2O) C, H, N.
N-(6-Ferrocenyl-2-naphthoyl)-L-alanine−glycine Ethyl Ester
5. See ref 8.
N-(6-Ferrocenyl-2-naphthoyl)-L-alanine−L-alanine Ethyl
Ester 6. See ref 8.
N-(6-Ferrocenyl-2-naphthoyl)-L-alanine−L-leucine Ethyl
Ester 7. Orange solid (0.10 g, 23%); mp 73−74 °C; E0 ́ 60 mV vs.
Fc/Fc+; [α]D
20 +29 (c 0.06 in CH3CN); IR νmax (neat) 3282, 3089,
1734, 1633, 1530, 1187 cm−1. UV−vis λmax (CH3CN): 370 (ε 3064),
445 (ε 1298) nm. 1H NMR (400 MHz, DMSO-d6): 8.58 (1H, d, J =
7.2 Hz, −CONH-), 8.46 (1H, s, ArH), 8.29 (1H, d, J = 7.2 Hz,
−CONH-), 8.05 (1H, s, ArH), 7.90−7.97 (3H, m, ArH), 7.79−7.86
(1H, m, ArH), 4.95 {2H, t, J = 1.6 Hz, ortho on (η5-C5H4)}, 4.60 (1H,
qt, J = 7.2 Hz, -NHCH-), 4.44 {2H, t, J = 1.6 Hz, meta on (η5-C5H4)},
4.26−4.32 (1H, m, -NHCH-), 4.00−4.14 (7H, m, -OCH2CH3, η5-
C5H5), 1.48−1.73 (3H, m, −CH2CH-), 1.39 (3H, d, J = 7.2 Hz,
−CH3), 1.17 (3H, t, J = 7.2 Hz, -OCH2CH3), 0.86−0.93 {6H, m,
−CH(CH3)2}. 13C NMR (100 MHz, DMSO-d6): 172.7 (CO),
172.4 (CO), 166.0 (CO), 138.7, 134.5, 130.6, 130.5, 128.7, 127.6,
127.2, 125.9, 124.7, 122.7, 84.1, 69.4, 66.6, 60.4 (-ve DEPT), 50.4,
48.6, 39.7 (-ve DEPT), 24.2, 22.7, 21.4, 17.9, 14.0; HRMS (ESI+) m/z
569.2103 calcd. [M + H]+; found, 569.2095. Anal. (C32H36N2O4Fe) C,
H, N.
N-(6-Ferrocenyl-2-naphthoyl)-L-alanine−L-phenylalanine
Ethyl Ester 8. Orange solid (0.12 g, 23%); mp 75 °C; E0 ́ 59 mV vs.
Fc/Fc+; [α]D
20 +36 (c 0.06 in CH3CN); IR νmax (neat) 3282, 2963,
1736, 1634, 1526, 1260, 1187 cm−1. UV−vis λmax (CH3CN): 370 (ε
2774), 445 (ε 1188) nm. 1H NMR (400 MHz, DMSO-d6): 8.58 (1H,
d, J = 7.2 Hz, −CONH-), 8.45 (1H, s, ArH), 8.36 (1H, d, J = 7.2 Hz,
−CONH-), 8.06 (1H, s, ArH), 7.93−7.97 (3H, m, ArH), 7.82 (1H, dd,
J = 1.6 and 8.4 Hz, ArH), 7.17−7.25 (5H, m, −CH2Ph), 4.96 {2H, t, J
= 2.0 Hz, ortho on (η5-C5H4)}, 4.60 (1H, qt, J = 7.2 Hz, -NHCH-),
4.43−4.50 {3H, m, -NHCH-, meta on (η5-C5H4)}, 4.00−4.08 (7H, m,
-OCH2CH3, η
5-C5H5), 2.96−3.07 (2H, m, −CH2Ph), 1.36 (3H, d, J =
7.2 Hz, −CH3), 1.10 (3H, t, J = 7.2 Hz, -OCH2CH3). 13C NMR (100
MHz, DMSO-d6): 172.6 (CO), 171.3 (CO), 166.0 (CO),
138.8, 137.0, 134.5, 130.6, 130.4, 129.1, 128.7, 128.2, 127.6, 127.2,
126.5, 125.9, 124.7, 122.7, 84.1, 69.4, 66.6, 60.4 (-ve DEPT), 53.7,
48.6, 36.6 (-ve DEPT), 17.8, 14.1; HRMS (ESI+) m/z 602.1868 calcd.
[M]+•; found, 602.1841. Anal. (C35H34N2O4Fe·0.45C4H8O2) C, H, N.
N-(6-Ferrocenyl-2-naphthoyl)-glycine−D-alanine Ethyl Ester
9. Orange solid (0.19 g, 41%); mp 73−74 °C; E0 ́ 63 mV vs. Fc/Fc+;
[α]D
20 +5 (c 0.05 in CH3CN); IR νmax (neat): 3290, 3084, 1733, 1640,
1529, 1450, 1206 cm−1. UV−vis λmax CH3CN: 370 (ε 3048), 445 (ε
1288) nm. 1H NMR (400 MHz, DMSO-d6): 8.83 (1H, t, J = 5.6 Hz,
−CONH-), 8.44 (1H, s, ArH), 8.39 (1H, d, J = 7.2 Hz, −CONH-),
8.06 (1H, s, ArH), 7.94−7.97 (3H, m, ArH), 7.83 (1H, dd, J = 1.6 and
8.4 Hz, ArH), 4.97 {2H, t, J = 2.0 Hz, ortho on (η5-C5H4)}, 4.46 {2H,
t, J = 2.0 Hz, meta on (η5-C5H4)}, 4.31 (1H, qt, J = 7.2 Hz, -NHCH-),
3.91−4.14 (9H, m, -OCH2CH3, η5-C5H5, -NHCH2-), 1.31 (3H, d, J =
7.2 Hz, −CH3), 1.20 (3H, t, J = 7.2 Hz, -OCH2CH3). 13C NMR (100
MHz, DMSO-d6): 172.5 (CO), 168.9 (CO), 166.4 (CO),
138.8, 134.5, 130.7, 130.5, 128.7, 127.5, 127.3, 125.9, 124.5, 122.7,
84.1, 69.4, 66.6, 60.4 (-ve DEPT), 47.7, 42.2 (-ve DEPT), 17.1, 14.0;
HRMS (ESI+) m/z 512.1398 calcd. [M]+•; found, 512.1397. Anal.
(C28H28N2O4Fe·0.45C4H8O2) C, H, N.
N-(2-Naphthoyl)-glycine−glycine Ethyl Ester 10. 2-Naphthoic
acid (0.18 g, 1.0 mmol) was treated in DCM at 0 °C with N-(3-
dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (0.25 g,
1.3 mmol) and 1-hydroxybenzotriazole (0.18 g, 1.3 mmol). After 30
min, an excess of triethylamine (5 mL) and glycine−glycine ethyl ester
hydrochloride (0.20 g, 1.0 mmol) was added to the solution; the
resulting mixture was raised to room temperature, and the reaction was
allowed to proceed for 48 h. The reaction mixture was washed with
water, and the DCM layer was then dried over MgSO4. The solvent
was removed in vacuo to give a residue that was then puriﬁed by silica
gel ﬂash chromatography, eluting with a 1:1 mixture of hexane/ethyl
acetate. The title compound was obtained as a white solid (0.28 g,
89%); mp 128−129 °C; IR νmax (neat) 3264, 3056, 1738, 1646, 1633,
1619, 1546, 1203 cm−1. 1H NMR (400 MHz, DMSO-d6): 9.05 (1H, t,
J = 5.6 Hz, −CONH-), 8.58 (1H, s, -ArH), 8.46 (1H, t, J = 5.6 Hz,
−CONH-), 8.10−8.02 (4H, m, -ArH), 7.71−7.64 (2H, m, -ArH), 4.15
(2H, q, J = 7.2 Hz, -OCH2CH3), 4.04 (2H, d, J = 5.6 Hz, -NHCH2-),
3.92 (2H, d, J = 5.6 Hz, -NHCH2-), 1.25 (3H, t, J = 7.2 Hz,
-OCH2CH3).
13C NMR (100 MHz, DMSO-d6): 169.8 (CO), 169.6
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(CO), 166.5 (CO), 134.2, 132.1, 131.3, 128.8, 127.8, 127.7,
127.62, 127.59, 126.7, 124.2, 60.4 (-ve DEPT), 42.5 (-ve DEPT), 40.7
(-ve DEPT), 14.0; HRMS (ESI+) m/z 315.1345 calcd. [M + H]+;
found, 315.1360. Anal. (C17H18N2O4) C, H, N.
N-(6-Ferrocenyl-2-naphthoyl)-glycine−β-alanine Ethyl Ester
11. Orange solid (0.20 g, 43%); mp 148−149 °C; E0 ́ 61 mV vs. Fc/
Fc+. IR νmax (neat): 3312, 3084, 1728, 1677, 1639, 1625, 1538, 1185
cm−1. UV−vis λmax CH3CN: 370 (ε 3006), 450 (ε 1288) nm. 1H
NMR (400 MHz, acetone-d6): 8.32 (1H, s, ArH), 8.01 (1H, t, J = 5.6
Hz, −CONH-), 7.93 (1H, s, ArH), 7.78−7.86 (3H, m, ArH), 7.71
(1H, dd, J = 1.6 and 8.4 Hz, ArH), 7.34 (1H, br. s, −CONH-), 4.79
{2H, t, J = 2.0 Hz, ortho on (η5-C5H4)}, 4.30 {2H, t, J = 2.0 Hz, meta
on (η5-C5H4)}, 3.91−3.97 (9H, m, -OCH2CH3, η5-C5H5, -NHCH2-),
3.35 (2H, q, J = 6.8 Hz, −CH2CH2−), 2.40 (2H, t, J = 6.8 Hz,
−CH2CH2-), 1.06 (3H, t, J = 7.2 Hz, -OCH2CH3). 13C NMR (100
MHz, acetone-d6): 172.2 (CO), 169.9 (CO), 167.7 (CO),
140.3, 136.1, 132.2, 131.7, 129.7, 128.5, 128.4, 126.9, 125.3, 123.9,
85.4, 70.4, 70.3, 67.6, 60.8 (-ve DEPT), 44.1 (-ve DEPT), 35.9 (-ve
DEPT), 34.9 (-ve DEPT), 14.5; HRMS (ESI+) m/z 512.1398 calcd.
[M]+•; found, 512.1410. Anal. (C28H28N2O4Fe·0.2C4H8O2·0.1H2O)
C, H, N.
N-(6-Ferrocenyl-2-naphthoyl)-glycine−γ-aminobutyric Acid
Ethyl Ester 12. Orange solid (0.18 g, 38%); mp 140−142 °C; E0 ́ 65
mV vs. Fc/Fc+. IR νmax (neat): 3374, 3246, 3082, 1704, 1672, 1638,
1566, 1538 cm−1. UV−vis λmax CH3CN: 375 (ε 3070), 450 (ε 1312)
nm. 1H NMR (400 MHz, acetone-d6): 8.32 (1H, s, ArH), 8.01 (1H, t,
J = 5.6 Hz, −CONH-), 7.94 (1H, s, ArH), 7.78−7.86 (3H, m, ArH),
7.71 (1H, dd, J = 1.6 and 8.4 Hz, ArH), 7.33 (1H, br. s, −CONH-),
4.78 {2H, t, J = 2.0 Hz, ortho on (η5-C5H4)}, 4.30 {2H, t, J = 2.0 Hz,
meta on (η5-C5H4)}, 3.90−3.96 (9H, m, -OCH2CH3, η5-C5H5,
-NHCH2-), 3.15 (2H, q, J = 6.8 Hz, −CH2CH2CH2−), 2.22 (2H, t,
J = 7.2 Hz, −CH2CH2CH2-), 1.66 (2H, qt, J = 7.2 Hz,
−CH2CH2CH2−), 1.06 (3H, t, J = 7.2 Hz, -OCH2CH3). 13C NMR
(100 MHz, acetone-d6): 173.5 (CO), 169.8 (CO), 167.7 (C
O), 140.3, 136.1, 132.2, 131.8, 129.7, 128.5, 128.4, 126.9, 125.4, 123.9,
85.4, 70.4, 70.3, 67.6, 60.6 (-ve DEPT), 44.1 (-ve DEPT), 39.1 (-ve
DEPT), 32.0 (-ve DEPT), 25.8 (-ve DEPT), 14.5; HRMS (ESI+) m/z
527.1633 calcd. [M + H]+; found, 527.1622. Anal. (C29H30N2O4Fe) C,
H, N.
N-(6-Ferrocenyl-2-naphthoyl)-β-alanine−glycine Ethyl Ester
13. Orange solid (0.16 g, 34%); mp 171−172 °C; E0 ́ 60 mV vs. Fc/
Fc+; IR νmax (neat) 3357, 3282, 3073, 1735, 1678, 1633, 1600, 1540,
1214 cm−1. UV−vis λmax CH3CN: 370 (ε 2758), 450 (ε 1154) nm. 1H
NMR (400 MHz, acetone-d6): 8.28 (1H, s, ArH), 7.92 (1H, s, ArH),
7.76−7.84 (4H, m, −CONH-, ArH), 7.69 (1H, dd, J = 1.6 and 8.8 Hz,
ArH), 7.51 (1H, br. s, −CONH-), 4.78 {2H, t, J = 1.6 Hz, ortho on
(η5-C5H4)}, 4.29 {2H, t, J = 1.6 Hz, meta on (η
5-C5H4)}, 4.02 (2H, q, J
= 7.2 Hz, -OCH2CH3), 3.92 (5H, s, η
5-C5H5), 3.84 (2H, d, J = 5.6 Hz,
-NHCH2-), 3.59 (2H, q, J = 6.4 Hz, −CH2CH2−), 2.47 (2H, t, J = 6.4
Hz, −CH2CH2-), 1.09 (3H, t, J = 7.2 Hz, -OCH2CH3). 13C NMR (100
MHz, acetone-d6): 172.4 (CO), 170.8 (CO), 167.3 (CO),
140.0, 135.9, 132.4, 132.2, 129.6, 128.4, 128.1, 126.9, 125.4, 123.9,
85.5, 70.4, 70.3, 67.6, 61.4 (-ve DEPT), 41.7 (-ve DEPT), 37.2 (-ve
DEPT), 36.3 (-ve DEPT), 14.5; HRMS (ESI+) m/z 512.1398 calcd.
[M]+•; found, 512.1384. Anal. (C28H28N2O4Fe·0.25C4H8O2·0.1H2O)
C, H, N.
N-(6-Ferrocenyl-2-naphthoyl)-γ-aminobutyric Acid−Glycine
Ethyl Ester 14. Orange solid (0.14 g, 27%); mp 150−151 °C; E0 ́ 60
mV vs. Fc/Fc+. IR νmax (neat): 3256, 3081, 1750, 1656, 1634, 1622,
1575, 1551, 1201 cm−1. UV−vis λmax CH3CN: 370 (ε 2700), 450 (ε
1112) nm. 1H NMR (400 MHz, DMSO-d6): 8.67 (1H, t, J = 5.6 Hz,
−CONH-), 8.45 (1H, s, ArH), 8.38 (1H, t, J = 6.0 Hz, −CONH-),
8.11 (1H, s, ArH), 7.94−8.01 (3H, m, ArH), 7.87 (1H, dd, J = 1.6 and
8.4 Hz, ArH), 5.02 {2H, t, J = 2.0 Hz, ortho on (η5-C5H4)}, 4.50 {2H,
t, J = 2.0 Hz, meta on (η5-C5H4)}, 4.08−4.17 (7H, m, -OCH2CH3, η5-
C5H5), 3.88 (2H, d, J = 5.6 Hz, -NHCH2-), 3.37−3.42 (2H, m,
−CH2CH2CH2−), 2.30 (2H, t, J = 7.2 Hz, −CH2CH2CH2-), 1.87
(2H, qt, J = 7.2 Hz, −CH2CH2CH2−), 1.25 (3H, t, J = 7.2 Hz,
-OCH2CH3).
13C NMR (100 MHz, DMSO-d6): 172.5 (CO), 170.0
(CO), 166.2 (CO), 138.6, 134.4, 131.1, 130.7, 128.7, 127.3,
127.2, 125.9, 124.5, 122.7, 84.1, 69.4, 66.6, 60.3 (-ve DEPT), 40.6 (-ve
DEPT), 39.0 (-ve DEPT), 32.7 (-ve DEPT), 25.3 (-ve DEPT), 14.0;
HRMS (ESI+) m/z 527.1633 calcd. [M + H]+; found, 527.1611. Anal.
(C29H30N2O4Fe) C, H, N.
N-(6-Ferrocenyl-2-naphthoyl)-glycine−sarcosine Ethyl Ester
15. Orange solid (0.20 g, 43%); mp 64−65 °C; E0 ́ 63 mV vs. Fc/Fc+.
IR νmax (neat): 3300, 2928, 1739, 1626, 1507, 1480, 1200 cm
−1. UV−
vis λmax CH3CN: 370 (ε 2670), 450 (ε 1098) nm.
1H NMR (400
MHz, DMSO-d6): 8.72, 7.45−7.51 (1H, t, J = 5.6 Hz, m, −CONH-,
rotamers), 8.44−8.48 (1H, m, ArH), 8.05−8.07 (1H, m, ArH), 7.81−
7.98 (4H, m, ArH), 4.95−4.97 {2H, m, ortho on (η5-C5H4), rotamers},
4.44−4.46 {2H, m, meta on (η5-C5H4), rotamers}, 3.96−4.36 (11H, m,
-OCH2CH3, η
5-C5H5, Gly CH2, Sar CH2, rotamers), 3.12, 3.01, 2.88
(3H, s, br. s, s, Sar CH3, rotamers), 1.18−1.26 (3H, m, -OCH2CH3,
rotamers). 13C NMR (100 MHz, DMSO-d6): 171.2 (CO), 169.2
(CO), 166.4 (CO), 138.8, 134.5, 133.4, 130.7, 128.7, 128.2,
127.4, 125.9, 124.4, 122.7, 84.1, 69.4, 66.6, 60.9 (-ve DEPT), 60.5 (-ve
DEPT), 49.3 (-ve DEPT), 40.8 (-ve DEPT), 35.2, 34.5, 30.7, 14.0;
HRMS (ESI+) m/z 512.1398 calcd. [M]+•; found, 512.1398. Anal.
(C28H28N2O4Fe) C, H, N.
N-(6-Ferrocenyl-2-naphthoyl)-sarcosine−glycine Ethyl Ester
16. Red solid (0.18 g, 35%); mp 66−67 °C; E0 ́ 55 mV vs Fc/Fc+. IR
νmax (neat): 3291, 2930, 1745, 1677, 1623, 1507, 1396, 1196 cm
−1.
UV−vis λmax CH3CN: 370 (ε 2492), 450 (ε 988) nm. 1H NMR (600
MHz, DMSO-d6): 8.61, 8.53 (1H, 2xbr. s, −CONH-, rotamers), 8.11
(1H, s, ArH), 7.95−8.03 (3H, m, ArH), 7.87 (1H, d, J = 8.4 Hz, ArH),
7.54−7.58 (1H, m, ArH), 5.01 {2H, t, J = 1.8 Hz, ortho on (η5-C5H4)},
4.49−4.52 {2H, m, meta on (η5-C5H4)}, 3.96−4.26 (11H, m,
-OCH2CH3, η
5-C5H5, Gly CH2, Sar CH2, rotamers), 3.08 (3H, s,
Sar CH3), 1.27 (3H, t, J = 7.2 Hz, -OCH2CH3).
13C NMR (150 MHz,
DMSO-d6): 171.1 (CO), 169.7 (CO), 168.6 (CO), 138.2,
133.4, 132.4, 130.7, 128.3, 126.5, 125.9, 125.0, 124.8, 122.8, 84.1,
69.41, 69.38, 66.6, 60.5 (-ve DEPT), 59.7 (-ve DEPT), 53.9 (-ve
DEPT), 49.7 (-ve DEPT), 40.7 (-ve DEPT), 39.3, 34.1, 14.1; HRMS
(ESI+) m/z 512.1398 calcd. [M]+•; found, 512.1399. Anal.
(C28H28N2O4Fe·0.2C4H8O2·0.25H2O) C, H, N.
N-(6-Ferrocenyl-2-naphthoyl)-sarcosine−sarcosine Ethyl
Ester 17. Orange solid (0.05 g, 12%); mp 68−69 °C; E0 ́ 58 mV vs.
Fc/Fc+. IR νmax (neat): 2926, 1739, 1663, 1626, 1479, 1394, 1198
cm−1. UV−vis λmax CH3CN: 370 (ε 2106), 450 (ε 836) nm. 1H NMR
(600 MHz, DMSO-d6): 8.08−8.11 (1H, m, ArH), 7.86−8.02 (4H, m,
ArH), 7.54, 7.42−7.46 (1H, d, J = 8.4 Hz, m, ArH, rotamers), 5.01
{2H, s, ortho on (η5-C5H4)}, 3.87−4.51 {13H, meta on (η5-C5H4),
-OCH2CH3, η
5-C5H5, Sar CH2, Sar CH2, rotamers}, 3.03−3.16 (3H,
m, Sar CH3, rotamers), 2.88−3.01 (3H, m, Sar CH3, rotamers), 1.24−
1.32, 1.00 (3H, m, s, J = 7.2 Hz, -OCH2CH3, rotamers).
13C NMR
(150 MHz, DMSO-d6): 171.0 (CO), 169.1 (CO), 168.1 (CO),
138.1, 133.4, 132.5, 130.7, 128.2, 127.5, 126.3, 125.9, 124.7, 122.8,
84.2, 69.40, 69.38, 66.6, 60.58 (-ve DEPT), 60.54 (-ve DEPT), 52.48
(-ve DEPT), 49.60 (-ve DEPT), 49.23 (-ve DEPT), 48.36 (-ve
DEPT), 38.34, 35.19, 34.47, 34.35, 14.1; HRMS (ESI+) m/z 526.1555
calcd. [M]+•; found, 526.1536. Anal. (C29H30N2O4Fe·0.5C4H8O2) C,
H, N.
Biological Assays: Cell Lines. Sk-Mel-28 was obtained from the
Department of Developmental Therapeutics, National Cancer
Institute (NCI) and H1299 from the American Tissue Culture Centre
(ATCC). Cell lines were grown in RPMI-1640 supplemented with
10% fetal calf serum (FCS) at 37 °C in a 5% CO2 humidiﬁed chamber.
In Vitro Proliferation Assays. Cells in the exponential phase of
growth were harvested by trypsinization, and a cell suspension of 1 ×
104 cells/mL was prepared in fresh culture medium. The cell
suspension (100 μL) was added to a ﬂat bottom 96-well plate
(Costar, 3599), plates were agitated gently in order to ensure even
dispersion of cells over the surface of the wells, and then cells were
incubated for an initial 24 h in a 37 °C, 5% CO2 incubator to allow cell
attachment to the wells. A 10 mM stock solution of a test sample was
prepared in dimethyl sulfoxide; dilute solutions of the test sample were
prepared at 2× ﬁnal concentration by spiking the cell culture medium
with a calculated amount of the stock solution. Then, 100 μL aliquot
of each dilute solution was added to each well of the plate, the plate
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was gently agitated, and then incubated at 37 °C, 5% CO2 for 5−6
days, until cell conﬂuency reached 80−90%. Assessment of cell survival
in the presence of the compounds 1−17 was determined by the acid
phosphatase assay.21 The acid phosphatase assay is highly sensitive and
is easier to perform than the neutral red assay as it involves fewer steps
and fewer reagents. It is also more convenient than the MTT assay
because of the inherent problem of removal of the medium from the
insoluble crystals. The reproducibility between replicate wells is
excellent in the acid phosphatase assay, and in many cases, it has been
shown to be better than the neutral red assay and the MTT assay. The
percentage cell growth in the presence of each compound was
determined relative to the control cells. The concentration of
compounds causing 50% growth inhibition (IC50 of the compound)
was determined using Calcusyn (Biosoft, UK).
Cell Cycle Assays. H1299 cells were plated at a density of 2.5 ×
104 cells/well in 24-well plates, in RPMI-1640 media containing 10%
FCS. After 24 h, the cells were treated with the test compound.
Dimethyl sulfoxide (DMSO) control wells were included in each assay.
After 48 and 72 h, the media was collected into microcentrifuge tubes,
and the wells were washed with PBS, which was also collected. Cells
were trypsinized and added to the media collected for each sample.
The tubes were centrifuged at 300g for 5 min, and the media were
aspirated. The cell pellets were resuspended in PBS, and each cell
suspension was transferred to a well of a round bottomed 96 well
plate. The plate was centrifuged at 450g for 5 min and the supernatant
aspirated leaving approximately 20 μL in each well. The remaining
volume was used to resuspend the cells, and 200 μL of ice cold 70%
ethanol was added gradually to each well. The plates were then stored
at 4 °C overnight. After ﬁxing, the cells were stained according to the
protocol for the Guava Cell Cycle assay. Cells were analyzed on Guava
EasyCyte (Guava Technologies), and the data was analyzed using
Modﬁt LT software (Verity).
Statistical Analysis. Analysis of the response to treatment was
performed using Student’s t-test (two-tailed with unequal variance),
and p-value <0.05 was considered statistically signiﬁcant.
Guanine Oxidation Studies: Chemicals. Guanine was purchased
from Sigma-Aldrich. 8-Oxo-7,8-dihydroguanine was purchased from
Cayman Chemicals. Deionized water was puriﬁed using an ELGA
purelab ultrasystem to a speciﬁc resistance of greater than 18.2 MΩ
cm. All other chemicals were of analytical grade and used without
further puriﬁcation. All buﬀers and HPLC mobile phases were ﬁltered
through a 47 mm, 0.45 μm polyvinylidine ﬂuoride (PVDF) micropore
ﬁlter (Sartorius Stedim Biotech) before use.
Oxidation of Guanine. Ten millimolar guanine prepared in 84%
50 mM ammonium acetate, 85 mM acetic acid buﬀer, and 16% 1 M
NaOH were incubated with 1 mM iron(II) sulfate (FeSO4·6H2O) or 1
mM N-(6-ferrocenyl-2-naphthoyl)-glycine−glycine ethyl ester 2 and
0.5 M hydrogen peroxide (H2O2) at 37 °C with constant stirring.
Aliquots of 100 μL were taken in duplicate at various incubation times.
The reaction was quenched with 1 mL of cold ethanol. The solution
was dried immediately under a stream of nitrogen gas. Samples were
stored at −20 °C until further use. Prior to analysis they were
redissolved in 1 mL of 84% 50 mM ammonium acetate, 85 mM acetic
acid buﬀer, and 16% 1 M NaOH. Samples were injected in triplicate.
HPLC-UV-EC Analysis of 8-oxoGua Formation. For 8-oxoGua
analysis, the HPLC System consisted of a Varian ProStar 230 solvent
delivery module and a Varian ProStar 310 UV−vis detector. A
Phenomenex Onyn Monolithic C18 reversed phase column (100 ×
4.6 mm) with 1 cm guard column was used. The eluent comprised
1.2% acetonitrile (ACN) and 50 mM ammonium acetate and was
adjusted to pH 4.6 with glacial acetic acid. It was run at a ﬂow rate of 4
mL min−1 with an injection volume of 20 μL. The column temperature
was ambient, and 8-oxoGua formation was monitored using an
electrochemical detector at a detection potential of +550 mV versus an
Ag/AgCl reference electrode.
Controlled Experiments. Control incubations were performed
with guanine to ensure that no artiﬁcial oxidation was caused by the
reaction conditions. Each of the reagents was sequentially replaced
with deionized water to ensure that none of them could generate
oxidative damage individually. The highest background reading for
these controls is plotted as the baseline in Figures 3 and 4.
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The synthesis, structural characterization and
biological evaluation of N-(ferrocenylmethyl
amino acid) ﬂuorinated benzene-carboxamide
derivatives as potential anticancer agents
William E. Butlera,b, Paula N. Kellya,b, Andy G. Harryb, Rachel Tiedta,b,
Blanaid Whiteb, Rosaleen Deveryc and Peter T. M. Kennya,b*
A series of N-(ferrocenylmethyl amino acid) ﬂuorinated benzene-carboxamide derivatives 4b–i and 5b–i have been synthesized
by coupling ferrocenylmethyl amine 3 with various substituted N-(ﬂuorobenzoyl) amino acid derivatives using the standard
N-(3-dimethylaminopropyl)-N0-ethylcarbodiimide hydrochloride, 1-hydroxybenzotriazole protocol. The amino acids employed in
this study were glycine and L-alanine. All of the compounds were fully characterized using a combination of 1H NMR, 13C NMR, 19F
NMR, distortionless enhancement by polarization transfer (DEPT)-135, 1H–1H correlation spectroscopy (COSY) and 1H–13C COSY
(heteronuclear multiple-quantum correlation) spectroscopy. The compounds were biologically evaluated on the oestrogen-positive
MCF-7 breast cancer cell line. Compounds 4g, 4i, 5h and 5i exhibited cytotoxic effects on the MCF-7 breast cancer cell line.
N-(Ferrocenylmethyl-L-alanine)-3,4,5-triﬂuorobenzene-carboxamide (5h) was the most active compound, with an IC50 value
of 2.84 mM. Compounds 4i, 5h and 5i had lower IC50 values than that found for the clinically employed anticancer drug
cisplatin (IC50 = 16.3 mM against MCF-7). Guanine oxidation studies conﬁrmed that 5h was capable of generating oxidative
damage via a reactive oxygen species-mediated mechanism. Copyright © 2013 John Wiley & Sons, Ltd.
Supporting information may be found in the online version of this article.
Keywords: ferrocene; bioorganometallic chemistry; breast cancer; MCF-7
Introduction
Interest in metal complexes with biological applications has
grown at a phenomenal rate since the serendipitous discovery
of the inhibition of cell division by Pt complexes in 1965, and
the subsequent identiﬁcation of cis-dichlorodiamineplatinum(II)
or cisplatin as an effective anticancer drug.[1] A recent review
article has categorized the diverse range of metal anticancer
compounds according to their mode of action.[2] Some of the
most promising novel non-platinum metal anticancer agents
are emerging from the ﬁeld of bioorganometallic chemistry.[3] A
perspective article on organometallic anticancer compounds
has been published recently.[4] Ferrocene is perhaps the quintes-
sential organometallic molecule and indeed was the ﬁrst
example of the well-known ‘metallocene’ compounds to be
discovered.[5] Ferrocene is also a particularly attractive candidate
for incorporation into biomolecules and biologically active
compounds because of its aromatic character, redox properties
and low toxicity. The redox properties of ferrocene have often
been implicated in its cytotoxicity.[6] Indeed, ferricenium salts
that are known to inhibit tumour growth have been shown to
produce hydroxyl (HO•) radicals under physiological conditions,
leading to oxidatively damaged DNA.[7] The catalytic generation
of intracellular reactive oxygen species (ROS) such as the HO•
radical offers an attractive and alternative method to target and
kill cancer cells.[8]
The medicinal application of ferrocene derivatives is currently a
thriving area of research, with countless reports showing their ac-
tivity in vitro and in vivo against several diseases, including fungal
and bacterial infections, human immunodeﬁciency virus (HIV),
malaria and cancer.[9] Perhaps the most popular and well-
researched application of ferrocene and its derivatives is in the
area of cancer research.[10] Over the past decade Jaouen and
co-workers have comprehensively investigated the in vitro anti-
cancer activity of ferrocifen, a ferrocenyl analogue of tamoxifen,
and various related derivatives.[11] Their most promising drug
candidates contain a [13]-ferrocenophane motif and have a po-
tent in vitro antiproliferative effect in breast and prostate cancer
cell lines.[12–14] This research group has reported the antiproliferative
effects of ferrocenyl benzoyl and ferrocenyl naphthoyl bioconjugates
in the H1299 lung cancer cell line.[15–21] Also in a previous study
we reported the biological activity of novel N-(ferrocenylmethyl)
benzene-carboxamide derivatives.[22] We now report the results
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of a structure–activity relationship (SAR) study of a series of
N-(ferrocenylmethyl amino acid) ﬂuorinated benzene-carboxamide
derivatives. The incorporation of C-F bonds is a recognized strategy
often employed in the development of pharmaceuticals.[23] The
success of ﬂuorine substitution is evident from the large number
of ﬂuorinated drugs approved by the US Food and Drug
Administration and currently being used as anticancer, antide-
pressant, antiviral and anaesthetic agents. There are generally
two consequences of introducing ﬂuorine into a potential drug
molecule. Firstly, there are the physiochemical properties.
Fluorine has the ability to modulate electronic, lipophilic and
steric parameters that can critically inﬂuence the pharmacological
properties of a potential drug molecule. The introduction of a
ﬂuorine atom will generally increase lipophilicity, decrease basicity
and alter the hydrogen bonding interactions of a molecule.
Secondly, there is the inﬂuence of ﬂuorine substitution on the
biological stability through altering the metabolism of the drug
molecule. In this study the position and also the number of
ﬂuorine atoms on the aromatic ring were investigated and
several analogues were shown to have an antiproliferative effect. In
addition, we report guanine oxidation studies that were conducted
to elucidate the mode of action of the N-(ferrocenylmethyl amino
acid) ﬂuorinated benzene-carboxamide derivatives.
Results and Discussion
The parent compound ferrocenylmethylamine 3 was synthesized
from ferrocenecarboxaldehyde 1 via the ferrocene oxime 2 inter-
mediate (Scheme 1). The condensation of ferrocenylmethyl
amine with N-(ﬂuorobenzoyl) amino acids in the presence of
N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride
(EDC) and 1-hydroxybenzotriazole (HOBt) yielded the corre-
sponding N-(ferrocenylmethyl amino acid) ﬂuorobenzene-
carboxamides 4b–i and 5b–i as orange/yellow compounds. All
of the compounds gave analytical and spectroscopic data in
accordance with the proposed structures Fig 1. All of the proton
and carbon chemical shifts for compounds 4a–i and 5a–i were
unambiguously assigned by a combination of distortionless
enhancement by polarization transfer (DEPT)-135 and 1H–13C
correlation spectroscopy (COSY) (heteronuclear multiple-quantum
correlation). The 1H NMR and 13C NMR spectra for the compounds
showed peaks in the ferrocene region characteristic of a mono-
substituted ferrocene moiety.[24]
Thearomatic signals in the 1HNMRspectra of theN-(ferrocenylmethyl
amino acid)-ﬂuorinated benzene-carboxamide derivatives var-
ied, depending on the position and number of ﬂuorine atoms
on the benzoyl moiety. The aromatic protons of the benzene
ring appear in the range d 7.75–7.50 for 4a and d 7.90–7.45
for the 5a derivative. For the mono-, di- and triﬂuorobenzoyl
derivatives, the protons of the ﬂuorobenzoyl rings exhibit 1H-19F
coupling interactions and appear as complex multiplets in the
range d 7.99–7.14 for derivatives 4b–h, while for derivatives
5b–h these signals appear as complex multiplets in the range
of d 8.02–7.13. The 13C NMR spectra of the N-(ferrocenylmethyl
amino acid) ﬂuorinated benzene-carboxamide derivatives 4a–i
and 5a–i show signals typical of a monosubstituted ferrocene
moiety. The 13C-19F coupling can be seen in the 13C NMR and
DEPT-135 spectra of the ﬂuorinated compounds. Complete
spectroscopic data for the compounds are presented as
supporting information. As the compounds were not amenable
to electron ionization measurements, electrospray ionization
mass spectrometry (ESI-MS) was employed in the analysis. In
the ESI mass spectra both radical cations, [M]+• as well as
[M +H]+ species were observed. An intense fragment ion was
also present at m/z 199 and is due to the [FcCH2]
+ cation.
The in vitro activity of the compounds 4a–i and 5a–i against
the oestrogen receptor-positive breast cancer cell line MCF-7
was evaluated using the acid phosphatase assay as previously
described.[25] The acid phosphatase assay is highly sensitive
and is easier to perform than the neutral red assay as it involves
fewer steps and fewer reagents. It is also more convenient than
the MTT assay because of the inherent problem of removal of
the medium from the insoluble crystals. Reproducibility between
replicate wells is also excellent in the acid phosphatase assay.
The percentage cell growth in the presence of each compound
was determined relative to the control cells. The concentration of
compounds causing a 50% growth inhibition (IC50 of the
compound) was determined using Calcusyn (Biosoft, UK). In a
previous study a series of N-(ferrocenylmethyl) ﬂuorobenzene-
carboxamide derivatives were synthesized and biologically
evaluated on the human breast cancer cell line MDA-MB-435-S-F.
Scheme 1. Synthesis of N-(ferrocenylmethyl amino acid) ﬂuorinated benzene-carboxamide derivatives: (i) NH2OH. HCl, EtOH; (ii) LiAlH4, THF; (iii) EDC,
HOBt, N-(ﬂuorobenzoyl) amino acid derivative, CH2Cl2, 48 h. 4 and 5a X=H, b X= 2F, c X= 3F, d X= 4F, e X= 2F and 6F, f X= 2F and 4F, g X= 3F and 5F, h
X= 3F, 4F and 5F, i X= 2F, 3F, 4F, 5F and 6F.
W. E. Butler et al.
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The most active compound was N-(ferrocenylmethyl)-4-ﬂuorobenzene-
carboxamide (6), which had an IC50 value in the range of 11–14
mM.[23] Therefore this compound was used as a comparative
standard for the current biological evaluation in conjunction
with the positive control drug cisplatin. In a preliminary screen
on the MCF-7 human breast cancer cell line the following
compounds were tested at 10 mM concentration: 4a, 4d, 4g,
4h, 4i, 5a, 5d, 5g, 5h and 5i. Of the 10 compounds screened,
the four most active compounds were selected for further
evaluation namely: 4g (57% inhibition), 4i (69% inhibition),
5h (63% inhibition) and 5i (42% inhibition). The percent
inhibition of the other compounds was deemed to be too
low and was not evaluated further, e.g. 4h (11% inhibition)
and 5d (17% inhibition).
The compounds 4g, 4i, 5h and 5i were then selected for IC50
studies. The four N-(ferrocenylmethyl amino acid) ﬂuorinated
benzene-carboxamides were shown to exert an antiproliferative
effect on the MCF-7 cell line, as three of the derivatives are
considerably more active than compound 6 (Table 1). Com-
pounds 4i, 5h and 5i also had lower IC50 values than that found
for the clinically employed anticancer drug cisplatin (Table 1).[26]
A potential mechanism by which N-(ferrocenylmethyl-L-alanine)-
3,4,5-triﬂuorobenzene-carboxamide may induce DNA damage is
by the generation of a reactive oxygenated species via the
Fenton reaction. To investigate this, the rate of Fenton reaction-
mediated 8-oxoguanine formation from the DNA nucleotide
base guanine was monitored. Guanine was chosen as it has
the lowest oxidation potential of all the DNA bases and is consid-
ered the clinical biomarker for oxidative DNA damage.[26,27]
Guanine was oxidized using N-(ferrocenylmethyl-L-alanine)-
3,4,5-triﬂuorobenzene-carboxamide (5h) and H2O2 at 37C. Sam-
ples were taken in duplicate over 15 min. Each sample was
injected in triplicate and analysed by high-performance liquid
chromatography–electrochemical detection using an electro-
chemical detector at +550 mV versus Ag/AgCl. The iron-
mediated Fenton oxidation of guanine and the kinetic proﬁle of
8-oxoguanine formed as a result have previously been investi-
gated, utilizng FeSO4 as the model iron complex.
[27] To examine
whether the N-(ferrocenylmethyl-L-alanine)-3,4,5-triﬂuorobenzene-
carboxamide (5h) induced guanine oxidation via a similar
mechanism, kinetic 8-oxoguanine formation proﬁles were compared
using both iron complexes. Control experiments were carried
out utilizing both the iron complexes in the absence of peroxide,
and peroxide in the absence of iron, to verify that any oxidation
was Fenton mediated. Additionally, they ensured that no artifac-
tual oxidation was occurring from the sample preparation or
analysis methodology. For these experiments, deionized water
was used to sequentially replace each of the reagents used.
The highest background reading for these controls is plotted
as the base line (Figs 2 and 3) Error bars show the standard
deviation of duplicate samples injected in triplicate. Incubation
of free guanine with FeSO4 and peroxide lead to oscillating
concentrations of 8-oxoguanine over the incubation, as previ-
ously reported.[27] The formation is signiﬁcantly higher than
the control baselines, conﬁrming that the oxidation is Fenton
mediated. The 8-oxoguanine concentration maxima were 1.39
mM at 6 min and 2.29 mM at 8.5 min. This trend is analagous to
that reported previously.[28] These maxima occur with a different
oscillation frequency, which can be attributed to differences in solu-
tion pH (previously these maxima were reported at 4 and 15 min
respectively). Incubation of free guanine with N-(ferrocenylmethyl-
L-alanine)-3,4,5-triﬂuorobenzene-carboxamide and peroxide, which
was suspected to result in Fenton-mediated oxidation, also resulted
in the formation of oscillating concentrations of 8-oxoguanine over
the incubation period, as found with FeSO4. Again, the formation is
signiﬁcantly higher than the control base lines, clearly illustrating
that both the iron complex and peroxide are required to form this
concentration of 8-oxoguanine, conﬁrming that the oxidation of
guanine was Fenton mediated.
Themaximumconcentrationof 8-oxoguanineachievedwas0.72mM.
The concentrationof 8-oxoguaninegeneratedbyN-(ferrocenylmethyl-L-
alanine)-3,4,5-triﬂuorobenzene-carboxamide (5h) is signiﬁcantly
lower than that of the FeSO4. Ferrocene may produce a weaker
response than the FeSO4 due to the presence of the
cyclopentadienyl ligands and the size of the molecule. However,
the generation of 8-oxoguanine by N-(ferrocenylmethyl-
L-alanine)-3,4,5-triﬂuorobenzene-carboxamide (5h) illustrates that
the oxidation is occurring by Fenton chemistry and generating
DNA damage via a reactive oxygenated species (ROS)-mediated
mechanism. The oscillation period for 8-oxoguanine mediated by the
Table 1. IC50 data of N-(ferrocenylmethylamino acid)-ﬂuorinated
benzene-carboxamide derivatives, 4g, 4i, 5h, 5i, N-(ferrocenylmethyl)-
4-ﬂuorobenzene-carboxamide 6 and cisplatin
Compound name IC50 value (mM) (RSD
%)
Cisplatin 16.3 17%
N-(Ferrocenylmethyl)-4-ﬂuorobenzene-
carboxamide (6)
24.8 12%
N-(Ferrocenylmethylglycine)-3,
5-diﬂuorobenzene-carboxamide (4g)
46.5 11%
N-(Ferrocenylmethylglycine)-2,3,4,5,
6-pentaﬂuorobenzene-carboxamide (4i)
11.1 12%
N-(Ferrocenylmethyl-L-alanine)-3,4,
5-triﬂuorobenzene- carboxamide (5h)
2.84 10%
N-(Ferrocenylmethyl-L-alanine)-2,3,4,5,
6-pentaﬂuorobenzene-carboxamide (5i)
10.3 12%
Figure 1. N-(Ferrocenylmethylglycine)-ﬂuorinated benzene-carboxamide
derivatives 4b–i and N-(ferrocenylmethyl-L-alanine)-ﬂuorinated benzene
carboxamide derivatives 5b–i, b X=2F, c X=3F, d X=4F, e X=2F and 6F,
f X=2F and 4F, g X=3F and 5F, h X=3F, 4F and 5F, i X=2F, 3F, 4F, 5F
and 6F and N-(ferrocenylmethyl)-4-ﬂuorobenzene-carboxamide (6).
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N-(ferrocenylmethyl-L-alanine)-3,4,5-triﬂuorobenzene-carboxamide (5h)
differs from that of FeSO4. After the initial maxima at 0.0 and
up to 2 min, the 8-oxoguanine concentration continues to
oscillate for the rest of the incubation period, with concentrations
consistently higher than control levels, further conﬁrming that
oxidation is Fenton mediated.
Conclusion
TheN-(ferrocenylmethyl amino acid) ﬂuorinated benzene-carboxamide
derivatives which have shown anti-proliferative activity have
more than one ﬂuorine atom on the aromatic ring. N-
(Ferrocenylmethyl-L-alanine)-3,4,5-triﬂuorobenzene-carboxamide (5h)
was the most active compound and had an IC50 value of 2.84
mM. N-(Ferrocenylmethylglycine)-2,3,4,5,6-pentaﬂuorobenzene-
carboxamide (4i) and N-(ferrocenylmethyl-L-alanine)-2,3,4,5,6-
pentaﬂuorobenzene-carboxamide (5i) had IC50 values of 11.1
mM and 10.3 mM respectively. The three derivatives are consider-
ably more active than N-(ferrocenylmethyl)-4-ﬂuorobenzene-
carboxamide 6 and also had lower IC50 values than that
found for the clinically employed anticancer drug cisplatin.
These results show that the inclusion of the amino acids,
glycine and L-alanine, in combination with the position and
number of ﬂuorine atoms, plays a vital role in increasing the
biological activity and anticancer effect of these compounds.
Guanine oxidation studies conﬁrmed that N-(ferrocenylmethyl-L-al-
anine)-3,4,5-triﬂuorobenzene-carboxamide (5h) is capable of
generating oxidative damage via a ROS-mediated mechanism.
The ease of preparation and stability of these compounds together
with the encouraging cytotoxicity against the oestrogen receptor-
positive breast cancer cell line MCF-7 clearly promote further
research in this area. We are currently in the process of synthesizing
other derivatives with the aim of improving cytotoxicity and
identifying derivatives with lower IC50 values.
Experimental
Materials and Methods
All chemicals were purchased fromSigma-Aldrich, Lennox Chemicals,
Fluorochem Ltd or Tokyo Chemical Industry UK Ltd and used as
received. Commercial-grade reagents were used without further
puriﬁcation. When necessary, all solvents were puriﬁed and
dried prior to use. Riedal-Haën silica gel was used for thin-layer
chromatography and column chromatography. Melting points
were determined using a Grifﬁn melting point apparatus and
are uncorrected. Optical rotation measurements were made on a
PerkinElmer 343 polarimeter and are quoted in units of 101 deg
cm2 g1. Infrared spectra were recorded on either a Nicolet 405
FT-IR spectrometer or a PerkinElmer 100 FT-IR spectrometer with
ATR. UV-visible spectra were recorded on a Hewlett-Packard
8452A diode array UV-visible spectrophotometer. NMR spectra
were obtained on a Bruker AC 400 NMR spectrometer operating
at 400 MHz for 1H NMR, 376 MHz for 19F NMR and 100 MHz for
13C NMR. The 1H and 13C NMR chemical shifts (d) are relative to
tetramethylsilane and the 19F NMR chemical shifts (d) are relative
to triﬂuoroacetic acid. All coupling constants (J) are in hertz (Hz).
The abbreviations for the peak multiplicities are as follows: s
(singlet), d (doublet), t (triplet), q (quartet), qt (quintet), st (sextet)
and m (multiplet). ESI mass spectra were performed on either a
Micromass LCT mass spectrometer or a Brűker Daltonics Esquire-LC
ion trap mass spectrometer. Elemental analysis was carried out by
the microanalytical laboratory at University College Dublin.
General Procedure for the Synthesis of Compounds 4a–i
and 5a–i
Synthesis of N-(ferrocenylmethyl-L-alanine)-3,4,5-triﬂuorobenzene-
carboxamide (5h)
1-Hydroxybenzotriazole (0.55 g, 4.07 mmol) was added to a
solution of ferrocenylmethyl amine (1.15 g, 5.34 mmol), N-(3-
dimethylaminopropyl)-N0-ethylcarbodiimide hydrochloride (0.61 g,
3.18 mmol) and triethylamine (2 ml) in dichloromethane (40 ml) at
0C. After 30 min, N-(3,4,5-triﬂuorobenzoyl)-L-alanine (1.27 g, 5.14
mmol) was added and the reaction was stirred at room temperature
for 72 h. Diethyl ether (100 ml) was then added. The organic layer
was then washed with water, dried over MgSO4 and the solvent
was removed in vacuo. The compound was puriﬁed by column chro-
matography (eluant 2:1 hexane–ethyl acetate) and isolated as red
crystals (1.10 g, 46.6%); m.p. 134–136C. [a]D
20 =+32 (c 0.005,
ACN); UV-visible lmax ACN: (320, 432) IR: υmax (KBr): 3279, 3075,
1641, 1621, 1559, 1455, 1232, 1043, 1001, 889 cm1; 1H NMR (400
MHz) d (DMSO-d6): 8.78 (1H, d, J= 7.2 Hz, Ar-CO-NH),
8.25 (1H, t, J= 6 Hz, FcCH2NH), 7.93–7.85 (2H, m, Ar-H),
4.53–4.46 {1H, m, NH-CH(CH3)}, 4.19–4.17 {7H, m, (Z
5-C5H5)
Figure 2. 8-Oxoguanine concentration as a function of time after incu-
bation of free guanine with reagents Fe(II) and H2O2 at 37C.
Figure 3. 8-Oxoguanine concentration as a function of time after incubation
of free guanine with N-(ferrocenylmethyl-L-alanine)-3,4,5-triﬂuorobenzene-
carboxamide (5h) and H2O2 at 37C.
W. E. Butler et al.
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and ortho on (Z5-C5H4)}, 4.10 {2H, t, J=2 Hz, meta on (Z
5-C5H4)},
4.05–3.95 (2H, m, FcCH2), 1.41 {3H, d, J=7.2 Hz, NH-CH(CH3)};
13C NMR (100 MHz) d (DMSO-d6): 170.3 (CO), 167.7 (CO),
155.9–155.7 (C3,C5), 147.5–147.4 (C4), 130.2–130.0 (C1), 112.7–112.5
(C2,C6), 86.2 (Fc), 68.3 (Fc), 67.4 (Fc), 67.1 (Fc), 49.7 (CH) , 37.5
(CH2, ve DEPT), 17.9 (CH3); 19F (376 MHz, DMSO): d 134.6
(2F, m), 157.1 (1F, m) . Anal. Calcd for C21H19F3FeN2O2: C, 56.78;
H, 4.31; N, 6.31. Found: C, 56.62; H, 4.28; N, 5.98. m/z (ESI) 444.07
[M]+•. C21H19F3FeN2O2 requires 444.075.
General Procedure for In Vitro Cytotoxicity Assays
Conﬂuent cells in the exponential growth phase were harvested by
trypsination and a cell suspension of 5  104 cells ml1 was pre-
pared in fresh culture medium. The cell suspension (40 ml) was
added to a ﬂat-bottom 96-well plate (Costar 3599), followed by cul-
ture medium (60 ml). The plate was slightly agitated in order to
ensure complete dispersion of the cells. The cells were then incu-
bated for an initial 24 h in a 37C, 5% CO2 incubator to allow the
adhesion of cells to ﬂat-bottom wells. The compounds for testing
were prepared in 1 mM stock solutions. The different concentra-
tions used in the preliminary scans and for the further IC50 data
studies were made up accordingly by adding the desired amount
of compound stock solution to fresh culture media. Once the com-
pounds and media were added to the 96-well ﬂat-bottom plates,
the plate was gently agitated and then incubated at 37C, 5%
CO2, for 4–5 days until cell conﬂuency reached over 85%. Assess-
ment of cell survival in the presence of test sample was determined
by the acid phosphatase assay. For the full comprehensive screen,
cell growth percentage in the presence of each sample was
calculated relative to the DMSO control cells. For the preliminary
studies and IC50 data studies, the concentration of drug that causes
50% growth inhibition was determined by plotting the percentage
survival of cells (relative to control cells) against the concentration
of the test sample. In relation to IC50 data studies, IC50 values were
calculated using Calcusyn software (Biosoft, UK).
Supporting information
Supporting information may be found in the online version of
this article.
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a b s t r a c t
N-{6-(Ferrocenyl) ethynyl-2-naphthoyl} amino acid and dipeptide ethyl esters 2e8 were prepared by
coupling 6-(ferrocenyl) ethynyl-2-naphthoic acid 1 to the amino acid ethyl ester GABA(OEt) and the
dipeptide ethyl esters GlyGly(OEt), GlyAla(OEt), SarGly(OEt), SarAla(OEt), ProGly(OEt) and ProAla(OEt)
using the standard N-(3-dimethylaminopropyl)-N0-ethylcarbodiimide hydrochloride (EDC), 1-
hydroxybenzotriazole (HOBt) protocol. All the compounds were fully characterized using a combina-
tion of 1H NMR, 13C NMR, DEPT-135 and 1He13C COSY (HMQC) spectroscopy, electrospray ionization
mass spectrometry (ESI-MS) and cyclic voltammetry (CV). Compounds, 2e8 showed micromolar activity
in the H1299 NSCLC cell line, with IC50 values in the range of 3.2e7.2 mM.
 2012 Elsevier B.V. All rights reserved.
1. Introduction
Ferrocene is a particularly attractive candidate for incorporation
into biomolecules and biologically active compounds due to its
aromatic character, redox properties and low toxicity [1e3]. The
redox properties of ferrocene have often been implicated in its
cytotoxicity [4]. Ferricenium salts that are known to inhibit tumour
growth have been shown to produce hydroxyl (HO) radicals under
physiological conditions, leading to oxidatively damaged DNA [5].
The catalytic generation of intracellular reactive oxygen species
(ROS) such as the HO radical offers an attractive and alternative
method to target and kill cancer cells [6].
The medicinal application of ferrocene derivatives is currently
an active area of research, with countless reports showing their
activity in vitro and in vivo against several diseases including fungal
and bacterial infections, human immunodeﬁciency virus (HIV),
malaria and cancer [7]. Perhaps the most popular and well-
researched application of ferrocene and its derivatives is in the
area of cancer research [8]. Over the past decade Jaouen and co-
workers have comprehensively investigated the in vitro anti-
cancer activity of ferrocifen, a ferrocenyl analogue of tamoxifen,
and various related derivatives [9]. Their most promising drug
candidates contain a [3]-ferrocenophane motif and have a potent
in vitro anti-proliferative effect in breast and prostate cancer cell
lines [10e12]. This research group has reported the anti-
proliferative effects of ferrocenyl benzoyl and ferrocenyl naph-
thoyl bioconjugates in the H1299 lung cancer cell line [13e19].
These N-(ferrocenyl)benzoyl and naphthoyl dipeptide esters
consist of three components, namely: (i) an electroactive core, (ii)
a conjugated linker that lowers the oxidation potential of the
ferrocene moiety and (iii) an amino acid or peptide derivative that
can interact with other biomolecules via secondary interactions
such as hydrogen bonding. In an effort to improve the cytotoxicity
of these derivatives, we are currently modifying the conjugated
linker moiety and conducting variations of the peptide chain. The
compounds prepared in this study have an ethynyl group linked to
the ferrocene and the naphthoyl spacer group.
* Corresponding author. School of Chemical Sciences, Dublin City University,
Dublin 9, Ireland. Tel.: þ353 1 7005689; fax: þ353 1 7005503.
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Herein, we report the synthesis and structural characterization
of novel N-{6-(ferrocenyl) ethynyl-2-naphthoyl} amino acid and
dipeptide ethyl esters. The dipeptide ethyl esters GlyGly(OEt),
SarGly(OEt) and GlyAla(OEt) were employed in this investigation as
they were shown to have IC50 values of 0.13, 0.14 and 1.3 mM
respectively, in the H1299 lung cancer cell line. The dipeptide ethyl
esters SarAla(OEt), ProGly(OEt) and ProAla(OEt) were selected as
they are closely related analogues of the most active compounds.
The synthesis of the new ferrocenyl bioconjugates involved
Sonogashira coupling of ethynyl ferrocene to generate 6-(ferro-
cenyl) ethynyl-2-naphthoic acid [20]. A series of dipeptide esters
were coupled to the 6-(ferrocenyl) ethynyl-2-naphthoic acid to
generate the new class of compounds which were characterized by
a combination of 1H NMR, 13C NMR, DEPT-135, 1He13C COSY
spectroscopy, cyclic voltammetry and mass spectrometry. In addi-
tion, we present the in vitro anti-cancer activity of compounds 2e8
against the human lung carcinoma cell line H1299.
2. Results and discussion
2.1. Synthesis
2.1.1. Synthesis of N-{6-(ferrocenyl) ethynyl-2-naphthoyl} amino
acid and dipeptide ethyl esters 2e8
6-(Ferrocenyl) ethynyl-2-naphthoic acid 1 was prepared by
coupling ethynyl ferrocene to 6-bromo-2-naphthoic acid via the
Sonogashira reaction [20]. The 1H NMR spectrum showed signals for
the aromatic ring protons at d 8.13 (1H, s) and between d 7.95e7.48
(5H, m) for the 2,6-disubstituted naphthalene ring system. The
carboxylic acid proton was present at d 12.87. The ferrocenyl ortho
andmeta protons on the (h5-C5H4) ring were observed at d 4.27 and
d 4.19, respectively, and an intense signal was present at d 4.19 for the
(h5-C5H5) ring. The free N-terminal amino acid GABA(OEt) and the
free N-terminal dipeptide ethyl esters GlyGly(OEt), GlyAla(OEt),
SarGly(OEt), SarAla(OEt), ProGly(OEt) and ProAla(OEt) were coupled
to 6-(ferrocenyl) ethynyl-2-naphthoic acid 1 using EDC and HOBt in
the presence of excess triethylamine in dichloromethane (Scheme
1). EDC was used in preference to the less expensive coupling
reagent N,N0-dicyclohexylcarbodiimide (DCC) as its reaction by-
products are easier to remove compared to those of DCC, namely
dicyclohexylurea (DCU). Puriﬁcation by column chromatography
furnished the pure products in yields of 11e32% and all compounds
gave spectroscopic data in accordancewith the proposed structures.
The relatively low yields of products obtained are partly due to the
coupling procedure. The ﬁrst step in amide bond formation in the
coupling protocol is formation of the O-acylisourea ester interme-
diate. This intermediate is highly reactive and thus, side-reactions
can pose a serious problem and can result in extensive race-
misation resulting in low yields. The addition of HOBt stabilizes the
O-acylisourea ester intermediate thus suppressing side reactions,
however the addition does not result in 100% suppression. As the
reaction proceeds upon addition of the amino acid and dipeptide
ethyl esters the HOBt is displaced resulting in the formation of
compounds 2e8. As a result of the complexity of the reactionwhich
is associated with the competing reactions, low yields for
compounds 2e8 were obtained. Also in the EDC/HOBt coupling
reactionwhen primary amine amino acid and dipeptide ethyl esters,
namely, GABA(OEt), GlyGly(OEt) and GlyAla(OEt)} are used, the
yields are generally higher than that of the secondary amine
dipeptide ethyl esters SarGly(OEt), SarAla(OEt), ProGly(OEt) and
ProAla(OEt). For example the percentage yield of N-{6-(ferrocenyl)
ethynyl-2-naphthoyl}-glycine-glycine ethyl ester 3 obtained was
28% whereas the percentage yield of N-{6-(ferrocenyl) ethynyl-2-
naphthoyl}-sarcosine-glycine ethyl ester 5 was only 13%.
The N-{6-(ferrocenyl) ethynyl-2-naphthoyl} amino acid and
dipeptide ethyl esters 2e8 were characterized by a combination of
IR, UVeVis, 1H NMR, 13C NMR, DEPT-135 and 1He13C COSY (HMQC)
spectroscopy and cyclic voltammetry (CV). Electrospray ionization
(ESI) mass spectrometry in conjunction with tandem mass spec-
trometry (MS/MS) was also employed in the analysis.
2.2. 1H and 13C spectroscopic analysis
All the proton and carbon chemical shifts for compounds 2e8
were unambiguously assigned by a combination of DEPT-135
and 1He13C COSY (HMQC). The 1H and 13C NMR spectra for
compounds 2e8 showed peaks in the ferrocene region charac-
teristic of a monosubstituted ferrocene moiety [21e25]. The ortho
protons on the cyclopentadiene ring attached to the (eC^Ce)
spacer moiety appear in the region d 4.4 to d 4.72, the meta
protons occur in the range d 4.33 to d 3.9 and usually overlap with
the unsubstituted (h5-C5H5) ring which also appears between
d 4.33 and d 3.90.
The 13C NMR spectra of compounds 2e8 show signals in the
region d 63.6 to d 74.2 indicative of amonosubstituted ferroceneunit.
The ipso carbon of the (h5-C5H4) ring appears in the range of d 63.6 to
d67.8. This signal is absent in theDEPT-135spectra. The carbonatoms
of theethynyl groupappear in the rangeof d85.0 to d91.4 andare also
Scheme 1. Synthesis of N-{6-(ferrocenyl) ethynyl-2-naphthoyl} amino acid and dipeptide ethyl esters 2e8, (i) TEA, PPh3, Bis(triphenylphosphine)palladium(II) dichloride, THF, Cu(I)
(ii) EDC, HOBt, triethylamine, amino acid and dipeptide ethyl esters, R ¼ GABA(OEt) 2, GlyGly(OEt) 3, GlyAla(OEt) 4, SarGly(OEt) 5, SarAla(OEt) 6, ProGly(OEt) 7 and ProAla(OEt) 8.
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absent in the DEPT-135 spectra. The carbon atoms of the aromatic
naphthalene ring are non-equivalent and therefore ten signals are
visible in the region of d 120.8 to d 135.8 for compounds 2e8. The
quaternary carbon atoms of the aromatic ring and the methylene
carbon atoms of derivatives 2e8 were identiﬁed by DEPT-135.
Complete spectroscopic data for all the compounds is presented in
the experimental section.
2.3. Mass spectrometry
Soft ionization techniques such as electrospray ionization (ESI)
mass spectrometry permit the analysis of thermolabile and non-
volatile analytes [26]. Electrospray ionization (ESI) mass spec-
trometry was employed in the analysis of compounds 2e8 and
conﬁrmed the correct relative molecular mass for all the
compounds.
Tandem mass spectrometry was used to determine the fragmen-
tation pattern of N-{6-(ferrocenyl) ethynyl-2-naphthoyl}-glycine-
glycine ethyl ester 3. In the MS/MS spectrum of N-{6-(ferrocenyl)
ethynyl-2-naphthoyl}-glycine-glycine ethyl ester 3 the sequence
speciﬁc fragment ions are present atm/z 335,m/z 363,m/z 391 andm/
z 419 (Fig. 1). The product ions atm/z 335 andm/z 363 correspond to
the N-{6-(ferrocenyl) ethynyl-2-naphthyl and N-{6-(ferrocenyl)
ethynyl-2-naphthoyl} subunits respectively ﬁgure. However, the ex-
pected a1 and b1 product ions at m/z 392 and m/z 420 were not
observed, instead a11 and b11 product ionswere observed atm/z
391 and m/z 419 respectively. Obviously a hydrogen atom has also
been lost during the fragmentationprocess. This is unusual as these a1
and b1 fragment ions are usually producedwithout loss of a hydrogen
atom [27]. The formation of a11 and b11 ions in the mass spectra
of N-{para-(ferrocenyl)benzoyl}-glycine-L-alanine ethyl ester was
investigated by tandem mass spectrometry and deuterium labelling
studies. The results showed that b11product ions arise from the loss
of a hydrogen atomattached to the nitrogen andnot to thea-carbon of
the glycine residue [28].
2.4. Electrochemistry
The CV curves for compounds 2e8 exhibit quasi-reversible
behaviour similar to the Fc/Fcþ redox couple. The E0 (oxidation
potential) values for the N-{6-(ferrocenyl) ethynyl-2-naphthoyl}
amino acid and dipeptide ethyl esters 2e8 showed values in the 119e
162 mV range (versus Fc/Fcþ). The values for compounds 2e8 are
higher than those reported for the N-(6-ferrocenyl-2-naphthoyl)
derivatives (42e56 mV versus Fc/Fcþ), but are lower than ferrocenyl
dipeptide ester derivatives [17,19]. For example, Fc-Ala-Ala-OMe, was
reported as E0 ¼ 230 mV (vs Fc/Fcþ) [29].
2.5. In vitro anti-cancer activity of 2e8
The N-{6-(ferrocenyl) ethynyl-2-naphthoyl} amino acid and
dipeptide ethyl esters 2e8 have been prepared as part of an
ongoing SAR study. The in vitro anti-proliferative effect of
compounds 2e8 was studied in the H1299 non-small cell lung
cancer (NSCLC) cell line. Proliferation was measured using the acid
phosphatase assay. Thus 1  103 cells per well were seeded in 96
well plates. The plates were incubated overnight at 37 C followed
by addition of the compound at a concentration of 10 mM and
incubated for a further 5 days. The results of this biological study
are reported in Table 1 and are expressed as % cell growth inhi-
bition relative to the untreated controls. The % cell growth inhi-
bition was lowest for compound 2 at 68% and highest for
compounds 6 and 8 at 94% cell growth inhibition. The IC50 values
for derivatives 2e8were then determined by the acid phosphatase
assay as previously described [30]. This colorimetric end-point
assay is an indirect measure of cytotoxicity which evaluates the
enzyme activity of cells after a given treatment period. Acid
phosphatase is an enzyme which dephosphorylates p-nitrophenyl
phosphate substrate converting it to p-nitrophenol which in the
presence of strong alkali can be quantiﬁed colorimetrically. The
cells were treated with the N-{6-(ferrocenyl) ethynyl-2-naphthoyl}
amino acid and dipeptide ethyl esters 2e8 at a range of concen-
trations (from 1 mM to 100 mM) and were incubated for 5 days
until cell conﬂuency reached 80e90%. Cell survival was estab-
lished through determination of the acid phosphatase activity of
surviving cells and growth inhibition calculated relative to
controls (untreated cells). The results for compounds 2e8 are
depicted in Fig. 2 and Table 2 displays the IC50 values for deriva-
tives 2e8 and the control drug cisplatin.
It can be seen from Fig. 2 that the N-{6-(ferrocenyl) ethynyl-2-
naphthoyl} amino acid and dipeptide ethyl esters 2e8 all exert
a cytotoxic effect on the human lung carcinoma cell line H1299. All
seven derivatives have an IC50 value that is lower than 7.2 mM. The
most active compound was N-{6-(ferrocenyl) ethynyl-2-
naphthoyl}-sarcosine-L-alanine ethyl ester which had an IC50
value of 3.2 mM. It is interesting to note that this compound has the
lowest E0 value of 119 mV. However for compounds 2e5 the
presence of the ethynyl moiety had a negative effect of anti-
proliferative effect compared to analogous compounds
prepared previously lacking the ethynyl group [17e19]. For
Fig. 1. MS/MS spectrum of N-{6-(ferrocenyl) ethynyl-2-naphthoyl}-glycine-glycine ethyl ester 3.
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example for N-{6-(ferrocenyl) ethynyl-2-naphthoyl}-g-amino-
butyric acid ethyl ester the IC50 value is 7.2 mM whereas for N-(6-
ferrocenyl-2-naphthoyl)-g-aminobutyric acid ethyl ester the IC50
value was 0.62 mM. The in vitro cytotoxicity of the platinum(II)-
based anti-cancer drug cisplatin was also evaluated against the
H1299 cell line, and was found to have an IC50 value of 1.5  0.1 mM
(Table 2). Thus, compounds 2e8 are less cytotoxic in vitro than the
clinically employed anti-cancer drug cisplatin.
3. Conclusions
In conclusion, the novel N-{6-(ferrocenyl) ethynyl-2-naphthoyl}
amino acid and dipeptide ethyl esters 2e8 were synthesized and
fully characterized by a range of NMR spectroscopic techniques,
mass spectrometry and cyclic voltammetry. Compounds 2e8 were
tested in vitro against the human lung carcinoma cell line H1299.
Compounds 2e8 showed micromolar activity in the H1299 NSCLC
cell line, with IC50 values in the range of 3.2e7.2 mM. However
insertion of the ethynyl group had a negative effect on the anti-
proliferative effect compared to analogous compounds prepared
previously lacking the ethynyl group.
4. Experimental
4.1. General procedures
All chemicals were purchased from SigmaeAldrich, Lennox
Chemicals, Fluorochem Limited or Tokyo Chemical Industry UK
Limited; and used as received. Commercial grade reagents were
used without further puriﬁcation. When necessary, all solvents
were puriﬁed and dried prior to use. Riedel-Haën silica gel was
used for thin layer and column chromatography. Melting points
were determined using a Stuart melting point (SMP3) apparatus
and are uncorrected. Optical rotation measurements were made on
a PerkineElmer 343 Polarimeter and are quoted in units of
101 deg cm2 g1. Infrared spectra were recorded on a Perkine
Elmer Spectrum 100 FT-IR with ATR. UVeVis spectra were recorded
on a Hewlett Packard 8452 A diode array UVeVis spectrophotom-
eter. 1H and 13C NMR spectra were recorded in deuterated solvents
on a Bruker Avance 400 NMR. The 1H and 13C NMR chemical shifts
are reported in ppm (parts per million). Tetramethylsilane (TMS) or
the residual solvent peaks were used as an internal reference. All
coupling constants (J) are in Hertz. Electrospray ionisation mass
spectra were performed on a Micromass LCT mass spectrometer.
Tandem mass spectra were obtained on a Micromass Quattro
micro LCeMS/MS triple quadrupole mass spectrometer.
Cyclic voltammograms were recorded in anhydrous acetonitrile
(SigmaeAldrich), with 0.1 M tetrabutylammonium hexa-
ﬂuorophosphate (TBAPF6) as a supporting electrolyte, using a CH
Instruments 600a electrochemical analyzer (Pico-Amp Booster and
Faraday Cage). The experiments were carried out at room
temperature. A three-electrode cell consisting of a glassy carbon
working-electrode, a platinum wire counter-electrode and an
AgjAgCl reference electrode was used. The glassy carbon electrode
was polished with 0.3 mm alumina followed by 0.05 mm alumina,
between each experiment to remove any surface contaminants. The
scan rate was 0.1 V s1. The concentration range of the ferrocene
compounds was 1.0 mM in acetonitrile. The E0 values obtained for
the test samples were referenced relative to the ferrocene/ferrice-
nium redox couple.
4.2. General procedure for the synthesis of the starting
materials
4.2.1. 6-Ferrocenyl ethynyl-2-naphthoic acid 1
Ethynyl ferrocene (2.00 g, 9.52 mmol) and 6-bromo-2-
naphthoic acid (2.39 g, 9.52 mmol) were mixed together and
dissolved in 50 ml of a 1:1 mixture of dry triethylamine and
tetrahydrofuran under nitrogen for 10 min. Triphenylphosphine
(0.20 g, 0.76 mmol), bis(triphenylphosphine)palladium(II)
dichloride (0.28 g, 0.38 mmol) and copper(I) iodide (0.07 g,
0.38 mmol) were mixed together and added to the reaction
mixture. The reaction mixture was stirred for 10 min and
reﬂuxed at 80 C for 12 h. The reaction mixture was vacuumFig. 2. Cytotoxicity of derivatives 2e8.
Table 2
IC50 values for compounds 2e8 and cisplatin against human lung carcinoma cell line
H1299.
Compound IC50 value (mM)
Cisplatin 1.5  0.1
N-{6-(Ferrocenyl) ethynyl-2-naphthoyl}-
g-aminobutyric acid ethyl ester 2
7.2  1.5
N-{6-(Ferrocenyl) ethynyl-2-naphthoyl}-
glycine-glycine ethyl ester 3
5.0  4.1
N-{6-(Ferrocenyl) ethynyl-2-naphthoyl}-
glycine-L-alanine ethyl ester 4
5.0  3.6
N-{6-(Ferrocenyl) ethynyl-2-naphthoyl}-
sarcosine-glycine ethyl ester 5
4.7  3.7
N-{6-(Ferrocenyl) ethynyl-2-naphthoyl}-
sarcosine-L-alanine ethyl ester 6
3.2  6.6
N-{6-(Ferrocenyl) ethynyl-2-naphthoyl}-
L-proline-glycine ethyl ester 7
5.1  1.3
N-{6-(Ferrocenyl) ethynyl-2-naphthoyl}-
L-proline-L-alanine ethyl ester 8
3.8  2.0
Table 1
% Growth inhibition values for compounds 2e8 against human lung carcinoma cell
line H1299.
Compound name % Growth inhibition
N-{6-(Ferrocenyl) ethynyl-2-naphthoyl}-
g-aminobutyric acid ethyl ester 2
68
N-{6-(Ferrocenyl) ethynyl-2-naphthoyl}-
glycine-glycine ethyl ester 3
89
N-{6-(Ferrocenyl) ethynyl-2-naphthoyl}-
glycine-L-alanine ethyl ester 4
84
N-{6-(Ferrocenyl) ethynyl-2-naphthoyl}-
sarcosine-glycine ethyl ester 5
90
N-{6-(Ferrocenyl) ethynyl-2-naphthoyl}-
sarcosine-L-alanine ethyl ester 6
94
N-{6-(Ferrocenyl) ethynyl-2-naphthoyl}-L-
proline-glycine ethyl ester 7
82
N-{6-(Ferrocenyl) ethynyl-2-naphthoyl}-L-
proline-L-alanine ethyl ester 8
94
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ﬁltered. The solvent was removed in vacuo to yield the crude
product. The crude product was puriﬁed by column chroma-
tography (eluant 1:1 hexane:ethyl acetate) to yield the desired
product as a red solid (2.34 g, 64%), mp 167e169 C.
1H NMR (400MHz) d (DMSO-d6): 12.87 (1H, s,eCOOH), 8.13 (1H,
s, ArH), 7.95e7.48 (5H, m, (ArH)), 4.60 (2H, t, J ¼ 2.0 Hz, ortho on h5-
C5H4eC^Ce), 4.27 (2H, t, J ¼ 2.0 Hzmeta on h5-C5H4eC^Ce), 4.19
(5H, s, h5-C5H5).
13C NMR (100 MHz) d (DMSO-d6): 172.7 (C]O), 134.9 (Cq), 134.6
(Cq),134.0 (Cq),132.2 (Cq),131.6,130.3,128.1,128.0,127.8,120.8, 90.3
(h5-C5H4eC^Ce), 85.7 (h5-C5H4eC^Ce), 71.4 (Cortho h5-C5H4e
C^Ce), 69.9 (h5-C5H5), 68.7 (Cmeta h5-C5H4eC^Ce), 65.8 (Cipso
h5-C5H4eC^Ce).
4.3. General procedure for the synthesis of N-{6-(ferrocenyl)
ethynyl-2-naphthoyl} amino acid and dipeptide ethyl esters
4.3.1. N-{6-(Ferrocenyl) ethynyl-2-naphthoyl}-g-aminobutyric acid
ethyl ester 2
6-(Ferrocenyl) ethynyl-2-naphthoic acid (1.00 g, 2.63 mmol)
was dissolved in dichloromethane (100 ml) at 0 C. N-(3-
dimethylaminopropyl)-N0-ethylcarbodiimide hydrochloride
(0.50 g, 2.63 mmol), 1-hydroxybenotriazole (0.36 g, 2.63 mmol), g-
aminobutyric acid ethyl ester hydrochloride (0.34 g, 2.63 mmol)
and triethylamine (6 ml) were added and the reaction mixture was
allowed to stir at 0 C for 45 min. The reaction mixture was then
allowed to stir at room temperature for 48 h. The reaction mixture
was washed with water and brine. The organic layer was dried over
MgSO4. The solvent was removed in vacuo to yield the crude
product. The crude product was puriﬁed by column chromatog-
raphy (eluant 1:1 hexane:ethyl acetate) and recrystallisation from
hexane:ethyl acetate yielded the desired product as a red solid
(0.42 g, 32%), m.p. 71e73 C; E0 ¼ 131 mV (vs Fc/Fcþ).
Mass spectrum: found: [M þ Na]þ 516.1255.
C29H27NO3FeNa requires: 516.1340.
I.R. ymax (KBr): 3283 (NH), 2205 (eC^Ce), 1726 (C]Oester), 1605
(C]Oamide) cm1.
UVeVis lmax EtOH: 268 (ε 308) nm.
1H NMR (400 MHz) d (CDCl3): 8.18 (1H, s, ArH), 7.81{1H, s, ArH},
7.75e7.49 {5H, m, (eCONHe), (ArH)}, 4.47 (2H, t, J¼ 1.6 Hz, ortho on
h5-C5H4eC^Ce), 4.19e4.18 {7H, m, (meta on h5-C5H4eC^Ce), (h5-
C5H5)}, 4.04 (2H, q, J ¼ 7.2 Hz, eOCH2CH3), 3.46 (2H, q, J ¼ 5.6 Hz, e
NHCH2CH2CH2e), 2.37 (2H, t, J ¼ 6.8 Hz, eNHCH2CH2CH2e),
1.87 (2H, quin, J ¼ 6.4 Hz, eNHCH2CH2CH2e), 1.15 (3H, t,
J ¼ 7.2 Hz, eOCH2CH3).
13C NMR (100 MHz) d (CDCl3): 171.5 (C]O), 167.4 (C]O), 131.5
(Cq), 130.1 (Cq), 129.1 (Cq), 128.9 (Cq), 128.2, 127.6, 127.7, 126.0, 125.1,
123.0, 89.2 (h5-C5H4eC^Ce), 85.0 (h5-C5H4eC^Ce), 71.9 (Cortho
h5-C5H4eC^Ce), 69.2 (h5-C5H5), 68.4 (Cmeta h5-C5H4eC^Ce), 63.8
(Cipso h5-C5H4eC^Ce), 60.0 (eOCH2CH3, -ve DEPT), 39.0 (e
NHCH2CH2CH2e, -ve DEPT), 31.2 (eNHCH2CH2CH2e, -ve DEPT),
23.3 (eNHCH2CH2CH2e, -ve DEPT), 13.1 (eOCH2CH3).
4.3.2. N-{6-(Ferrocenyl) ethynyl-2-naphthoyl}-glycine-glycine
ethyl ester 3
Glycine-glycine ethyl ester hydrochloride (0.42 g, 2.63 mmol)
was used as a starting material. The crude product was puriﬁed by
column chromatography (eluant 1:1 hexane:ethyl acetate) and
recrystallisation from hexane:ethyl acetate yielded the desired
product as a red solid (0.38 g, 28%), m.p. 128e130 C; E0 ¼ 141 mV
(vs Fc/Fcþ).
Mass spectrum: [M þ Na]þ found: 545.1130.
C29H26N2O4FeNa requires: 545.1140.
I.R. ymax (KBr): 3261 (NH), 2204 (eC^Ce), 1736 (C]Oester), 1658
(C]Oamide), 1603 (C]Oamide) cm1.
UVeVis lmax EtOH: 278 (ε 310) nm.
1H NMR (400 MHz) d (CDCl3): 8.13 (1H, s, ArH), 7.95e7.48 {7H,
m, (ArH), (eCONHe), (eCONHe)}, 4.61 (2H, t, J ¼ 2.0 Hz, ortho on
h5-C5H4eC^Ce), 4.30 (2H, t, J ¼ 2.0 Hz, meta on h5-C5H4eC^Ce),
4.19e4.15 {11H, m, (h5-C5H5), (eNHCH2COe), (eNHCH2COe), (e
OCH2CH3)}, 1.23 (3H, t, J ¼ 7.2 Hz, eOCH2CH3).
13C NMR (100 MHz) d (CDCl3): 172.7 (C]O), 170.9 (C]O), 169.6
(C]O), 133.9 (Cq), 132.6 (Cq), 131.0 (Cq), 130.2 (Cq), 129.6, 129.3,
128.9, 128.1, 127.8, 125.8, 90.3 (h5-C5H4eC^Ce), 84.7 (h5-C5H4e
C^Ce), 72.1 (Cortho h5-C5H4eC^Ce), 70.0 (h5-C5H5), 69.7 (Cmeta
h5-C5H4eC^Ce), 67.8 (Cipso h5-C5H4eC^Ce), 61.6 (eOCH2CH3, -ve
DEPT), 42.3 (eNHCH2COe, -ve DEPT), 40.1 (eNHCH2COe, -ve
DEPT), 14.8 (eOCH2CH3).
4.3.3. N-{6-(Ferrocenyl) ethynyl-2-naphthoyl}-glycine-L-alanine
ethyl ester 4
Glycine-L-alanine ethyl ester hydrochloride (0.46 g, 2.63 mmol)
was used as a starting material. The crude product was puriﬁed by
column chromatography (eluant 1:1 hexane:ethyl acetate) and
recrystallisation from hexane:ethyl acetate yielded the
desired product as a red solid (0.23 g, 16%), m.p. 58e60 C;
E0 ¼ 139 mV (vs Fc/Fcþ); [a]D20 ¼ 14 (c 0.1, EtOH).
Mass spectrum: [M þ Na]þ found: 559.1305.
C30H28N2O4FeNa requires: 559.1398.
I.R. ymax (KBr): 3287 (NH), 2204 (eC^Ce), 1734 (C]Oester), 1658
(C]Oamide), 1625 (C]Oamide) cm1.
UVeVis lmax EtOH: 242 (ε 316) nm.
1H NMR (400 MHz) d (CDCl3): 8.21 (1H, s, ArH), 7.87e7.51 {7H,
m, (ArH), (eCONHe), (eCONHe)}, 4.48e4.47 {3H, m, (eCHCH3),
(ortho on h5-C5H4eC^Ce)}, 4.19e4.07 {11H, m, (meta on h5-
C5H4eC^Ce), (h5-C5H5), (eOCH2CH3), (eNHCH2COe)}, 1.36
(3H, d, J ¼ 7.2 Hz, eCHCH3), 1.28 (3H, t, J ¼ 6.8 Hz, eOCH2CH3).
13C NMR (100 MHz) d (CDCl3): 171.8 (C]O), 169.1 (C]O), 167.9
(C]O),134.5 (Cq),131.5 (Cq),130.8 (Cq),130.4 (Cq),129.3,128.9,128.0,
127.7, 124.3, 123.4, 90.4 (h5-C5H4eC^Ce), 84.9 (h5-C5H4eC^Ce),
71.3 (Cortho h5-C5H4eC^Ce), 70.1 (h5-C5H5), 69.5 (Cmeta h5-C5H4e
C^Ce), 65.9 (Cipso h5-C5H4eC^Ce), 60.3 (eOCH2CH3, -ve DEPT),
48.9 (eCHCH3), 43.1 (eNHCH2COe, -ve DEPT), 17.2 (eCHCH3), 13.7
(eOCH2CH3).
4.3.4. N-{6-(Ferrocenyl) ethynyl-2-naphthoyl}-sarcosine-glycine
ethyl ester 5
Sarcosine-glycine ethyl ester hydrochloride (0.46 g, 2.63 mmol)
was used as a starting material. The crude product was puriﬁed by
column chromatography (eluant 1:1 hexane:ethyl acetate) and
recrystallisation from hexane:ethyl acetate yielded the desired
product as a red solid (0.19 g, 13%), m.p. 32e34 C; E0 ¼ 162 mV (vs
Fc/Fcþ).
Mass spectrum: found: [M þ Na]þ 559.1307.
C30H28N2O4FeNa requires: 559.1398.
I.R. ymax (KBr): 3284 (NH), 2205 (eC^Ce), 1744 (C]Oester), 1676
(C]Oamide), 1605 (C]Oamide) cm1.
UVeVis lmax EtOH: 252 (ε 313) nm.
1H NMR (400 MHz) d (CDCl3): 7.92e7.49 {7H, m, (eCONHe),
(ArH)}, 4.48 (2H, s, ortho on h5-C5H4eC^Ce), 4.30e3.90 {13H, m,
(meta on h5-C5H4eC^Ce), (h5-C5H5), (eN(CH3)CH2COe), (e
NHCH2COe) (eOCH2CH3)}, 3.10 (3H, s, eN(CH3)CH2COe), 1.19
(3H, t, J ¼ 7.2 Hz, eOCH2CH3).
13C NMR (100 MHz) d (CDCl3): 172.7 (C]O), 170.4 (C]O), 167.2
(C]O), 133.6 (Cq), 132.7 (Cq), 131.9 (Cq), 130.8 (Cq), 129.5, 128.5,
128.1, 127.3, 125.0, 122.9, 90.1 (h5-C5H4eC^Ce), 85.9 (h5-C5H4e
C^Ce), 71.8 (Cortho h5-C5H4eC^Ce), 70.5 (h5-C5H5), 69.5 (Cmeta
h5-C5H4eC^Ce), 65.4 (Cipso h5-C5H4eC^Ce), 61.7 (eOCH2CH3, -ve
DEPT), 48.2 (eN(CH3)CH2COe, -ve DEPT), 41.2 (eNHCH2COe,
-ve DEPT), 38.4 (eN(CH3)CH2COe), 14.2 (eOCH2CH3).
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4.3.5. N-{6-(Ferrocenyl) ethynyl-2-naphthoyl}-sarcosine-L-alanine
ethyl ester 6
Sarcosine-L-alanine ethyl ester hydrochloride (0.50 g,
2.63 mmol) was used as a starting material. The crude product was
puriﬁed by column chromatography (eluant 1:1 hexane:ethyl
acetate) and recrystallisation from hexane:ethyl acetate yielded the
desired product as a red solid (0.19 g, 13%), m.p. 59e61 C;
E0 ¼ 119 mV (vs Fc/Fcþ); [a]D20 ¼ 23 (c 0.1, EtOH).
Mass spectrum: [M þ Na]þ found: 573.1879.
C31H30N2O4FeNa requires: 573.1555.
I.R. ymax (KBr): 3308 (NH), 2206 (eC^Ce), 1732 (C]Oester), 1625
(C]Oamide), 1538 (C]Oamide) cm1.
UVeVis lmax EtOH: 261 (ε 304) nm.
1H NMR (400 MHz) d (CDCl3): 7.93e7.50 {7H, m, (eCONHe),
(ArH)}, 4.53e4.40 {3H, m, (ortho on h5-C5H4eC^Ce), (eCHCH3)},
4.20e4.10 {11H, m, (meta on h5-C5H4eC^Ce), (h5-C5H5), (e
N(CH3)CH2COe), (eOCH2CH3)}, 3.07 (3H, s, eN(CH3)CH2COe),
1.38 (2H, d, J ¼ 7.2 Hz, eCHCH3), 1.21 (3H, t, J ¼ 7.2 Hz, eOCH2CH3).
13C NMR (100 MHz) d (CDCl3): 172.0 (C]O), 170.2 (C]O), 169.1
(C]O), 134.4 (Cq), 132.7 (Cq), 131.6 (Cq), 130.6 (Cq), 129.4, 128.5, 128.0,
127.3,125.0,123.9, 91.3 (h5-C5H4eC^Ce), 84.7 (h5-C5H4eC^Ce), 71.1
(Cortho h5-C5H4eC^Ce), 69.7 (h5-C5H5), 68.2 (Cmeta h5-C5H4eC^Ce),
66.2 (Cipso h5-C5H4eC^Ce), 61.9 (eOCH2CH3, -ve DEPT), 49.7 (e
CHCH3), 45.1 (eN(CH3)CH2COe, -ve DEPT), 38.2 (eN(CH3)CH2COe),
19.0 (eCHCH3), 13.8 (eOCH2CH3).
4.3.6. N-{6-(Ferrocenyl) ethynyl-2-naphthoyl}-L-proline-glycine
ethyl ester 7
L-Proline-glycine ethyl ester hydrochloride (0.53 g, 2.63mmol)was
used as a startingmaterial. The crude product was puriﬁed by column
chromatography (eluant 1:1 hexane:ethyl acetate) and recrystallisa-
tion from hexane:ethyl acetate yielded the desired product as a red
solid (0.22 g, 15%), m.p. 53e55 C; E0 ¼ 153 mV (vs Fc/Fcþ);
[a]D20 ¼ þ27 (c 0.1, EtOH).
Mass spectrum: [M þ Na]þ found: 585.1467.
C32H30N2O4FeNa requires: 585.1555.
I.R. ymax (KBr): 3313 (NH), 2205 (eC^Ce), 1735 (C]Oester), 1652
(C]Oamide), 1604 (C]Oamide) cm1.
UVeVis lmax EtOH: 254 (ε 317) nm.
1H NMR (400 MHz) d (CDCl3): 7.96e7.38 {7H, m, (ArH), (e
CONHe)}, 4.82 (1H, t, J ¼ 5.2 Hz, eN(CH2CH2CH2)CHCOe), 4.47
(2H, s, ortho on h5-C5H4eC^Ce), 4.21e4.18 {7H, m, (meta on h5-
C5H4eC^Ce), (h5-C5H5)}, 4.16 (2H, q, J ¼ 7.2 Hz, eOCH2CH3), 4.00
(2H, d, J¼ 5.6Hz,eNHCH2COe), 3.61e3.50 ( 2H,m,eN(CH2CH2CH2)
CHCOe), 2.40e1.70 (4H, m, eN(CH2CH2CH2)CHCOe), 1.21 (3H, t,
J ¼ 7.2 Hz, eOCH2CH3).
13C NMR (100 MHz) d (CDCl3): 171.7 (C]O), 171.0 (C]O), 169.2
(C]O), 133.7 (Cq), 131.5 (Cq), 130.6 (Cq), 129.4 (Cq), 128.1, 127.9,
127.0, 127.2, 124.9, 123.0, 90.1 (h5-C5H4eC^Ce), 84.8 (h5-C5H4e
C^Ce), 71.0 (Cortho h5-C5H4eC^Ce), 70.1 (h5-C5H5), 69.1 (Cmeta
h5-C5H4eC^Ce), 64.9 (Cipso h5-C5H4eC^Ce), 61.4 (eOCH2CH3,
-ve DEPT), 50.8 (eN(CH2CH2CH2)CHCOe), 47.6 (eN(CH2CH2CH2)
CHCOe, -ve DEPT), 42.5 (eNHCH2COe, -ve DEPT), 27.4 (e
N(CH2CH2CH2)CHCOe, -ve DEPT), 25.0 (eN(CH2CH2CH2)CHCOe,
-ve DEPT), 13.2 (eOCH2CH3).
4.3.7. N-{6-(Ferrocenyl) ethynyl-2-naphthoyl}-L-proline-L-alanine
ethyl ester 8
L-Proline-L-alanine ethyl ester hydrochloride (0.56 g, 2.63mmol)
was used as a starting material. The crude product was puriﬁed by
column chromatography (eluant 1:1 hexane:ethyl acetate) and
recrystallisation from hexane:ethyl acetate yielded the desired
product as a red solid (0.17 g, 11%), m.p. 56e58 C; E0 ¼ 133 mV (vs
Fc/Fcþ); [a]D20 ¼ 67 ( c 0.1, EtOH).
Mass spectrum: found: [M þ Na]þ 599.1639.
C33H32N2O4FeNa requires: 599.1711.
I.R. ymax (KBr): 3285 (NH), 2202 (eC^Ce), 1736 (C]Oester), 1672
(C]Oamide), 1608 (C]Oamide) cm1.
UVeVis lmax EtOH: 270 (ε 311) nm.
1HNMR (400MHz) d (CDCl3): 8.12 (1H, s, ArH), 7.96e7.54 {6H,m,
(ArH), (eCONHe)}, 4.72e4.65 {3H, m, (eN(CH2CH2CH2)CHCOe),
(ortho on h5-C5H4eC^Ce)}, 4.55e4.45 (1H, m, eCHCH3), 4.33
(2H, s, meta on h5-C5H4eC^Ce), 4.33e4.12 {7H, m, (h5-C5H5), (e
OCH2CH3)}, 3.61e3.49 (2H, m, eN(CH2CH2CH2)CHCOe),2.40e1.70
(4H, m, eN(CH2CH2CH2)CHCOe), 1.38 (3H, d, J ¼ 4.4 Hz, eCHCH3),
1.17 (3H, t, J ¼ 7.2 Hz, eOCH2CH3).
13C NMR (100 MHz) d (CDCl3): 172.1 (C]O), 169.7 (C]O), 168.2
(C]O), 134.5 (Cq), 133.5 (Cq), 132.8 (Cq), 131.6 (Cq), 130.1, 128.4, 128.0,
127.1,124.7,121.0, 90.1 (h5-C5H4eC^Ce), 85.8 (h5-C5H4eC^Ce), 71.9
(Cortho h5-C5H4eC^Ce), 70.2 (h5-C5H5), 69.4 (Cmeta h5-C5H4eC^Ce),
67.6 (Cipso h5-C5H4eC^Ce), 61.9 (eOCH2CH3, -ve DEPT), 60.1 (e
N(CH2CH2CH2)CHCOe), 50.7 (eN(CH2CH2CH2)CHCOe, -ve DEPT),
48.5 (eCHCH3), 27.2 (eN(CH2CH2CH2)CHCOe, -ve DEPT), 25.0 (e
N(CH2CH2CH2)CHCOe, -ve DEPT), 19.2 (eCHCH3), 14.0 (eOCH2CH3).
4.4. General procedure for in vitro cytotoxicity assays
4.4.1. Biological assays. Cell line
H1299 was obtained from the American Tissue Culture Centre
(ATCC). The cell line was grown in RPMI-1640 supplemented with
10% foetal calf serum (FCS) and 1% Sodium Pyruvate at 37 C in a 5%
CO2 humidiﬁed chamber.
4.4.2. In vitro proliferation assays
Cells in the exponential phase of growth were harvested by
trypsinisation and a cell suspension of 1  103 cells per ml was
prepared in fresh culturemedium. The cell suspension (100 mL) was
added to a ﬂat bottom 96-well plate (Costar, 3599), the plates were
agitated gently in order to ensure even dispersion of cells over the
surface of the wells, and then the cells were incubated for an initial
24 h in a 37 C, 5% CO2 incubator, to allow cell attachment to the
wells. A 10 mM stock solution of a test sample was prepared in
dimethyl sulfoxide; dilute solutions of the test sample were
prepared at 2 ﬁnal concentration by spiking the cell culture
medium with a calculated amount of the stock solution.
100 mL aliquots of each dilute solutionwas added to each well of
the plate, the platewas gently agitated, and then incubated at 37 C,
5% CO2 for 5 days, until cell conﬂuency reached 80e90%. Assess-
ment of cell survival in the presence of the compounds 2e8 was
determined by the acid phosphatase assay [30]. The acid phos-
phatase assay is highly sensitive and is easier to perform than the
neutral red assay as it involves fewer steps and fewer reagents. It is
also more convenient than the MTT assay because of the inherent
problem of removal of the medium from the insoluble crystals. The
reproducibility between replicate wells is excellent in the acid
phosphatase assay and inmany cases it has been shown to be better
than the neutral red assay and the MTT assay.
The percentage cell growth in the presence of each compound
was determined relative to the control cells. The concentration of
compounds causing a 50% growth inhibition (IC50 of the
compound) was determined using Calcusyn (Biosoft, UK).
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